<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004679.pub3" GROUP_ID="RENAL" ID="078403080710324137" MERGED_FROM="" MODIFIED="2017-06-08 05:33:13 +0100" MODIFIED_BY="Fiona Russell" REVIEW_NO="060" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2017-06-08 14:30:40 +1000" MODIFIED_BY="Fiona A Russell">
<TITLE>Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients</TITLE>
<CONTACT>
<PERSON ID="16154" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS>FM</MIDDLE_INITIALS>
<LAST_NAME>Strippoli</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>giovanni.strippoli@uniba.it</EMAIL_1>
<EMAIL_2>gfmstrippoli@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Kidney and Transplant, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+39 080 5580776</PHONE_1>
<PHONE_2>+39 349 5705884</PHONE_2>
<FAX_1>+39 080 5580776</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-06-08 14:29:56 +1000" MODIFIED_BY="Fiona Russell">
<PERSON ID="32919551428217828621110718063119" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Denise</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Campbell</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>denise.campbell@health.nsw.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1>Locked Bag 4001</ADDRESS_1>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 9845 1477</PHONE_1>
<PHONE_2/>
<FAX_1>+ 61 2 9845 1491</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="64438182733131664827101206004908" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>Mudge</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>David.Mudge@health.qld.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>0432462428</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>University of Queensland at Princess Alexandra Hospital</ORGANISATION>
<ADDRESS_1>Level 2, ARTS Building</ADDRESS_1>
<ADDRESS_2>Ipswich Rd</ADDRESS_2>
<CITY>Woolloongabba</CITY>
<ZIP>4102</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 3176 5080</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 3176 5480</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4552" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Jonathan</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Craig</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jonathan.craig@sydney.edu.au</EMAIL_1>
<EMAIL_2>JonC@health.usyd.edu.au</EMAIL_2>
<URL>http://kidneyandtransplant.cochrane.org</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Sydney School of Public Health</DEPARTMENT>
<ORGANISATION>The University of Sydney</ORGANISATION>
<ADDRESS_1>Edward Ford Building A27</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP>2006</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16113" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>Johnson</LAST_NAME>
<SUFFIX/>
<POSITION>Director of Nephrology</POSITION>
<EMAIL_1>david.johnson2@health.qld.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Princess Alexandra Hospital</ORGANISATION>
<ADDRESS_1>199 Ipswich Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Woolloongabba</CITY>
<ZIP>4102</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 31765080</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 31765480</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19795" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Allison</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tong</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>allison.tong@sydney.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1>Locked Bag 4001</ADDRESS_1>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 98451482</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 98451491</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16154" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS>FM</MIDDLE_INITIALS>
<LAST_NAME>Strippoli</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>giovanni.strippoli@uniba.it</EMAIL_1>
<EMAIL_2>gfmstrippoli@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Kidney and Transplant, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+39 080 5580776</PHONE_1>
<PHONE_2>+39 349 5705884</PHONE_2>
<FAX_1>+39 080 5580776</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<UP_TO_DATE>
<DATE DAY="4" MONTH="10" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="10" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="4" MONTH="4" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-06-08 14:30:40 +1000" MODIFIED_BY="Fiona A Russell">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-06-06 11:09:33 +1000" MODIFIED_BY="Gail Y Higgins">
<DATE DAY="6" MONTH="6" YEAR="2017"/>
<DESCRIPTION>
<P>Corrections made to numbering in MEDLINE &amp; CENTRAL search strategies</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-06-08 14:30:40 +1000" MODIFIED_BY="Fiona A Russell">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-06-08 14:30:37 +1000" MODIFIED_BY="Fiona A Russell">
<DATE DAY="12" MONTH="1" YEAR="2017"/>
<DESCRIPTION>
<P>New studies and comparisons added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-06-08 14:30:40 +1000" MODIFIED_BY="Fiona A Russell">
<DATE DAY="12" MONTH="1" YEAR="2017"/>
<DESCRIPTION>
<P>20 new studies added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-12-28 12:44:57 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="30" MONTH="4" YEAR="2014"/>
<DESCRIPTION>
<P>Minor copy-edit made</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-12-28 12:44:53 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="18" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-03-18 14:07:21 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="13" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-13 17:49:25 +1000" MODIFIED_BY="Narelle Willis">
<DATE DAY="16" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-09-16 17:41:12 +1000" MODIFIED_BY="Narelle S Willis">
<DATE DAY="18" MONTH="12" YEAR="2007"/>
<DESCRIPTION>
<P>New trials sought but none found</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-04-04 16:08:05 +1000" MODIFIED_BY="Narelle S Willis">
<SUMMARY MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<TITLE MODIFIED="2017-01-12 09:39:47 +1100" MODIFIED_BY="Narelle Willis">Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients</TITLE>
<SUMMARY_BODY MODIFIED="2017-01-12 11:37:00 +1100" MODIFIED_BY="Narelle Willis">
<P>
<B>What is the Issue?</B>
</P>
<P>People with kidney failure may be treated with peritoneal dialysis where a catheter is permanently inserted into the peritoneum (lining around abdominal contents) through the abdominal wall and sterile fluid is drained in and out a few times each day. The most common serious complication is infection of the peritoneum, which is called peritonitis. This may be caused by bacteria accidentally being transferred from the catheter.</P>
<P>
<B>What did we do?</B>
</P>
<P>We searched the literature up until 4 October 2016 and identified 39 studies randomising 4435 patients undergoing peritoneal dialysis that were evaluated in this review.</P>
<P>
<B>What did we find?</B>
</P>
<P>We found that antibiotics given when a peritoneal dialysis catheter is implanted may reduce the risk of early peritonitis but not of exit-site/tunnel infection. Antifungal prophylaxis with oral nystatin or fluconazole reduces the risk of fungal peritonitis following an antibiotic course. The available studies are of low quality evidence and consequently, it is uncertain if there is any benefit from using nasal mupirocin or topical disinfectants or other interventions to reduce exit-site/tunnel infection or peritonitis.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<ABS_BACKGROUND MODIFIED="2017-01-12 11:56:21 +1100" MODIFIED_BY="Narelle Willis">
<P>Peritoneal dialysis (PD) is an important therapy for patients with end-stage kidney disease and is used in more than 200,000 such patients globally. However, its value is often limited by the development of infections such as peritonitis and exit-site and tunnel infections. Multiple strategies have been developed to reduce the risk of peritonitis including antibiotics, topical disinfectants to the exit site and antifungal agents. However, the effectiveness of these strategies has been variable and are based on a small number of randomised controlled trials (RCTs). The optimal preventive strategies to reduce the occurrence of peritonitis remain unclear.</P>
<P>This is an update of a Cochrane review first published in 2004.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-01-12 09:34:31 +1100" MODIFIED_BY="Narelle Willis">
<P>To evaluate the benefits and harms of antimicrobial strategies used to prevent peritonitis in PD patients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>We searched the Cochrane Kidney and Transplant's Specialised Register to 4 October 2016 through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference proceedings; and searching the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-01-12 09:35:10 +1100" MODIFIED_BY="Narelle Willis">
<P>RCTs or quasi-RCTs in patients receiving chronic PD, which evaluated any antimicrobial agents used systemically or locally to prevent peritonitis or exit-site/tunnel infection were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>Two authors independently assessed risk of bias and extracted data. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratio (RR) with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>Thirty-nine studies, randomising 4435 patients, were included. Twenty additional studies have been included in this update. The risk of bias domains were often unclear or high; risk of bias was judged to be low in 19 (49%) studies for random sequence generation, 12 (31%) studies for allocation concealment, 22 (56%) studies for incomplete outcome reporting, and in 12 (31%) studies for selective outcome reporting. Blinding of participants and personnel was considered to be at low risk of bias in 8 (21%) and 10 studies (26%) for blinding of outcome assessors. It should be noted that blinding of participants and personnel was not possible in many of the studies because of the nature of the intervention or control treatment.</P>
<P>The use of oral or topical antibiotic compared with placebo/no treatment, had uncertain effects on the risk of exit-site/tunnel infection (3 studies, 191 patients, low quality evidence: RR 0.45, 95% CI 0.19 to 1.04) and the risk of peritonitis (5 studies, 395 patients, low quality evidence: RR 0.82, 95% CI 0.57 to 1.19).</P>
<P>The use of nasal antibiotic compared with placebo/no treatment had uncertain effects on the risk of exit-site/tunnel infection (3 studies, 338 patients, low quality evidence: RR 1.34, 95% CI 0.62 to 2.87) and the risk of peritonitis (3 studies, 338 patients, low quality evidence: RR 0.94, 95% CI 0.67 to 1.31).</P>
<P>Pre/perioperative intravenous vancomycin compared with no treatment may reduce the risk of early peritonitis (1 study, 177 patients, low quality evidence: RR 0.08, 95% CI 0.01 to 0.61) but has an uncertain effect on the risk of exit-site/tunnel infection (1 study, 177 patients, low quality evidence: RR 0.36, 95% CI 0.10 to 1.32).</P>
<P>The use of topical disinfectant compared with standard care or other active treatment (antibiotic or other disinfectant) had uncertain effects on the risk of exit-site/tunnel infection (8 studies, 973 patients, low quality evidence, RR 1.00, 95% CI 0.75 to 1.33) and the risk of peritonitis (6 studies, 853 patients, low quality evidence: RR 0.83, 95% CI 0.65 to 1.06).</P>
<P>Antifungal prophylaxis with oral nystatin/fluconazole compared with placebo/no treatment may reduce the risk of fungal peritonitis occurring after a patient has had an antibiotic course (2 studies, 817 patients, low quality evidence: RR 0.28, 95% CI 0.12 to 0.63).</P>
<P>No intervention reduced the risk of catheter removal or replacement. Most of the available studies were small and of suboptimal quality. Only six studies enrolled 200 or more patients. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-01-12 09:38:49 +1100" MODIFIED_BY="Narelle Willis">
<P>In this update, we identified limited data from RCTs and quasi-RCTs which evaluated strategies to prevent peritonitis and exit-site/tunnel infections. This review demonstrates that pre/peri-operative intravenous vancomycin may reduce the risk of early peritonitis and that antifungal prophylaxis with oral nystatin or fluconazole reduces the risk of fungal peritonitis following an antibiotic course. However, no other antimicrobial interventions have proven efficacy. In particular, the use of nasal antibiotic to eradicate <I>Staphylococcus</I> <I>aureus</I>, had an uncertain effect on the risk of peritonitis and raises questions about the usefulness of this approach. Given the large number of patients on PD and the importance of peritonitis, the lack of adequately powered and high quality RCTs to inform decision making about strategies to prevent peritonitis is striking.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-04-04 16:08:05 +1000" MODIFIED_BY="Narelle S Willis">
<BACKGROUND MODIFIED="2017-04-04 16:08:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>Peritoneal dialysis (PD) is one of the renal replacement therapies available to people with end-stage kidney disease (ESKD). There is considerable variation in its use from country to country, with the proportion of total dialysis patients on PD in developed countries ranging from 3.3% (Japan), to 7.0% (USA), 8.3% (Greece), 17.0 % (UK), 36.3% (New Zealand), and up to 79.4% (Hong Kong) (<LINK REF="REF-Jain-2012" TYPE="REFERENCE">Jain 2012</LINK>). Because PD and haemodialysis have similar outcomes and patients feel that PD, compared with HD, allows them to live life more fully (<LINK REF="REF-Morton-2011" TYPE="REFERENCE">Morton 2011</LINK>), PD should be used more frequently than it is but the perceived risk of peritonitis may prevent this from occurring (<LINK REF="REF-Heaf-2004" TYPE="REFERENCE">Heaf 2004</LINK>; <LINK REF="REF-Piraino-1998" TYPE="REFERENCE">Piraino 1998</LINK>).</P>
<CONDITION MODIFIED="2017-01-12 11:39:40 +1100" MODIFIED_BY="Narelle Willis">
<P>Peritonitis due to various organisms<I> (</I>e.g.<I> Staphylococcus aureus</I>, <I>Pseudomonas</I> <I>aeruginosa</I>, coagulase-negative staphylococci) is a leading complication of PD resulting in technique failure (<LINK REF="REF-Woodrow-1997" TYPE="REFERENCE">Woodrow 1997</LINK>), hospitalisation (<LINK REF="REF-Choi-2004" TYPE="REFERENCE">Choi 2004</LINK>; <LINK REF="REF-Churchill-1997" TYPE="REFERENCE">Churchill 1997</LINK>), peritoneal membrane failure, switching to haemodialysis (<LINK REF="REF-Jaar-2009" TYPE="REFERENCE">Jaar 2009</LINK>; <LINK REF="REF-Piraino-1989" TYPE="REFERENCE">Piraino 1989</LINK>) and increased mortality (<LINK REF="REF-Annigeri-2001" TYPE="REFERENCE">Annigeri 2001</LINK>; <LINK REF="REF-Digenis-1990" TYPE="REFERENCE">Digenis 1990</LINK>; <LINK REF="REF-Fried-1996" TYPE="REFERENCE">Fried 1996</LINK>; <LINK REF="REF-Piraino-2000" TYPE="REFERENCE">Piraino 2000</LINK>). There has been a dramatic reduction in the rates of peritonitis from the start of continuous ambulatory PD (CAPD), but rates above the minimum acceptable peritonitis rate recommended by the International Society for Peritoneal Dialysis (ISPD) of one episode every 33 months (0.36 episodes/year at risk) are still common (<LINK REF="REF-Piraino-2011" TYPE="REFERENCE">Piraino 2011</LINK>).</P>
<P>Risk factors for peritonitis include older age (<LINK REF="REF-Nessim-2009" TYPE="REFERENCE">Nessim 2009</LINK>; <LINK REF="REF-Oxton-1994" TYPE="REFERENCE">Oxton 1994</LINK>; <LINK REF="REF-Salusky-1997" TYPE="REFERENCE">Salusky 1997</LINK>), depression (<LINK REF="REF-Troidle-2003" TYPE="REFERENCE">Troidle 2003</LINK>), coexisting diseases such as diabetes (<LINK REF="REF-Chow-2005" TYPE="REFERENCE">Chow 2005</LINK>; <LINK REF="REF-Ghali-2011" TYPE="REFERENCE">Ghali 2011</LINK>) and cardiovascular disease (<LINK REF="REF-McDonald-2004" TYPE="REFERENCE">McDonald 2004</LINK>; <LINK REF="REF-Nolph-1987" TYPE="REFERENCE">Nolph 1987</LINK>), obesity (<LINK REF="REF-McDonald-2004" TYPE="REFERENCE">McDonald 2004</LINK>), connection methodology (<LINK REF="REF-Daly-2001" TYPE="REFERENCE">Daly 2001</LINK>), presence of a peritoneal catheter exit-site infection (<LINK REF="REF-Lloyd-2013" TYPE="REFERENCE">Lloyd 2013</LINK>; <LINK REF="REF-van-Diepen-2012" TYPE="REFERENCE">van Diepen 2012</LINK>), and the presence of nasal carriage of <I>S. aureus </I>(<LINK REF="REF-Golper-1996" TYPE="REFERENCE">Golper 1996</LINK>; <LINK REF="STD-Mupirocin-Study-1996" TYPE="STUDY">Mupirocin Study 1996</LINK>; <LINK REF="REF-Perez_x002d_Fontan-1993" TYPE="REFERENCE">Perez-Fontan 1993</LINK>; <LINK REF="REF-Schaefer-2003" TYPE="REFERENCE">Schaefer 2003</LINK>). Race is also an independent risk factor, with African-American, native Canadian and indigenous Australian Aborigines on PD being shown to be at increased risk (<LINK REF="REF-Farias-1994" TYPE="REFERENCE">Farias 1994</LINK>; <LINK REF="REF-Fine-1994" TYPE="REFERENCE">Fine 1994</LINK>; <LINK REF="REF-Golper-1996" TYPE="REFERENCE">Golper 1996</LINK>; <LINK REF="REF-Holley-1993" TYPE="REFERENCE">Holley 1993</LINK>; <LINK REF="REF-Lim-2005" TYPE="REFERENCE">Lim 2005</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2017-04-04 16:08:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>Different antimicrobial interventions are used at PD catheter insertion and on an ongoing basis to prevent peritonitis. These include intravenous antibiotics, oral antibiotics, topical antibiotics (<LINK REF="REF-Thodis-2000" TYPE="REFERENCE">Thodis 2000</LINK>), topical disinfectants, prophylactic treatment of <I>S. aureus</I> nasal carriage primarily with intranasal antibiotic ointment (<LINK REF="REF-Piraino-2002" TYPE="REFERENCE">Piraino 2002</LINK>), different exit-site dressing systems and antifungal prophylaxis. All of these strategies, particularly the use of antibiotic at catheter insertion and the cleansing and disinfection of the exit-site, are widely accepted, but practice patterns are variable and it is not clear which practices have most benefit (<LINK REF="REF-Piraino-2011" TYPE="REFERENCE">Piraino 2011</LINK>; <LINK REF="REF-Van-Biesen-2014" TYPE="REFERENCE">Van Biesen 2014</LINK>). Studies on preventing PD-related infections are limited in number and quality (<LINK REF="REF-Piraino-2011" TYPE="REFERENCE">Piraino 2011</LINK>). International guidelines differ in their recommendations on preventing PD-related infections, with some countries not having relevant guidelines (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>None of these interventions are free of risks or without cost. Antibiotic prophylaxis carries the risk of gastrointestinal toxicity and may be a cause of antibiotic resistance (<LINK REF="REF-Annigeri-2001" TYPE="REFERENCE">Annigeri 2001</LINK>; <LINK REF="STD-Bernardini-1996" TYPE="STUDY">Bernardini 1996</LINK>); it may also be ineffective when patients already have resistance to some antibiotics. Care should be taken that any disinfectant used is at a concentration that is non-cytotoxic (<LINK REF="REF-Piraino-2011" TYPE="REFERENCE">Piraino 2011</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2017-01-05 17:35:56 +1100" MODIFIED_BY="Narelle Willis">
<P>For a patient to be able to successfully use PD as a dialysis therapy, PD-related infections (exit-site infections, tunnel infections and peritonitis) need to be avoided. The most important infection is peritonitis and a number of prophylactic strategies have been employed to limit its occurrence. Bacteria are known to be able to gain entry to the peritoneum in a variety of ways and hence, various strategies have been used to prevent this occurring (<LINK REF="REF-Campbell-2015" TYPE="REFERENCE">Campbell 2015</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Oral antibiotics</HEADING>
<P>Oral antibiotics such as rifampin have been given as prophylaxis to PD patients to reduce catheter infections and peritonitis due to <I>S. aureus</I> (<LINK REF="STD-Bernardini-1996" TYPE="STUDY">Bernardini 1996</LINK>; <LINK REF="STD-Zimmerman-1991" TYPE="STUDY">Zimmerman 1991</LINK>). This organism is a major cause of PD catheter infections which can result in <I>S. aureus</I> peritonitis and catheter removal. <I>S. aureus</I> nasal carriage is known to be a significant risk factor for <I>S. aureus</I> PD-related infections (<LINK REF="STD-Bernardini-1996" TYPE="STUDY">Bernardini 1996</LINK>). Cyclic oral rifampin is superior to placebo in preventing <I>S. aureus</I> infections. Other oral antibiotics used include ofloxacin (<LINK REF="STD-Sesso-1994" TYPE="STUDY">Sesso 1994</LINK>), cephalexin (<LINK REF="STD-Low-1980" TYPE="STUDY">Low 1980</LINK>), and trimethoprim/sulphamethoxazole (<LINK REF="STD-Churchill-1988" TYPE="STUDY">Churchill 1988</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical antibiotics</HEADING>
<P>Topical antibiotics such as mupirocin have been applied to the exit site once daily because this antibiotic has good activity against gram-positive organisms such as staphylococci and streptococci, which are a common cause of exit-site infection and peritonitis in PD patients (<LINK REF="REF-Keane-2000" TYPE="REFERENCE">Keane 2000</LINK>; <LINK REF="REF-Troidle-1998" TYPE="REFERENCE">Troidle 1998</LINK>; <LINK REF="REF-Ward-1986" TYPE="REFERENCE">Ward 1986</LINK>). However, mupirocin is less active against most gram-negative bacilli and anaerobes (<LINK REF="REF-Sutherland-1985" TYPE="REFERENCE">Sutherland 1985</LINK>). Sodium fusidate ointment (2%) has also been applied to the exit site at one-month intervals and is known to have activity against staphylococci (<LINK REF="STD-Sesso-1994" TYPE="STUDY">Sesso 1994</LINK>). Gentamicin cream is active against both gram-positive and gram-negative organisms and has been used long term on a once-daily basis at the exit site as prophylaxis for exit-site infection (<LINK REF="STD-Bernardini-2005" TYPE="STUDY">Bernardini 2005</LINK>; <LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>). Gentamicin is active against both <I>S. aureus</I> and <I>P. aeruginosa</I>, two important causes of exit-site infection (<LINK REF="STD-Bernardini-2005" TYPE="STUDY">Bernardini 2005</LINK>). Polysporin triple ointment (P3) consists of bacitracin/gramicidin/polymyxin and has bacteriostatic activity against a wide range of skin flora and other organisms including gram-negative bacteria (<LINK REF="STD-MP3-Study-2008" TYPE="STUDY">MP3 Study 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Nasal antibiotic prophylaxis</HEADING>
<P>Various antibiotic treatments have been trialled in attempts to eliminate <I>S. aureus</I> nasal carriage in PD patients. The nasal carriage of <I>S. aureus </I>is a well-recognised risk factor for the development of <I>S. aureus</I> infections in CAPD patients (<LINK REF="REF-Davies-1989" TYPE="REFERENCE">Davies 1989</LINK>; <LINK REF="STD-Luzar-1990" TYPE="STUDY">Luzar 1990</LINK>; <LINK REF="REF-Piraino-1990" TYPE="REFERENCE">Piraino 1990</LINK>). Neomycin sulphate ointment has been used prophylactically. Mupirocin has also been used to eliminate nasal <I>S. aureus</I>. While mupirocin is effective at reducing <I>S. aureus</I> nasal carriage rates, re-colonisation frequently occurs. Sodium fusidate ointment (2%) has also been used and is effective at reducing <I>S. aureus</I> nasal carriage rates (<LINK REF="STD-Sesso-1994" TYPE="STUDY">Sesso 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pre/peri-operative intravenous antibiotic prophylaxis</HEADING>
<P>The administration of intravenous antibiotics at catheter insertion has been trialled in order to determine if this practice reduces the risk of post-operative peritonitis or exit-site infection after PD catheter insertion. Although the insertion of a PD catheter involves "clean surgery involving the placement of a prosthesis or implant", there is the potential for contamination of the peritoneum with micro-organisms from the patient's own body during surgery. Hence, the giving of a single dose of antibiotic prophylaxis intravenously on starting anaesthesia is recommended (<LINK REF="REF-Collier-2008" TYPE="REFERENCE">Collier 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical disinfectants of the exit site</HEADING>
<P>Topical disinfectants have been applied to the exit site for many years, in an attempt to reduce the bacterial load around the exit site. It has been shown that PD patients with a history of an exit-site infection have twice the risk of experiencing a peritonitis episode (<LINK REF="REF-Canadian-CAPD-Clinical-Trials-Group-1989" TYPE="REFERENCE">Canadian CAPD Clinical Trials Group 1989</LINK>) so it is important to keep the exit-site infection-free. Povidone iodine ointment is a broad spectrum antiseptic ointment that has been used and has minimal adverse events associated with its use (<LINK REF="STD-Waite-1997" TYPE="STUDY">Waite 1997</LINK>). Povidone iodine solution (20g/L) has also been used and shown to successfully reduce the number of exit-site infections (<LINK REF="STD-Luzar-1990" TYPE="STUDY">Luzar 1990</LINK>). Other antiseptic agents such as hydrogen peroxide, sodium hypochlorite and chlorhexidine have been used (<LINK REF="REF-Piraino-2011" TYPE="REFERENCE">Piraino 2011</LINK>). The daily use of antibacterial honey at the exit site was trialled in the <LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK> This agent was used because it does not induce antimicrobial resistance and has been shown to be active against a broad range of bacteria and fungi (<LINK REF="REF-Cho-2014" TYPE="REFERENCE">Cho 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dressing systems for exit sites</HEADING>
<P>A number of exit-site dressing systems have been devised, all with the aim of reducing exit-site/tunnel infection and any subsequent peritonitis. The agents used include topical disinfectants and different dressing types and require more or less frequent removal. More frequent removal is seen to risk damaging the skin around the exit site and less frequent removal is felt to possibly encourage the growth of anaerobes. The concentration of topical disinfectants used need to be at non-cytotoxic levels.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Silver ring system on catheter</HEADING>
<P>The addition of a silver ring device mounted onto the PD catheter was trialled by German researchers in the 1990s (<LINK REF="STD-SIPROCE-Study-1997" TYPE="STUDY">SIPROCE Study 1997</LINK>). The silver ring was used because of the antimicrobial properties of silver. The use of silver-coated catheters in animals had shown a reduction in infectious events (<LINK REF="REF-Dasgupta-1994" TYPE="REFERENCE">Dasgupta 1994</LINK>; <LINK REF="REF-Fung-1996" TYPE="REFERENCE">Fung 1996</LINK>) and offered a non-pharmaceutical approach to reducing PD catheter-related infections.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antistaphylococcal vaccine</HEADING>
<P>An antistaphylococcal vaccine was trialled in the 1990s for the purpose of immunising patients with an anti-staphylococcal agent. The expectation was that the vaccine would promote a significant increase in the dialysate level of specific antibodies against <I>S. aureus</I> and that this would lead to reduced peritonitis and exit-site/tunnel infection rates (<LINK REF="STD-Poole_x002d_Warren-1991" TYPE="STUDY">Poole-Warren 1991</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antifungal agents</HEADING>
<P>Antifungal prophylaxis to prevent fungal peritonitis when a PD patient receives an antibiotic course is based on the fact that most episodes of fungal peritonitis are preceded by courses of antibiotics (<LINK REF="REF-Piraino-2011" TYPE="REFERENCE">Piraino 2011</LINK>). Patients receiving prolonged or repeated antibiotic courses are at increased risk of fungal peritonitis, mostly due to <I>Candida</I> spp. The co-administration of an oral antifungal agent with an antibiotic course has been trialled to determine if this practice reduces the risk of fungal peritonitis (<LINK REF="STD-Lo-1996" TYPE="STUDY">Lo 1996</LINK>; <LINK REF="STD-Restrepo-2010" TYPE="STUDY">Restrepo 2010</LINK>).</P>
</SUBSECTION>
</THEORY>
<IMPORTANCE MODIFIED="2015-10-20 17:10:59 +1100" MODIFIED_BY="[Empty name]">
<P>The aim of this update was to include any new studies of antimicrobial interventions designed to prevent peritonitis in PD patients that have been published since the original review was published in 2004. We also aim to provide a critical appraisal of the current available evidence. As peritonitis is a significant problem for patients using PD, frequently leading to morbidity and technique failure and sometimes to mortality, we have updated the review.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-01-06 16:27:24 +1100" MODIFIED_BY="[Empty name]">
<P>To evaluate the benefits and harms of antimicrobial strategies used to prevent peritonitis in PD patients.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<SELECTION_CRITERIA MODIFIED="2017-01-05 17:38:22 +1100" MODIFIED_BY="Narelle Willis">
<CRIT_STUDIES MODIFIED="2015-03-04 14:18:40 +1100" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) and quasi-RCTs (studies in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) in which antimicrobial interventions designed to prevent peritonitis were compared in patients on PD. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-01-05 17:37:49 +1100" MODIFIED_BY="Narelle Willis">
<P>We included adults and children with ESKD who were undergoing PD treatment.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-01-05 17:38:10 +1100" MODIFIED_BY="Narelle Willis">
<P>We included studies involving the use of any antimicrobial agent, whether the interventions were tested between themselves (head-to-head) or against placebo/no treatment. The inclusion criteria have been expanded in this update, with the intervention "oral antibiotics" becoming "oral or topical or intraperitoneal antibiotics" and with the interventions "dressing systems for exit sites" and "silver ring system on catheter" being added.</P>
<P>Specifically, the following antimicrobial interventions were analysed.</P>
<UL>
<LI>Oral or topical or intraperitoneal antibiotics</LI>
<LI>Nasal antibiotic prophylaxis (mupirocin, rifampicin, other)</LI>
<LI>Pre/peri-operative intravenous antibiotic prophylaxis</LI>
<LI>Topical disinfectants of the exit-site (povidone-iodine, chlorhexidine, triclosan, soap and water, other)</LI>
<LI>Germicidal systems for connection devices</LI>
<LI>Dressing systems for exit sites</LI>
<LI>Silver ring system on catheter</LI>
<LI>Antistaphylococcal vaccine</LI>
<LI>Antifungal agents</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-01-05 17:38:22 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis-number of patients with peritonitis and peritonitis rate (peritonitis defined as dialysate count of &gt; 100 cells/mm<SUP>3</SUP> with &gt; 50% being polymorphonuclear leukocytes; peritonitis rate defined as number of episodes of peritonitis over total patient months on PD)</LI>
<LI>Peritonitis relapse (reoccurrence of peritonitis due to the same organism within two to four weeks)</LI>
<LI>Death due to peritonitis</LI>
<LI>All-cause mortality</LI>
<LI>Exit-site and tunnel infection-number of patients with exit-site and tunnel infections and exit-site and tunnel infection rate</LI>
<LI>Catheter removal/catheter replacement</LI>
<LI>Technique failure (transfer from PD to haemodialysis/transplant due to peritonitis)</LI>
<LI>Toxicity of antimicrobial treatments (nasal irritation, sneezing, generalised pruritus, headache, diarrhoea, nausea, vomiting, jaundice, local irritation, rash)</LI>
<LI>Time to first peritonitis episode</LI>
</UL>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-01-05 18:42:59 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Peritonitis</LI>
<LI>Exit-site infection/tunnel infection</LI>
<LI>Catheter removal/catheter replacement</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-03-04 14:22:19 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Peritonitis relapse</LI>
<LI>Death due to peritonitis</LI>
<LI>All-cause mortality</LI>
<LI>Technique failure</LI>
<LI>Toxicity of antimicrobial treatments</LI>
<LI>Time to first peritonitis episode</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<ELECTRONIC_SEARCHES MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>We searched the <A HREF="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register">Cochrane Kidney and Transplant Specialised Register</A> to 4 October 2016 through contact with the Information Specialist using search terms relevant to this review. The Cochrane Kidney and Transplant Specialised Register contains studies identified from the following sources.</P>
<OL>
<LI>Monthly searches of the Cochrane Central Register of Controlled Trials CENTRAL</LI>
<LI>Weekly searches of MEDLINE OVID SP</LI>
<LI>Handsearching of kidney-related journals &amp; the proceedings of major kidney conferences</LI>
<LI>Searching of the current year of EMBASE OVID SP</LI>
<LI>Weekly current awareness alerts for selected kidney journals</LI>
<LI>Searches of the International Clinical Trials Register (ICTRP) Search Portal &amp; ClinicalTrials.gov.</LI>
</OL>
<P>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of <A HREF="http://kidneyandtransplant.cochrane.org/our-scope">Cochrane Kidney and Transplant</A>. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html">Cochrane Kidney and Transplant</A>.</P>
<P>See <A HREF="http://archie.cochrane.org/sections/documents/view?document=13925506130498709040110327035142&amp;format=REVMAN#APP-01">Appendix 1</A> for search terms used in strategies for this review.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-01-05 17:15:16 +1100" MODIFIED_BY="Narelle Willis">
<OL>
<LI>Reference lists of review articles, relevant studies and clinical practice guidelines.</LI>
<LI>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-01-12 10:22:52 +1100" MODIFIED_BY="Narelle Willis">
<P>
<B>
<BR/>
</B>
</P>
<STUDY_SELECTION MODIFIED="2017-01-05 17:45:42 +1100" MODIFIED_BY="Narelle Willis">
<P>The search strategy described was used to obtain titles and abstracts of studies that were potentially relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable. However, studies and reviews that might include relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts and where necessary, the full text of these studies, to determine which satisfied the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-01-05 17:46:52 +1100" MODIFIED_BY="Narelle Willis">
<P>Data extraction and assessment of the risk of bias were performed independently by the same authors using standardised data extraction forms. Studies reported in non-English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions, these data were used. Any discrepancy between published versions was highlighted. Any further information required from the original author was requested by written correspondence and any relevant information obtained in this manner was included in the review.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-01-05 17:06:34 +1100" MODIFIED_BY="Narelle Willis">
<P>The following items were assessed using the risk of bias assessment tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<UL>
<LI>Was there adequate sequence generation (selection bias)?</LI>
<LI>Was allocation adequately concealed (selection bias)?</LI>
<LI>Was knowledge of the allocated interventions adequately prevented during the study?</LI>
<UL>
<LI>Participants and personnel (performance bias)</LI>
<LI>Outcome assessors (detection bias)</LI>
</UL>
<LI>Were incomplete outcome data adequately addressed (attrition bias)?</LI>
<LI>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?</LI>
<LI>Was the study apparently free of other problems that could put it at a risk of bias?</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-01-05 17:07:16 +1100" MODIFIED_BY="Narelle Willis">
<P>For dichotomous outcomes (peritonitis (number), peritonitis (rate), death due to peritonitis, all-cause mortality, exit-site/tunnel infection (number), exit-site/tunnel infection (rate), catheter removal/replacement, technique failure, toxicity of antimicrobial treatments) results were expressed as risk ratios (RR) with 95% confidence intervals (CI). No continuous outcomes were identified.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2017-01-05 17:47:20 +1100" MODIFIED_BY="Narelle Willis">
<P>Where data on the number of subjects with events (e.g. number of subjects with one or more episodes of peritonitis) were available, the RR was calculated as the ratio of the incidence of the event (one or more episodes) in the experimental treatment group over the incidence in the control group. Where data on the number of episodes were available the RR was calculated as the ratio of the rate of the outcome (e.g. the peritonitis rate) in the experimental treatment group (given by number of episodes of the outcome over total patient months on PD) over the rate in the control group.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-01-05 17:47:37 +1100" MODIFIED_BY="Narelle Willis">
<P>Where necessary, we contacted triallists to request missing patient data due to loss to follow-up and exclusion from study analyses in an effort to conduct intention-to-treat analyses. With the update, four authors responded to our requests. Where missing dichotomous data were few, and unlikely to affect the overall results, we analysed available data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-01-05 17:09:02 +1100" MODIFIED_BY="Narelle Willis">
<P>Heterogeneity was analysed using a Chi<SUP>2</SUP> test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I<SUP>2</SUP> test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). I<SUP>2</SUP> values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-01-09 09:10:18 +1100" MODIFIED_BY="Narelle Willis">
<P>The search strategy included searching major databases, conference proceedings and prospective trial registers without language restriction in an attempt to reduce publication bias related to failure of authors to publish negative results or inability to publish negative results in journals indexed in major databases. Insufficient studies were available to assess for publication bias using funnel plots. Where multiple publications of the same study were identified, data were included from the most recent publication, and preferably, the definitive publication. However, all publications were reviewed to identify outcomes not reported in the index publication in an attempt to reduce outcome reporting bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-01-08 11:41:32 +1100" MODIFIED_BY="[Empty name]">
<P>Data were pooled using the random-effects model for dichotomous data. </P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-10-20 17:10:59 +1100" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis was planned to explore potential sources of variability in observed treatment effect where possible (paediatric versus adult population, diabetic versus non-diabetic, time on PD before beginning of antimicrobial treatment). However, no subgroup analyses were performed due to lack of available data from the included studies.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-01-12 10:22:52 +1100" MODIFIED_BY="Narelle Willis">
<P>Sensitivity analysis was planned to investigate the effect of year of study and study performance. However, there were insufficient studies to do this.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summarising and interpreting results</HEADING>
<P>We used the GRADE approach to assess the quality of evidence for each of the key outcomes (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>). We used the GRADE profiler to create 'Summary of Findings' tables (<LINK REF="REF-Sch_x00fc_nemann-2011a" TYPE="REFERENCE">Schünemann 2011a</LINK>).</P>
<P>For assessments of the overall quality of evidence for each outcome that included pooled data from RCTs, we downgraded the evidence from 'high quality' by one level for serious study limitations and by two levels for very serious study limitations. The evidence was appraised using the five GRADE considerations: risk of bias, imprecision of effect estimates, inconsistency, indirectness and potential publication bias. None were upgraded to moderate or high quality as most pooled estimates did not reveal a large magnitude of effect, there was potential for impact by confounders, and most did not show a strong dose-response gradient (<LINK REF="REF-Sch_x00fc_nemann-2011b" TYPE="REFERENCE">Schünemann 2011b</LINK>). The exception was the pooled estimate obtained for the comparison of the use of an antifungal agent versus placebo/no treatment for preventing fungal peritonitis, but the evidence was not upgraded from 'low' because only two studies contributed data for the outcome of fungal peritonitis and one of the studies had a high risk of bias. We used these assessments and the evidence for absolute benefit or harm of the interventions and the sum of available data on all important outcomes from each study included for each comparison, to arrive at conclusions about the effectiveness of antimicrobial agents at preventing catheter-related infection or the need for catheter removal/replacement in PD patients.</P>
<P>'Summary of Findings' tables consisted of the following clinically important outcomes identified in the selected studies:</P>
<UL>
<LI>Peritonitis (number of patients with one or more episodes)</LI>
<LI>Exit-site/tunnel infection (number of patients with one or more episodes)</LI>
<LI>Catheter removal or replacement (number of patients)</LI>
<LI>Fungal peritonitis (number of patients with one or more episodes).</LI>
</UL>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-04-04 16:08:05 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY_DESCRIPTION MODIFIED="2017-04-04 16:08:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>For this update we searched the Specialised Register to 4 October 2016 and identified 48 new reports. After full-text assessment 31 new studies were identified. Twenty new studies (33 reports) were included, 10 were excluded (14 reports), and one ongoing study was identified. We also identified four new reports of four existing included studies. Search results are shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-04-04 16:08:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>We included 39 studies in the review, 19 of which had been included in the original review. Of the 20 new studies, 10 had been published since the search was done for the previous review and 10 (<LINK REF="STD-Axelrod-1973" TYPE="STUDY">Axelrod 1973</LINK>; <LINK REF="STD-Cheng-1999a" TYPE="STUDY">Cheng 1999a</LINK>; <LINK REF="STD-Cocksedge-1993" TYPE="STUDY">Cocksedge 1993</LINK>; <LINK REF="STD-Fuchs-1990" TYPE="STUDY">Fuchs 1990</LINK>; <LINK REF="STD-Moore-1989" TYPE="STUDY">Moore 1989</LINK>; <LINK REF="STD-Ryckelynck-1987" TYPE="STUDY">Ryckelynck 1987</LINK>; <LINK REF="STD-Sharma-1971" TYPE="STUDY">Sharma 1971</LINK>; <LINK REF="STD-SIPROCE-Study-1997" TYPE="STUDY">SIPROCE Study 1997</LINK>; <LINK REF="STD-Wadhwa-1995" TYPE="STUDY">Wadhwa 1995</LINK>; <LINK REF="STD-Wadhwa-1997" TYPE="STUDY">Wadhwa 1997</LINK>) had not been identified in the previous search. There was one four-arm study (<LINK REF="STD-Swartz-1991" TYPE="STUDY">Swartz 1991</LINK>), three three-arm studies (<LINK REF="STD-Fuchs-1990" TYPE="STUDY">Fuchs 1990</LINK>; <LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>; <LINK REF="STD-Sesso-1994" TYPE="STUDY">Sesso 1994</LINK>), and the remaining studies were two-arm studies. No cross-over studies were identified.</P>
<P>Of the 39 studies included (4435 randomised participants), all were parallel group studies. All participants were chronic PD patients treated in-centre or in satellite facilities. Two studies (<LINK REF="STD-Axelrod-1973" TYPE="STUDY">Axelrod 1973</LINK>; <LINK REF="STD-Sharma-1971" TYPE="STUDY">Sharma 1971</LINK>) reported the number of dialyses but not the number of participants in each group and hence, the data from these studies could not be added to the meta-analyses. Most studies included only adult patients; two studies (<LINK REF="STD-Blowey-1994" TYPE="STUDY">Blowey 1994</LINK>; <LINK REF="STD-Mendoza_x002d_Guevara-2007" TYPE="STUDY">Mendoza-Guevara 2007</LINK>) included only children and young adults on PD. Twenty-six studies (<LINK REF="STD-Bernardini-2005" TYPE="STUDY">Bernardini 2005</LINK>; <LINK REF="STD-Bernardini-1996" TYPE="STUDY">Bernardini 1996</LINK>; <LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>; <LINK REF="STD-Cocksedge-1993" TYPE="STUDY">Cocksedge 1993</LINK>; <LINK REF="STD-Fuchs-1990" TYPE="STUDY">Fuchs 1990</LINK>; <LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>; <LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK>; <LINK REF="STD-Lo-1996" TYPE="STUDY">Lo 1996</LINK>; <LINK REF="STD-Luzar-1990" TYPE="STUDY">Luzar 1990</LINK>; <LINK REF="STD-Lye-1992" TYPE="STUDY">Lye 1992</LINK>; <LINK REF="STD-MP3-Study-2008" TYPE="STUDY">MP3 Study 2008</LINK>; <LINK REF="STD-Mupirocin-Study-1996" TYPE="STUDY">Mupirocin Study 1996</LINK>; <LINK REF="STD-Nolph-1985" TYPE="STUDY">Nolph 1985</LINK>; <LINK REF="STD-Nunez_x002d_Moral-2014" TYPE="STUDY">Nunez-Moral 2014</LINK>; <LINK REF="STD-Perez_x002d_Fontan-1992" TYPE="STUDY">Perez-Fontan 1992</LINK>; <LINK REF="STD-Poole_x002d_Warren-1991" TYPE="STUDY">Poole-Warren 1991</LINK>; <LINK REF="STD-Restrepo-2010" TYPE="STUDY">Restrepo 2010</LINK>; <LINK REF="STD-Sesso-1994" TYPE="STUDY">Sesso 1994</LINK>; <LINK REF="STD-SIPROCE-Study-1997" TYPE="STUDY">SIPROCE Study 1997</LINK>; <LINK REF="STD-Swartz-1991" TYPE="STUDY">Swartz 1991</LINK>; <LINK REF="STD-Wadhwa-1995" TYPE="STUDY">Wadhwa 1995</LINK>; <LINK REF="STD-Wadhwa-1997" TYPE="STUDY">Wadhwa 1997</LINK>; <LINK REF="STD-Waite-1997" TYPE="STUDY">Waite 1997</LINK>; <LINK REF="STD-Wikdahl-1997" TYPE="STUDY">Wikdahl 1997</LINK>; <LINK REF="STD-Wong-2003" TYPE="STUDY">Wong 2003</LINK>; <LINK REF="STD-Zimmerman-1991" TYPE="STUDY">Zimmerman 1991</LINK>) identified the proportion of patients who had diabetes mellitus.</P>
<P>Most studies reported only some of the primary outcomes of interest to this review. The primary outcomes reported in the studies were as follows: peritonitis - number of patients (22 studies), peritonitis rate (14 studies), exit-site/tunnel infection - number of patients (22 studies), exit-site/tunnel infection - rate (12 studies) and catheter removal/replacement (15 studies). Other outcomes reported included death due to peritonitis (2 studies), all-cause mortality (13 studies), technique failure (3 studies) and toxicity of antimicrobial treatments (5 studies). No studies had data on peritonitis relapse and only two had time to first peritonitis episode (<LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK>; <LINK REF="STD-MP3-Study-2008" TYPE="STUDY">MP3 Study 2008</LINK>).</P>
<P>Three study authors responded to queries about study methods and/or requests for additional unpublished information (<LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>; <LINK REF="STD-Danguilan-2003" TYPE="STUDY">Danguilan 2003</LINK>; <LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Oral or topical antibiotics versus placebo/no treatment</HEADING>
<P>In seven studies (469 participants), patients were randomised to oral, or topical (exit site, nasal) or intraperitoneal prophylactic antibiotics versus placebo or no treatment (<LINK REF="STD-Blowey-1994" TYPE="STUDY">Blowey 1994</LINK>; <LINK REF="STD-Churchill-1988" TYPE="STUDY">Churchill 1988</LINK>; <LINK REF="STD-Low-1980" TYPE="STUDY">Low 1980</LINK>; <LINK REF="STD-Sesso-1994" TYPE="STUDY">Sesso 1994</LINK>; <LINK REF="STD-Swartz-1991" TYPE="STUDY">Swartz 1991</LINK>; <LINK REF="STD-Wong-2003" TYPE="STUDY">Wong 2003</LINK>; <LINK REF="STD-Zimmerman-1991" TYPE="STUDY">Zimmerman 1991</LINK>). The duration of follow-up ranged from one to 12 months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral or topical antibiotics versus other antibiotic</HEADING>
<P>Seven studies (640 participants) randomised patients to oral, or topical (exit site, nasal) or intraperitoneal antibiotics versus other antibiotics (<LINK REF="STD-Bernardini-1996" TYPE="STUDY">Bernardini 1996</LINK>; <LINK REF="STD-Bernardini-2005" TYPE="STUDY">Bernardini 2005</LINK>; <LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>; <LINK REF="STD-Danguilan-2003" TYPE="STUDY">Danguilan 2003</LINK>; <LINK REF="STD-MP3-Study-2008" TYPE="STUDY">MP3 Study 2008</LINK>; <LINK REF="STD-Perez_x002d_Fontan-1992" TYPE="STUDY">Perez-Fontan 1992</LINK>; <LINK REF="STD-Sesso-1994" TYPE="STUDY">Sesso 1994</LINK>) with follow-up ranging from 7.8 to 18 months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Nasal antibiotic prophylaxis versus placebo/no treatment</HEADING>
<P>Three studies (338 participants) compared the use of nasal prophylactic antibiotics with placebo (<LINK REF="STD-Mupirocin-Study-1996" TYPE="STUDY">Mupirocin Study 1996</LINK>; <LINK REF="STD-Sesso-1994" TYPE="STUDY">Sesso 1994</LINK>; <LINK REF="STD-Sit-2007" TYPE="STUDY">Sit 2007</LINK>). The duration of follow-up ranged from 7.8 to 18 months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pre/peri-operative antibiotic prophylaxis versus placebo/no treatment or other antibiotic</HEADING>
<P>One study (178 participants) assessed the use of vancomycin with cefazolin as perioperative intravenous prophylaxis head-to-head (<LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>), and four studies (379 patients) compared the use of perioperative intravenous antibiotic prophylaxis against no antibiotic treatment (<LINK REF="STD-Bennet_x002d_Jones-1988" TYPE="STUDY">Bennet-Jones 1988</LINK>; <LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>; <LINK REF="STD-Lye-1992" TYPE="STUDY">Lye 1992</LINK>; <LINK REF="STD-Wikdahl-1997" TYPE="STUDY">Wikdahl 1997</LINK>). Follow-up periods ranged from 10 to 28 days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant)</HEADING>
<P>Nine studies (1039 participants) evaluated the effect of topical disinfectants versus standard care or other intervention at the exit site on a range of outcomes (<LINK REF="STD-Cheng-1999a" TYPE="STUDY">Cheng 1999a</LINK>; <LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK>; <LINK REF="STD-Luzar-1990" TYPE="STUDY">Luzar 1990</LINK>; <LINK REF="STD-Mendoza_x002d_Guevara-2007" TYPE="STUDY">Mendoza-Guevara 2007</LINK>; <LINK REF="STD-Nunez_x002d_Moral-2014" TYPE="STUDY">Nunez-Moral 2014</LINK>; <LINK REF="STD-Wadhwa-1995" TYPE="STUDY">Wadhwa 1995</LINK>; <LINK REF="STD-Wadhwa-1997" TYPE="STUDY">Wadhwa 1997</LINK>; <LINK REF="STD-Waite-1997" TYPE="STUDY">Waite 1997</LINK>; <LINK REF="STD-Wilson-1997" TYPE="STUDY">Wilson 1997</LINK>). The duration of follow-up ranged from 6 to 24 months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other interventions</HEADING>
<P>Other interventions included one study (167 participants) which compared the use of an ultraviolet germicidal chamber to disinfect the spike and the solution bag outlet port versus no treatment (<LINK REF="STD-Nolph-1985" TYPE="STUDY">Nolph 1985</LINK>) while another study (50 participants) directed one group to soak their connectors in antiseptic before performing a bag exchange while the control group did not use antiseptic (<LINK REF="STD-Ryckelynck-1987" TYPE="STUDY">Ryckelynck 1987</LINK>). Three studies (140 participants) compared different dressing systems (<LINK REF="STD-Cocksedge-1993" TYPE="STUDY">Cocksedge 1993</LINK>; <LINK REF="STD-Fuchs-1990" TYPE="STUDY">Fuchs 1990</LINK>; <LINK REF="STD-Moore-1989" TYPE="STUDY">Moore 1989</LINK>) and one study (195 participants) compared the addition of a silver ring device on the catheter versus no ring (<LINK REF="STD-SIPROCE-Study-1997" TYPE="STUDY">SIPROCE Study 1997</LINK>). One study (124 participants) compared the antistaphylococcal vaccine Staphypan Berna against placebo (<LINK REF="STD-Poole_x002d_Warren-1991" TYPE="STUDY">Poole-Warren 1991</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antifungal prophylaxis versus placebo/no treatment interventions</HEADING>
<P>Two studies (817 participants) compared the administration of an antifungal agent with an antibiotic course against no treatment (<LINK REF="STD-Lo-1996" TYPE="STUDY">Lo 1996</LINK>; <LINK REF="STD-Restrepo-2010" TYPE="STUDY">Restrepo 2010</LINK>). Follow-up periods ranged from 1 to 18 months.</P>
<P>See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for comparisons included in <LINK REF="REF-Strippoli-2004a" TYPE="REFERENCE">Strippoli 2004a</LINK> and this 2017 update.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>Twelve studies (17 reports) were excluded after full text review. The characteristics of the excluded studies are shown in "Characteristics of excluded studies". Reasons for excluding studies included focus of study was about treatment of PD-related infection not prevention, report was of a pharmacokinetics study, agent used in intervention was not an antimicrobial, and PD-related infection data was not readily available in the published report.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>The assessment of risk of bias is shown in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> shows relative proportional rankings of studies for each risk of bias indicator. <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> shows the risk of bias items for individual studies. </P>
<ALLOCATION MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>Randomisation of sequence generation was judged to be at low risk of bias in 19 studies (<LINK REF="STD-Axelrod-1973" TYPE="STUDY">Axelrod 1973</LINK>; <LINK REF="STD-Bennet_x002d_Jones-1988" TYPE="STUDY">Bennet-Jones 1988</LINK>; <LINK REF="STD-Bernardini-2005" TYPE="STUDY">Bernardini 2005</LINK>; <LINK REF="STD-Churchill-1988" TYPE="STUDY">Churchill 1988</LINK>; <LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK>; <LINK REF="STD-Low-1980" TYPE="STUDY">Low 1980</LINK>; <LINK REF="STD-Luzar-1990" TYPE="STUDY">Luzar 1990</LINK>; <LINK REF="STD-Mendoza_x002d_Guevara-2007" TYPE="STUDY">Mendoza-Guevara 2007</LINK>; <LINK REF="STD-MP3-Study-2008" TYPE="STUDY">MP3 Study 2008</LINK>; <LINK REF="STD-Nolph-1985" TYPE="STUDY">Nolph 1985</LINK>; <LINK REF="STD-Nunez_x002d_Moral-2014" TYPE="STUDY">Nunez-Moral 2014</LINK>; <LINK REF="STD-Perez_x002d_Fontan-1992" TYPE="STUDY">Perez-Fontan 1992</LINK>; <LINK REF="STD-Restrepo-2010" TYPE="STUDY">Restrepo 2010</LINK>; <LINK REF="STD-SIPROCE-Study-1997" TYPE="STUDY">SIPROCE Study 1997</LINK>; <LINK REF="STD-Sit-2007" TYPE="STUDY">Sit 2007</LINK>; <LINK REF="STD-Swartz-1991" TYPE="STUDY">Swartz 1991</LINK>; <LINK REF="STD-Waite-1997" TYPE="STUDY">Waite 1997</LINK>; <LINK REF="STD-Wilson-1997" TYPE="STUDY">Wilson 1997</LINK>; <LINK REF="STD-Zimmerman-1991" TYPE="STUDY">Zimmerman 1991</LINK>). Randomisation method was unclear in 15 studies and was judged to be at high risk of bias in five studies (<LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>; <LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>; <LINK REF="STD-Lo-1996" TYPE="STUDY">Lo 1996</LINK>; <LINK REF="STD-Lye-1992" TYPE="STUDY">Lye 1992</LINK>; <LINK REF="STD-Moore-1989" TYPE="STUDY">Moore 1989</LINK>).</P>
<P>Twelve studies reported allocation concealment adequately (<LINK REF="STD-Axelrod-1973" TYPE="STUDY">Axelrod 1973</LINK>; <LINK REF="STD-Bennet_x002d_Jones-1988" TYPE="STUDY">Bennet-Jones 1988</LINK>; <LINK REF="STD-Bernardini-2005" TYPE="STUDY">Bernardini 2005</LINK>; <LINK REF="STD-Churchill-1988" TYPE="STUDY">Churchill 1988</LINK>; <LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK>; <LINK REF="STD-Low-1980" TYPE="STUDY">Low 1980</LINK>; <LINK REF="STD-Luzar-1990" TYPE="STUDY">Luzar 1990</LINK>; <LINK REF="STD-MP3-Study-2008" TYPE="STUDY">MP3 Study 2008</LINK>; <LINK REF="STD-Nolph-1985" TYPE="STUDY">Nolph 1985</LINK>; <LINK REF="STD-Poole_x002d_Warren-1991" TYPE="STUDY">Poole-Warren 1991</LINK>; <LINK REF="STD-Sharma-1971" TYPE="STUDY">Sharma 1971</LINK>; <LINK REF="STD-SIPROCE-Study-1997" TYPE="STUDY">SIPROCE Study 1997</LINK>). Allocation concealment was unclear in 21 studies and six studies were judged to be at high risk of bias (<LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>; <LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>; <LINK REF="STD-Lo-1996" TYPE="STUDY">Lo 1996</LINK>; <LINK REF="STD-Lye-1992" TYPE="STUDY">Lye 1992</LINK>; <LINK REF="STD-Moore-1989" TYPE="STUDY">Moore 1989</LINK>; <LINK REF="STD-Wikdahl-1997" TYPE="STUDY">Wikdahl 1997</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2017-01-09 12:45:53 +1100" MODIFIED_BY="Narelle Willis">
<P>Performance bias (blinding of participants and investigators) was judged to be at low risk of bias in eight studies (<LINK REF="STD-Axelrod-1973" TYPE="STUDY">Axelrod 1973</LINK>; <LINK REF="STD-Bennet_x002d_Jones-1988" TYPE="STUDY">Bennet-Jones 1988</LINK>; <LINK REF="STD-Bernardini-2005" TYPE="STUDY">Bernardini 2005</LINK>; <LINK REF="STD-Churchill-1988" TYPE="STUDY">Churchill 1988</LINK>; <LINK REF="STD-Low-1980" TYPE="STUDY">Low 1980</LINK>; <LINK REF="STD-MP3-Study-2008" TYPE="STUDY">MP3 Study 2008</LINK>; <LINK REF="STD-Poole_x002d_Warren-1991" TYPE="STUDY">Poole-Warren 1991</LINK>; <LINK REF="STD-Sharma-1971" TYPE="STUDY">Sharma 1971</LINK>), was unclear in 15 studies, and was judged to be a high risk of bias in 16 studies (<LINK REF="STD-Bernardini-1996" TYPE="STUDY">Bernardini 1996</LINK>; <LINK REF="STD-Blowey-1994" TYPE="STUDY">Blowey 1994</LINK>; <LINK REF="STD-Cheng-1999a" TYPE="STUDY">Cheng 1999a</LINK>; <LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>; <LINK REF="STD-Cocksedge-1993" TYPE="STUDY">Cocksedge 1993</LINK>; <LINK REF="STD-Danguilan-2003" TYPE="STUDY">Danguilan 2003</LINK>; <LINK REF="STD-Fuchs-1990" TYPE="STUDY">Fuchs 1990</LINK>; <LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>; <LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK>; <LINK REF="STD-Lo-1996" TYPE="STUDY">Lo 1996</LINK>; <LINK REF="STD-Luzar-1990" TYPE="STUDY">Luzar 1990</LINK>; <LINK REF="STD-Lye-1992" TYPE="STUDY">Lye 1992</LINK>; <LINK REF="STD-Moore-1989" TYPE="STUDY">Moore 1989</LINK>; <LINK REF="STD-Nolph-1985" TYPE="STUDY">Nolph 1985</LINK>; <LINK REF="STD-SIPROCE-Study-1997" TYPE="STUDY">SIPROCE Study 1997</LINK>; <LINK REF="STD-Zimmerman-1991" TYPE="STUDY">Zimmerman 1991</LINK>).</P>
<P>Detection bias (blinding of outcome assessors) was judged to be at low risk of bias in 10 studies (<LINK REF="STD-Axelrod-1973" TYPE="STUDY">Axelrod 1973</LINK>; <LINK REF="STD-Bennet_x002d_Jones-1988" TYPE="STUDY">Bennet-Jones 1988</LINK>; <LINK REF="STD-Bernardini-2005" TYPE="STUDY">Bernardini 2005</LINK>; <LINK REF="STD-Churchill-1988" TYPE="STUDY">Churchill 1988</LINK>; <LINK REF="STD-Low-1980" TYPE="STUDY">Low 1980</LINK>; <LINK REF="STD-Mendoza_x002d_Guevara-2007" TYPE="STUDY">Mendoza-Guevara 2007</LINK>; <LINK REF="STD-MP3-Study-2008" TYPE="STUDY">MP3 Study 2008</LINK>; <LINK REF="STD-Poole_x002d_Warren-1991" TYPE="STUDY">Poole-Warren 1991</LINK>; <LINK REF="STD-Sharma-1971" TYPE="STUDY">Sharma 1971</LINK>; <LINK REF="STD-Waite-1997" TYPE="STUDY">Waite 1997</LINK>), was unclear in 13 studies, and was judged to be at high risk of bias in 16 studies (<LINK REF="STD-Bernardini-1996" TYPE="STUDY">Bernardini 1996</LINK>; <LINK REF="STD-Blowey-1994" TYPE="STUDY">Blowey 1994</LINK>; <LINK REF="STD-Cheng-1999a" TYPE="STUDY">Cheng 1999a</LINK>; <LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>; <LINK REF="STD-Cocksedge-1993" TYPE="STUDY">Cocksedge 1993</LINK>; <LINK REF="STD-Danguilan-2003" TYPE="STUDY">Danguilan 2003</LINK>; <LINK REF="STD-Fuchs-1990" TYPE="STUDY">Fuchs 1990</LINK>; <LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>; <LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK>; <LINK REF="STD-Lo-1996" TYPE="STUDY">Lo 1996</LINK>; <LINK REF="STD-Luzar-1990" TYPE="STUDY">Luzar 1990</LINK>; <LINK REF="STD-Lye-1992" TYPE="STUDY">Lye 1992</LINK>; <LINK REF="STD-Moore-1989" TYPE="STUDY">Moore 1989</LINK>; <LINK REF="STD-Nolph-1985" TYPE="STUDY">Nolph 1985</LINK>; <LINK REF="STD-SIPROCE-Study-1997" TYPE="STUDY">SIPROCE Study 1997</LINK>; <LINK REF="STD-Zimmerman-1991" TYPE="STUDY">Zimmerman 1991</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-01-09 12:47:05 +1100" MODIFIED_BY="Narelle Willis">
<P>Outcomes data reporting was considered to be complete with a low risk of bias in 22 studies (<LINK REF="STD-Bennet_x002d_Jones-1988" TYPE="STUDY">Bennet-Jones 1988</LINK>; <LINK REF="STD-Bernardini-1996" TYPE="STUDY">Bernardini 1996</LINK>; <LINK REF="STD-Bernardini-2005" TYPE="STUDY">Bernardini 2005</LINK>; <LINK REF="STD-Blowey-1994" TYPE="STUDY">Blowey 1994</LINK>; <LINK REF="STD-Churchill-1988" TYPE="STUDY">Churchill 1988</LINK>; <LINK REF="STD-Fuchs-1990" TYPE="STUDY">Fuchs 1990</LINK>; <LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>; <LINK REF="STD-Lo-1996" TYPE="STUDY">Lo 1996</LINK>; <LINK REF="STD-Low-1980" TYPE="STUDY">Low 1980</LINK>; <LINK REF="STD-Luzar-1990" TYPE="STUDY">Luzar 1990</LINK>; <LINK REF="STD-Lye-1992" TYPE="STUDY">Lye 1992</LINK>; <LINK REF="STD-MP3-Study-2008" TYPE="STUDY">MP3 Study 2008</LINK>; <LINK REF="STD-Mupirocin-Study-1996" TYPE="STUDY">Mupirocin Study 1996</LINK>; <LINK REF="STD-Nunez_x002d_Moral-2014" TYPE="STUDY">Nunez-Moral 2014</LINK>; <LINK REF="STD-Perez_x002d_Fontan-1992" TYPE="STUDY">Perez-Fontan 1992</LINK>; <LINK REF="STD-Poole_x002d_Warren-1991" TYPE="STUDY">Poole-Warren 1991</LINK>; <LINK REF="STD-Sit-2007" TYPE="STUDY">Sit 2007</LINK>; <LINK REF="STD-Swartz-1991" TYPE="STUDY">Swartz 1991</LINK>; <LINK REF="STD-Waite-1997" TYPE="STUDY">Waite 1997</LINK>; <LINK REF="STD-Wikdahl-1997" TYPE="STUDY">Wikdahl 1997</LINK>; <LINK REF="STD-Wilson-1997" TYPE="STUDY">Wilson 1997</LINK>; <LINK REF="STD-Wong-2003" TYPE="STUDY">Wong 2003</LINK>). Eight studies (<LINK REF="STD-Axelrod-1973" TYPE="STUDY">Axelrod 1973</LINK>; <LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>; <LINK REF="STD-Danguilan-2003" TYPE="STUDY">Danguilan 2003</LINK>; <LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK>; <LINK REF="STD-Nolph-1985" TYPE="STUDY">Nolph 1985</LINK>; <LINK REF="STD-Sesso-1994" TYPE="STUDY">Sesso 1994</LINK>; <LINK REF="STD-SIPROCE-Study-1997" TYPE="STUDY">SIPROCE Study 1997</LINK>; <LINK REF="STD-Zimmerman-1991" TYPE="STUDY">Zimmerman 1991</LINK>) reported that from 9.2% to 77.7% of patients were excluded from analyses, so were considered to be at high risk of bias. The risk of bias was unclear in nine studies because there was insufficient information provided to determine if data from all patients who entered the study were included in the analysis.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>We identified 12 studies (<LINK REF="STD-Bernardini-2005" TYPE="STUDY">Bernardini 2005</LINK>; <LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK>; <LINK REF="STD-Lye-1992" TYPE="STUDY">Lye 1992</LINK>; <LINK REF="STD-MP3-Study-2008" TYPE="STUDY">MP3 Study 2008</LINK>; <LINK REF="STD-Mupirocin-Study-1996" TYPE="STUDY">Mupirocin Study 1996</LINK>; <LINK REF="STD-Poole_x002d_Warren-1991" TYPE="STUDY">Poole-Warren 1991</LINK>; <LINK REF="STD-Sesso-1994" TYPE="STUDY">Sesso 1994</LINK>; <LINK REF="STD-SIPROCE-Study-1997" TYPE="STUDY">SIPROCE Study 1997</LINK>; <LINK REF="STD-Wadhwa-1995" TYPE="STUDY">Wadhwa 1995</LINK>; <LINK REF="STD-Wadhwa-1997" TYPE="STUDY">Wadhwa 1997</LINK>; <LINK REF="STD-Wilson-1997" TYPE="STUDY">Wilson 1997</LINK>; <LINK REF="STD-Wong-2003" TYPE="STUDY">Wong 2003</LINK>) and reported all outcomes based on the protocols described in the study methods and could be meta-analysed. Twelve studies were judged to be at high risk of bias of reporting bias (<LINK REF="STD-Axelrod-1973" TYPE="STUDY">Axelrod 1973</LINK>; <LINK REF="STD-Bennet_x002d_Jones-1988" TYPE="STUDY">Bennet-Jones 1988</LINK>; <LINK REF="STD-Churchill-1988" TYPE="STUDY">Churchill 1988</LINK>; <LINK REF="STD-Cocksedge-1993" TYPE="STUDY">Cocksedge 1993</LINK>; <LINK REF="STD-Fuchs-1990" TYPE="STUDY">Fuchs 1990</LINK>; <LINK REF="STD-Lo-1996" TYPE="STUDY">Lo 1996</LINK>; <LINK REF="STD-Mendoza_x002d_Guevara-2007" TYPE="STUDY">Mendoza-Guevara 2007</LINK>; <LINK REF="STD-Moore-1989" TYPE="STUDY">Moore 1989</LINK>; <LINK REF="STD-Nolph-1985" TYPE="STUDY">Nolph 1985</LINK>; <LINK REF="STD-Ryckelynck-1987" TYPE="STUDY">Ryckelynck 1987</LINK>; <LINK REF="STD-Sharma-1971" TYPE="STUDY">Sharma 1971</LINK>; <LINK REF="STD-Swartz-1991" TYPE="STUDY">Swartz 1991</LINK>) because only one our primary outcomes cold be meta-analysed; two studies reported outcomes incompletely so they could not be included in any of our meta-analyses (<LINK REF="STD-Axelrod-1973" TYPE="STUDY">Axelrod 1973</LINK>; <LINK REF="STD-Sharma-1971" TYPE="STUDY">Sharma 1971</LINK>). Reporting bias was unclear for 15 studies because only two (of our three) primary outcomes were reported or could be meta-analysed.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-01-09 13:49:49 +1100" MODIFIED_BY="Narelle Willis">
<P>Eight studies (<LINK REF="STD-Axelrod-1973" TYPE="STUDY">Axelrod 1973</LINK>; <LINK REF="STD-Churchill-1988" TYPE="STUDY">Churchill 1988</LINK>; <LINK REF="STD-Luzar-1990" TYPE="STUDY">Luzar 1990</LINK>; <LINK REF="STD-Mupirocin-Study-1996" TYPE="STUDY">Mupirocin Study 1996</LINK>; <LINK REF="STD-Nolph-1985" TYPE="STUDY">Nolph 1985</LINK>; <LINK REF="STD-Poole_x002d_Warren-1991" TYPE="STUDY">Poole-Warren 1991</LINK>; <LINK REF="STD-SIPROCE-Study-1997" TYPE="STUDY">SIPROCE Study 1997</LINK>; <LINK REF="STD-Waite-1997" TYPE="STUDY">Waite 1997</LINK>; <LINK REF="STD-Zimmerman-1991" TYPE="STUDY">Zimmerman 1991</LINK>) reported receiving monetary support from pharmaceutical companies; one study received combined funding from industry and government (<LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK>) and was judged to at unclear risk of bias. Four studies were judged to be at low risk bias (<LINK REF="STD-Bernardini-2005" TYPE="STUDY">Bernardini 2005</LINK>; <LINK REF="STD-Low-1980" TYPE="STUDY">Low 1980</LINK>; <LINK REF="STD-MP3-Study-2008" TYPE="STUDY">MP3 Study 2008</LINK>; <LINK REF="STD-Sesso-1994" TYPE="STUDY">Sesso 1994</LINK>) and the remaining 26 studies were judged unclear.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>See: <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>: Oral or topical or intraperitoneal antibiotics versus placebo/no treatment for preventing peritonitis in PD patients; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>: Nasal antibiotics versus no treatment for preventing peritonitis in PD patients; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>: Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant) for preventing peritonitis in PD patients; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>: Antifungal versus placebo/no treatment for preventing fungal peritonitis in PD patients.</P>
<P>In most studies, the primary outcomes were peritonitis (number of patients), peritonitis rate, exit-site/tunnel infection (number of patients), exit-site/tunnel infection rate, and catheter removal or replacement (number). Many studies only included one or two of these outcomes. Other outcomes included all-cause mortality, time to first catheter-related infection, hospitalisation, death due to catheter-related infection, technique failure, local pruritus/rash, and toxicity.</P>
<SUBSECTION>
<HEADING LEVEL="3">Oral or topical antibiotics versus placebo or no treatment</HEADING>
<P>The oral antibiotic used was ofloxacin, cephalexin, rifampin or cotrimoxazole, and the topical antibiotic used was mupirocin ointment (exit site, nasal).</P>
<P>The use of oral or topical antibiotic prophylaxis had uncertain effects on the risk of peritonitis (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (5 studies, 395 participants): RR 0.82, 95% CI 0.57 to 1.19). There was low to moderate heterogeneity across these studies (I<SUP>2</SUP> = 33%). The risk of peritonitis outcome was assessed as low quality because of unclear or high risk of bias in 3 of 5 studies and because of wide confidence intervals in all 5 studies due to small patient numbers.</P>
<P>The two interventions also had uncertain effects on the peritonitis rate (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.1 (3 studies, 1440 patient-months): RR 0.68, 95% CI 0.40 to 1.14), the risk of exit-site and tunnel infection (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.1 (3 studies, 191 participants): RR 0.45, 95% CI 0.19 to 1.04), exit-site/tunnel infection rate (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.1 (2 studies, 939 patient-months): RR 0.42, 95% CI 0.17 to 1.05), risk of catheter removal or replacement (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.1 (5 studies, 395 participants): RR 0.82, 95% CI 0.46 to 1.46), and all-cause mortality (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>.1 (4 studies, 201 participants): RR 0.88, 95% CI 0.41 to 1.89), with no significant heterogeneity across studies for any of these analyses (I<SUP>2</SUP> = 0%).</P>
<P>The risk of exit-site/tunnel infection outcome was assessed as low quality because of unclear or high risk of bias in all 3 studies and because of wide confidence intervals in all 3 studies due to small patient numbers. The risk of catheter removal/replacement outcome was also assessed as low quality because of unclear or high risk of bias in 3 of 5 studies and because of wide confidence intervals in all 5 studies due to small patient numbers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral or topical antibiotics versus other antibiotic</HEADING>
<P>The use of antibiotic ointment prophylaxis (either sodium fusidate (exit site plus nasal) or mupirocin (exit site)) was compared with another antibiotic (oral ofloxacin, oral rifampin or gentamicin cream (exit site)) in four studies.</P>
<P>The interventions had uncertain effects on the risk of peritonitis (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> (4 studies, 314 participants): RR 1.28, 95% CI 0.89 to 1.84). There was low heterogeneity across these studies (I<SUP>2</SUP> = 9%). Similarly, topical antibiotic prophylaxis (either mupirocin ointment (exit site), sodium fusidate ointment (exit site plus nasal) or mupirocin cream (exit site)) compared with other antibiotic (either sodium fusidate ointment (exit site), oral ofloxacin or gentamicin cream (exit site)) had uncertain effects on the risk of exit-site and tunnel infection (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK> (4 studies, 336 participants): RR 1.28, 95% CI 0.71 to 2.31). There was medium heterogeneity across these studies (I<SUP>2</SUP> = 56%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Nasal antibiotic prophylaxis versus placebo or no treatment</HEADING>
<P>The use of nasal antibiotic prophylaxis had uncertain effects on the risk of peritonitis (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> (3 studies, 338 participants): RR 0.94, 95% CI 0.67 to 1.31), the peritonitis rate (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> (2 studies, 2797 patient-months): RR 0.67, 95% CI 0.16 to 2.77), the risk of exit-site and tunnel infection (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK> (3 studies, 338 participants): RR 1.34, 95% CI 0.62 to 2.87), the exit-site and tunnel infection rate (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK> (2 studies, 2796 patient-months): RR 0.91, 95% CI 0.29 to 2.92), and the number of patients with catheter removal or replacement (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK> (2 studies, 289 participants): RR 0.92, 95% CI 0.48 to 1.78). There was no significant heterogeneity across the studies for any of these analyses. Although in 1 study, there was a significant reduction in the exit-site/tunnel infection rate when CAPD patients identified as <I>S. aureus</I> carriers (nasal) were treated with mupirocin ointment (nasal application, twice/day for 5 days, every 1 month), there were no significant differences with any of the other primary outcomes of interest (<LINK REF="STD-Mupirocin-Study-1996" TYPE="STUDY">Mupirocin Study 1996</LINK>).</P>
<P>The risk of peritonitis and the risk of exit-site/tunnel infection outcomes were assessed as low quality because of unclear or high risk of bias in all 3 studies and because of wide confidence intervals in all 3 studies due to small patient numbers. The risk of catheter removal/replacement was assessed as low quality because of unclear to high risk of bias in the 2 studies and because of wide confidence intervals in the 2 studies due to small patient numbers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pre- or peri-operative antibiotic prophylaxis versus placebo or no treatment or other antibiotic</HEADING>
<P>Pre- or peri-operative intravenous antibiotic prophylaxis compared with no treatment may reduce the risk of early peritonitis (less than one month from catheter insertion) in one study (<LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>) but there was no difference between the interventions in three other studies using different antibiotics (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK> (4 studies, 379 participants). The single 3-arm study (<LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>) compared vancomycin with placebo, cefazolin with placebo and vancomycin with cefazolin and found the risk of peritonitis was reduced by vancomycin compared with placebo (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>.1 (1 study, 177 participants): RR 0.08. 95% CI 0.01 to 0.61) and by vancomycin compared with cefazolin (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>.6 (1 study, 178 participants): RR 0.11, 95% CI 0.01 to 0.84); there was no difference between cefazolin compared with placebo. None of the antibiotic interventions made a difference to the risk of exit-site and tunnel infection (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK> (4 studies, 379 participants). When outcomes at more than one month after catheter insertion were considered, there was no difference between the interventions for the risk of peritonitis or exit-site/tunnel infection.</P>
<P>Because each study used a different antibiotic intervention, it is not possible to comment on heterogeneity across the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant)</HEADING>
<P>Eight studies reported on the use of disinfectant at the exit site versus standard care or other active treatment. As the test for subgroup differences was not significant for any of our outcomes the total summary estimates are reported here.</P>
<P>Overall topical disinfectants versus standard care or other active treatment had uncertain effects on the risk of peritonitis (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK> (6 studies, 853 participants): RR 0.83, 95% CI 0.65 to 1.06). exit-site/tunnel infection (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK> (8 studies, 973 participants): RR 1.00, 95% CI 0.75 to 1.33), catheter removal or replacement (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK> (7 studies, 852 participants): RR 0.89, 95% CI 0.57 to 1.38), and all-cause mortality (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK> (4 studies, 697 participants): RR 0.88, 95% CI 0.53 to 1.44), with no significant heterogeneity across studies for any of these analyses.</P>
<P>The risk of peritonitis outcome was assessed as low quality because of unclear allocation concealment and blinding in four of six studies and imprecision due to the small number of patients and events in five of six studies. The risk of exit-site/tunnel infection outcome was assessed as low quality because of unclear allocation concealment and blinding in six of eight studies and imprecision due to the small number of patients and events in seven of eight studies. The risk of catheter removal/replacement outcome was assessed as low quality because of unclear allocation concealment and blinding in five of seven studies and imprecision due to the small number of patients and events in six of seven studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other interventions</HEADING>
<P>Seven studies reported on other interventions designed to reduce PD-related infections. There was no difference in the peritonitis rate with other interventions.</P>
<UL>
<LI>Germicidal chamber for connection devices or soaking of the connector in antiseptic prior to bag exchange versus none (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK> (2 studies, 1855 patient-months): RR 1.05, 95% CI 0.74 to 1.51)</LI>
<LI>Staphypan Berna antistaphylococcal vaccine (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK> (1 study, 1099 patient-months): RR 1.11, 95% CI 0.77 to 1.59). Staphypan Berna compared with placebo was also shown to make no difference to the exit-site and tunnel infection rate (<LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK> (1 study, 1107 patient-months): RR 0.98, 95% CI 0.65 to 1.48).</LI>
</UL>
<P>Three studies (140 participants) reported on the use of different dressing systems. There was no difference between the comparisons for the number of patients with one or more episodes of exit-site/tunnel infection (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>) or the exit-site/tunnel infection rate (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK> (1 study, 679 patient-months).</P>
<P>There was no difference between use of a silver ring on the PD catheter versus none for the risk of peritonitis (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK> (1 study, 195 participants): RR 0.90, 95% CI 0.49 to 1.66), risk of exit-site/tunnel infection (<LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK> (1 study, 195 participants): RR 1.26, 95% CI 0.84 to 1.90) or risk of catheter removal/replacement (<LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK> (1 study, 195 participants): RR 1.26, 95% CI 0.35 to 4.56).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antifungal prophylaxis versus placebo or no treatment</HEADING>
<P>The use of antifungal agents (oral fluconazole or oral nystatin) compared with no antifungal agent being given when a patient receives a course of antibiotics for bacterial peritonitis were reported in 2 studies. The antifungal intervention may reduce the risk of fungal peritonitis (<LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK> (2 studies, 817 participants): RR 0.28, 95% CI 0.12 to 0.63). There was low heterogeneity across the two studies for this analysis. The risk of fungal peritonitis outcome was assessed as low quality because of unclear risk of bias in 1 study and high risk of bias in 1 study and imprecision due to the small number of events and patient numbers. One study of oral nystatin in PD patients who were receiving treatment for bacterial peritonitis showed a significant reduction in the rate of fungal peritonitis due to <I>Candida</I> spp. with nystatin prophylaxis (<LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK> (1 study, 6864 patient-months): RR 0.31, 95% CI 0.10 to 0.95).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>For the comparisons which included oral or topical antibiotics versus placebo/no treatment, two studies (86 participants) provided some information on adverse effects of therapy. They were reported in relation to the use of oral rifampin and sodium fusidate ointment (nasal and exit site). More patients reported adverse effects with oral rifampin therapy but the results did not achieve significance. Heterogeneity could not be determined (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
<P>For the studies which included oral or topical antibiotics versus other antibiotic, three studies (419 participants) reported on adverse effects of therapy. The antibiotics used were applied daily/routinely to the exit site and included Polysporin triple ointment, gentamicin cream and cyclic oral rifampin against mupirocin ointment or cream. There were fewer patients who reported adverse effects with mupirocin but the result was not significantly different; nausea (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>.1 (1 study, 82 participants): RR 0.09, 95% CI 0.01 to 1.59); pruritus (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>.2 (2 studies, 337 participants): RR 0.65, 95% CI 0.29 to 1.49).</P>
<P>Three studies (289 participants) compared nasal antibiotics against placebo/no treatment and two of them reported information on adverse effects of therapy. The antibiotics used included mupirocin ointment (nasal) and sodium fusidate ointment (nasal and exit site) versus placebo ointment (nasal) or placebo tablets. More patients reported adverse effects with the antibiotic treatments (headache, diarrhoea, nausea, vomiting, pruritus, nasal irritation/rhinitis) but the results did not achieve significance. Heterogeneity could not be determined (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>).</P>
<P>For the studies which included topical disinfectant versus standard care or other active treatment at the exit site, four studies reported on adverse effects of therapy. The interventions that these reports related to were sodium hypochlorite solution, antibacterial honey and povidone iodine dry powder spray against povidone iodine solution, mupirocin ointment (nasal) or alcohol wipes. More patients reported adverse effects with use of the former agents and a statistically significant increase in pruritus occurred with topical disinfectants versus standard care (<LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK> (4 studies, 609 participants): RR 2.80, 95% CI 1.21 to 6.48; I<SUP>2</SUP> = 44%). There was low heterogeneity of results.</P>
<P>Antibiotic resistance was not adequately reported in the included studies (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes sought but not reported</HEADING>
<P>Very few studies reported on peritonitis relapse, development of antibiotic resistance (topical use), hospitalisation due to PD-related infections or peritonitis, time to first peritonitis episode, technique failure (transfer from PD to haemodialysis/transplant due to peritonitis), or death due to peritonitis.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<SUMMARY_OF_RESULTS MODIFIED="2017-01-12 12:09:02 +1100" MODIFIED_BY="Narelle Willis">
<P>We identified 39 studies that compared antimicrobial agents with placebo/no treatment or other antimicrobial agent or standard care in CKD patients on PD. A range of antimicrobial agents were found and studies using antibiotic prophylaxis showed wide variability regarding the dose and duration of the interventions trialled. The duration of studies ranged from 1 month to 8 years. The quality of the evidence for all of the findings listed below was low.</P>
<P>Key findings are as follows.</P>
<UL>
<LI>The use of oral or topical antibiotic had uncertain effects on the risk of exit-site/tunnel infection and the risk of peritonitis.</LI>
<LI>The topical administration of antibiotic ointment to the anterior nares of PD patients (sodium fusidate or mupirocin ointment) had uncertain effects on the risk of exit-site/tunnel infection and the risk of peritonitis.</LI>
<LI>Pre/peri-operative intravenous vancomycin may reduce the risk of early peritonitis in the first few weeks (&lt; 1 month) following Tenckhoff catheter insertion but has an uncertain effect on the risk of exit-site/tunnel infection. The comparisons using other antibiotics (i.e. IV gentamicin; IV cefazolin plus gentamicin; IV cefuroxime plus cefuroxime intraperitoneal) did not reduce the risk of peritonitis or exit-site/tunnel infection.</LI>
<LI>The use of topical disinfectant had uncertain effects on the risk of exit-site/tunnel infection and the risk of peritonitis.</LI>
<LI>Oral antifungal prophylaxis (fluconazole or nystatin) with each antibiotic course given to a PD patient may reduce the risk of fungal peritonitis.</LI>
<LI>No intervention reduced the risk of catheter removal or replacement.</LI>
</UL>
<P>Oral or topical antibiotics versus placebo/no treatment, oral or topical antibiotics versus other antibiotic, nasal antibiotics versus placebo/no treatment, pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, topical disinfectants versus standard care or other active treatment, germicidal chamber versus none, or silver ring system on catheter versus none had an effect on all-cause mortality. Neither oral or topical antibiotics versus other antibiotic nor topical disinfectants versus standard care or other active treatment had an effect on the risk of technique failure.</P>
<P>Heterogeneity among the studies was low except for the interventions oral or topical antibiotics versus placebo/no treatment and oral or topical antibiotics versus other antibiotic. Heterogeneity in the former comparison for the risk of peritonitis was 33% and was likely related to the variety of antibiotics used, the frequency of administration (daily, monthly, every three months), the route of administration (oral, topical) and the population studied (adults in Brazil, Canada, USA, Hong Kong). Heterogeneity in the latter comparison for the risk of exit-site/tunnel infection was 56% and was probably related to the range of antibiotics used, the frequency of administration (twice daily, daily, every 2 days, weekly), the route of administration (oral, topical) and the population studied (adults in the Philippines, Brazil, Hong Kong, USA).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-01-12 12:09:23 +1100" MODIFIED_BY="Narelle Willis">
<P>Twelve studies reported all three primary outcomes of interest and could be meta-analysed (peritonitis, exit-site/tunnel infection, catheter removal/replacement), 15 studies reported two primary outcomes of interest, and 12 studies reported on one primary outcome of interest; two studies reported all primary outcomes in a way that could not be meta-analysed (<LINK REF="STD-Axelrod-1973" TYPE="STUDY">Axelrod 1973</LINK>; <LINK REF="STD-Sharma-1971" TYPE="STUDY">Sharma 1971</LINK>). Our meta-analyses identified that use of oral or topical antibiotics had uncertain effects on the risk of exit-site/tunnel infection and the risk of peritonitis and did not appear to affect the exit-site/tunnel infection rate, peritonitis rate, or the risk of catheter removal/replacement. It is unclear if the use of nasal mupirocin in identified nasal carriers of <I>S. aureus</I> reduces the risk of exit-site/tunnel infection or peritonitis. The use of pre/peri-operative IV antibiotics at PD catheter insertion may reduce the occurrence of early peritonitis (within 1 month of insertion) with vancomycin being the most effective antibiotic to use. The RR of 0.08 for the outcome of early peritonitis could be classified as clinically important, should it be confirmed with future studies. The use of topical disinfectant had uncertain effects on the risk of exit-site/tunnel infection and the risk of peritonitis. The co-administration of antifungal agents with an antibiotic course appears to reduce the risk of fungal peritonitis developing in a PD patient. The risk ratio of 0.28 for the outcome of fungal peritonitis could prove to be clinically important, should it be confirmed with future studies.</P>
<P>No RCT was found which had the comparison of routine courses of intranasal mupirocin versus daily exit-site mupirocin. Likewise, no RCT was found which compared <I>S. aureus</I> nasal carriage eradication at the time of PD catheter insertion versus no eradication of <I>S. aureus </I>nasal carriage. In addition, some outcomes were either not addressed (development of antibiotic resistance with topical use) or not often addressed (peritonitis relapse, hospitalisation rates due to PD-related infections or peritonitis, technique failure due to peritonitis). It should also be mentioned that for most comparisons there are only a few studies and small numbers of patients.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>Our review included 39 studies that involved 4374 patients; all were either on PD (CAPD, CCPD or APD) or were having surgery to insert the Tenckhoff catheter prior to commencing PD. Two studies had paediatric populations, two studies had a mix of adults and children, with the remainder having only adult patients. We found the quality of evidence for all outcomes to be of low quality mainly due to unclear or high risk of bias in a majority of studies and imprecise results because of small patient numbers and events. This means that further research is likely to have an important impact on our confidence in the estimates of effect and is likely to change those estimates.</P>
<P>Of the 39 included studies, four were available only as abstracts; 19 reported adequate sequence generation, and 12 had adequate allocation concealment. Hence, allocation concealment was either unclear or inadequate in two-thirds of the studies. Studies that do not have adequate allocation concealment are felt to be at increased risk of bias (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Eight studies reported adequate blinding of patients and personnel, and 10 studies reported adequate blinding of outcome assessment. Therefore, blinding methodology was either unclear or inadequate in three-quarters of the studies. We found that 22 studies provided complete data reporting, and 12 reported all primary outcomes. Seven studies reported receiving some form of sponsorship from pharmaceutical companies, four studies reported complete or partial funding from an institute or government organisation, one study received funding from both pharmaceutical and a government organisation, and 27 studies did not report any funding source. In this review, we did not observe a difference between studies that were sponsored by pharmaceutical companies and those that were not. Of the eight pharma-sponsored/pharma plus government funded studies, five had adequate allocation concealment; of the four studies with partial or full funding from an institute/government organisation, three reported adequate allocation concealment; and of the 27 studies that did not report a funding source, only four demonstrated adequate allocation concealment. Likewise, in terms of selective outcome reporting, two of the eight pharma-sponsored/pharma plus government funded studies reported all of our primary outcomes; three of the four institute/ government-sponsored studies reported all our primary outcomes; and seven of the 27 studies without a declared funding source included all our primary outcomes.</P>
<P>For the comparison of oral or topical antibiotics versus placebo/no treatment, the variable quality of relevant studies and the small patient numbers, meant the quality of evidence was rated as low for the outcomes of peritonitis, exit-site/tunnel infection and catheter removal/replacement (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). For the comparison of nasal antibiotics versus placebo/no treatment, the variable quality of relevant studies and the small patient numbers, reduced the quality of evidence to low for the outcomes of peritonitis, exit-site/tunnel infection and catheter removal/replacement (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). With the comparison of topical disinfectants versus standard care or other active treatment, the unclear allocation in several studies and imprecision due to small patient numbers and events in several studies, meant the quality of evidence was rated as low for the outcomes of peritonitis, exit-site/tunnel infection and catheter removal/replacement (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<P>With the comparison of antifungal prophylaxis versus placebo/no treatment, the quality of evidence for the outcome of fungal peritonitis was considered to be low because of high risk of bias in one study and modest patient numbers and the limited number of studies reporting this outcome (<LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-01-12 12:28:17 +1100" MODIFIED_BY="Narelle Willis">
<P>Four of the 39 included studies were available only as abstracts but this was not considered a major source of bias. Since the original version of this review was published, the literature search has been run several times (up to 4 October 2016), to increase the chance that all eligible studies published before that time have been included. Although the Cochrane Kidney and Transplant Specialised Register includes references of reports of studies identified by handsearching resources including conference proceedings, it is a possibility that relevant studies may have been added since our last search of the register. Some outcomes were reported in only a few studies, which increased the risk of the non-randomised selection of patients for the intervention or control group in a study. For example, the outcome of fungal peritonitis was reported in two studies (817 patients), with one study finding a significant difference between the fungal prophylaxis and control groups, while the second study did not have this finding. In addition, adverse effects were reported in only five studies.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-01-12 12:34:18 +1100" MODIFIED_BY="Narelle Willis">
<P>A systematic review was performed as part of the <LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK> and was published in 2014 (<LINK REF="REF-Johnson-2014" TYPE="REFERENCE">Johnson 2014</LINK>). The authors systematically reviewed studies of topical antimicrobial prophylaxis for prevention of infections in PD. Nine studies were identified using a search strategy that included electronic searches of MEDLINE (through Ovid) and the Cochrane Central Register of Controlled Trials. Our review included all of the studies included by <LINK REF="REF-Johnson-2014" TYPE="REFERENCE">Johnson 2014</LINK>, as well as two studies not reported in that review (<LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>; <LINK REF="STD-Danguilan-2003" TYPE="STUDY">Danguilan 2003</LINK>). This review concluded that the evidence from the nine studies was inconclusive for nasal mupirocin, exit-site mupirocin and exit-site gentamicin prophylaxis. In the present review, we reached a similar conclusion, with some individual studies making a significant difference to the risk of exit-site/tunnel infection or the exit-site/tunnel infection rate but not having an effect on the other outcomes of peritonitis, catheter removal/replacement and technique failure.</P>
<P>The Renal Association (UK) guidelines currently recommend that "topical antibiotic administration be used to reduce the frequency of <I>S. aureus</I> and Gram-negative exit-site infection and peritonitis" (<LINK REF="REF-Woodrow-2010" TYPE="REFERENCE">Woodrow 2010</LINK>). The suggested antibiotics are mupirocin ointment or gentamicin cream (the latter for patients with a known history of <I>Pseudomonas</I> infections). The ISPD position statement on exit-site care to prevent peritonitis (<LINK REF="REF-Piraino-2011" TYPE="REFERENCE">Piraino 2011</LINK>) states that "antibiotic protocols against <I>S. aureus</I> are effective in reducing the risk of <I>S. aureus</I> catheter infections" and that "all PD patients should use topical antibiotic either at the catheter exit-site or intranasally or both". The Kidney Health Australia-Caring for Australasians with Renal Impairment (KHA-CARI) guidelines (<LINK REF="REF-Walker-2014" TYPE="REFERENCE">Walker 2014</LINK>) recommend that "prophylactic therapy using mupirocin ointment be used, especially for <I>S. aureus</I> carriage (intranasally or at the exit site) to decrease the risk of <I>S. aureus</I> catheter exit-site/tunnel infections and peritonitis" and suggest that the "PD catheter exit site be cleaned daily and a topical antimicrobial agent (either mupirocin or gentamicin) be applied". This review found that the use of oral antibiotic or mupirocin ointment (at the exit site) may reduce the risk of exit-site/tunnel infection and the risk of peritonitis but was not seen to reduce the exit-site/tunnel infection rate, the peritonitis rate or the number of patients with catheter removal/replacement. The head-to-head comparison of application of mupirocin ointment or cream against gentamicin cream is based on two studies and shows that there is no difference between the effectiveness of mupirocin and gentamicin in terms of preventing exit-site/tunnel infection and peritonitis. It is unclear if the nasal application of mupirocin reduces the risk of exit-site/tunnel infection or the risk of peritonitis.</P>
<P>The Renal Association (UK) guidelines state it is "recommended that initial catheter insertion be accompanied by antibiotic prophylaxis" and refer to the RCT evidence supporting the use of vancomycin (<LINK REF="REF-Figueiredo-2010" TYPE="REFERENCE">Figueiredo 2010</LINK>; <LINK REF="REF-Woodrow-2010" TYPE="REFERENCE">Woodrow 2010</LINK>). The ISPD position statement says that "prophylactic antibiotics administered at the time of insertion decrease the infection risk. A first-generation cephalosporin or vancomycin can be used, but suggested each program should weigh the potential benefit against the risk of vancomycin use (development of resistant organisms)" (<LINK REF="REF-Piraino-2011" TYPE="REFERENCE">Piraino 2011</LINK>). The KHA-CARI guidelines say it is "recommended that intravenous antibiotic prophylaxis be used prior to PD catheter insertion to reduce the risk of early peritonitis" and "vancomycin, cephalosporins and gentamicin have demonstrated effectiveness in reducing the risk of peritonitis" (<LINK REF="REF-Walker-2014" TYPE="REFERENCE">Walker 2014</LINK>). The inclusion of first generation cephalosporins is based on extrapolations from the results of pre-operative antibiotic studies in patients without chronic kidney disease. However, our study indicates that the evidence supporting the use of first generation cephalosporins in PD patients undergoing Tenckhoff catheter insertion is scant. In the present review, we identified four RCTs of different pre-operative antibiotic prophylaxis regimens, including parenteral gentamicin, vancomycin, cephazolin and cefuroxime, with only two evaluating a first generation cephalosporin. One small study involving 50 PD patients found that cephazolin and gentamicin were no better than no treatment (<LINK REF="STD-Lye-1992" TYPE="STUDY">Lye 1992</LINK>). The largest of the studies (265 patients) showed that cephazolin was inferior to vancomycin in preventing post-operative catheter-associated infections (7% versus 1%, respectively; P &lt; 0.05) (<LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>). However, the recommendation to use a first generation cephalosporin or vancomycin is understandable because of the risk of selecting for resistant organisms such as vancomycin-resistant enterococci and <I>S. aureus</I> (<LINK REF="REF-HICPAC-1995" TYPE="REFERENCE">HICPAC 1995</LINK>) and the development of <I>Clostridium difficile</I> colitis (<LINK REF="REF-Figueiredo-2010" TYPE="REFERENCE">Figueiredo 2010</LINK>). The postoperative incidence of peritonitis in the control arms of three of the evaluated studies were high, ranging from 14% to 46% (<LINK REF="STD-Bennet_x002d_Jones-1988" TYPE="STUDY">Bennet-Jones 1988</LINK>; <LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>; <LINK REF="STD-Wikdahl-1997" TYPE="STUDY">Wikdahl 1997</LINK>) and the applicability of these data to PD units with lower infection rates following PD catheter insertion is unclear.</P>
<P>The ISPD position statement suggests "most episodes of fungal peritonitis are preceded by courses of antibiotics" and "fungal prophylaxis during antibiotic therapy may prevent some cases of <I>Candida</I> peritonitis in programs that have high rates of fungal peritonitis" (<LINK REF="REF-Piraino-2011" TYPE="REFERENCE">Piraino 2011</LINK>). The KHA-CARI guidelines recommend "oral antifungal prophylaxis should be considered when antibiotics are administered to patients undergoing PD to reduce the risk of developing fungal peritonitis" (<LINK REF="REF-Walker-2014" TYPE="REFERENCE">Walker 2014</LINK>). This review indicates that fluconazole reduced the risk of fungal peritonitis following antibiotic treatment and that nystatin reduced the rate of <I>Candida</I> peritonitis in PD patients. The authors of the fluconazole study (<LINK REF="STD-Restrepo-2010" TYPE="STUDY">Restrepo 2010</LINK>) noted that a growing number of <I>Candida</I> strains were resistant to fluconazole during their study, and this would limit its use.</P>
<P>The ISPD no longer recommends that the exit site be regularly disinfected with antibacterial soap or a medical antiseptic to keep the exit site clean and reduce the numbers of resident bacteria. The current position statement states that "water and antibacterial soap are recommended by many centres. Use of an antiseptic to clean the exit site is preferred in some programs, but the agent must be non-cytotoxic" (<LINK REF="REF-Piraino-2011" TYPE="REFERENCE">Piraino 2011</LINK>). The four studies in this review which compared the use of disinfectant against standard care did not show any benefit with the use of disinfectant (povidone-iodine 10% ointment; povidone-iodine 2.5% dry powder spray; povidone-iodine 20g/L solution; sodium hypochlorite 10% solution) compared with standard care (povidone-iodine 10% solution; alcohol chlorhexidine hand wash and use of alcohol wipes; non-disinfectant soap and water; pH neutral soap and water). Three of the studies did not report on adverse effects of the interventions and one study observed that skin rashes/pruritus occurred in 6% of patients following use of the povidone-iodine dry powder spray (<LINK REF="STD-Wilson-1997" TYPE="STUDY">Wilson 1997</LINK>). The three studies in this review which looked at the use of disinfectant versus antibiotic or other disinfectant also did not show any benefit with the use of disinfectant (sodium hypochlorite 10% solution; sodium hypochlorite 5% solution; antibacterial honey 10 mg) compared with antibiotic (2% mupirocin ointment) or other disinfectant (povidone iodine 10% solution). Adverse effects were reported in each of these studies. Sodium hypochlorite solution was associated with more irritation around the exit site than povidone iodine solution (<LINK REF="STD-Wadhwa-1995" TYPE="STUDY">Wadhwa 1995</LINK>; <LINK REF="STD-Wadhwa-1997" TYPE="STUDY">Wadhwa 1997</LINK>) and 5.9% of patients using antibacterial honey at the exit site in <LINK REF="STD-HONEYPOT-Study-2009" TYPE="STUDY">HONEYPOT Study 2009</LINK> reported local reaction as the reason for withdrawing from the study whereas no patients in the control group reported this adverse effect.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-01-12 12:11:55 +1100" MODIFIED_BY="Narelle Willis">
<IMPLICATIONS_PRACTICE MODIFIED="2017-01-12 09:18:40 +1100" MODIFIED_BY="Narelle Willis">
<P>This update of a systematic review identified low quality evidence for the outcomes under consideration. Our findings are as follows.<BR/>
</P>
<UL>
<LI>The use of oral or topical antibiotic had uncertain effects on the risk of exit-site/tunnel infection and the risk of peritonitis</LI>
<LI>It is uncertain whether the use of nasal antibiotic reduces the risk of exit-site/tunnel infection or the risk of peritonitis</LI>
<LI>The use of pre/perioperative intravenous vancomycin may reduce the risk of early peritonitis but has an uncertain effect on the risk of exit-site/tunnel infection</LI>
<LI>The use of topical disinfectant has an uncertain effect on the risk of exit-site/tunnel infection and the risk of peritonitis</LI>
<LI>Antifungal prophylaxis with oral nystatin/fluconazole may reduce the risk of fungal peritonitis occurring after a PD patient has had an antibiotic course.</LI>
</UL>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-01-12 12:11:55 +1100" MODIFIED_BY="Narelle Willis">
<P>Many of the studies included in this review have significant methodological limitations, including lack of statistical power, and potential for bias. Further large randomised studies with sufficiently long follow-up periods are required. These need to assess patient-important outcomes such as adverse effects of the interventions given as well as quality of life. Studies need to be designed so they yield useful data on the key outcomes of exit-site/tunnel infection, peritonitis, catheter loss/replacement, and technique failure due to infection.</P>
<P>These studies should be large enough to enable subgroup analyses to determine which patients would benefit most from a prophylactic intervention and to clearly identify any harms associated with an intervention. There is a pressing need for more well-designed RCTs in this area, which adequately assess safety, as well as efficacy.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>2004 review</P>
<P>We acknowledge the contribution of Drs Peter Wilson, Ignatius Fong, Gerald Coles and Cliff Holmes of the Mupirocin Study Group, David Churchill and Judy Bernardini, who responded to our queries about their studies. We are indebted to Dr R Russo and Dr R Curciulo of the University of Bari, Italy, who commented on the original project and provided useful background information. Particular thanks to Dr Paolo Strippoli, Head of the Nephrology Unit of Ospedale "A. Perrino", Brindisi, Italy, for his intellectual input in this manuscript with comments on the original project and final manuscript and providing abundant background information and advice. We acknowledge the contribution of Narelle Willis, Coordinator of the Cochrane Renal Group, who coordinated our activities throughout the project and edited the latest draft of this review.</P>
<P>2017 review</P>
<P>We would like to thank Drs Chu, Danguilan, Johnson, Jassal, Ayliffe and Selgas for their responses to our queries about their studies.</P>
<P>We would like to thank Dr E Hodson for her comments and feedback during the preparation of this updated review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Denise Campbell: none</LI>
<LI>David W Mudge has received consultancy fees, speakers' honoraria and travel assistance from Baxter Healthcare for activities unrelated to this review</LI>
<LI>Jonathan C Craig: none</LI>
<LI>David W Johnson has received consultancy fees, speakers' honoraria, travel sponsorships and research funding from Fresenius Medical Care and Baxter Healthcare for activities unrelated to this review</LI>
<LI>Allison Tong: none</LI>
<LI>Giovanni FM Strippoli: none</LI>
</UL>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-01-12 14:44:04 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Designing the review: GS, DJ, JC</LI>
<LI>Coordinating the update of the review: DC, GS, JC</LI>
<LI>Data collection for the update of the review: DC and GS, independently</LI>
<LI>Developing search strategy: DC and GS, independently</LI>
<LI>Undertaking searches: DC and GS, independently</LI>
<LI>Screening search results: DC and GS, independently</LI>
<LI>Organising retrieval of papers: DC and GS, independently</LI>
<LI>Screening retrieved papers against inclusion criteria; DC and GS, independently</LI>
<LI>Appraising quality of papers: DC and GS, independently</LI>
<LI>Abstracting data from papers (modified Cochrane Kidney and Transplant's data extraction form): DC and GS, independently</LI>
<LI>Searching for additional data in unpublished studies: DC and GS, independently</LI>
<LI>Entering data into RevMan: DC</LI>
<LI>Analysis of data: DC, GS, JC</LI>
<LI>Interpretation of data: DC, GS, JC</LI>
<LI>Providing a methodological perspective: GS, JC</LI>
<LI>Providing a clinical perspective: GS, DJ, JC</LI>
<LI>Providing a policy perspective: GS, DJ, JC</LI>
<LI>Providing a consumer perspective: GS, DJ, JC</LI>
<LI>Writing the review: DC, GS, DJ, JC</LI>
<LI>Providing general advice on the review: JC, GS</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>The risk of bias assessment tool has replaced the quality assessment checklist used in the original review</LI>
<LI>Summary of findings tables have been incorporated into this update</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-06-08 05:33:13 +0100" MODIFIED_BY="Fiona Russell">
<STUDIES MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<INCLUDED_STUDIES MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Axelrod-1973" MODIFIED="2015-02-23 17:32:20 +1100" MODIFIED_BY="[Empty name]" NAME="Axelrod 1973" YEAR="1973">
<REFERENCE MODIFIED="2015-02-23 17:32:20 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Axelrod J, Meyers BR, Hirschman SZ, Stein R</AU>
<TI>Prophylaxis with cephalothin in peritoneal dialysis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1973</YR>
<VL>132</VL>
<NO>3</NO>
<PG>368-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848396"/><IDENTIFIER TYPE="MEDLINE" VALUE="4593192"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848395"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bennet_x002d_Jones-1988" MODIFIED="2016-02-15 15:48:00 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Bennet-Jones 1988" YEAR="1988">
<REFERENCE MODIFIED="2016-02-15 15:48:00 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennet-Jones D, Martin J, Barratt AJ, Duffy TJ, Naish PF, Aber GM</AU>
<TI>Prophylactic gentamicin in the prevention of early exit-site infections and peritonitis in CAPD</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1988</YR>
<VL>4</VL>
<PG>147-50</PG>
<IDENTIFIERS MODIFIED="2016-02-15 15:48:00 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-15 15:48:00 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00775909"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848398"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848397"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernardini-1996" MODIFIED="2016-12-29 14:13:17 +1100" MODIFIED_BY="Narelle Willis" NAME="Bernardini 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-12-29 14:13:17 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R</AU>
<TI>A randomized trial of staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1996</YR>
<VL>27</VL>
<NO>5</NO>
<PG>695-700</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848400"/><IDENTIFIER TYPE="MEDLINE" VALUE="8629630"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848399"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernardini-2005" MODIFIED="2014-06-20 16:50:40 +1000" MODIFIED_BY="Denise J Campbell" NAME="Bernardini 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-06-20 16:50:40 +1000" MODIFIED_BY="Denise J Campbell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernardini J, Bender F, Florio T, Sloand J, Palmmontalbano L, Fried L, et al</AU>
<TI>Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>2</NO>
<PG>539-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848402"/><IDENTIFIER TYPE="MEDLINE" VALUE="15625071"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848401"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blowey-1994" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="Blowey 1994" YEAR="1994">
<REFERENCE MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blowey DL, Warady BA, McFarland KS</AU>
<TI>Treatment of staphylococcus aureus nasal carriage in pediatric peritoneal dialysis patients</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1994</YR>
<VL>10</VL>
<PG>297-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848404"/><IDENTIFIER TYPE="MEDLINE" VALUE="7999849"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848403"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-1999a" MODIFIED="2016-12-28 14:59:07 +1100" MODIFIED_BY="Narelle Willis" NAME="Cheng 1999a" YEAR="1999">
<REFERENCE MODIFIED="2016-12-28 14:59:07 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng YY, Ho YW, Chiu SW</AU>
<TI>Exit site care, an open labelled randomized prospective study comparing the use of povidone-iodine and chlorhexidine soap [abstract no: 6]</TI>
<SO>Hong Kong Journal of Nephrology</SO>
<YR>1999</YR>
<VL>1</VL>
<NO>1</NO>
<PG>A3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848406"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848405"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chu-2008" MODIFIED="2014-09-08 16:47:25 +1000" MODIFIED_BY="[Empty name]" NAME="Chu 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-09-08 16:47:25 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chu KH, Choy WY, Cheung CC, Fung KS, Tang HL, Lee W, et al</AU>
<TI>A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>5</NO>
<PG>505-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848408"/><IDENTIFIER TYPE="MEDLINE" VALUE="18708544"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848407"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Churchill-1988" MODIFIED="2016-12-28 15:04:58 +1100" MODIFIED_BY="Narelle Willis" NAME="Churchill 1988" YEAR="1988">
<REFERENCE MODIFIED="2016-12-28 15:02:35 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Churchill DN, Oreopoulos DG, Taylor DW, Vas SI, Manuel MA, Wu G</AU>
<TI>Peritonitis in CAPD patients - a randomized clinical trial (RCT) of trimethoprim-sulfamethoxazole (TMP/SMX) prophylaxis [abstract]</TI>
<SO>Kidney International</SO>
<YR>1988</YR>
<VL>33</VL>
<NO>1</NO>
<PG>244</PG>
<IDENTIFIERS MODIFIED="2016-02-15 15:54:41 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-15 15:54:41 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00636126"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848410"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-28 15:04:58 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Churchill DN, Taylor DW, Vas SI, Singer J, Beecroft ML, Wu G, et al</AU>
<TI>Peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients: a randomized clinical trial of cotrimoxazole prophylaxis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>2</NO>
<PG>125-8</PG>
<IDENTIFIERS MODIFIED="2016-12-28 15:04:55 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848411"/><IDENTIFIER MODIFIED="2016-12-28 15:04:55 +1100" MODIFIED_BY="Narelle Willis" TYPE="EMBASE" VALUE="18252568"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848409"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cocksedge-1993" MODIFIED="2016-12-28 15:06:07 +1100" MODIFIED_BY="Narelle Willis" NAME="Cocksedge 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-12-28 15:06:07 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cocksedge B, Hunt D, Westerholm W, Heathcote K, Pollock C</AU>
<TI>Peritoneal dialysis catheter exit site care for the maintenance continuous ambulatory peritoneal dialysis (CAPD) patient: report of a randomised prospective study</TI>
<SO>Renal Educator</SO>
<YR>1993</YR>
<VL>13</VL>
<NO>1</NO>
<PG>4-6</PG>
<IDENTIFIERS MODIFIED="2016-12-28 15:06:07 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 15:06:07 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00626103"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848413"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848412"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Danguilan-2003" MODIFIED="2014-07-06 19:03:57 +1000" MODIFIED_BY="[Empty name]" NAME="Danguilan 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-07-06 19:03:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Danguilan RA, Evangelista LP, Abrenica MS, Rondilla SM</AU>
<TI>Comparative study of mupirocin and sodium fucidate in the prophylaxis of exit-site infections in CAPD patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>6</NO>
<PG>593-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848415"/><IDENTIFIER TYPE="MEDLINE" VALUE="14703203"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848414"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fuchs-1990" MODIFIED="2016-12-28 15:07:48 +1100" MODIFIED_BY="Narelle Willis" NAME="Fuchs 1990" YEAR="1990">
<REFERENCE MODIFIED="2016-12-28 15:07:48 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fuchs J, Gallagher ME, Jackson-Bey D, Krawtz D, Schreiber J</AU>
<TI>A prospective randomized study of peritoneal catheter exit-site care</TI>
<SO>Dialysis &amp; Transplantation</SO>
<YR>1990</YR>
<VL>19</VL>
<NO>2</NO>
<PG>81-4</PG>
<IDENTIFIERS MODIFIED="2016-12-28 15:07:48 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848417"/><IDENTIFIER MODIFIED="2016-12-28 15:07:48 +1100" MODIFIED_BY="Narelle Willis" TYPE="EMBASE" VALUE="20066020"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848416"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gadallah-2000c" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="Gadallah 2000c" YEAR="2000">
<REFERENCE MODIFIED="2016-12-29 14:12:56 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gadallah MF, Ramdeen G, Mignone J, Patel D, Mitchell L, Tatro S</AU>
<TI>Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>5</NO>
<PG>1014-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848419"/><IDENTIFIER TYPE="MEDLINE" VALUE="11054359"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-15 15:35:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gadallah MF, Ramdeen G, Torres C, Mignone J, Patel D, Mitchell L, et al</AU>
<TI>Preoperative vancomycin prophylaxis for newly placed peritoneal dialysis catheters prevents postoperative peritonitis</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>2000</YR>
<VL>16</VL>
<PG>199-203</PG>
<IDENTIFIERS MODIFIED="2014-04-17 14:15:40 +1000" MODIFIED_BY="Ruth L Mitchell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848420"/><IDENTIFIER MODIFIED="2014-04-17 14:15:40 +1000" MODIFIED_BY="Ruth L Mitchell" TYPE="MEDLINE" VALUE="11045293"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848418"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HONEYPOT-Study-2009" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="HONEYPOT Study 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-02-15 15:57:08 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DW, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, et al</AU>
<TI>Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2014</YR>
<VL>14</VL>
<NO>1</NO>
<PG>23-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848422"/><IDENTIFIER TYPE="MEDLINE" VALUE="24119840"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-04 13:31:05 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DW, Clark C, Isbel NM, Hawley CM, Beller E, Cass A, et al</AU>
<TI>The Honeypot study protocol: a randomized controlled trial of exit-site application of medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>3</NO>
<PG>303-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848423"/><IDENTIFIER TYPE="MEDLINE" VALUE="19458303"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-04 13:31:32 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pascoe EM, Lo S, Scaria A, Badve SV, Beller EM, Cass A, et al</AU>
<TI>The HONEYPOT randomized controlled trial statistical analysis plan</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2013</YR>
<VL>33</VL>
<NO>4</NO>
<PG>426-35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848424"/><IDENTIFIER TYPE="MEDLINE" VALUE="23843589"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-28 15:14:23 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, et al</AU>
<TI>Microbiological results of the Honeypot study-secondary analysis of a randomised, controlled trial of exit site application of MEDIHONEY for the prevention of catheter-associated infections in PD patients [abstract]</TI>
<SO>Nephrology</SO>
<YR>2014</YR>
<VL>19</VL>
<NO>Suppl 4</NO>
<PG>30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848426"/><IDENTIFIER TYPE="EMBASE" VALUE="71587829"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, et al</AU>
<TI>The effect of exit-site antibacterial honey versus nasal mupirocin prophylaxis on the microbiology and outcomes of peritoneal dialysis-associated peritonitis and exit-site infections: a sub-study of the Honeypot Trial</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2015</YR>
<VL>35</VL>
<NO>7</NO>
<PG>712-21</PG>
<IDENTIFIERS MODIFIED="2016-02-15 16:38:34 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848425"/><IDENTIFIER TYPE="MEDLINE" VALUE="26224790"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848421"/><IDENTIFIER TYPE="OTHER" VALUE="ACTRN12607000537459"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lo-1996" MODIFIED="2016-12-29 14:12:48 +1100" MODIFIED_BY="Narelle Willis" NAME="Lo 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-12-29 14:12:48 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lo WK, Chan CY, Cheng SW, Poon JF, Chan DT, Cheng IK</AU>
<TI>A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>4</NO>
<PG>549-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848428"/><IDENTIFIER TYPE="MEDLINE" VALUE="8840945"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848427"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Low-1980" MODIFIED="2017-01-12 14:54:47 +1100" MODIFIED_BY="Narelle Willis" NAME="Low 1980" YEAR="1980">
<REFERENCE MODIFIED="2016-02-15 15:57:46 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Low DE, Vas S, Oreopoulos DG, Manuel A, Saiphoo C, Finer C, et al</AU>
<TI>Randomized clinical trial of cephalexin in preventing peritonitis in patients on continuous ambulatory peritoneal dialysis [abstract]</TI>
<SO>Kidney International</SO>
<YR>1981</YR>
<VL>19</VL>
<NO>2</NO>
<PG>392</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848430"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-29 14:12:43 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Low DE, Vas SI, Oreopoulos DG, Manuel MA, Saiphoo MM, Finer C, et al</AU>
<TI>Prophylactic cephalexin ineffective in chronic ambulatory peritoneal dialysis</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>2</VL>
<NO>8197</NO>
<PG>753-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848431"/><IDENTIFIER TYPE="MEDLINE" VALUE="6106868"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848429"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luzar-1990" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="Luzar 1990" YEAR="1990">
<REFERENCE MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luzar MA, Brown CB, Balf D, Hill L, Issad B, Monnier B, et al</AU>
<TI>Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>1</NO>
<PG>25-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848433"/><IDENTIFIER TYPE="MEDLINE" VALUE="2085577"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848432"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lye-1992" MODIFIED="2016-12-28 15:19:41 +1100" MODIFIED_BY="Narelle Willis" NAME="Lye 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-12-28 14:06:17 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lye WC, Lee EJ, Tan CC</AU>
<TI>Prophylactic antibiotics in the insertion of Tenckhoff catheters</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology</SO>
<YR>1992</YR>
<VL>26</VL>
<NO>2</NO>
<PG>177-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848435"/><IDENTIFIER TYPE="MEDLINE" VALUE="1626207"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-28 15:19:41 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Lye WC, van der Straaten JC, Lee EJ</AU>
<TI>A prospective study on the use of prophylactic antibiotics for the implantation of tenckhoff catheters in CAPD patients [abstract]</TI>
<SO>12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel</SO>
<YR>1993</YR>
<PG>343</PG>
<IDENTIFIERS MODIFIED="2016-12-28 15:19:25 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 15:19:25 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00626018"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848436"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848434"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendoza_x002d_Guevara-2007" MODIFIED="2014-07-09 14:27:27 +1000" MODIFIED_BY="[Empty name]" NAME="Mendoza-Guevara 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-07-09 14:27:27 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendoza-Guevara L, Castro-Vazquez F, Aguilar-Kitsu A, Morales-Nava A, Rodriguez-Leyva F, Sanchez-Barbosa JL</AU>
<TI>Amuchina 10% solution, safe antiseptic for preventing infections of exit-site of Tenckhoff catheters, in the pediatric population of a dialysis program</TI>
<SO>Contributions to Nephrology</SO>
<YR>2007</YR>
<VL>154</VL>
<PG>139-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848438"/><IDENTIFIER TYPE="MEDLINE" VALUE="17099309"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848437"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-1989" MODIFIED="2016-12-28 14:44:08 +1100" MODIFIED_BY="Narelle Willis" NAME="Moore 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-09-08 17:41:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore C</AU>
<TI>A clinical study comparing a polyurethane dressing, blisterfilm, to standard gauze dressing on the tenckhoff catheter [abstract]</TI>
<SO>ANNA Journal</SO>
<YR>1989</YR>
<VL>16</VL>
<NO>2</NO>
<PG>105</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848440"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-15 15:58:55 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore CG</AU>
<TI>Comparison of Blisterfilm and gauze for peritoneal catheter exit site care</TI>
<SO>ANNA Journal</SO>
<YR>1989</YR>
<VL>16</VL>
<NO>7</NO>
<PG>475-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848441"/><IDENTIFIER TYPE="MEDLINE" VALUE="2604449"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848439"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MP3-Study-2008" MODIFIED="2016-10-04 13:32:13 +1100" MODIFIED_BY="Gail Y Higgins" NAME="MP3 Study 2008" YEAR="2012">
<REFERENCE MODIFIED="2016-10-04 13:32:13 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jassal SV, Lok CE, MP3 Study Group</AU>
<TI>A randomized controlled trial comparing mupirocin versus polysporin triple for the prevention of catheter-related infections in peritoneal dialysis patients (the MP3 study)</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>1</NO>
<PG>67-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848443"/><IDENTIFIER TYPE="MEDLINE" VALUE="18178950"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-20 14:52:15 +1000" MODIFIED_BY="Denise J Campbell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McQuillan RF, Chiu E, Nessim S, Lok CE, Roscoe JM, Tam P, et al</AU>
<TI>A randomized controlled trial comparing mupirocin and polysporin triple ointments in peritoneal dialysis patients: the MP3 Study</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>2</NO>
<PG>297-303</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848444"/><IDENTIFIER TYPE="MEDLINE" VALUE="22134627"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-20 14:52:15 +1000" MODIFIED_BY="Denise J Campbell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Diepen AT, Tomlinson GA, Jassal SV</AU>
<TI>The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>8</NO>
<PG>1266-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848445"/><IDENTIFIER TYPE="MEDLINE" VALUE="22745277"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-02-15 15:59:38 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848442"/><IDENTIFIER MODIFIED="2016-02-15 15:59:24 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CTG" VALUE="NCT00400595"/><IDENTIFIER MODIFIED="2016-02-15 15:59:38 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="OTHER" VALUE="CRG020600039"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mupirocin-Study-1996" MODIFIED="2016-12-29 14:12:28 +1100" MODIFIED_BY="Narelle Willis" NAME="Mupirocin Study 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-12-29 14:12:28 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Nasal mupirocin prevents staphylococcus aureus exit-site infection during peritoneal dialysis. Mupirocin Study Group</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>11</NO>
<PG>2403-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848449"/><IDENTIFIER TYPE="MEDLINE" VALUE="8959632"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-28 15:23:45 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coles GA, Mupirocin Study Group</AU>
<TI>The effect of intranasal mupirocin on CAPD exit site infection (ESI) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>3</NO>
<PG>439</PG>
<IDENTIFIERS MODIFIED="2014-04-17 14:12:14 +1000" MODIFIED_BY="Ruth L Mitchell"><IDENTIFIER MODIFIED="2014-04-17 14:12:14 +1000" MODIFIED_BY="Ruth L Mitchell" TYPE="CENTRAL" VALUE="CN-00550592"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848447"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-29 14:12:24 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davey P, Craig AM, Hau C, Malek M</AU>
<TI>Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized placebo-controlled trial</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1999</YR>
<VL>43</VL>
<NO>1</NO>
<PG>105-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848448"/><IDENTIFIER TYPE="MEDLINE" VALUE="10381107"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848446"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nolph-1985" MODIFIED="2016-12-29 14:12:21 +1100" MODIFIED_BY="Narelle Willis" NAME="Nolph 1985" YEAR="1985">
<REFERENCE MODIFIED="2016-12-29 14:12:21 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nolph KD, Prowant B, Serkes KD, Morgan LM</AU>
<TI>A randomized multicenter clinical trial to evaluate the effects of an ultraviolet germicidal system on peritonitis rate in continuous ambulatory peritoneal dialysis</TI>
<SO>Peritoneal Dialysis Bulletin</SO>
<YR>1985</YR>
<VL>5</VL>
<NO>1</NO>
<PG>19-24</PG>
<IDENTIFIERS MODIFIED="2016-12-28 15:27:29 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848451"/><IDENTIFIER MODIFIED="2016-12-28 15:27:29 +1100" MODIFIED_BY="Narelle Willis" TYPE="EMBASE" VALUE="15143789"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848450"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nunez_x002d_Moral-2014" MODIFIED="2016-12-28 14:44:16 +1100" MODIFIED_BY="Narelle Willis" NAME="Nunez-Moral 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-05-06 16:42:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nunez-Moral M, Sanchez-Alvarez E, Gonzalez-Diaz I, Pelaez-Requejo B, Fernandez-Vina A, Quintana-Fernandez A, et al</AU>
<TI>Exit-site infection of peritoneal catheter is reduced by the use of polyhexanide. results of a prospective randomized trial</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2014</YR>
<VL>34</VL>
<NO>3</NO>
<PG>271-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848453"/><IDENTIFIER TYPE="MEDLINE" VALUE="24497599"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848452"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perez_x002d_Fontan-1992" MODIFIED="2016-12-29 14:12:16 +1100" MODIFIED_BY="Narelle Willis" NAME="Perez-Fontan 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-12-29 14:12:16 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Moncalian J, Femindez-Rivera C, Cao M, et al</AU>
<TI>Treatment of staphylococcus aureus nasal carriers in CAPD with mupirocin</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1992</YR>
<VL>8</VL>
<PG>242-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848455"/><IDENTIFIER TYPE="MEDLINE" VALUE="1361797"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848454"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poole_x002d_Warren-1991" MODIFIED="2016-12-29 14:12:13 +1100" MODIFIED_BY="Narelle Willis" NAME="Poole-Warren 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-12-29 14:12:13 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poole-Warren LA, Hallett MD, Hone PW, Burden SH, Farrell PC</AU>
<TI>Vaccination for prevention of CAPD associated staphylococcal infection: results of a prospective multicentre clinical trial</TI>
<SO>Clinical Nephrology</SO>
<YR>1991</YR>
<VL>35</VL>
<NO>5</NO>
<PG>198-206</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848457"/><IDENTIFIER TYPE="MEDLINE" VALUE="1855327"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848456"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Restrepo-2010" MODIFIED="2016-12-28 14:44:21 +1100" MODIFIED_BY="Narelle Willis" NAME="Restrepo 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-02-15 16:04:37 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Restrepo C, Chacon J, Manjarres G</AU>
<TI>Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial.[Erratum appears in Perit Dial Int. 2011 Mar-Apr;31(2):120]</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>6</NO>
<PG>619-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848459"/><IDENTIFIER TYPE="MEDLINE" VALUE="20634438"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848458"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryckelynck-1987" MODIFIED="2017-01-12 12:18:23 +1100" MODIFIED_BY="Narelle Willis" NAME="Ryckelynck 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-01-12 12:18:23 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ryckelynck JP, Verger C, Cam G, Faller B, Pierre D</AU>
<TI>A prospective study to evaluate the role of antiseptics in CAPD Y-line systems [abstract]</TI>
<SO>24th Annual Congress. EDTA-ERA; 1987 Oct 25-29; West Berlin, Germany</SO>
<YR>1987</YR>
<PG>161</PG>
<IDENTIFIERS MODIFIED="2016-02-15 16:07:40 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-15 16:07:40 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00644147"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848461"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848460"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sesso-1994" MODIFIED="2016-12-29 14:12:06 +1100" MODIFIED_BY="Narelle Willis" NAME="Sesso 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-12-29 14:12:06 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sesso R, Parisio K, Dalboni A, Rabelo T, Barbosa D, Cendoroglo M, et al</AU>
<TI>Effect of sodium fusidate and ofloxacin on staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis</TI>
<SO>Clinical Nephrology</SO>
<YR>1994</YR>
<VL>41</VL>
<NO>6</NO>
<PG>370-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848463"/><IDENTIFIER TYPE="MEDLINE" VALUE="8076441"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-28 15:33:45 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sesso R, Parisio K, Draibe S, Ajzen H</AU>
<TI>Effect of sodium fusidate and ofloxacin on staphylococcus aureus carriage and infection in patients on peritoneal dialysis (CAPD) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1993</YR>
<VL>4</VL>
<NO>Program &amp; Abstracts</NO>
<PG>417</PG>
<IDENTIFIERS MODIFIED="2016-12-28 15:33:45 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 15:33:45 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00485819"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848464"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848462"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-1971" MODIFIED="2014-10-23 17:14:33 +1100" MODIFIED_BY="[Empty name]" NAME="Sharma 1971" YEAR="1971">
<REFERENCE MODIFIED="2014-10-23 17:14:33 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma BK, Rodriguez H, Ghandi VC, Smith EC, Pillay VK, Dunea G</AU>
<TI>Trial of oral neomycin during peritoneal dialysis</TI>
<SO>American Journal of the Medical Sciences</SO>
<YR>1971</YR>
<VL>262</VL>
<NO>3</NO>
<PG>175-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848466"/><IDENTIFIER TYPE="MEDLINE" VALUE="4946828"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848465"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SIPROCE-Study-1997" MODIFIED="2016-12-28 15:38:32 +1100" MODIFIED_BY="Narelle Willis" NAME="SIPROCE Study 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-10-04 13:33:07 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pommer W, Brauner M, Westphale HJ, Brunkhorst R, Kramer R, Bundschu D, et al</AU>
<TI>Effect of a silver device in preventing catheter-related infections in peritoneal dialysis patients: silver ring prophylaxis at the catheter exit study</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1998</YR>
<VL>32</VL>
<NO>5</NO>
<PG>752-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848468"/><IDENTIFIER TYPE="MEDLINE" VALUE="9820444"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-28 15:38:32 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pommer W</AU>
<TI>The efficiency of a silver ring to prevent exit-site and other catheter-related infections in PD-patients-final results of the SIPROCE study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1997</YR>
<VL>8</VL>
<PG>182A</PG>
<IDENTIFIERS MODIFIED="2016-12-28 15:37:40 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 15:37:40 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00447255"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848469"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-15 16:11:26 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>SIPROCE Study</AU>
<TI>Efficiency of a silver ring in preventing exit-site infections in adult PD patients: results of the SIPROCE Study. Silver ring Prophylaxis of the Catheter Exit Site</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>227-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848470"/><IDENTIFIER TYPE="MEDLINE" VALUE="9360688"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848467"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sit-2007" MODIFIED="2014-06-21 17:20:52 +1000" MODIFIED_BY="[Empty name]" NAME="Sit 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-06-21 17:20:52 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME</AU>
<TI>Prophylactic intranasal mupirocin ointment in the treatment of peritonitis in continuous ambulatory peritoneal dialysis patients</TI>
<SO>Advances in Therapy</SO>
<YR>2007</YR>
<VL>24</VL>
<NO>2</NO>
<PG>387-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848472"/><IDENTIFIER TYPE="MEDLINE" VALUE="17565930"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848471"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swartz-1991" MODIFIED="2016-12-29 14:11:35 +1100" MODIFIED_BY="Narelle Willis" NAME="Swartz 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-12-29 14:11:35 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swartz R, Messana J, Starmann B, Weber M, Reynolds J</AU>
<TI>Preventing Staphylococcus aureus infection during chronic peritoneal dialysis</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1991</YR>
<VL>2</VL>
<NO>6</NO>
<PG>1085-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848474"/><IDENTIFIER TYPE="MEDLINE" VALUE="1777589"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848473"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wadhwa-1995" MODIFIED="2016-02-15 16:14:03 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Wadhwa 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-02-15 16:14:03 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wadhwa NK, Suh H, Cabralda T, Stratos J, Cascio C, Irwin C, et al</AU>
<TI>A randomized trial of amuchina 10% versus povidone-iodine 10% solution for exit-site care/infection in peritoneal dialysis patients [abstract]</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>Suppl 1</NO>
<PG>S64</PG>
<IDENTIFIERS MODIFIED="2016-02-15 16:14:03 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848476"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848475"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wadhwa-1997" MODIFIED="2016-12-28 15:42:52 +1100" MODIFIED_BY="Narelle Willis" NAME="Wadhwa 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-12-28 15:42:52 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wadhwa NK, Suh H, Cabralda T</AU>
<TI>Amuchina 5% versus povidone-iodine 10% solution for exit-site care/infection in peritoneal dialysis patients [abstract]</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>Suppl 1</NO>
<PG>S46</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848478"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848477"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waite-1997" MODIFIED="2016-12-29 14:11:29 +1100" MODIFIED_BY="Narelle Willis" NAME="Waite 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-12-29 14:11:29 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waite N, Webster N, Laurel M, Johnson M, Fong IW</AU>
<TI>The efficacy of exit site povidone-iodine ointment in the prevention of early peritoneal dialysis-related infections</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>5</NO>
<PG>763-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848480"/><IDENTIFIER TYPE="MEDLINE" VALUE="9159313"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848479"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wikdahl-1997" MODIFIED="2016-12-29 14:11:26 +1100" MODIFIED_BY="Narelle Willis" NAME="Wikdahl 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-12-29 14:11:26 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wikdahl AM, Engman U, Stegmayr BJ, Sorenson JG</AU>
<TI>One-dose cefuroxime i.v. and i.p. reduces microbial growth in PD patients after catheter insertion</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>1</NO>
<PG>157-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848482"/><IDENTIFIER TYPE="MEDLINE" VALUE="9027792"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848481"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1997" MODIFIED="2016-12-29 14:11:23 +1100" MODIFIED_BY="Narelle Willis" NAME="Wilson 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-12-29 14:11:23 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson AP, Lewis C, O'Sullivan HO, Shetty N, Neild GH, Mansell M</AU>
<TI>The use of povidone iodine in exit site care for patients undergoing continuous peritoneal dialysis (CAPD)</TI>
<SO>Journal of Hospital Infection</SO>
<YR>1997</YR>
<VL>35</VL>
<NO>4</NO>
<PG>287-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848484"/><IDENTIFIER TYPE="MEDLINE" VALUE="9152821"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848483"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-2003" MODIFIED="2014-06-21 16:31:33 +1000" MODIFIED_BY="[Empty name]" NAME="Wong 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-06-21 16:31:33 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong SS, Chu KH, Cheuk A, Tsang WK, Fung SK, Chan HW, et al</AU>
<TI>Prophylaxis against gram-positive organisms causing exit-site infection and peritonitis in continuous ambulatory peritoneal dialysis patients by applying mupirocin ointment at the catheter exit site</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2003</YR>
<VL>23 Suppl 2</VL>
<PG>S153-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848486"/><IDENTIFIER TYPE="MEDLINE" VALUE="17986538"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848485"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zimmerman-1991" MODIFIED="2016-12-29 14:11:16 +1100" MODIFIED_BY="Narelle Willis" NAME="Zimmerman 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-12-29 14:11:16 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zimmerman SW, Ahrens E, Johnson CA, Craig W, Leggett J, O'Brien M, et al</AU>
<TI>Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1991</YR>
<VL>18</VL>
<NO>2</NO>
<PG>225-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848488"/><IDENTIFIER TYPE="MEDLINE" VALUE="1867179"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-04 13:34:11 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zimmerman SW, Ahrens E, Johnson CA, Craig W, Leggett J, O'Brien M, et al</AU>
<TI>Randomized, controlled trial of prophylactic rifampin (RIF) for PD catheter-related infections (CRI) and peritonitis (P) [abstract]</TI>
<SO>Kidney International</SO>
<YR>1990</YR>
<VL>37</VL>
<NO>1</NO>
<PG>335</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848489"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848487"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Cavdar-2004" MODIFIED="2014-09-09 16:43:12 +1000" MODIFIED_BY="[Empty name]" NAME="Cavdar 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-09-09 16:43:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavdar C, Saglam F, Sifil A, Celik A, Atay T, Gungor O, et al</AU>
<TI>Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience</TI>
<SO>Renal Failure</SO>
<YR>2008</YR>
<VL>30</VL>
<NO>4</NO>
<PG>417-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848497"/><IDENTIFIER TYPE="MEDLINE" VALUE="18569916"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-09 16:43:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavdar C, Zeybel M, Atay T, Sifil A, Sanlidag C, Gulay Z, et al</AU>
<TI>The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis--first 6 months' experience</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>2004</YR>
<VL>20</VL>
<PG>62-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848498"/><IDENTIFIER TYPE="MEDLINE" VALUE="15384797"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848496"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Churchill-1989" MODIFIED="2016-12-28 15:53:39 +1100" MODIFIED_BY="Narelle Willis" NAME="Churchill 1989" YEAR="1989">
<REFERENCE MODIFIED="2016-12-28 15:53:06 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Churchill DN, Canadian CAPD Clinical Trials Group</AU>
<TI>Randomized clinical trial (RCT) comparing peritonitis rates among new CAPD patients using the Y set disinfectant system (Y) to standard systems (S) [abstract]</TI>
<SO>Kidney International</SO>
<YR>1989</YR>
<VL>35</VL>
<NO>1</NO>
<PG>268</PG>
<IDENTIFIERS MODIFIED="2016-12-28 15:53:06 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 15:53:06 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00602155"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848500"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-28 15:53:39 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Churchill DN, Taylor DW, Vas SI, Oreopoulos DG, Bettcher KB, Fenton SA, et al</AU>
<TI>Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multi-centre randomized clinical trial comparing the Y connector disinfectant system to standard systems</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>3</NO>
<PG>159-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848501"/><IDENTIFIER TYPE="MEDLINE" VALUE="2488361"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848499"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crabtree-2003" MODIFIED="2014-09-09 16:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Crabtree 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-09-09 16:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crabtree JH, Burchette RJ, Siddiqi RA, Huen IT, Hadnott LL, Fishman A</AU>
<TI>The efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-related infections</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>4</NO>
<PG>368-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848503"/><IDENTIFIER TYPE="MEDLINE" VALUE="12968845"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848502"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Fijter-1992a" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="de Fijter 1992a" YEAR="1992">
<REFERENCE MODIFIED="2016-10-04 13:41:22 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Fijter CW, Biemond A, Oe LP, Moesker HL, Verhoef J, Donker AJ, et al</AU>
<TI>Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1992</YR>
<VL>8</VL>
<PG>18-21</PG>
<IDENTIFIERS MODIFIED="2016-10-04 13:41:22 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848508"/><IDENTIFIER MODIFIED="2016-10-04 13:41:22 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="1361781"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848507"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gadallah-2000" MODIFIED="2016-02-15 16:49:42 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Gadallah 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-07-15 15:59:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gadallah MF, Tamayo A, Sandborn M, Ramdeen G, Moles K</AU>
<TI>Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>2000</YR>
<VL>16</VL>
<PG>233-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848512"/><IDENTIFIER TYPE="MEDLINE" VALUE="11045301"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848511"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maiorca-1983" MODIFIED="2016-02-15 16:21:28 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Maiorca 1983" YEAR="1983">
<REFERENCE MODIFIED="2014-09-09 17:17:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maiorca R, Cantaluppi A, Cancarini GC, Scalamogna A, Broccoli R, Graziani G, et al</AU>
<TI>Prospective controlled trial of a Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>2</VL>
<NO>8351</NO>
<PG>642-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848517"/><IDENTIFIER TYPE="MEDLINE" VALUE="6136794"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-15 16:19:07 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maiorca R, Cantaluppi A, Cancarini GC, Scalamogna A, Strada A, Graziani G, et al</AU>
<TI>'Y' connector system for prevention of peritonitis in CAPD: a controlled study</TI>
<SO>Proceedings of the European Dialysis &amp; Transplant Association</SO>
<YR>1983</YR>
<VL>20</VL>
<PG>223-9</PG>
<IDENTIFIERS MODIFIED="2016-02-15 16:18:59 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848518"/><IDENTIFIER TYPE="MEDLINE" VALUE="6361737"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848516"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naylor-1997" MODIFIED="2014-09-09 17:24:28 +1000" MODIFIED_BY="[Empty name]" NAME="Naylor 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-09-09 17:24:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naylor M, Roe B</AU>
<TI>A study of the efficacy of dressings in preventing infections of continuous ambulatory peritoneal dialysis catheter exit sites</TI>
<SO>Journal of Clinical Nursing</SO>
<YR>1997</YR>
<VL>6</VL>
<NO>1</NO>
<PG>17-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848522"/><IDENTIFIER TYPE="MEDLINE" VALUE="9052106"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848521"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oh-2000" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="Oh 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-12-28 15:58:42 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klaus G, van Baum H, Wuhl E, Schaefer F, European Pediatric Peritoneal Dialysis Study Group (EPPS)</AU>
<TI>Efficacy of Mupirocin prophylaxis in reducing the incidence of peritoneal dialysis (PD)-related Staphylococcus aureus infections in children on chronic PD: results of a double blind, placebo-controlled trial [abstract]</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>1</NO>
<PG>149</PG>
<IDENTIFIERS MODIFIED="2016-12-28 15:58:42 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 15:58:42 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00401508"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848514"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-04 13:41:54 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oh J, von Baum H, Klaus G, Schaefer F</AU>
<TI>Nasal carriage of staphylococcus aureus in families of children on peritoneal dialysis. European Pediatric Peritoneal Dialysis Study Group (EPPS)</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>2000</YR>
<VL>16</VL>
<PG>324-7</PG>
<IDENTIFIERS MODIFIED="2014-04-17 14:17:07 +1000" MODIFIED_BY="Ruth L Mitchell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848515"/><IDENTIFIER MODIFIED="2014-04-17 14:17:07 +1000" MODIFIED_BY="Ruth L Mitchell" TYPE="MEDLINE" VALUE="11045321"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848513"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plum-1997a" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="Plum 1997a" YEAR="1997">
<REFERENCE MODIFIED="2016-10-04 13:42:15 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Artic S, Busch T, Sahin K, Grabensee B, Plum J</AU>
<TI>Oral versus intraperitoneal application of clindamycin in tunnel infections: a prospective, randomized study in CAPD patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>Program &amp; Abstracts</NO>
<PG>260A-1A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848524"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-28 16:01:46 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Plum J, Artik S, Busch T, Sahin K, Grabensee B</AU>
<TI>Oral versus intraperitoneal application of clindamycin in tunnel infections: a prospective, randomized study in CAPD patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>5</NO>
<PG>486-92</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:01:46 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848525"/><IDENTIFIER MODIFIED="2016-12-28 16:01:46 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="9358531"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848523"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez_x002d_Perez-1989" MODIFIED="2016-10-04 13:42:34 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Rodriguez-Perez 1989" YEAR="1989">
<REFERENCE MODIFIED="2016-10-04 13:42:34 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez-Perez JC, Vega N, Plaza C, Fernandez A, Hortal L, Palop L</AU>
<TI>Prospective randomized trial with the use of antibiotic bonding to peritoneal catheters. A method to reduce tunnel and exit site infection in CAPD patients [abstract]</TI>
<SO>Kidney International</SO>
<YR>1989</YR>
<VL>36</VL>
<NO>1</NO>
<PG>154</PG>
<IDENTIFIERS MODIFIED="2016-10-04 13:42:34 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848529"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848528"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomae-1982" MODIFIED="2016-12-28 16:04:32 +1100" MODIFIED_BY="Narelle Willis" NAME="Thomae 1982" YEAR="1982">
<REFERENCE MODIFIED="2016-12-28 16:04:32 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomae U, Boos W, Adam D</AU>
<TI>Transperitoneal resorption of ampicillin, cefuroxim and gentamicin in continuous ambulatory peritoneal dialysis</TI>
<TO>Transperitoneale resorption von ampicillin, cefuroxim and gentamicin unter kontinuierlicher ambulanter peritonealdialyse</TO>
<SO>Medizinische Welt</SO>
<YR>1982</YR>
<VL>33</VL>
<NO>5</NO>
<PG>182-4</PG>
<IDENTIFIERS MODIFIED="2014-04-17 13:46:19 +1000" MODIFIED_BY="Ruth L Mitchell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848535"/><IDENTIFIER MODIFIED="2014-04-17 13:46:19 +1000" MODIFIED_BY="Ruth L Mitchell" TYPE="MEDLINE" VALUE="7070273"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848534"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trooskin-1990" MODIFIED="2014-09-09 17:29:14 +1000" MODIFIED_BY="[Empty name]" NAME="Trooskin 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-09-09 17:29:14 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trooskin SZ, Harvey RA, Lennard TW, Greco RS</AU>
<TI>Failure of demonstrated clinical efficacy of antibiotic-bonded continuous ambulatory peritoneal dialysis (CAPD) catheters</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>1</NO>
<PG>57-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2848537"/><IDENTIFIER TYPE="MEDLINE" VALUE="2085584"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2848536"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-05-06 16:42:47 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2016-12-28 16:06:10 +1100" MODIFIED_BY="Narelle Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02547103" MODIFIED="2016-12-28 16:06:10 +1100" MODIFIED_BY="Narelle Willis" NAME="NCT02547103" YEAR="2016">
<REFERENCE MODIFIED="2016-12-28 16:06:10 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Ruengorn C</AU>
<TI>Efficacy and safety of local application of chlorhexidine gluconate versus mupirocin ointment in the prevention of peritoneal dialysis-related infection: a pilot study, double- blind, stratified randomized controlled trial</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT02547103</SO>
<YR>(accessed 28 December 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5369700"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-10-04 14:04:27 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5369699"/><IDENTIFIER MODIFIED="2016-10-04 14:04:27 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CTG" VALUE="NCT02547103"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_REFERENCES MODIFIED="2017-01-12 11:46:52 +1100" MODIFIED_BY="Narelle Willis">
<REFERENCE ID="REF-Annigeri-2001" MODIFIED="2016-12-28 16:07:17 +1100" MODIFIED_BY="Narelle Willis" NAME="Annigeri 2001" TYPE="JOURNAL_ARTICLE">
<AU>Annigeri R, Conly J, Vas S, Dedier H, Prakashan K P, Bargman JM, et al</AU>
<TI>Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>6</NO>
<PG>554-9</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:07:17 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:07:17 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="11783763"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Campbell-2015" MODIFIED="2016-12-28 16:08:40 +1100" MODIFIED_BY="Narelle Willis" NAME="Campbell 2015" TYPE="JOURNAL_ARTICLE">
<AU>Campbell DJ, Johnson DW, Mudge DW, Gallagher MP, Craig JC</AU>
<TI>Prevention of peritoneal dialysis-related infections</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2015</YR>
<VL>30</VL>
<NO>9</NO>
<PG>1461-72</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:08:40 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:08:40 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="25294849"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Canadian-CAPD-Clinical-Trials-Group-1989" MODIFIED="2016-12-28 16:25:12 +1100" MODIFIED_BY="Narelle Willis" NAME="Canadian CAPD Clinical Trials Group 1989" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multi-centre randomized clinical trial comparing the Y connector disinfectant system to standard systems. Canadian CAPD Clinical Trials Group</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>3</NO>
<PG>159-63</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:25:12 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:25:12 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2488361"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cho-2014" MODIFIED="2016-12-28 16:09:21 +1100" MODIFIED_BY="Narelle Willis" NAME="Cho 2014" TYPE="JOURNAL_ARTICLE">
<AU>Cho Y, Johnson DW</AU>
<TI>Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2014</YR>
<VL>64</VL>
<NO>2</NO>
<PG>278-89</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:09:21 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:09:21 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="24751170"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Choi-2004" MODIFIED="2016-12-28 16:09:58 +1100" MODIFIED_BY="Narelle Willis" NAME="Choi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Choi P, Nemati E, Banerjee A, Preston E, Levy J, Brown E</AU>
<TI>Peritoneal dialysis catheter removal for acute peritonitis: a retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>1</NO>
<PG>103-11</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:09:58 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:09:58 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="14712433"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chow-2005" MODIFIED="2016-12-28 16:10:33 +1100" MODIFIED_BY="Narelle Willis" NAME="Chow 2005" TYPE="JOURNAL_ARTICLE">
<AU>Chow KM, Szeto CC, Leung CB, Kwan BC, Law MC, Li PK</AU>
<TI>A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>4</NO>
<PG>374-9</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:10:33 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:10:33 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="16022095"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Churchill-1997" MODIFIED="2016-12-28 17:07:04 +1100" MODIFIED_BY="Narelle Willis" NAME="Churchill 1997" TYPE="JOURNAL_ARTICLE">
<AU>Churchill DN, Thorpe KE, Vonesh EF, Keshaviah PR</AU>
<TI>Lower probability of patient survival with continuous peritoneal dialysis in the United States compared with Canada. Canada-USA (CANUSA) Peritoneal Dialysis Study Group</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>6</NO>
<PG>965-71</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:11:21 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:11:21 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="9189865"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Collier-2008" MODIFIED="2016-12-28 16:15:00 +1100" MODIFIED_BY="Narelle Willis" NAME="Collier 2008" TYPE="OTHER">
<AU>Collier M, Evans D, Farrington M, Gibbs E, Gould K, Jenkinson H, et al</AU>
<TI>Surgical site infection: prevention and treatment. Clinical guideline [CG74], 2008</TI>
<SO>www.nice.org.uk/guidance/cg74</SO>
<YR>(accessed 28 December 2016)</YR>
<PG>1-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Daly-2001" MODIFIED="2016-12-28 17:07:10 +1100" MODIFIED_BY="Narelle Willis" NAME="Daly 2001" TYPE="JOURNAL_ARTICLE">
<AU>Daly CD, Campbell MK, MacLeod AM, Cody DJ, Vale LD, Grant AM, et al</AU>
<TI>Do the Y-set and double-bag systems reduce the incidence of CAPD peritonitis? A systematic review of randomized controlled trials</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>2</NO>
<PG>341-7</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:16:02 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:16:02 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="11158410"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dasgupta-1994" MODIFIED="2016-12-28 16:16:31 +1100" MODIFIED_BY="Narelle Willis" NAME="Dasgupta 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dasgupta MK</AU>
<TI>Silver peritoneal catheters reduce bacterial colonization</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1994</YR>
<VL>10</VL>
<PG>195-8</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:16:31 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:16:31 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="7999826"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Davies-1989" MODIFIED="2016-12-28 16:17:27 +1100" MODIFIED_BY="Narelle Willis" NAME="Davies 1989" TYPE="JOURNAL_ARTICLE">
<AU>Davies SJ, Ogg CS, Cameron JS, Poston S, Noble WC</AU>
<TI>Staphylococcus aureus nasal carriage, exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD)</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>1</NO>
<PG>61-4</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:17:21 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:17:21 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2488184"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Digenis-1990" MODIFIED="2016-12-28 16:18:06 +1100" MODIFIED_BY="Narelle Willis" NAME="Digenis 1990" TYPE="JOURNAL_ARTICLE">
<AU>Digenis GE, Abraham G, Savin E, Blake P, Dombros N, Sombolos K, et al</AU>
<TI>Peritonitis-related deaths in continuous ambulatory peritoneal dialysis (CAPD) patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>1</NO>
<PG>45-7</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:18:06 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:18:06 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2085582"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Farias-1994" MODIFIED="2016-12-28 16:19:00 +1100" MODIFIED_BY="Narelle Willis" NAME="Farias 1994" TYPE="JOURNAL_ARTICLE">
<AU>Farias MG, Soucie JM, McClellan W, Mitch WE</AU>
<TI>Race and the risk of peritonitis: an analysis of factors associated with the initial episode</TI>
<SO>Kidney International</SO>
<YR>1994</YR>
<VL>46</VL>
<NO>5</NO>
<PG>1392-6</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:19:00 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:19:00 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="7853799"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Figueiredo-2010" MODIFIED="2016-12-28 17:04:06 +1100" MODIFIED_BY="Narelle Willis" NAME="Figueiredo 2010" TYPE="OTHER">
<AU>Figueiredo A, Goh BL, Jenkins S, Johnson DW, Mactier R, Ramalakshmi S, et al</AU>
<TI>Clinical practice guidelines for peritoneal access</TI>
<SO>Peritoneal Dialysis International.</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>4</NO>
<PG>424-9</PG>
<IDENTIFIERS MODIFIED="2016-12-28 17:03:39 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 17:03:39 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="20628103"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fine-1994" MODIFIED="2016-12-28 16:19:34 +1100" MODIFIED_BY="Narelle Willis" NAME="Fine 1994" TYPE="JOURNAL_ARTICLE">
<AU>Fine A, Cox D, Bouw M</AU>
<TI>Higher incidence of peritonitis in native Canadians on continuous ambulatory peritoneal dialysis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>3</NO>
<PG>227-30</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:19:34 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:19:34 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="7948232"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fried-1996" MODIFIED="2016-12-28 16:20:12 +1100" MODIFIED_BY="Narelle Willis" NAME="Fried 1996" TYPE="JOURNAL_ARTICLE">
<AU>Fried LF, Bernardini J, Johnston JR, Piraino B</AU>
<TI>Peritonitis influences mortality in peritoneal dialysis patients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>10</NO>
<PG>2176-82</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:20:12 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:20:12 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8915978"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fung-1996" MODIFIED="2016-12-28 17:07:15 +1100" MODIFIED_BY="Narelle Willis" NAME="Fung 1996" TYPE="JOURNAL_ARTICLE">
<AU>Fung LC, Khoury AE, Vas SI, Smith C, Oreopoulos DG, Mittelman MW</AU>
<TI>Biocompatibility of silver-coated peritoneal dialysis catheter in a porcine model</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>4</NO>
<PG>398-405</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:20:58 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:20:58 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8863334"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ghali-2011" MODIFIED="2016-12-28 16:22:08 +1100" MODIFIED_BY="Narelle Willis" NAME="Ghali 2011" TYPE="JOURNAL_ARTICLE">
<AU>Ghali JR, Bannister KM, Brown FG, Rosman JB, Wiggins KJ, Johnson DW, et al</AU>
<TI>Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>6</NO>
<PG>651-62</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:22:08 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:22:08 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="21719685"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Golper-1996" MODIFIED="2016-12-28 17:07:18 +1100" MODIFIED_BY="Narelle Willis" NAME="Golper 1996" TYPE="JOURNAL_ARTICLE">
<AU>Golper TA, Brier ME, Bunke M, Schreiber MJ, Bartlett DK, Hamilton RW, et al</AU>
<TI>Risk factors for peritonitis in long-term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>3</NO>
<PG>428-36</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:23:12 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:23:12 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8804243"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2016-12-29 13:24:32 +1100" MODIFIED_BY="Narelle Willis" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="18436948"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heaf-2004" MODIFIED="2016-12-28 17:07:21 +1100" MODIFIED_BY="Narelle Willis" NAME="Heaf 2004" TYPE="JOURNAL_ARTICLE">
<AU>Heaf J</AU>
<TI>Underutilization of peritoneal dialysis</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>6</NO>
<PG>740-2</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:26:21 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:26:21 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="14871920"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-HICPAC-1995" MODIFIED="2016-12-28 17:07:29 +1100" MODIFIED_BY="Narelle Willis" NAME="HICPAC 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hospital Infection Control Practices Advisory Committee (HICPAC)</AU>
<TI>Recommendations for preventing the spread of vancomycin resistance.[Erratum appears in Infect Control Hosp Epidemiol 1995 Sep;16(9):498]</TI>
<SO>Infection Control &amp; Hospital Epidemiology</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>2</NO>
<PG>105-13</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:33:46 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:33:46 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="7759811"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2016-12-28 17:07:24 +1100" MODIFIED_BY="Narelle Willis" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:27:51 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:27:51 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="12958120"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-12-28 16:31:44 +1100" MODIFIED_BY="Narelle Willis" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holley-1993" MODIFIED="2016-12-28 17:07:27 +1100" MODIFIED_BY="Narelle Willis" NAME="Holley 1993" TYPE="JOURNAL_ARTICLE">
<AU>Holley JL, Bernardini J, Piraino B</AU>
<TI>A comparison of peritoneal dialysis-related infections in black and white patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1993</YR>
<VL>13</VL>
<NO>1</NO>
<PG>45-9</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:32:44 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:32:44 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8443276"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jaar-2009" MODIFIED="2016-12-28 17:07:40 +1100" MODIFIED_BY="Narelle Willis" NAME="Jaar 2009" TYPE="JOURNAL_ARTICLE">
<AU>Jaar BG, Plantinga LC, Crews DC, Fink NE, Hebah N, Coresh J, et al</AU>
<TI>Timing, causes, predictors and prognosis of switching from peritoneal dialysis to hemodialysis: a prospective study</TI>
<SO>BMC Nephrology</SO>
<YR>2009</YR>
<VL>10</VL>
<PG>3</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:35:26 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:35:26 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="19200383"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jain-2012" MODIFIED="2016-12-28 17:07:43 +1100" MODIFIED_BY="Narelle Willis" NAME="Jain 2012" TYPE="JOURNAL_ARTICLE">
<AU>Jain AK, Blake P, Cordy P, Garg AX</AU>
<TI>Global trends in rates of peritoneal dialysis</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>3</NO>
<PG>533-44</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:36:18 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:36:18 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="22302194"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johnson-2014" MODIFIED="2016-12-28 16:36:56 +1100" MODIFIED_BY="Narelle Willis" NAME="Johnson 2014" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DW, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, et al</AU>
<TI>Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2014</YR>
<VL>14</VL>
<NO>1</NO>
<PG>23-30</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="24119840"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Keane-2000" MODIFIED="2016-12-28 17:07:52 +1100" MODIFIED_BY="Narelle Willis" NAME="Keane 2000" TYPE="JOURNAL_ARTICLE">
<AU>Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, et al</AU>
<TI>Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update.[Erratum appears in Perit Dial Int 2000 Nov-Dec;20(6):828-9]</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>4</NO>
<PG>396-411</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:38:04 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:38:04 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="11007371"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lim-2005" MODIFIED="2016-12-28 17:07:54 +1100" MODIFIED_BY="Narelle Willis" NAME="Lim 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lim WH, Johnson DW, McDonald SP</AU>
<TI>Higher rate and earlier peritonitis in Aboriginal patients compared to non-Aboriginal patients with end-stage renal failure maintained on peritoneal dialysis in Australia: analysis of ANZDATA</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>2</NO>
<PG>192-7</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:38:55 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:38:55 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="15877681"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lloyd-2013" MODIFIED="2016-12-28 17:07:59 +1100" MODIFIED_BY="Narelle Willis" NAME="Lloyd 2013" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd A, Tangri N, Shafer LA, Rigatto C, Perl J, Komenda P, et al</AU>
<TI>The risk of peritonitis after an exit site infection: a time-matched, case-control study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2013</YR>
<VL>28</VL>
<NO>7</NO>
<PG>1915-21</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:39:50 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:39:50 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="23382265"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McDonald-2004" MODIFIED="2016-12-28 17:08:04 +1100" MODIFIED_BY="Narelle Willis" NAME="McDonald 2004" TYPE="JOURNAL_ARTICLE">
<AU>McDonald SP, Collins JF, Rumpsfeld M, Johnson DW</AU>
<TI>Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>4</NO>
<PG>340-6</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:40:52 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:40:52 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="15335147"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2016-12-28 16:42:10 +1100" MODIFIED_BY="Narelle Willis" NAME="Moher 1998" TYPE="OTHER">
<AU>Moher D; Pham B; Jones A; Cook DJ; Jadad AR; Moher M; et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:42:10 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:42:10 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="9746022"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morton-2011" MODIFIED="2016-12-28 17:08:08 +1100" MODIFIED_BY="Narelle Willis" NAME="Morton 2011" TYPE="JOURNAL_ARTICLE">
<AU>Morton RL, Tong A, Webster AC, Snelling P, Howard K</AU>
<TI>Characteristics of dialysis important to patients and family caregivers: a mixed methods approach</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>12</NO>
<PG>4038-46</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:43:23 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:43:23 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="21482637"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nessim-2009" MODIFIED="2016-12-28 17:08:12 +1100" MODIFIED_BY="Narelle Willis" NAME="Nessim 2009" TYPE="JOURNAL_ARTICLE">
<AU>Nessim SJ, Bargman JM, Austin PC, Nisenbaum R, Jassal SV</AU>
<TI>Predictors of peritonitis in patients on peritoneal dialysis: results of a large, prospective Canadian database</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>7</NO>
<PG>1195-200</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:44:34 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:44:34 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="19406969"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nolph-1987" MODIFIED="2016-12-28 17:08:16 +1100" MODIFIED_BY="Narelle Willis" NAME="Nolph 1987" TYPE="JOURNAL_ARTICLE">
<AU>Nolph KD, Cutler SJ, Steinberg SM, Novak JW, Hirschman GH</AU>
<TI>Factors associated with morbidity and mortality among patients on CAPD</TI>
<SO>ASAIO Transactions</SO>
<YR>1987</YR>
<VL>33</VL>
<NO>2</NO>
<PG>57-65</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:45:13 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:45:13 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="3606901"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oxton-1994" MODIFIED="2016-12-28 17:08:18 +1100" MODIFIED_BY="Narelle Willis" NAME="Oxton 1994" TYPE="JOURNAL_ARTICLE">
<AU>Oxton LL, Zimmerman SW, Roecker EB, Wakeen M</AU>
<TI>Risk factors for peritoneal dialysis-related infections</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>2</NO>
<PG>137-44</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:46:03 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:46:03 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8043666"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Perez_x002d_Fontan-1993" MODIFIED="2016-12-28 17:08:22 +1100" MODIFIED_BY="Narelle Willis" NAME="Perez-Fontan 1993" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Fontan M, Garcia-Falcon T, Rosales M, Rodriguez-Carmona A, Adeva M, Rodriguez-Lozano I, et al</AU>
<TI>Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1993</YR>
<VL>22</VL>
<NO>5</NO>
<PG>708-12</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:46:53 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:46:53 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8238017"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Piraino-1989" MODIFIED="2016-12-28 16:47:42 +1100" MODIFIED_BY="Narelle Willis" NAME="Piraino 1989" TYPE="JOURNAL_ARTICLE">
<AU>Piraino B, Bernardini J, Sorkin M</AU>
<TI>Catheter infections as a factor in the transfer of continuous ambulatory peritoneal dialysis patients to hemodialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>5</NO>
<PG>365-9</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:47:42 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:47:42 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2719024"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Piraino-1990" MODIFIED="2016-12-28 16:48:13 +1100" MODIFIED_BY="Narelle Willis" NAME="Piraino 1990" TYPE="JOURNAL_ARTICLE">
<AU>Piraino B</AU>
<TI>A review of Staphylococcus aureus exit-site and tunnel infections in peritoneal dialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1990</YR>
<VL>16</VL>
<NO>2</NO>
<PG>89-95</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:48:13 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:48:13 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2200261"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Piraino-1998" MODIFIED="2016-12-28 16:48:49 +1100" MODIFIED_BY="Narelle Willis" NAME="Piraino 1998" TYPE="JOURNAL_ARTICLE">
<AU>Piraino B</AU>
<TI>Peritonitis as a complication of peritoneal dialysis</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>10</NO>
<PG>1956-64</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:48:49 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:48:49 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="9773798"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Piraino-2000" MODIFIED="2016-12-28 16:49:24 +1100" MODIFIED_BY="Narelle Willis" NAME="Piraino 2000" TYPE="JOURNAL_ARTICLE">
<AU>Piraino B</AU>
<TI>Staphylococcus aureus infections in dialysis patients: focus on prevention</TI>
<SO>ASAIO Journal</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>6</NO>
<PG>S13-7</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:49:24 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:49:24 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="11110288"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Piraino-2002" MODIFIED="2016-12-28 16:50:16 +1100" MODIFIED_BY="Narelle Willis" NAME="Piraino 2002" TYPE="JOURNAL_ARTICLE">
<AU>Piraino B</AU>
<TI>ADEMEX: how should it change our practice? Adequacy of peritoneal dialysis in Mexico</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>5</NO>
<PG>552-4</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:50:16 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:50:16 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="12455564"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Piraino-2011" MODIFIED="2016-12-28 17:08:27 +1100" MODIFIED_BY="Narelle Willis" NAME="Piraino 2011" TYPE="JOURNAL_ARTICLE">
<AU>Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye WC, et al</AU>
<TI>ISPD position statement on reducing the risks of peritoneal dialysis-related infections</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>6</NO>
<PG>614-30</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:51:13 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:51:13 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="21880990"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Salusky-1997" MODIFIED="2016-12-28 17:08:32 +1100" MODIFIED_BY="Narelle Willis" NAME="Salusky 1997" TYPE="JOURNAL_ARTICLE">
<AU>Salusky IB, Holloway M</AU>
<TI>Selection of peritoneal dialysis for pediatric patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1997</YR>
<VL>17 Suppl 3</VL>
<PG>S35-7</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:51:45 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:51:45 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="9304656"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schaefer-2003" MODIFIED="2016-12-28 17:08:34 +1100" MODIFIED_BY="Narelle Willis" NAME="Schaefer 2003" TYPE="JOURNAL_ARTICLE">
<AU>Schaefer F</AU>
<TI>Management of peritonitis in children receiving chronic peritoneal dialysis</TI>
<SO>Paediatric Drugs</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>5</NO>
<PG>315-25</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:52:31 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:52:31 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="12716218"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2016-12-28 17:08:37 +1100" MODIFIED_BY="Narelle Willis" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:53:17 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:53:17 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="7823387"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011a" MODIFIED="2016-12-29 13:24:35 +1100" MODIFIED_BY="Narelle Willis" NAME="Schünemann 2011a" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011b" MODIFIED="2016-12-29 13:24:38 +1100" MODIFIED_BY="Narelle Willis" NAME="Schünemann 2011b" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sutherland-1985" MODIFIED="2016-12-28 17:08:47 +1100" MODIFIED_BY="Narelle Willis" NAME="Sutherland 1985" TYPE="JOURNAL_ARTICLE">
<AU>Sutherland R, Boon RJ, Griffin KE, Masters PJ, Slocombe B, White AR</AU>
<TI>Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1985</YR>
<VL>27</VL>
<NO>4</NO>
<PG>495-8</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:56:11 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:56:11 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="3923922"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thodis-2000" MODIFIED="2016-12-28 17:08:49 +1100" MODIFIED_BY="Narelle Willis" NAME="Thodis 2000" TYPE="JOURNAL_ARTICLE">
<AU>Thodis E, Passadakis P, Panagoutsos S, Bacharaki D, Euthimiadou A, Vargemezis V</AU>
<TI>The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>2000</YR>
<VL>16</VL>
<PG>257-61</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:56:54 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:56:54 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="11045306"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Troidle-1998" MODIFIED="2016-12-28 17:08:53 +1100" MODIFIED_BY="Narelle Willis" NAME="Troidle 1998" TYPE="JOURNAL_ARTICLE">
<AU>Troidle L, Gorban-Brennan N, Kliger A, Finkelstein F</AU>
<TI>Differing outcomes of gram-positive and gram-negative peritonitis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1998</YR>
<VL>32</VL>
<NO>4</NO>
<PG>623-8</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:57:22 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:57:22 +1100" MODIFIED_BY="Narelle Willis" TYPE="OTHER" VALUE="9774124"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Troidle-2003" MODIFIED="2016-12-28 17:08:56 +1100" MODIFIED_BY="Narelle Willis" NAME="Troidle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Troidle L, Watnick S, Wuerth DB, Gorban-Brennan N, Kliger AS, Finkelstein FO</AU>
<TI>Depression and its association with peritonitis in long-term peritoneal dialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>2</NO>
<PG>350-4</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:58:34 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:58:34 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="12900818"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-Biesen-2014" MODIFIED="2016-12-28 17:06:53 +1100" MODIFIED_BY="Narelle Willis" NAME="Van Biesen 2014" TYPE="JOURNAL_ARTICLE">
<AU>Van Biesen W, Jorres A</AU>
<TI>Medihoney: let nature do the work?</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2014</YR>
<VL>14</VL>
<NO>1</NO>
<PG>2-3</PG>
<IDENTIFIERS MODIFIED="2016-12-28 16:59:44 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 16:59:44 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="24119839"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-Diepen-2012" MODIFIED="2016-12-28 17:08:59 +1100" MODIFIED_BY="Narelle Willis" NAME="van Diepen 2012" TYPE="JOURNAL_ARTICLE">
<AU>van Diepen AT, Tomlinson GA, Jassal SV</AU>
<TI>The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>8</NO>
<PG>1266-71</PG>
<IDENTIFIERS MODIFIED="2016-12-28 17:00:34 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 17:00:34 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="22745277"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walker-2014" MODIFIED="2016-12-28 17:01:39 +1100" MODIFIED_BY="Narelle Willis" NAME="Walker 2014" TYPE="OTHER">
<AU>Walker A, Bannister K, George C, Mudge D, Yehia M, Lonergan M, et al</AU>
<TI>KHA-CARI Guideline: peritonitis treatment and prophylaxis</TI>
<SO>Nephrology</SO>
<YR>2014</YR>
<VL>19</VL>
<NO>2</NO>
<PG>69-71</PG>
<IDENTIFIERS MODIFIED="2016-12-28 17:01:39 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 17:01:39 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="23944845"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ward-1986" MODIFIED="2016-12-28 17:09:02 +1100" MODIFIED_BY="Narelle Willis" NAME="Ward 1986" TYPE="JOURNAL_ARTICLE">
<AU>Ward RA, Chang BS</AU>
<TI>Systems and devices used for peritoneal dialysis</TI>
<SO>Medical Instrumentation</SO>
<YR>1986</YR>
<VL>20</VL>
<NO>2</NO>
<PG>85-92</PG>
<IDENTIFIERS MODIFIED="2016-12-28 17:02:13 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 17:02:13 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="3702785"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Woodrow-1997" MODIFIED="2016-12-28 17:04:47 +1100" MODIFIED_BY="Narelle Willis" NAME="Woodrow 1997" TYPE="JOURNAL_ARTICLE">
<AU>Woodrow G, Turney JH, Brownjohn AM</AU>
<TI>Technique failure in peritoneal dialysis and its impact on patient survival</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>4</NO>
<PG>360-4</PG>
<IDENTIFIERS MODIFIED="2016-12-28 17:04:47 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 17:04:47 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="9284463"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Woodrow-2010" MODIFIED="2016-12-28 17:15:47 +1100" MODIFIED_BY="Narelle Willis" NAME="Woodrow 2010" TYPE="OTHER">
<AU>Woodrow G, Davies S</AU>
<TI>Peritoneal dialysis in CKD. 2010</TI>
<SO>www.renal.org/guidelines/modules/peritoneal-dialysis-in-ckd#sthash.gkEx1Y5v.dpbs</SO>
<YR>(accessed 28 December 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Strippoli-2003" MODIFIED="2016-12-28 17:14:19 +1100" MODIFIED_BY="Narelle Willis" NAME="Strippoli 2003" TYPE="COCHRANE_PROTOCOL">
<AU>Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC</AU>
<TI>Anti-infective (antiseptics and antibiotics) agents for preventing peritonitis in peritoneal dialysis patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-12-28 17:12:59 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 17:12:59 +1100" MODIFIED_BY="Narelle Willis" TYPE="DOI" VALUE="10.1002/14651858.CD004679"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strippoli-2004a" MODIFIED="2016-12-28 17:22:12 +1100" MODIFIED_BY="Narelle Willis" NAME="Strippoli 2004a" TYPE="COCHRANE_REVIEW">
<AU>Strippoli GF, Tong A, Johnson DW, Schena FP, Craig JC</AU>
<TI>Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-12-28 17:10:53 +1100" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-12-28 17:10:53 +1100" MODIFIED_BY="Narelle Willis" TYPE="DOI" VALUE="10.1002/14651858.CD004679.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strippoli-2004b" MODIFIED="2016-12-28 17:14:48 +1100" MODIFIED_BY="Narelle Willis" NAME="Strippoli 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC</AU>
<TI>Antimicrobial agents to prevent peritonitis in peritoneal dialysis: A systematic review of randomized controlled trials</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>44</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS MODIFIED="2010-11-23 13:56:26 +1100" MODIFIED_BY="Narelle S Willis"><IDENTIFIER MODIFIED="2010-11-23 13:56:26 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15384009"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2017-04-04 15:57:07 +1000" MODIFIED_BY="Narelle S Willis"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-01-05 16:05:35 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Axelrod-1973">
<CHAR_METHODS MODIFIED="2016-12-29 14:40:26 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 2 months at Bronx VA Hospital; 12 months at Mt Sinai Hospital</LI>
<LI>Follow-up period: not reported</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-29 14:34:07 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: 2 tertiary centres</LI>
<LI>Country: USA</LI>
<LI>Health status: PD patients</LI>
<LI>Number: 36 (no numbers given for intervention and control group)</LI>
<LI>Mean age: Bronx VA Hospital (47 years); Mt Sinai Hospital (not reported)</LI>
<LI>Sex (M/F): Bronx VA Hospital (24/0); Mt Sinai Hospital (3/9)</LI>
<LI>Proportion of diabetic patients: Bronx VA Hospital (8.3%); Mt Sinai Hospital (8.3%)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-29 14:38:44 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cephalothin added to 2 L bottle of dialysate (100 µg/mL)</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo solution added to 2 L bottle of dialysate</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-29 14:48:43 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (number of dialyses)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 16:05:35 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: Public Health Service grant and Eli Lilly &amp; Company, Indianapolis</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-05 16:14:11 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Bennet_x002d_Jones-1988">
<CHAR_METHODS MODIFIED="2016-12-29 14:42:33 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 28 days</LI>
<LI>Follow-up period: 28 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-29 14:47:34 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: UK</LI>
<LI>Health status: all patients who were to undergo the insertion of a Tenckhoff catheter prior to starting CAPD</LI>
<LI>Number: treatment group (13); control group (14)</LI>
<LI>Mean age ± SD (years): treatment group (52.7 ± 18.6); control group (53.1 ± 13.0)</LI>
<LI>Sex (M/F): treatment group (8/5); control group (9/4)</LI>
<LI>Proportion of diabetic patients: 0% in either group</LI>
<LI>Exclusion criteria: receiving any antibiotic in the previous 7 days; receiving vancomycin in the previous 3 weeks; history of gentamicin toxicity; any pre-existing hearing deficit</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-29 16:44:15 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Gentamicin (IV) 1.5 mg/kg at time of catheter placement</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No antibiotic treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-29 14:48:57 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (number of patients)</LI>
<LI>Exit-site/tunnel infection (number of patients)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 16:14:11 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: none</LI>
<LI>Stop or end point/s: review after 25 patients had completed 28 day follow-up period</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bernardini-1996">
<CHAR_METHODS MODIFIED="2016-12-29 14:51:32 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: August 1992 to end September 1994</LI>
<LI>Follow-up period: 1 year (mean)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-29 14:56:39 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: 2 tertiary centres</LI>
<LI>Country: USA</LI>
<LI>Health status: adult CAPD and CCPD patients (prevalent and incident); no catheter infection or peritonitis; no antibiotics for at least 2 weeks prior to the study</LI>
<LI>Number: treatment group 1 (41); treatment group 2 (41)</LI>
<LI>Mean age ± SD (years): not reported</LI>
<LI>Sex (M/F): treatment group 1 (24/17); treatment group 2 (20/21)</LI>
<LI>Proportion of diabetic patients: treatment group 1 (27%); treatment group 2 (41%)</LI>
<LI>Exclusion criteria: refusal to participate; contraindication to rifampin; patient on daily erythromycin therapy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 16:11:10 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Mupirocin ointment (2%) daily application to exit site</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Rifampin (oral) 300 mg, twice/day for 5 days, every 3 months</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-29 14:57:49 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (rate)</LI>
<LI>Peritonitis (number of patients)</LI>
<LI>Catheter removal/replacement</LI>
<LI>Adverse effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-29 15:00:03 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: when patient ceased PD or study ended</LI>
<LI>Additional data requested from authors: further information on methods and more detailed results were obtained from the corresponding author</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bernardini-2005">
<CHAR_METHODS MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: July 2001 to August 2003</LI>
<LI>Duration of follow-up: to December 2003 (8 months median)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-29 15:05:11 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: 3 tertiary centres</LI>
<LI>Country: USA</LI>
<LI>Health status: &#8805; 18 years; on PD; able to give informed consent; already enrolled in a registry permitting data collection</LI>
<LI>Number: treatment group 1 (67); treatment group 2 (66)</LI>
<LI>Mean age ± SD (years): treatment group 1 (54 ± 15); treatment group 2 (51 ± 15)</LI>
<LI>Sex (M/F): treatment group 1 (34/33); treatment group 2 (38/28)</LI>
<LI>Proportion of diabetic patients: treatment group 1 (40%); treatment group 2 (41%)</LI>
<LI>Exclusion criteria: allergy to either study cream; those in another interventional study; those with catheter infections or peritonitis in the past 30 days</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-29 15:05:41 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Daily application of gentamicin cream (gentamicin sulfate 0.1%)</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Mupirocin cream (mupirocin 2%) at exit site</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 16:11:31 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>
<I>P. aeruginosa</I> and <I>S. aureus</I> catheter infection rate</LI>
<LI>Gram-negative and gram-positive peritonitis</LI>
<LI>Overall catheter infection rate</LI>
<LI>Overall peritonitis rate</LI>
<LI>Causative organisms</LI>
<LI>catheter removal (due to infection)</LI>
<LI>Time to first catheter infection</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-29 15:08:00 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: National Kidney Foundation of Western Pennsylvania, National Kidney Foundation of Upstate New York, Paul Teschan Fund of Dialysis Clinic, Inc</LI>
<LI>Exclusions post-randomisation but pre-intervention: 3 in mupirocin group (did not start PD)</LI>
<LI>Stop or end point/s: stopped at 118 patient-years when a difference in peritonitis rates between the groups was found</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-12 09:59:36 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Blowey-1994">
<CHAR_METHODS MODIFIED="2016-12-29 15:10:07 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 1991 to 1993</LI>
<LI>Duration of follow-up: 1 month</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-12 09:59:36 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: USA</LI>
<LI>Health status: no evidence of a dialysis-related infection in the preceding month; no antibiotic therapy in the preceding month; duration of dialysis of at least 3 months</LI>
<LI>Number: treatment group (7); control group (8)</LI>
<LI>Mean age (range): 11.5 years (8 months to 21 years)</LI>
<LI>Sex (M/F): 18/16</LI>
<LI>Proportion of diabetic patients: not reported</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 16:12:06 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Rifampin: 20 mg/kg/d in 2 doses for 5 days</LI>
<LI>Nasal bacitracin (mupirocin): twice/d for 7 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No antibiotic treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-29 15:16:34 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (number of patients)</LI>
<LI>exit-site/tunnel infection (number of patients)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-29 15:18:42 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-05 16:19:30 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Cheng-1999a">
<CHAR_METHODS MODIFIED="2016-12-29 15:22:57 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: not reported</LI>
<LI>Duration of follow-up: treatment group 1 (17.2 ± 5 months); treatment group 2 (16.6 ± 6 months)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 16:19:30 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: Single centre</LI>
<LI>Country: Hong Kong</LI>
<LI>Health status: CAPD patients with infection-free exit sites</LI>
<LI>Number: treatment group 1 (33); treatment group 2 (33)</LI>
<LI>Mean age: not reported</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Proportion of diabetic patients: not reported</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-29 15:35:14 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Chlorhexidine soap at exit site: daily</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Povidone iodine at exit site: daily</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 11:31:14 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Exit-site infection (rate)</LI>
<LI>Catheter removal (number)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-29 15:25:06 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Abstract-only publication</LI>
<LI>Funding source: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Chu-2008">
<CHAR_METHODS MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: quasi RCT</LI>
<LI>Study duration/time frame: June to November 2005</LI>
<LI>Duration of follow-up: not reported</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 11:31:17 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: Single centre</LI>
<LI>Country: Hong Kong</LI>
<LI>Health status: adult PD patients without any exclusion criteria</LI>
<LI>Number (analysed/randomised): 81/95; treatment group 1 (43); treatment group 2 (38)</LI>
<LI>Mean age: treatment group 1 (57.6 years); treatment group 2 (61.2 years)</LI>
<LI>Sex (M/F): treatment group 1 (27/16); treatment group 2 (31/7)</LI>
<LI>Proportion of diabetic patients: treatment group 1 (41.9%); treatment group 2 (28.9%)</LI>
<LI>Exclusion criteria: active infection; exit-site infection or peritonitis within the previous 4 weeks; allergy to either gentamicin or mupirocin; inability to apply the drug; inability to give consent</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-29 15:36:16 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Gentamicin cream: daily at exit site</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Mupirocin ointment: daily at exit site</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 11:31:22 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (number of patients)</LI>
<LI>Peritonitis rate</LI>
<LI>Exit-site/tunnel infection (number of patients)</LI>
<LI>Exit-site/tunnel infection rate</LI>
<LI>All-cause mortality</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-29 15:45:57 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
<LI>Additional data requested from authors: further information on methods were obtained from the corresponding author (KH Chu)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-29 16:43:51 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Churchill-1988">
<CHAR_METHODS MODIFIED="2016-12-29 16:00:39 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 12 months</LI>
<LI>Duration of follow-up: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:02:10 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: 4 tertiary centres</LI>
<LI>Country: Canada</LI>
<LI>Health status: CAPD patients aged 18 to 80 years</LI>
<LI>Number: treatment group (56); control group (49)</LI>
<LI>Mean age: not reported</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Proportion of diabetic patients: not reported</LI>
<LI>Exclusion criteria: allergy to either trimethoprim or sulfamethoxazole; elective transplantation; move from study area; unlikely to survive the study period; noncompliance; active tunnel infection; no previous peritonitis in patients who had been on CAPD for 18 months or more</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-29 16:43:51 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Trimethoprim 160 mg/sulfamethoxazole 800 mg/day for 12 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No antibiotic treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-29 16:03:41 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>All-cause mortality</LI>
<LI>Mortality due to peritonitis</LI>
<LI>Peritonitis (number of patients)</LI>
<LI>Transfers to HD or transplantation</LI>
<LI>Withdrawals</LI>
<LI>Adverse reactions</LI>
<LI>Response to peritonitis treatment</LI>
<LI>Peritoneal catheter loss</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-29 16:04:34 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: Hoffman La Roche supplied the antibiotic (cotrimoxazole) and placebo tablets</LI>
<LI>Exclusions post-randomisation but pre-intervention: 49 eligible patients refused to participate</LI>
<LI>Stop or end point/s: 12 months from start of treatment</LI>
<LI>Additional data requested from authors: Further information on methods and more detailed results were obtained from the corresponding author</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-05 11:31:29 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Cocksedge-1993">
<CHAR_METHODS MODIFIED="2016-12-29 16:06:35 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 1 January 1988 to 31 December 1989</LI>
<LI>Duration of follow-up: not reported</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:08:04 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single tertiary centre</LI>
<LI>Country: Australia</LI>
<LI>Health status: current and new adult CAPD patients</LI>
<LI>Number: treatment group 1 (30); treatment group 2 (30)</LI>
<LI>Mean age: not reported (most patients were &gt; 60 years)</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Proportion of diabetic patients: 11.7% (7/60)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-29 16:08:40 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Shower and gauze</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Dressing pack and Fixomull dressing at exit site</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 11:31:29 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Exit-site infection (rate)</LI>
<LI>Exit-site infection (number of patients)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-29 16:10:34 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Danguilan-2003">
<CHAR_METHODS MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: May 1998 to 31 January 2000</LI>
<LI>Duration of follow-up: 1.5 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 11:31:32 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: Single centre</LI>
<LI>Country: Philippines</LI>
<LI>Health status: new exit-site infection-free CAPD patients</LI>
<LI>Number: treatment group 1 (50); treatment group 2 (50)</LI>
<LI>Mean age: not reported</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Proportion of diabetic patients (%): not reported</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-29 16:16:52 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Sodium fusidate ointment at exit site after weekly dressing change</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Mupirocin ointment at exit site after weekly dressing change (weekly)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 11:31:38 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Exit-site infection (number of patients)</LI>
<LI>Exit-site infection (rate)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-29 16:17:30 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
<LI>Additional data requested from authors: Further information on methods and results were obtained from the corresponding author (R Danguilan)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-05 16:22:16 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Fuchs-1990">
<CHAR_METHODS MODIFIED="2016-12-29 16:20:13 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 1 October 1987 to 31 December 1988</LI>
<LI>Duration of follow-up: 15 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 11:31:47 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: USA</LI>
<LI>Health status: CAPD and APD patients over 18 years of age with well-healed non-inflamed exit sites; no previous exit-site infection associated with the current catheter</LI>
<LI>Number: treatment group 1 (18); treatment group 2 (13); treatment group 3 (20)</LI>
<LI>Mean age (years): treatment group 1 (46); treatment group 2 (47); treatment group 3 (55)</LI>
<LI>Sex (M/F): treatment group 1 (7/11); treatment group 2 (7/6); treatment group 3 (13/7)</LI>
<LI>Proportion of diabetic patients: treatment group 1 (55.6%); treatment group 2 (53.8%); treatment group 3 (25%)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 11:31:55 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Exit-site cleaning with chlorhexidine gluconate and water</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Exit-site cleaning with sodium hypochlorite solution</LI>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>Exit-site cleaning with povidone-iodine solution</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 11:31:57 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Exit-site infection (number of patients)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 16:22:16 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: none</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-05 11:32:03 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Gadallah-2000c">
<CHAR_METHODS MODIFIED="2016-12-29 16:36:04 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 8 years</LI>
<LI>Duration of follow-up: 14 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:40:07 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single tertiary centre</LI>
<LI>Country: USA</LI>
<LI>Health status: patients undergoing permanent PD catheter placement</LI>
<LI>Number: treatment group 1 (90); treatment group 2 (88); control group (87)</LI>
<LI>Mean age, range (years): treatment group 1 (46, 15 to 72); treatment group 2 (47, 20 to 81); control group (45, 19 to 76)</LI>
<LI>Sex (M/F): treatment group 1 (38/52); treatment group 2 (43/45); control group (38/49)</LI>
<LI>Proportion of diabetic patients: treatment group 1 (35.6%); treatment group 2 (34.1%); control group (32.2%)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-29 16:43:24 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Vancomycin (IV): 1000 mg 12 h before catheter placement</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Cefazolin (IV): 1000 mg 3 h before catheter placement</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No antibiotic treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 11:32:03 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (number of patients)</LI>
<LI>Exit-site/tunnel infection (number of patients, within 14 days of date of catheter insertion)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-29 16:46:32 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-09 16:36:32 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-HONEYPOT-Study-2009">
<CHAR_METHODS MODIFIED="2016-12-29 16:49:09 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 17 September 2008 to 16 June 2012</LI>
<LI>Duration of follow-up: minimum of 12 months; maximum of 24 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-09 16:36:24 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: 26 tertiary centres</LI>
<LI>Country: Australia; New Zealand</LI>
<LI>Health status: adults and children of all ages with ESKD who were undergoing PD</LI>
<LI>Number: treatment group 1 (186); treatment group 2 (185)</LI>
<LI>Mean age ± SD (years): treatment group 1 (61.2 ± 14.5); treatment group 2 (62.1 ± 14.6)</LI>
<LI>Sex (M/F): treatment group 1 (108/78); treatment group 2 (116/69)</LI>
<LI>Proportion of diabetic patients: treatment group 1 (34%); treatment group 2 (28%)</LI>
<LI>Exclusion criteria: exit-site infection, tunnel infection or peritonitis in the preceding month; current or recent (within the preceding 4 weeks) treatment with an antibiotic administered by any route; nasal carriage of mupirocin-resistant <I>S. aureus</I>; known hypersensitivity to or intolerance of honey or mupirocin; inability to provide informed consent; history of psychological illness or disorder that interfered with the ability to understand or comply with the requirements of the study</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 16:24:20 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Daily topical exit-site application of antibacterial honey (10 mg) plus standard exit-site care</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Intranasal application of mupirocin ointment (2% mupirocin) (only in carriers of nasal <I>S. aureus</I>) plus standard exit-site care. Mupirocin to be applied twice daily for 5 days, each month</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-09 16:36:32 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Time to first episode of exit-site infection, tunnel infection or peritonitis, whichever came first</LI>
<LI>Time to first exit-site infection</LI>
<LI>Time to first tunnel infection</LI>
<LI>Time to first peritonitis</LI>
<LI>Time to infection-associated catheter removal</LI>
<LI>Death</LI>
<LI>Serious adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 16:24:34 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: Baxter Healthcare; Queensland government; Comvita; Gambro</LI>
<LI>Exclusions post-randomisation but pre-intervention: none</LI>
<LI>Stop or end point/s: once 185 individuals per group had been followed up for at least 12 months</LI>
<LI>Additional data requested from authors: Further information about results were obtained from the biostatistician (E Pascoe)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Lo-1996">
<CHAR_METHODS MODIFIED="2017-01-09 16:54:13 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 1 May 1991 to 30 April 1993</LI>
<LI>Duration of follow-up: treatment group (8.0 ± 7.6 months); control group (16.6 ± 8.5 months)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-29 17:10:04 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: 2 tertiary centres</LI>
<LI>Country: Hong Kong</LI>
<LI>Health status: all patients receiving CAPD</LI>
<LI>Number: treatment group (199); control group (198)</LI>
<LI>Mean age ± SD (years): treatment group (48.4 ± 14.5); control group (48.5 ± 14.2)</LI>
<LI>Sex (M/F): treatment group (86/113); control group (98/100)</LI>
<LI>Proportion of diabetic patients: treatment group (18.6%); control group (15.2%)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 16:24:50 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Nystatin: 500,000 units, 4 times/day (whenever antibiotics were prescribed to patient)</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No fungal treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-29 17:11:25 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (number of patients)</LI>
<LI>Peritonitis (rate due to Candida spp.)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 17:13:57 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study focusing on prophylaxis to prevent Candida peritonitis in CAPD patients receiving antibiotics for any indication</LI>
<LI>Funding source: not reported</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-12 10:03:14 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Low-1980">
<CHAR_METHODS MODIFIED="2016-12-29 17:15:06 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: April to September 1979</LI>
<LI>Duration of follow-up: not reported</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-12 10:03:14 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: 2 tertiary centres</LI>
<LI>Country: Canada</LI>
<LI>Health status: patients receiving CAPD</LI>
<LI>Number: treatment group (25); control group (25)</LI>
<LI>Mean age: not reported</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Proportion of diabetic patients: not reported</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 16:25:24 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cefalexin: 500 mg, twice/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-29 17:17:15 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (number of patients)</LI>
<LI>Peritonitis (rate)</LI>
<LI>Catheter removal/replacement (number of patients)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-29 17:17:48 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: National Institutes of Health</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Luzar-1990">
<CHAR_METHODS MODIFIED="2016-12-29 17:19:16 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: May 1987 to September 1988</LI>
<LI>Duration of follow-up: 9.03 months/patient</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-29 17:20:36 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: 8 tertiary centres</LI>
<LI>Country: UK, France, Belgium</LI>
<LI>Health status: new and current CAPD patients</LI>
<LI>Number: treatment group (74); control group (53)</LI>
<LI>Mean age: not reported</LI>
<LI>Sex (M/F): treatment group (47/27); control group (31/22)</LI>
<LI>Proportion of diabetic patients: treatment group (17%); control group (11%)</LI>
<LI>Exclusion criteria: patients with any current infection</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-29 17:21:19 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Povidone iodine (20 g/L) and nonocclusive dressing 2 to 3 times/wk</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Non-disinfectant soap and water</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-29 17:21:42 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>All-cause mortality</LI>
<LI>Peritonitis (rate)</LI>
<LI>Exit-site/tunnel infection (rate)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 16:26:59 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported but lead author employed by Baxter R &amp; D Europe, Belgium</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: 9 patients randomised to control group refused to do that type of exit-site care</LI>
<LI>Stop or end point/s: 1 year of follow-up per patient or until a significant difference in rate of exit-site infection</LI>
<LI>Four patients in control group changed to treatment group</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-29 17:27:47 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Lye-1992">
<CHAR_METHODS MODIFIED="2016-12-29 17:23:49 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 1 May 1989 to 31 May 1990</LI>
<LI>Duration of follow-up: not reported</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-29 17:25:50 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single tertiary centre</LI>
<LI>Country: Singapore</LI>
<LI>Health status: patients having CAPD catheters inserted</LI>
<LI>Number: treatment group (33); control group (33)</LI>
<LI>Mean age ± SD (years): treatment group (56.2 ± 12.3); control group (55.6 ± 13.4)</LI>
<LI>Sex (M/F): treatment group (12/21); control group (18/15)</LI>
<LI>Proportion of diabetic patients: treatment group (68%); control group (52%)</LI>
<LI>Exclusion criteria: recognised infection at the time of surgery; antibiotic therapy in the week prior to surgery; vancomycin therapy in the 2 weeks before surgery; history of allergy to beta-lactam antibiotics and aminoglycosides</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-29 17:26:41 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cefazolin (IV) 500 mg and gentamicin (IV) 80 mg 0.5 to 1.0 hour before catheter placement</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No antibiotic treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-29 17:27:05 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>All-cause mortality</LI>
<LI>peritonitis (number of patients)</LI>
<LI>Exit-site/tunnel infection (number of patients within 4 weeks of catheter insertion)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-29 17:27:47 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-05 11:32:21 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Mendoza_x002d_Guevara-2007">
<CHAR_METHODS MODIFIED="2016-12-29 17:29:17 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 22 January 2004 to 15 March 2005</LI>
<LI>Duration of follow-up: not reported</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-29 17:43:43 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: Mexico</LI>
<LI>Health status: CCPD patients that had been at least 3 months on the PD program and free of peritonitis or exit-site infection for at least 1 month since the last episode</LI>
<LI>Number: treatment group (30); control group (30)</LI>
<LI>Median age, Q25 to 75 (years): treatment group (12, 10 to 14); control group (12 8.75 to 14.25)</LI>
<LI>Sex (M/F): treatment group (19/11); control group (11/19)</LI>
<LI>Proportion of diabetic patients: not reported</LI>
<LI>Exclusion criteria: patients on steroids; patients with cancer; HIV positive patients</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-29 17:44:21 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Amuchina 10% (sodium hypochlorite) solution for cleaning exit site</LI>
</UL>
<P>Control group</P>
<UL>
<LI>pH neutral soap for cleaning exit site</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 11:32:21 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Exit-site infection (number of patients)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-29 17:44:39 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-05 16:28:13 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Moore-1989">
<CHAR_METHODS MODIFIED="2017-01-05 10:08:57 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel quasi RCT</LI>
<LI>Study duration/time frame: 1 October 1987 to 1 February 1988</LI>
<LI>Duration of follow-up: 4 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 16:28:13 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: Single centre</LI>
<LI>Country: USA</LI>
<LI>Health status: current CAPD patients (adult)</LI>
<LI>Number: treatment group (15); control group (14)</LI>
<LI>Mean age, range (years): treatment group (54, 30 to 75); control group (59, 28 to 72)</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Proportion of diabetic patients (%): not reported</LI>
<LI>Exclusion criteria: history of exit-site infection 2 months prior to possible study admission</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 10:12:58 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Blisterfilm adhesive dressing at exit site</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Gauze dressing at exit site</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 11:32:29 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Exit-site infection (number of patients)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 10:09:18 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-12 12:15:02 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-MP3-Study-2008">
<CHAR_METHODS MODIFIED="2017-01-12 12:15:02 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: not reported</LI>
<LI>Duration of follow-up (median, range): 18, 0.1 to 18 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 16:28:39 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: 3 tertiary centres</LI>
<LI>Country: Canada</LI>
<LI>Health status: current or new PD patients; &#8805; 18 years; have a PD catheter in situ; medically stable</LI>
<LI>Number: treatment group 1 (103); treatment group 2 (101)</LI>
<LI>Mean age ± SD (years): treatment group 1 (59.36 ± 15.04); treatment group 2 (61.02 ± 13.66)</LI>
<LI>Sex (M/F): treatment group 1 (63/37); treatment group 2 (66/34)</LI>
<LI>Proportion of diabetic patients: treatment group 1 (45.5%); treatment group 2 (42%)</LI>
<LI>Exclusion criteria: AKI; catheter-related infection at the time of recruitment or within the previous 3 months; use of an oral, IV or IP antibiotic at the time of randomisation or within the previous 1 week; a known allergy to any component of P3 or mupirocin; or a scheduled date for living donor transplant surgery within 6 months of the study completion date</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 16:29:08 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Polysporin triple (P3) antibiotic ointment (bacitracin 500 U/g, gramicidin 0.25 mg/g, polymyxin B 10 000 U/g) at exit site when dressing was changed</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Mupirocin ointment at exit site when dressing was changed</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 11:32:34 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Time to first catheter-related infection (exit-site infection, tunnel infection, PD peritonitis)</LI>
<LI>Catheter removal (catheter-related infection)</LI>
<LI>Hospitalisation (catheter-related infection)</LI>
<LI>Death due to catheter-related infection</LI>
<LI>All-cause mortality</LI>
<LI>Technique failure (i.e. transfer to HD)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-09 11:22:59 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: Kidney Foundation of Canada</LI>
<LI>Exclusions post-randomisation but pre-intervention: none</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-09 11:29:21 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Mupirocin-Study-1996">
<CHAR_METHODS MODIFIED="2017-01-05 10:28:25 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: up to 18 months</LI>
<LI>Duration of follow-up: up to 18 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 16:30:08 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: 9 centres</LI>
<LI>Country: Europe</LI>
<LI>Health status: patients undergoing CAPD who were identified as <I>S. aureus</I> nasal carriers</LI>
<LI>Number: treatment group (134); control group (133)</LI>
<LI>Mean age (years): treatment group (60.3); control group (60.3)</LI>
<LI>Sex (M/F): treatment group (81/53); control group (80/53)</LI>
<LI>Proportion of diabetic patients: treatment group (17.2%); control group (22.6%)</LI>
<LI>Exclusion criteria: patient negative for <I>S. aureus</I> nasal carriage; patient who had received antibiotics for a PD-related infection within the preceding month; patient with active exit-site infection</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 10:54:26 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Mupirocin (2%) nasal ointment twice/day for 5 days, every 1 month</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo nasal ointment twice/day for 5 days, every 1 month</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 10:55:04 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>All-cause mortality</LI>
<LI>Peritonitis (rate)</LI>
<LI>Exit-site/tunnel infection (number of patients)</LI>
<LI>Exit-site/tunnel infection (rate)</LI>
<LI>Catheter removal or replacement</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-09 11:29:21 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: SmithKline Beecham, UK; Baxter Healthcare, USA</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: 1413 patient-months in each group</LI>
<LI>Additional data requested from authors: further information on obtained from study authors</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-05 11:01:05 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Nolph-1985">
<CHAR_METHODS MODIFIED="2017-01-05 10:57:19 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 9 months</LI>
<LI>Duration of follow-up: 9 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 10:59:46 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: 10 tertiary centres</LI>
<LI>Country: USA</LI>
<LI>Health status: patients with ESKD treated with CAPD</LI>
<LI>Number: treatment group (74); control group (93)</LI>
<LI>Mean age ± SD (years): treatment group (49 ± 14); control group (49 ± 14)</LI>
<LI>Sex (M/F): treatment group (50/24); control group (49/44)</LI>
<LI>Proportion of diabetic patients: treatment group (16.2%); control group (23.7%)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 11:00:17 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Ultraviolet germicidal chamber for spike and bag outlet port</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 11:00:39 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>All-cause mortality</LI>
<LI>Peritonitis (number of patients)</LI>
<LI>Peritonitis (rate)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 11:01:05 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: Travenol Laboratories Inc., USA</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Nunez_x002d_Moral-2014">
<CHAR_METHODS MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: March 2009 to June 2010</LI>
<LI>Duration of follow-up: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 11:33:20 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: Single tertiary centre</LI>
<LI>Country: Spain</LI>
<LI>Health status: patients &gt; 18 years in PD program in which a peritoneal catheter had been implanted at least 6 weeks before; absence of infectious complications which had required either hospital admission or antibiotic treatment at least three months before entering the study; absence of known reaction or contingent polyhexanide intolerance; the patient or representatives had signed the informed consent form</LI>
<LI>Number: treatment group (30); control group (30)</LI>
<LI>Mean age ± SD (years): treatment group (61 ± 15); control group (60 ± 19)</LI>
<LI>Sex (M/F): treatment group (17/13); control group (16/14)</LI>
<LI>Proportion of diabetic patients: treatment group (41%); control group (40%)</LI>
<LI>Exclusion criteria: presence of exit-site infection at randomisation time; history of bad adherence to treatment and/or medical advice; withdrawal of the informed consent</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 11:17:51 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Polyhexanide solution at exit site</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Standard care: 0.9% saline solution and povidone iodine solution</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 11:32:49 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>All-cause mortality</LI>
<LI>Exit-site/tunnel infection (number of patients)</LI>
<LI>Exit-site/tunnel infection (rate)</LI>
<LI>Catheter removal or replacement (due to infection)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 11:18:53 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: Nephrological Nursing Investigation Baxter award 2010</LI>
<LI>Excluded from analysis: none</LI>
<LI>Exclusions post-randomisation but pre-intervention: none</LI>
<LI>Stop or end point/s: not reported</LI>
<LI>Additional data requested from authors: further information on peritonitis data were requested from the corresponding author</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-12 10:15:45 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Perez_x002d_Fontan-1992">
<CHAR_METHODS MODIFIED="2017-01-05 11:23:17 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: July to October 1990</LI>
<LI>Duration of follow-up: 9.5 ± 3.3 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-12 10:15:45 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: Spain</LI>
<LI>Health status: patients undergoing CAPD and their assisting partners</LI>
<LI>Number (patients/partners): treatment group 1 (11/1); treatment group 2 (8/2)</LI>
<LI>Mean age ± SD (years): treatment group 1 (51 ± 15); treatment group 2 (48 ± 21)</LI>
<LI>Sex (M/F): treatment group 1 (5/7); treatment group (5/5)</LI>
<LI>Proportion of diabetic patients: treatment group 1 (25%); treatment group (20%)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 11:27:21 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Mupirocin (2%) nasal ointment 3 times/d for 7 days</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Neomycin sulphate (0.1%) nasal ointment 3 times/d for 7 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 11:33:52 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (number of patients)</LI>
<LI>Peritonitis (rate)</LI>
<LI>Exit-site/tunnel infection (number of patients)</LI>
<LI>Exit-site/tunnel infection (rate)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 11:34:11 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Poole_x002d_Warren-1991">
<CHAR_METHODS MODIFIED="2017-01-05 11:36:24 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 12 months</LI>
<LI>Duration of follow-up: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: 8 tertiary centres</LI>
<LI>Country: Australia and New Zealand</LI>
<LI>Health status: current CAPD patients stabilised on the therapy</LI>
<LI>Number: treatment group (65); control group (59)</LI>
<LI>Mean age ± SD (years): treatment group (54 ± 11); control group (52 ± 14)</LI>
<LI>Sex (M/F): treatment group (39/26); control group (24/35)</LI>
<LI>Proportion of diabetic patients: treatment group (18.5%); control group (15.3%)</LI>
<LI>Exclusion criteria: current peritoneal infection; receipt of an antibiotic course within the 2 week period prior to study enrolment; use of assist devices; use of disconnect systems</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 12:02:48 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Staphypan Berna vaccine</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Saline placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 12:03:35 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (number of patients)</LI>
<LI>Peritonitis (rate)</LI>
<LI>Exit-site/tunnel infection (number of patients)</LI>
<LI>Exit-site/tunnel infection (rate)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 12:04:04 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: Baxter Healthcare Corporation, USA</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: 43 patient years/treatment group</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Restrepo-2010">
<CHAR_METHODS MODIFIED="2017-01-05 12:05:21 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 1 June 2004 to 30 October 2007</LI>
<LI>Duration of follow-up: 30 to 150 days after the end of treatment</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: Colombia</LI>
<LI>Health status: CKD patients stage 5 on PD (CAPD or APD) were included if they experienced peritonitis, exit-site infection or tunnel infection</LI>
<LI>Number: treatment group (210); control group (210)</LI>
<LI>Mean age: 50.9 years (men); 47.9 years (women)</LI>
<LI>Sex (M/F): treatment group (93/117); control group (116/94)</LI>
<LI>Proportion of diabetic patients: treatment group (33.3%); control group (37.1%)</LI>
<LI>Exclusion criteria: allergy to fluconazole, imidazoles, or triazoles; hepatic disease; pregnancy; &lt; 18 years; &gt; 70 years; patients that did not wish to participate</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 12:12:31 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Oral fluconazole (200 mg every 48 hours)</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No oral fluconazole with an antibiotic course for a PD-related infection</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 12:12:40 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Fungal peritonitis in the time period 30 to 150 days following the end of antibacterial treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 12:12:59 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: when 434 episodes of peritonitis had occurred</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ryckelynck-1987">
<CHAR_METHODS MODIFIED="2017-01-05 12:14:49 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel quasi RCT</LI>
<LI>Study duration/time frame: not reported</LI>
<LI>Duration of follow-up: not reported</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 12:15:27 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: 5 tertiary centres</LI>
<LI>Country: France</LI>
<LI>Health status: current CAPD patients using Y-line systems</LI>
<LI>Number: treatment group (24); control group (26)</LI>
<LI>Mean age: not reported</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Proportion of diabetic patients not reported</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 12:15:56 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Connector soaked in antiseptic prior to bag exchange</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No use of antiseptic</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 12:16:05 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (rate)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Abstract-only publication</LI>
<LI>Funding source: not reported</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-09 11:24:13 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Sesso-1994">
<CHAR_METHODS MODIFIED="2017-01-05 12:18:53 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: January 1991 through June 1992</LI>
<LI>Duration of follow-up: 7.8 months (mean)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 16:32:57 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: Brazil</LI>
<LI>Health status: continuing and new patients undergoing CAPD identified as <I>S. aureus</I> carriers</LI>
<LI>Number: treatment group 1 (9); treatment group 2 (9); control group (13)</LI>
<LI>Mean age ± SE (years): treatment group 1 (36.6 ± 4.6); treatment group 2 (46.1 ± 3.8); control group (42.1 ± 4.6)</LI>
<LI>Sex (M/F): treatment group 1 (6/3); treatment group 2 (6/3); control group (9/4)</LI>
<LI>Proportion of diabetic patients: treatment group (33.3%); treatment group (11.1%); control group (7.7%)</LI>
<LI>Exclusion criteria: patients who had peritonitis or exit-site infection within 1 month of the beginning of the study were excluded until being asymptomatic for at least 1 month; patients who had received antimicrobial therapy within 78 hours before the start of the study; &lt; 15 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 12:29:03 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Ofloxacin 200 mg every 2 days over 5 days, repeated monthly</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Sodium fusidate (2%) ointment applied twice daily (nasal and exit-site) for 5 days, repeated monthly</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo tablets, repeated monthly</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 14:00:15 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>All-cause mortality</LI>
<LI>Peritonitis (number of patients)</LI>
<LI>Peritonitis (rate)</LI>
<LI>Exit-site/tunnel infection (number of patients)</LI>
<LI>Exit-site/tunnel infection (rate)</LI>
<LI>Catheter removal or replacement</LI>
<LI>Nasal irritation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-09 11:24:13 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: Instituto Paulista de Estudos e Pesquisas em Nefrologia e Hipertensao</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: June 1992 or date patient ceased CAPD, if earlier</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-05 14:05:18 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Sharma-1971">
<CHAR_METHODS MODIFIED="2017-01-05 14:01:50 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: not reported</LI>
<LI>Duration of follow-up: not reported</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 14:03:52 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single tertiary centre</LI>
<LI>Country: USA</LI>
<LI>Health status: PD patients with AKI or CKD</LI>
<LI>Number: 41 patients</LI>
<LI>Age range: 11 to 75 years</LI>
<LI>Sex (M/F): 22/19</LI>
<LI>Proportion of diabetic patients: not reported</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 14:04:35 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Oral neomycin 0.5 g in suspension every 12 hours</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 14:04:43 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (number of dialyses)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 14:05:18 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Excluded from analysis: 6 dialyses excluded (6.3%)</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-09 16:39:51 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-SIPROCE-Study-1997">
<CHAR_METHODS MODIFIED="2017-01-05 14:07:24 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 1 October 1994 to 1 April 1996</LI>
<LI>Duration of follow-up: treatment group (857 months); control group (937 months)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 14:09:57 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: 10 dialysis centres (7 adult; 3 paediatric)</LI>
<LI>Country: Germany</LI>
<LI>Health status: all current patients on PD; new patients until December 1995</LI>
<LI>Number: treatment group (97); control group (98)</LI>
<LI>Mean age ± SD (years): treatment group (44.74 ± 17.6); control group (47.01 ± 18.5)</LI>
<LI>Sex (M/F): treatment group (63/34); control group (52/46)</LI>
<LI>Proportion of diabetic patients: treatment group (19.6%); control group (21.4%)</LI>
<LI>Exclusion criteria: patients with acute or chronic exit-site infections, sinus tract/tunnel infections, or peritonitis during the ascertainment period</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 14:10:21 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Silver ring mounted on PD catheter</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No silver ring</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 14:10:49 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>First occurrence of exit-site infection</LI>
<LI>Exit-site infection (number of patients)</LI>
<LI>Tunnel infection (number of patients)</LI>
<LI>Peritonitis (number of patients)</LI>
<LI>Catheter loss</LI>
<LI>All-cause mortality</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-09 16:39:51 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: supported in part by Baxter Deutschland GmbH, Ettlingen, Germany</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-05 17:17:51 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Sit-2007">
<CHAR_METHODS MODIFIED="2017-01-05 14:13:26 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: not reported</LI>
<LI>Duration of follow-up: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 16:34:36 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single tertiary centre</LI>
<LI>Country: Turkey</LI>
<LI>Health status: current CAPD patients (for at least 6 months)</LI>
<LI>Number: treatment group (25); control group (24)</LI>
<LI>Mean age ± SD (years): treatment group (42.0 ± 12.1); control group (37.5 ± 12.9)</LI>
<LI>Sex (M/F): treatment group (10/13); control group (11/13)</LI>
<LI>Proportion of diabetic patients: not reported</LI>
<LI>Exclusion criteria: treated with intranasal mupirocin before randomisation; known allergy to intranasal mupirocin; infection related to CAPD who were transferred to HD or transplantation</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 14:16:00 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Intranasal mupirocin ointment applied to nares twice/day for 5 days every 4 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No ointment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 14:16:40 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (number of patients)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 17:17:51 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Excluded from analysis: 2 (8%) excluded from analysis in mupirocin group due to kidney transplantation (1) and death (1)</LI>
<LI>Exclusions post-randomisation but pre-intervention: none</LI>
<LI>Stop or end point/s: When patient had been followed for 12 months</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Swartz-1991">
<CHAR_METHODS MODIFIED="2017-01-05 14:24:01 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: early 1987 to 1991</LI>
<LI>Duration of follow-up: (mean ± SE): treatment group (11.4 ± 1.3 months); control group (12.3 ± 1.4 months)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 14:26:22 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single tertiary centre</LI>
<LI>Country: USA</LI>
<LI>Health status: patients beginning chronic PD with a new catheter</LI>
<LI>Number: treatment group (29); control group (30)</LI>
<LI>Mean age ± SE (years): treatment group (49 ± 3.4); control group (51 ± 3.1)</LI>
<LI>Sex (M/F): treatment group (16/13); control group (16/14)</LI>
<LI>Proportion of diabetic patients: treatment group (34.5%); control group (33.3%)</LI>
<LI>Exclusion criteria: beginning chronic PD with a new catheter children; extensive prior surgery; given general anaesthesia; catheter placement incidental to another surgical procedure</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 14:41:36 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Trimethoprim/sulfamethoxazole (low dose) or cephalexin (250 mg) or clindamycin (300 mg) 3 days/week</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No prophylaxis</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 14:41:58 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>All-cause mortality</LI>
<LI>Peritonitis (rate)</LI>
<LI>Exit-site/tunnel infection (rate)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 14:42:35 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-05 15:16:07 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Wadhwa-1995">
<CHAR_METHODS MODIFIED="2017-01-05 15:16:07 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel quasi-RCT</LI>
<LI>Study duration/time frame: not reported</LI>
<LI>Duration of follow-up: not reported</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 14:46:52 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: USA</LI>
<LI>Health status: PD patients (presume they were current)</LI>
<LI>Number: treatment group 1 (25); treatment group 2 (25)</LI>
<LI>Mean age (years): treatment group 1 (59); treatment group 2 (53)</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Proportion of diabetic patients: treatment group 1 (48%); treatment group 2 (32%)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 14:47:39 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Amuchina 10% (sodium hypochlorite) at exit site</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Povidone iodine 10% solution at exit site</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 14:48:19 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Exit-site infection (number of patients)</LI>
<LI>Peritonitis (number of patients)</LI>
<LI>Catheter removal (number of patients)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 14:49:46 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Abstract-only publication</LI>
<LI>Funding source: not reported</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-05 15:16:01 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Wadhwa-1997">
<CHAR_METHODS MODIFIED="2017-01-05 15:16:01 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel quasi-RCT</LI>
<LI>Study duration/time frame: not reported</LI>
<LI>Duration of follow-up: not reported</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 14:58:52 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: USA</LI>
<LI>Health status: PD patients (presume they were current)</LI>
<LI>Number: treatment group 1 (18); treatment group 2 (21)</LI>
<LI>Mean age (years): treatment group 1 (55); treatment group 2 (60)</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Proportion of diabetic patients: treatment group 1 (27.8%); treatment group 2 (28.6%)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 14:59:29 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Amuchina 5% (sodium hypochlorite) at exit site</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Povidone iodine 10% solution at exit site</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 15:00:26 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Exit-site infection (number of patients)</LI>
<LI>Peritonitis (number of patients)</LI>
<LI>Catheter removal (number of patients)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 15:00:43 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Abstract-only publication</LI>
<LI>Funding source: not reported</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-05 15:05:55 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Waite-1997">
<CHAR_METHODS MODIFIED="2017-01-05 15:02:14 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: not reported</LI>
<LI>Duration of follow-up: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 15:04:06 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single tertiary centre</LI>
<LI>Country: Canada</LI>
<LI>Health status: patients with ESKD requiring PD catheter insertion</LI>
<LI>Number: treatment group (61); control group (56)</LI>
<LI>Mean age ± SD (years): treatment group (54.4 ± 15.1); control group (53.2 ± 14.5)</LI>
<LI>Sex (M/F): treatment group (33/28); control group (30/26)</LI>
<LI>Proportion of diabetic patients: treatment group (31.2%); control group (35.7%)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 15:04:40 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Povidone iodine (10%) ointment 3.5 g at every dressing change</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Standard care</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 15:05:09 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>All-cause mortality</LI>
<LI>Peritonitis (number of patients)</LI>
<LI>Exit-site/tunnel infection (number of patients)</LI>
<LI>Catheter removal or replacement</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 15:05:55 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: Purdue-Frederick, Toronto, Canada</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: 6 months after catheter insertion</LI>
<LI>Additional data requested from authors: further information on methods and more detailed results were obtained from the corresponding author</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Wikdahl-1997">
<CHAR_METHODS MODIFIED="2017-01-05 15:07:54 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 27 months</LI>
<LI>Duration of follow-up: 10 days post surgery</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 15:11:09 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single tertiary centre</LI>
<LI>Country: Sweden</LI>
<LI>Health status: new PD patients</LI>
<LI>Number: treatment group (18); control group (20)</LI>
<LI>Mean age, range (years): treatment group (56, 33 to 84); control group (61, 34 to 84)</LI>
<LI>Sex (M/F): treatment group (12/6); control group (15/5)</LI>
<LI>Proportion of diabetic patients: treatment group (33.3%); control group (35%)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 15:12:29 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cefuroxime: (IV) 1.5 g 0.5 to 2.0 h before surgery + 250 mg (IP) in first dialysis bag</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No antibiotic</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 15:13:29 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (number of patients)</LI>
<LI>Exit-site/tunnel infection (number of patients) within 10 days of catheter insertion</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 15:13:49 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-09 11:25:17 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Wilson-1997">
<CHAR_METHODS MODIFIED="2017-01-05 15:17:02 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: not reported</LI>
<LI>Duration of follow-up: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 15:19:29 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: Single tertiary centre</LI>
<LI>Country: UK</LI>
<LI>Health status: all patients in the PD program</LI>
<LI>Number: treatment group (77); control group (72)</LI>
<LI>Mean age, range (years): treatment group (53, 18 to 82); control group (51, 21 to 76)</LI>
<LI>Sex (M/F): treatment group (55/22); control group (43/29)</LI>
<LI>Proportion of diabetic patients: not reported</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 15:20:03 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Povidone iodine (2.5%) dry powder spray at exit-site at every dressing change</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 15:20:44 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>All-cause mortality</LI>
<LI>Peritonitis (number of patients)</LI>
<LI>Exit-site/tunnel infection (number of patients)</LI>
<LI>Catheter removal or replacement</LI>
<LI>Technique failure due to infection</LI>
<LI>Local pruritus/rash</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-09 11:25:17 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Follow-up period: 12 months</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: 12 months or until a significant difference was found between groups</LI>
<LI>Additional data requested from authors: further information on methods and more detailed results were obtained from the corresponding author</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Wong-2003">
<CHAR_METHODS MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 5 months</LI>
<LI>Duration of follow-up: varied according to the patients clinical condition </LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 15:27:53 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single tertiary centre</LI>
<LI>Country: Hong Kong</LI>
<LI>Health status: current CAPD patients</LI>
<LI>Number: treatment group (73); control group (81)</LI>
<LI>Mean age ± SD (years): treatment group (60 ± 12); control group (59 ± 13)</LI>
<LI>Sex (M/F): treatment group (32/41); control group (47/34)</LI>
<LI>Proportion of diabetic patients: treatment group (26%); control group (33.3%)</LI>
<LI>Exclusion criteria: presence of significant mental disorder; presence of a significant skin problem; antibiotic treatment within 1 month of the start of the study; regular daily mupirocin ointment prophylaxis at the catheter exit-site already prescribed before the start of the study; active exit-site infection or peritonitis; ill health; use of any exit-site dressing method other than 10% povidone iodine</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 15:29:07 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Application of mupirocin ointment to exit site once/day after routine exit-site dressing</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Usual daily exit-site care</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 15:29:48 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Exit-site infection (number of patients)</LI>
<LI>Exit-site infection (rate)</LI>
<LI>Peritonitis (number of patients)</LI>
<LI>Peritonitis (rate)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 15:30:44 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Zimmerman-1991">
<CHAR_METHODS MODIFIED="2017-01-05 15:38:20 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/time frame: 1 September 1987 to 31 May 1989</LI>
<LI>Duration of follow-up (mean ± SEM): treatment group (10.2 ± 1.2 months); control group (12.0 ± 1.3 months)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-05 15:36:15 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: single tertiary centre</LI>
<LI>Country: USA</LI>
<LI>Health status: adults who had completed at least 6 months of PD</LI>
<LI>Number: treatment group (32); control group (32)</LI>
<LI>Mean age ± SEM (years): treatment group (53 ± 3); control group (55 ± 4)</LI>
<LI>Sex (M/F): treatment group (17/15); control group (24/8)</LI>
<LI>Proportion of diabetic patients: treatment group (43.8%); control group (37.5%)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 16:14:41 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Rifampin 300 mg, twice/day for 5 days, every 3 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 15:37:34 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Peritonitis (number of patients)</LI>
<LI>Peritonitis (rate)</LI>
<LI>Catheter removal or replacement</LI>
<LI>Toxicity</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-05 15:39:29 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Funding source: Baxter Healthcare</LI>
<LI>Excluded from analysis: not reported</LI>
<LI>Exclusions post-randomisation but pre-intervention: not reported</LI>
<LI>Stop or end point/s: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AKI - acute kidney injury; APD - automated peritoneal dialysis; CAPD - continuous ambulatory peritoneal dialysis; CCPD - continuous cycling peritoneal dialysis; CKD - chronic kidney disease; ESKD - end-stage kidney disease; HD - haemodialysis; HIV - human immunodeficiency virus; IP - intraperitoneal; ITT - intention-to-treat; IV - intravenous; M/F - male/female; PD - peritoneal dialysis; RCT - randomised controlled trial; SD - standard deviation; SE - standard error; SEM - standard error of the mean</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-01-05 16:46:44 +1100" MODIFIED_BY="Narelle Willis" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-06-02 14:31:39 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Cavdar-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-02 14:31:39 +1000" MODIFIED_BY="Ann Jones">
<P>Not an intervention of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-02 14:31:38 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Churchill-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-02 14:31:38 +1000" MODIFIED_BY="Ann Jones">
<P>Not an intervention of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-02 14:31:36 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Crabtree-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-02 14:31:36 +1000" MODIFIED_BY="Ann Jones">
<P>Not an intervention of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-02 14:31:33 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-de-Fijter-1992a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-02 14:31:33 +1000" MODIFIED_BY="Ann Jones">
<P>Pharmacokinetics study not prevention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-05 10:05:59 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Gadallah-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-05 10:05:59 +1100" MODIFIED_BY="Narelle Willis">
<P>Urokinase is not an antimicrobial agent; treatment study not prevention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-02 14:31:23 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Maiorca-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-02 14:31:23 +1000" MODIFIED_BY="Ann Jones">
<P>Not an intervention of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-02 14:31:20 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Naylor-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-02 14:31:20 +1000" MODIFIED_BY="Ann Jones">
<P>Small pilot study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-05 10:06:07 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Oh-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-05 10:06:07 +1100" MODIFIED_BY="Narelle Willis">
<P>It is an RCT but peritonitis data is not readily available; no reply from authors to query email</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-02 14:31:18 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Plum-1997a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-02 14:31:18 +1000" MODIFIED_BY="Ann Jones">
<P>Treatment study not prevention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-02 14:31:14 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Rodriguez_x002d_Perez-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-02 14:31:14 +1000" MODIFIED_BY="Ann Jones">
<P>Not an intervention of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-05 10:06:22 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Thomae-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-05 10:06:22 +1100" MODIFIED_BY="Narelle Willis">
<P>Study only went for 84 hours; of the 7 patients, 3 had previously had peritonitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-02 14:31:01 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Trooskin-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-02 14:31:01 +1000" MODIFIED_BY="Ann Jones">
<P>Not an intervention of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT - randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-05-06 16:42:47 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-NCT02547103">
<CHAR_STUDY_NAME MODIFIED="2017-01-05 15:45:44 +1100" MODIFIED_BY="Narelle Willis">
<P>Efficacy and safety of local application of chlorhexidine gluconate versus mupirocin ointment in the prevention of peritoneal dialysis-related infection: a pilot study, double- blind, stratified randomized controlled trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-01-05 16:04:40 +1100" MODIFIED_BY="Narelle Willis">
<P>Allocation: randomised, parallel RCT</P>
<P>Double blind (subject, caregiver, investigator, outcomes assessor)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-04-04 15:56:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Patients with ESKD who were undergoing PD; either CAPD or APD</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>History of psychological illness or condition that interferes with ability to understand or comply with the requirements of the study</LI>
<LI>Recent (within 1 month) exit-site or tunnel infection, or peritonitis</LI>
<LI>Known hypersensitivity to, or intolerance of, chlorhexidine gluconate, or mupirocin</LI>
<LI>Current or recent (within 1 month) treatment with an antibiotic administered by any route</LI>
<LI>Nasal carriage of mupirocin-resistant Staphylococcus aureus or chlorhexidine-resistant <I>S. aureus</I>
</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-05 16:48:10 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>2% chlorhexidine gluconate-soaked cloths: clean topical area around catheter exit site with soaked cloths</LI>
<LI>Normal saline: clean topical area around catheter exit site</LI>
<LI>Mupirocin ointment 2%: clean topical area around catheter exit site with Mupirocin ointment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-05 15:50:54 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>PD-related infection</LI>
<LI>Adverse events related to treatments</LI>
<LI>Hospitalisation due to PD-related infection</LI>
<LI>Technical failure (change of modal of dialysis)</LI>
<LI>Death due to PD-related infection</LI>
<LI>Costs</LI>
<LI>Utility using Euro 5D-5L</LI>
<LI>Adherence</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2017-01-05 15:51:00 +1100" MODIFIED_BY="Narelle Willis">
<P>May 2016</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-01-05 15:52:16 +1100" MODIFIED_BY="Narelle Willis">
<P>Surapon Nochaiwong</P>
<P>Chidchanok Ruengorn</P>
<P>Maharaj Nakorn Chiang Mai Hospital</P>
<P>Chiang Mai, Thailand, 50200</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-01-05 15:52:52 +1100" MODIFIED_BY="Narelle Willis">
<P>Sponsors and Collaborators</P>
<P>Chiang Mai University, Health Systems Research Institute, Thailand</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>APD - automated peritoneal dialysis; CAPD - continuous ambulatory peritoneal dialysis; ESKD - end-stage kidney disease; PD - peritoneal dialysis</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-04-04 15:55:23 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:41:35 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Axelrod-1973">
<DESCRIPTION>
<P>Random number table "Patients were selected to receive placebo or antibiotic according to a random number list kept by the pharmacy..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-23 17:23:11 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennet_x002d_Jones-1988">
<DESCRIPTION>
<P>Consecutively numbered sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 14:58:44 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bernardini-1996">
<DESCRIPTION>
<P>Study said to be randomised but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:41:46 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Bernardini-2005">
<DESCRIPTION>
<P>Computer generated using a random number generator "Randomization lists were computer generated using a random number generator."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 15:18:45 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Blowey-1994">
<DESCRIPTION>
<P>Patients said to be randomised but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 15:25:10 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1999a">
<DESCRIPTION>
<P>Study said to be randomised but no information on method provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:42:00 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>Alternate allocation "The patients were assigned to either drug on a one-to-one alternate basis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-27 17:16:06 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Churchill-1988">
<DESCRIPTION>
<P>Stratified or block randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:42:18 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cocksedge-1993">
<DESCRIPTION>
<P>Sealed envelopes "New patients to the program were asked to select a sealed envelope from a pack. Each envelope contained a card allocating the patient to either Method One or Method Two."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 16:17:51 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Danguilan-2003">
<DESCRIPTION>
<P>Randomisation method not stated. "One hundred patients were enrolled in the study... 50 patients were randomly assigned to each treatment group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:42:35 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fuchs-1990">
<DESCRIPTION>
<P>Randomisation method not stated "Fifty-one patients were randomly assigned to one of three catheter exit site care regimens."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:42:43 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>Consecutive allocation of intervention "first patient received vancomycin; second, cefazolin; third, neither; fourth, vancomycin; and so on."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:42:51 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-HONEYPOT-Study-2009">
<DESCRIPTION>
<P>Minimization method "Participants were randomly assigned in a 1:1 ratio by use of an adaptive allocation algorithm designed to minimise imbalance in treatment groups for the three variables."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 17:11:59 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Lo-1996">
<DESCRIPTION>
<P>Patients were randomised according to odd or even identity numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 17:17:27 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Low-1980">
<DESCRIPTION>
<P>Minimisation method used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-29 16:54:21 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luzar-1990">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-29 18:04:19 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lye-1992">
<DESCRIPTION>
<P>Alternate allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:37:42 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-MP3-Study-2008">
<DESCRIPTION>
<P>Computer random number generator "All randomization is determined by a computer-generated random number list..." "...201 patients from two centers were randomly assigned to either mupirocin or P3 using stratified block randomization as per protocol."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:43:09 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Mendoza_x002d_Guevara-2007">
<DESCRIPTION>
<P>Random number tables "Patients were assigned 1:1 in two groups, with only one treatment; the Rand Corporation tables were used for randomization."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:43:18 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Moore-1989">
<DESCRIPTION>
<P>Alternate allocation "The numbering was consecutive so all participants were given an equal chance of being admitted to either group." "Odd numbers were admitted to the Blisterfilm group and even numbers admitted to the gauze group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:53:11 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Mupirocin-Study-1996">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:01:10 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Nolph-1985">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:43:40 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Nunez_x002d_Moral-2014">
<DESCRIPTION>
<P>Random number table "Randomization was performed by means of a randomization code via random number table..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:38:56 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Perez_x002d_Fontan-1992">
<DESCRIPTION>
<P>Stratified randomisation method used "Staph. aureus nasal carriers were assigned to one of two groups, randomized for age, time on CAPD and prevalence of diabetes."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-04 15:55:23 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Poole_x002d_Warren-1991">
<DESCRIPTION>
<P>Randomisation method not stated "Patients were randomly assigned by an independent third party to either the vaccinated group or the saline solution (SS) placebo administered group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:39:16 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Restrepo-2010">
<DESCRIPTION>
<P>Drawing of lots "The randomization procedure was performed by drawing from a bag cards indicating whether the patient would or would not receive this treatment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:39:20 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ryckelynck-1987">
<DESCRIPTION>
<P>Randomisation method not stated "24 patients using a single use Y-set and 26 using a reusable Y-set (O-set) were separately randomized into two groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:39:56 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-SIPROCE-Study-1997">
<DESCRIPTION>
<P>Stratified randomisation "After informed consent had been obtained, the patients were stratified by diabetes mellitus status (types I and II) and randomly assigned by the coordinating study center (Berlin) to either the silver ring or the control group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:39:32 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sesso-1994">
<DESCRIPTION>
<P>Randomisation method not stated "Each carrier was then randomly assigned to one of the three groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:54:18 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-1971">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:40:09 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Sit-2007">
<DESCRIPTION>
<P>Coin toss "Randomization was guided by the flip of a coin..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 18:39:11 +1100" MODIFIED_BY="Denise Campbell" RESULT="YES" STUDY_ID="STD-Swartz-1991">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:40:22 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wadhwa-1995">
<DESCRIPTION>
<P>Randomisation method not stated "Fifty PD patients were prospectively randomized to perform daily exit-site care with soap and water followed by Amuchina 10% or Povidone Iodine 10% solution."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:40:26 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wadhwa-1997">
<DESCRIPTION>
<P>Randomisation method not stated "Thirty nine PD patients were prospectively randomized to perform daily exit-site care with soap and water followed by Amuchina 5% or povidone iodine 10% solution."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 17:19:59 +1100" MODIFIED_BY="Denise Campbell" RESULT="YES" STUDY_ID="STD-Waite-1997">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 15:14:13 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wikdahl-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 16:05:38 +1100" MODIFIED_BY="Denise Campbell" RESULT="YES" STUDY_ID="STD-Wilson-1997">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:40:57 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wong-2003">
<DESCRIPTION>
<P>Randomisation method not stated "Patients not excluded were randomized into two groups." No description of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-14 22:26:54 +1100" MODIFIED_BY="Denise Campbell" RESULT="YES" STUDY_ID="STD-Zimmerman-1991">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-01-09 16:42:06 +1100" MODIFIED_BY="Narelle Willis" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-24 13:58:16 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axelrod-1973">
<DESCRIPTION>
<P>Central allocation (pharmacy)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-23 10:50:16 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennet_x002d_Jones-1988">
<DESCRIPTION>
<P>"Patients were randomised by being assigned consecutively numbered sealed envelopes, which contained either a prescription for gentamicin to be administered with the anaesthetic, or an instruction to the anaesthetist to give no antibiotic."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 14:58:43 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bernardini-1996">
<DESCRIPTION>
<P>Study said to be randomised but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-20 17:30:20 +1000" MODIFIED_BY="Denise J Campbell" RESULT="YES" STUDY_ID="STD-Bernardini-2005">
<DESCRIPTION>
<P>"The sequence of allocation was known only by the investigators at the coordinating center."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 15:18:46 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Blowey-1994">
<DESCRIPTION>
<P>Patients said to be randomised but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 15:25:11 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1999a">
<DESCRIPTION>
<P>Study said to be randomised but no information on method provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:42:06 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>Alternate allocation "The patients were assigned to either drug on a one-to-one alternate basis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-27 17:17:13 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Churchill-1988">
<DESCRIPTION>
<P>Central allocation by pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 16:21:22 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cocksedge-1993">
<DESCRIPTION>
<P>Do not know if the envelopes were opaque</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 16:17:53 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Danguilan-2003">
<DESCRIPTION>
<P>No details given re concealment of patient allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 16:30:37 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fuchs-1990">
<DESCRIPTION>
<P>No details given re concealment of patient allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-27 15:59:02 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>Non-random, predictable sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-08 19:01:51 +1100" MODIFIED_BY="Denise Campbell" RESULT="YES" STUDY_ID="STD-HONEYPOT-Study-2009">
<DESCRIPTION>
<P>Central allocation (web). "To ensure adequate concealment of allocation, the randomisation was done with a password-protected internet-based system."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 17:12:01 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Lo-1996">
<DESCRIPTION>
<P>A non-random, predictable sequence was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-29 15:58:44 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Low-1980">
<DESCRIPTION>
<P>Allocation done by a third party</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-29 16:54:35 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luzar-1990">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-29 18:04:40 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lye-1992">
<DESCRIPTION>
<P>Non-random, predictable sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:37:44 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-MP3-Study-2008">
<DESCRIPTION>
<P>Central allocation (pharmacy) "Randomization occurs centrally in coordination with the central clinical trials pharmacy... The ointments are placed in containers that are labeled only with the site investigator, study number, and expiry date."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:52:08 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Mendoza_x002d_Guevara-2007">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 10:13:08 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Moore-1989">
<DESCRIPTION>
<P>Non-random, predictable sequence. However, allocation concealment not possible - the two dressings are of different sizes and types</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:53:01 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Mupirocin-Study-1996">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:01:12 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Nolph-1985">
<DESCRIPTION>
<P>Central allocation (Travenol Laboratories)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:19:09 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nunez_x002d_Moral-2014">
<DESCRIPTION>
<P>Randomisation stated but no information on method used is available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:53:29 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Perez_x002d_Fontan-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:39:10 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Poole_x002d_Warren-1991">
<DESCRIPTION>
<P>Central allocation (independent third party) "The assigned injection group was not known to either patient or staff immediately connected with the patient's care at any time during the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:53:39 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Restrepo-2010">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:54:04 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ryckelynck-1987">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:11:06 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-SIPROCE-Study-1997">
<DESCRIPTION>
<P>Central allocation (coordinating study centre)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:54:10 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sesso-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:06:08 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Sharma-1971">
<DESCRIPTION>
<P>Central allocation (pharmacy)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:54:29 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sit-2007">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:54:36 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Swartz-1991">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:48:52 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wadhwa-1995">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:49:22 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wadhwa-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:54:54 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Waite-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 15:14:19 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Wikdahl-1997">
<DESCRIPTION>
<P>Sealed envelopes without all safeguards</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:55:10 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 15:30:55 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wong-2003">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:55:35 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Zimmerman-1991">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-10-23 11:05:44 +1100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2017-01-12 12:15:39 +1100" MODIFIED_BY="Narelle Willis" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-12-29 14:42:15 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Axelrod-1973">
<DESCRIPTION>
<P>Blinding, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-23 10:49:15 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennet_x002d_Jones-1988">
<DESCRIPTION>
<P>"Neither the surgeon nor physician knew whether or not the patient had received the antibiotic."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-12-29 14:58:50 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Bernardini-1996">
<DESCRIPTION>
<P>Blinding not possible - topical antibiotic ointment vs oral antibiotic therapy. The outcome could be influenced by lack of blinding and knowledge of the interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-23 11:24:15 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bernardini-2005">
<DESCRIPTION>
<P>"Investigators and patients were blinded to the cream used."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-12-29 15:18:48 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Blowey-1994">
<DESCRIPTION>
<P>Blinding not done - oral antibiotic + topical antibiotic ointment vs no therapy. The outcome could be influenced by lack of blinding and knowledge of the interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-23 11:47:27 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheng-1999a">
<DESCRIPTION>
<P>Lack of blinding could influence patient management</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-23 11:50:57 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>"Patients were not informed of which cream/ointment they were using. However the cream/ointment were not covered or blinded." (email from author)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-12-27 17:18:50 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Churchill-1988">
<DESCRIPTION>
<P>Blinding, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-12-29 16:10:40 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cocksedge-1993">
<DESCRIPTION>
<P>No blinding and the outcome is likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-12-29 16:17:54 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Danguilan-2003">
<DESCRIPTION>
<P>No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-12-29 16:30:39 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Fuchs-1990">
<DESCRIPTION>
<P>No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-12-29 16:46:24 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-04-06 12:30:06 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-HONEYPOT-Study-2009">
<DESCRIPTION>
<P>No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions. "Blinding of investigators and patients is not possible because of the completely different characteristics of Medihoney and mupirocin ointment." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-12-29 17:12:01 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Lo-1996">
<DESCRIPTION>
<P>No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-12-29 17:17:25 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Low-1980">
<DESCRIPTION>
<P>Blinding, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-09 16:37:01 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Luzar-1990">
<DESCRIPTION>
<P>No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-12-29 17:27:50 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Lye-1992">
<DESCRIPTION>
<P>No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-09 16:37:59 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-MP3-Study-2008">
<DESCRIPTION>
<P>Blinding, and unlikely that the blinding could have been broken "The treatments resemble each other in odor, color, and consistency to allow for a double blinded controlled trial." "Neither the healthcare workers not the participants know which intervention the participant will receive."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-15 16:46:23 +1100" MODIFIED_BY="Denise Campbell" RESULT="UNKNOWN" STUDY_ID="STD-Mendoza_x002d_Guevara-2007">
<DESCRIPTION>
<P>Patient cleans own exit site - impossible to conceal intervention allocation. "The study was blind for the investigators and laboratory personnel."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 10:13:09 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Moore-1989">
<DESCRIPTION>
<P>No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-12 12:15:39 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Mupirocin-Study-1996">
<DESCRIPTION>
<P>Blinding, and unlikely patients were aware of treatment group. Unclear if personnel were aware of patient treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 11:01:13 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Nolph-1985">
<DESCRIPTION>
<P>No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-06 17:50:20 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nunez_x002d_Moral-2014">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 11:34:20 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Perez_x002d_Fontan-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 12:04:25 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Poole_x002d_Warren-1991">
<DESCRIPTION>
<P>Blinding, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 12:13:18 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Restrepo-2010">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 12:16:52 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ryckelynck-1987">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 14:11:07 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-SIPROCE-Study-1997">
<DESCRIPTION>
<P>No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 14:00:49 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sesso-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 14:05:31 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Sharma-1971">
<DESCRIPTION>
<P>Blinding, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 14:17:26 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sit-2007">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 14:42:43 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Swartz-1991">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 14:48:54 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wadhwa-1995">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 14:49:24 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wadhwa-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 15:05:58 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Waite-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 14:55:01 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wikdahl-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 14:55:14 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 14:55:24 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wong-2003">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-01-05 15:39:19 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Zimmerman-1991">
<DESCRIPTION>
<P>No blinding and the outcomes are likely to be influenced by lack of blinding and knowledge of the interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-01-09 16:40:41 +1100" MODIFIED_BY="Narelle Willis" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-24 14:00:10 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axelrod-1973">
<DESCRIPTION>
<P>Blinding, and unlikely that the blinding could have been broken. "We conducted a random double-blind trial of cephalothin sodium as the prophylactic agent."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-26 19:02:48 +1100" MODIFIED_BY="Denise Campbell" RESULT="YES" STUDY_ID="STD-Bennet_x002d_Jones-1988">
<DESCRIPTION>
<P>"Neither the surgeon nor physician knew whether or not the patient had received the antibiotic." Physician assessing outcomes did not know whether patient had received antibiotic or not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-28 17:12:29 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bernardini-1996">
<DESCRIPTION>
<P>"Catheter infections were defined as ... and were diagnosed by the peritoneal dialysis nurse and physician, who were not blinded to the patient's treatment arm."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-12-29 15:08:09 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Bernardini-2005">
<DESCRIPTION>
<P>Outcome assessors were blinded to the cream used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-12-29 15:18:49 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Blowey-1994">
<DESCRIPTION>
<P>Clinical assessment of outcome could be influenced by knowledge of treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-23 11:47:59 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheng-1999a">
<DESCRIPTION>
<P>Knowledge of interventions could influence outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-23 11:52:21 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>No blinding and knowledge of interventions could influence outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-27 17:19:52 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Churchill-1988">
<DESCRIPTION>
<P>Blinding, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-12-29 16:10:41 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cocksedge-1993">
<DESCRIPTION>
<P>No blinding and knowledge of interventions could influence outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-04-06 12:09:12 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Danguilan-2003">
<DESCRIPTION>
<P>No blinding and knowledge of interventions could influence outcome assessment. "Exit sites were monitored weekly during regular follow up."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-12-29 16:30:40 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Fuchs-1990">
<DESCRIPTION>
<P>No blinding and knowledge of interventions could influence outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-12-29 16:46:25 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>No blinding and knowledge of interventions could influence outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-04-06 12:17:26 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-HONEYPOT-Study-2009">
<DESCRIPTION>
<P>No blinding and knowledge of the interventions could influence outcome assessment. "The trial was open label, but microbiology staff at the local laboratories were not informed of the treatment allocation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-12-29 17:12:03 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Lo-1996">
<DESCRIPTION>
<P>No blinding and knowledge of the interventions could influence outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-12-29 17:17:24 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Low-1980">
<DESCRIPTION>
<P>Blinding, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-09 16:37:03 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Luzar-1990">
<DESCRIPTION>
<P>No blinding and knowledge of interventions could influence outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-12-29 17:27:52 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Lye-1992">
<DESCRIPTION>
<P>No blinding and knowledge of interventions could influence outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 10:25:46 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-MP3-Study-2008">
<DESCRIPTION>
<P>Blinding, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-15 16:48:34 +1100" MODIFIED_BY="Denise Campbell" RESULT="YES" STUDY_ID="STD-Mendoza_x002d_Guevara-2007">
<DESCRIPTION>
<P>Blinding, and unlikely that the blinding could have been broken. "The study was blind for the investigators and laboratory personnel."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 10:13:10 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Moore-1989">
<DESCRIPTION>
<P>No blinding and knowledge of the interventions could influence outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 10:55:57 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Mupirocin-Study-1996">
<DESCRIPTION>
<P>No details given re who did the outcome assessment and if they were blind to patient treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 11:01:15 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Nolph-1985">
<DESCRIPTION>
<P>No blinding and knowledge of the interventions could influence outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-06 17:51:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nunez_x002d_Moral-2014">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 11:34:21 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Perez_x002d_Fontan-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 12:04:26 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Poole_x002d_Warren-1991">
<DESCRIPTION>
<P>Blinding, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 12:13:19 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Restrepo-2010">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 12:16:52 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ryckelynck-1987">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 14:11:08 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-SIPROCE-Study-1997">
<DESCRIPTION>
<P>No blinding and knowledge of the interventions could influence outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 14:00:49 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sesso-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 14:05:32 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Sharma-1971">
<DESCRIPTION>
<P>Blinding, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 14:17:27 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sit-2007">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 14:42:43 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Swartz-1991">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 14:48:58 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wadhwa-1995">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 14:49:27 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wadhwa-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-09 16:40:41 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Waite-1997">
<DESCRIPTION>
<P>"Investigators assessing response (presence or absence of infection) were blinded to the treatment received by the individual patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 14:55:04 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wikdahl-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 14:55:17 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 14:55:28 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wong-2003">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-05 15:39:17 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Zimmerman-1991">
<DESCRIPTION>
<P>No blinding and knowledge of the interventions could influence outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-01-12 12:14:47 +1100" MODIFIED_BY="Narelle Willis" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 14:42:13 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Axelrod-1973">
<DESCRIPTION>
<P>10/105 (9.5%) dialyses excluded from analysis because pre-dialysis serum showed antibiotic activity (9) and antibiotic had not been added to dialysate fluid (1). Data reported as no. episodes peritonitis/no. dialyses not no. episodes peritonitis/total patient-months on PD</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 14:50:31 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Bennet_x002d_Jones-1988">
<DESCRIPTION>
<P>1/27 (3.7%) patients not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 14:58:40 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Bernardini-1996">
<DESCRIPTION>
<P>All patients included in analysis including patients who ceased therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-23 11:26:52 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bernardini-2005">
<DESCRIPTION>
<P>All patients who received intervention included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-23 11:37:38 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blowey-1994">
<DESCRIPTION>
<P>All patients completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 15:25:17 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1999a">
<DESCRIPTION>
<P>Insufficient information to permit judgement; abstract only available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 15:45:33 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>14/95 (15%) withdrew from the study and were excluded from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 16:04:13 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Churchill-1988">
<DESCRIPTION>
<P>Intention to treat analysis for primary outcome; loss to follow-up: 20 in cotrimoxazole group (35.7%); 9 in placebo group (18.4%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 16:10:42 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cocksedge-1993">
<DESCRIPTION>
<P>No details given re loss to follow-up or any patient withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 16:17:55 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Danguilan-2003">
<DESCRIPTION>
<P>Total of 22/100 dropouts from the study (22%). Proportion missing enough to have a clinically relevant effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 16:30:41 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Fuchs-1990">
<DESCRIPTION>
<P>Proportion missing not enough to have a clinically relevant effect. 2/13 (15.4%) in sodium hypochlorite group withdrew from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 11:32:05 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>No missing data re peritonitis outcome; data for exit-site/tunnel infection excluded from analysis (vancomycin (3); cefazolin (6); no antibiotic (8))</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 16:54:28 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-HONEYPOT-Study-2009">
<DESCRIPTION>
<P>Missing data not balanced between groups. 17/185 (9.2%) withdrew from control group; 54/186 (29%) withdrew from honey group</P>
<P>Loss to follow-up: 1 in honey group (0.5%); 3 in mupirocin group (1.6%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 17:12:12 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Lo-1996">
<DESCRIPTION>
<P>ITT analysis for primary outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 17:17:22 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Low-1980">
<DESCRIPTION>
<P>No missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 17:22:10 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Luzar-1990">
<DESCRIPTION>
<P>Proportion missing not enough to have a clinically relevant effect; loss to follow-up: 8 of 127 (6.3%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-29 17:27:42 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Lye-1992">
<DESCRIPTION>
<P>Missing data balanced across groups, and reasons similar; 4 (16%) excluded from analysis in treatment group due to lack of effect of study antibiotics on MRSA bacteria; 3 (12%) excluded from analysis in control group for the same reason</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 16:29:41 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-MP3-Study-2008">
<DESCRIPTION>
<P>Missing data balanced across groups, and reasons similar (2 from each group lost to follow-up); data for 3 patients from 1 site were excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 14:52:12 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Mendoza_x002d_Guevara-2007">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-12 12:14:47 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Moore-1989">
<DESCRIPTION>
<P>The published report states percentage of patients in each group that experienced exit-site infection but does not state actual patient numbers. No report of loss to follow-up or withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 10:56:10 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Mupirocin-Study-1996">
<DESCRIPTION>
<P>Missing data balanced across groups, and reasons similar; ITT analysis used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 11:01:16 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Nolph-1985">
<DESCRIPTION>
<P>12.9% withdrew from control group; 24.3% withdrew from intervention group. Proportion missing enough to have a clinically relevant effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-06 17:51:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nunez_x002d_Moral-2014">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-09 16:39:02 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Perez_x002d_Fontan-1992">
<DESCRIPTION>
<P>Reasons for missing data not related to outcome "Patients of Group 2 in whom eradication was not obtained after two neomycin cycles were treated with mupirocin."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 12:04:26 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Poole_x002d_Warren-1991">
<DESCRIPTION>
<P>Missing data balanced across groups, and reasons similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 14:53:59 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Restrepo-2010">
<DESCRIPTION>
<P>No details of missing data given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 12:16:16 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ryckelynck-1987">
<DESCRIPTION>
<P>No details of missing data given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 14:11:11 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-SIPROCE-Study-1997">
<DESCRIPTION>
<P>Proportion missing enough to have a clinically relevant effect. Dropouts: 29/97 (29.9%) in silver ring group; 30/98 (30.6%) in control group. Withdrawals: 6/97 (6.2%) in silver ring group; 0/98 (0%) in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 14:00:51 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Sesso-1994">
<DESCRIPTION>
<P>44.4% withdrew from sodium fusidate group; 77.7% withdrew from ofloxacin group; 53.8% withdrew from control group. Proportion missing enough to have a clinically relevant effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 14:05:08 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-1971">
<DESCRIPTION>
<P>No details of missing data given on a patient basis; 6 dialyses excluded from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 17:17:53 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Sit-2007">
<DESCRIPTION>
<P>Proportion missing not enough to have a clinically relevant effect; 2 (8%) excluded from analysis in mupirocin group due to kidney transplantation (1) and death (1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 14:42:22 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Swartz-1991">
<DESCRIPTION>
<P>Missing data balanced across groups, and reasons similar; loss to follow-up: 2 of 29 in antibiotic prophylaxis group (6.9%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 14:49:07 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wadhwa-1995">
<DESCRIPTION>
<P>Insufficient information to permit judgement; no details re missing data provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 16:35:35 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wadhwa-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement. No details re missing data provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 15:05:37 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Waite-1997">
<DESCRIPTION>
<P>Proportion missing not enough to have a clinically relevant effect; 3 (2.5%) excluded from analysis due to withdrawal (2) and failure to have PD catheter inserted (1) - group allocation not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 15:13:54 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Wikdahl-1997">
<DESCRIPTION>
<P>No missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 15:21:37 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Wilson-1997">
<DESCRIPTION>
<P>Proportion missing not enough to have a clinically relevant effect; loss to follow-up: 1 in spray group (1.3%), 3 in control group (4.2%)</P>
<P>Withdrawals: 5 in spray group (6.5%) (adverse events) 1 (1.3%) excluded from analysis in povidone iodine spray group due to missing results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 15:30:32 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Wong-2003">
<DESCRIPTION>
<P>Missing data balanced across groups, and reasons similar. Outcome data for tunnel infection not reported - this is ok as this infection is the least frequent one in PD patients; 1 withdrawal (not stated which intervention group)</P>
<P>Excluded from analysis: 5 (6.4%) from mupirocin group; 7 (8.0%) from control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-05 15:39:15 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Zimmerman-1991">
<DESCRIPTION>
<P>12.5% in rifampin group withdrew; 0% in control group withdrew. Proportion missing enough to have a clinically relevant effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 14:41:03 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Axelrod-1973">
<DESCRIPTION>
<P>Outcomes not reported as expected. Also, only 1 of 3 expected primary outcomes reported (peritonitis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:31:00 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Bennet_x002d_Jones-1988">
<DESCRIPTION>
<P>2 of 3 primary outcomes of interest reported (exit-site infection, peritonitis). No report of adverse effects of intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bernardini-1996">
<DESCRIPTION>
<P>All pre-specified outcomes for this review were reported, however unable to meta-analyse exit-site infections (reported as infection rate/dialysis-year)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-23 11:27:31 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bernardini-2005">
<DESCRIPTION>
<P>All pre-specified outcomes for this review were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:31:05 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Blowey-1994">
<DESCRIPTION>
<P>Only 2 of 3 primary outcomes of interest for this review were reported (exit-site/tunnel infection, peritonitis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:31:16 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1999a">
<DESCRIPTION>
<P>Only 2 of 3 expected primary outcomes were reported (exit-site infection, catheter removal)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:31:24 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>Only 2 of 3 expected primary outcomes were reported (peritonitis, exit-site/tunnel infection)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:31:25 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Churchill-1988">
<DESCRIPTION>
<P>2 of 3 primary outcomes not reported (exit-site/tunnel infection, catheter removal/replacement)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:31:31 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cocksedge-1993">
<DESCRIPTION>
<P>Only 1 of 3 expected primary outcomes are reported (exit-site infection). No report of adverse effects of either intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:31:42 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Danguilan-2003">
<DESCRIPTION>
<P>Only 2 of 3 expected primary outcomes are reported (exit-site infection, peritonitis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:32:01 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Fuchs-1990">
<DESCRIPTION>
<P>Only 1 of 3 expected primary outcomes reported (exit-site infection)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 16:46:26 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>2 of 3 expected outcomes of interest are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 16:55:10 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-HONEYPOT-Study-2009">
<DESCRIPTION>
<P>3 of 3 expected primary outcomes are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-04 15:54:31 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Lo-1996">
<DESCRIPTION>
<P>The expected primary outcome is reported (peritonitis), however catheter removal and exit-site infection not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:32:14 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Low-1980">
<DESCRIPTION>
<P>1 of 3 primary outcomes not reported (exit-site/tunnel infection)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Luzar-1990">
<DESCRIPTION>
<P>3 of 3 primary outcomes of interest are reported, however unable to meta-analyse catheter removal</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-29 18:06:57 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lye-1992">
<DESCRIPTION>
<P>3 of 3 primary outcomes of interest are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 10:25:44 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-MP3-Study-2008">
<DESCRIPTION>
<P>Protocol is available and all pre-specified outcomes of interest to the review are reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:32:24 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Mendoza_x002d_Guevara-2007">
<DESCRIPTION>
<P>Only 1 of 3 expected primary outcomes reported (exit-site infection)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 16:36:38 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moore-1989">
<DESCRIPTION>
<P>Only 1 of 3 expected primary outcomes of interest reported (exit-site infection)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-31 15:46:23 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mupirocin-Study-1996">
<DESCRIPTION>
<P>3 of 3 expected primary outcomes of interest are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:01:17 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Nolph-1985">
<DESCRIPTION>
<P>Only 1 of 3 primary expected outcomes of interest is reported (peritonitis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:19:12 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nunez_x002d_Moral-2014">
<DESCRIPTION>
<P>Only 2 of 3 expected primary outcomes of interest reported fully</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:34:26 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Perez_x002d_Fontan-1992">
<DESCRIPTION>
<P>2 of 3 expected primary outcomes of interest are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 12:04:31 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Poole_x002d_Warren-1991">
<DESCRIPTION>
<P>3 of 3 expected primary outcomes of interest are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 12:13:21 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Restrepo-2010">
<DESCRIPTION>
<P>The expected primary outcome is reported. However, adverse effects of antifungal use are not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 12:16:54 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Ryckelynck-1987">
<DESCRIPTION>
<P>Only 1 of 3 expected primary outcomes is reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:11:12 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-SIPROCE-Study-1997">
<DESCRIPTION>
<P>3 of 3 expected primary outcomes are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:00:52 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Sesso-1994">
<DESCRIPTION>
<P>3 of 3 expected primary outcomes of interest are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:05:35 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Sharma-1971">
<DESCRIPTION>
<P>Outcomes not reported as expected - number of episodes peritonitis/number of dialyses not number of episodes peritonitis/total patient-months on dialysis. Also, only 1 of 3 expected primary outcomes reported (peritonitis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:17:32 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sit-2007">
<DESCRIPTION>
<P>2 of 3 expected primary outcomes are reported (exit-site/tunnel infection, peritonitis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Swartz-1991">
<DESCRIPTION>
<P>3 of 3 expected primary outcomes of interest are reported, however peritonitis, exit-site infection and catheter removal could not be meta-analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:49:11 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Wadhwa-1995">
<DESCRIPTION>
<P>3 of 3 expected primary outcomes are reported (exit-site infection, peritonitis, catheter loss)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 16:35:37 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Wadhwa-1997">
<DESCRIPTION>
<P>3 of 3 expected primary outcomes are reported (exit-site infection, peritonitis, catheter loss)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:40:46 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Waite-1997">
<DESCRIPTION>
<P>2 of 3 expected primary outcomes of interest are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wikdahl-1997">
<DESCRIPTION>
<P>3 of 3 expected primary outcomes of interest are reported, however unable to meta-analyse catheter removal</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 16:08:53 +1100" MODIFIED_BY="Denise Campbell" RESULT="YES" STUDY_ID="STD-Wilson-1997">
<DESCRIPTION>
<P>3 of 3 expected primary outcomes of interest are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 15:31:35 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Wong-2003">
<DESCRIPTION>
<P>3 of 3 expected primary outcomes are reported (exit-site infection, peritonitis, catheter loss)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-04 15:57:34 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Zimmerman-1991">
<DESCRIPTION>
<P>Protocol not available but all expected outcomes of interest are reported, however unable to meta-analyse exit-site infection</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-01-09 16:38:35 +1100" MODIFIED_BY="Narelle Willis" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 14:41:06 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Axelrod-1973">
<DESCRIPTION>
<P>Partly funded by Eli Lilly &amp; Company, Indianapolis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 14:50:05 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bennet_x002d_Jones-1988">
<DESCRIPTION>
<P>No information provided about funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-23 11:22:54 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bernardini-1996">
<DESCRIPTION>
<P>No information on funding provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-23 11:28:59 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bernardini-2005">
<DESCRIPTION>
<P>Supported by National Kidney Foundations of Western Pennsylvania and Upstate New York and by Paul Teschan Fund of Dialysis Clinic Inc</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-31 14:46:08 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blowey-1994">
<DESCRIPTION>
<P>No information on funding provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-08 14:03:02 +1100" MODIFIED_BY="Denise Campbell" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1999a">
<DESCRIPTION>
<P>No information on funding provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-08 15:18:37 +1100" MODIFIED_BY="Denise Campbell" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>No information on funding provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-27 17:24:52 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Churchill-1988">
<DESCRIPTION>
<P>Hoffman La Roche supplied the antibiotic (cotrimoxazole) and placebo tablets</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 16:10:45 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cocksedge-1993">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 16:17:57 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Danguilan-2003">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 16:30:46 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fuchs-1990">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 16:46:27 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 16:53:57 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-HONEYPOT-Study-2009">
<DESCRIPTION>
<P>The study appears to be free of other sources of risk. Although 3 of 4 funders are pharmaceutical companies, there is an explicit statement about their role on page 26 of the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 17:12:07 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lo-1996">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-29 17:17:36 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Low-1980">
<DESCRIPTION>
<P>Study appears to be free of other sources of risk. Funding was from a National Institutes of Health contract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-29 17:16:47 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Luzar-1990">
<DESCRIPTION>
<P>Funding source not specified but seems to be Baxter Healthcare Corporation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 16:36:00 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lye-1992">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 10:25:43 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-MP3-Study-2008">
<DESCRIPTION>
<P>Funded by the Kidney Foundation of Canada. Study appears to be free of other sources of risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-15 16:50:58 +1100" MODIFIED_BY="Denise Campbell" RESULT="UNKNOWN" STUDY_ID="STD-Mendoza_x002d_Guevara-2007">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-15 17:39:31 +1100" MODIFIED_BY="Denise Campbell" RESULT="UNKNOWN" STUDY_ID="STD-Moore-1989">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-31 15:47:07 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mupirocin-Study-1996">
<DESCRIPTION>
<P>Funding source: SmithKline Beecham, UK, and Baxter Healthcare, USA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:01:18 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Nolph-1985">
<DESCRIPTION>
<P>Funding source: Travenol Laboratories Inc., USA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:38:35 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nunez_x002d_Moral-2014">
<DESCRIPTION>
<P>Disclosure states that "Part of these data belong to Baxter S. L. funds as we received the Nephrological Nursing Investigation Baxter award 2010"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 11:34:29 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Perez_x002d_Fontan-1992">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-01 14:50:51 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poole_x002d_Warren-1991">
<DESCRIPTION>
<P>Funding source: Baxter Healthcare Corporation, USA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 12:13:21 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Restrepo-2010">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 12:17:07 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ryckelynck-1987">
<DESCRIPTION>
<P>No report of funding source; abstract-only publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-15 19:31:07 +1100" MODIFIED_BY="Denise Campbell" RESULT="UNKNOWN" STUDY_ID="STD-SIPROCE-Study-1997">
<DESCRIPTION>
<P>"Supported in part by Baxter Deutschland GmbH, Ettlingen, Germany."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:00:53 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Sesso-1994">
<DESCRIPTION>
<P>Supported by a grant from Instituto Paulista de Estudos e Pesquisas em Nefrologia e Hipertensao. Study appears to be free of other sources of risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:05:36 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-1971">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:17:29 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sit-2007">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:42:45 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Swartz-1991">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 14:49:00 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wadhwa-1995">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 15:00:48 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wadhwa-1997">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 17:30:09 +1100" MODIFIED_BY="Denise Campbell" RESULT="NO" STUDY_ID="STD-Waite-1997">
<DESCRIPTION>
<P>Funding source: Purdue-Frederick</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 15:13:56 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wikdahl-1997">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 15:22:09 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1997">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-05 15:31:32 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wong-2003">
<DESCRIPTION>
<P>No report of funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 16:42:33 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zimmerman-1991">
<DESCRIPTION>
<P>Funding source: Baxter Healthcare</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-01-05 16:53:16 +1100" MODIFIED_BY="Narelle Willis">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-01-05 16:52:08 +1100" MODIFIED_BY="Narelle Willis" NO="1" READONLY="YES">
<TITLE MODIFIED="2017-01-05 15:40:29 +1100" MODIFIED_BY="Narelle Willis">Oral or topical or intraperitoneal antibiotics versus placebo/no treatment for preventing peritonitis in peritoneal dialysis patients</TITLE>
<TABLE COLS="7" ROWS="22">
<TR>
<TD COLSPAN="7">
<P>
<B>Oral or topical or intraperitoneal antibiotics versus placebo/no treatment for preventing peritonitis in peritoneal dialysis patients</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with CKD on peritoneal dialysis<BR/>
<B>Settings: </B>tertiary settings<BR/>
<B>Intervention:</B> oral or topical or intraperitoneal antibiotics versus placebo/no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Oral or topical or intraperitoneal antibiotics versus placebo/no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Peritonitis (number of patients with one or more episodes)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.82 </B>
<BR/>(0.57 to 1.19)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>395 (5)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>360 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>295 per 1000</B>
<BR/>(205 to 428)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>385 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>316 per 1000</B>
<BR/>(219 to 458)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Exit-site/tunnel infection (number of patients with one or more episodes)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.45 </B>
<BR/>(0.19 to 1.04)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>191 (3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>176 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>79 per 1000</B>
<BR/>(34 to 184)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>231 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>104 per 1000</B>
<BR/>(44 to 240)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Catheter removal or replacement (number of patients)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.82 </B>
<BR/>(0.46 to 1.46)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>395 (5)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>115 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>94 per 1000</B>
<BR/>(53 to 168)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>156 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>128 per 1000</B>
<BR/>(72 to 228)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Unclear or high risk of bias in 3 of 5 studies<BR/>
<SUP>2</SUP> Wide confidence intervals due to small patient numbers</P>
<P>Abbreviations: CKD - chronic kidney disease; GRADE - Grading of Recommendations Assessment, Development and Evaluation</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2017-01-05 16:53:16 +1100" MODIFIED_BY="Narelle Willis" NO="2" READONLY="YES">
<TITLE MODIFIED="2015-06-02 14:19:54 +1000" MODIFIED_BY="Ann Jones">Nasal antibiotics versus placebo/no treatment for preventing peritonitis in peritoneal dialysis patients</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Nasal antibiotics versus no treatment for preventing peritonitis in peritoneal dialysis patients</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with CKD on peritoneal dialysis<BR/>
<B>Settings: </B>tertiary settings<BR/>
<B>Intervention:</B> nasal antibiotics versus placebo/no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Nasal antibiotics versus placebo/no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Peritonitis (number of patients with one or more episodes)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.94 </B>
<BR/>(0.67 to 1.31)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>338 (3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>¹<SUP>,</SUP>²</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>294 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>276 per 1000</B>
<BR/>(197 to 385)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>331 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>311 per 1000</B>
<BR/>(222 to 434)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Exit-site/ tunnel infection (number of patients with one or more episodes)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.34 </B>
<BR/>(0.62 to 2.87)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>338 (3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>¹<SUP>,</SUP>²</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>165 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>221 per 1000</B>
<BR/>(102 to 473)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>188 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>252 per 1000</B>
<BR/>(117 to 540)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Catheter removal or replacement (number of patients)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.92 </B>
<BR/>(0.48 to 1.78)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>289 (2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>¹<SUP>,</SUP>²</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>103 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>95 per 1000</B>
<BR/>(49 to 183)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>265 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>244 per 1000</B>
<BR/>(127 to 472)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).</P>
<P>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio<BR/>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>¹ Unclear risk of bias for allocation concealment in largest study (<LINK REF="STD-Mupirocin-Study-1996" TYPE="STUDY">Mupirocin Study 1996</LINK>)<BR/>² Wide confidence intervals due to small patient numbers</P>
<P>Abbreviations: CKD - chronic kidney disease; GRADE - Grading of Recommendations Assessment, Development and Evaluation</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2017-01-05 16:52:48 +1100" MODIFIED_BY="Narelle Willis" NO="3" READONLY="YES">
<TITLE MODIFIED="2015-08-21 16:55:36 +1000" MODIFIED_BY="Grade Profiler">Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant) for preventing peritonitis in peritoneal dialysis patients</TITLE>
<TABLE COLS="7" ROWS="18">
<TR>
<TD COLSPAN="7">
<P>
<B>Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant) for preventing peritonitis in peritoneal dialysis patients</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with CKD on peritoneal dialysis<BR/>
<B>Settings: </B>tertiary settings<BR/>
<B>Intervention:</B> topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant)<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Peritonitis (number of patients with one or more episodes)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.83 </B>
<BR/>(0.65 to 1.06)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>853 (6)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>235 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>195 per 1000</B>
<BR/>(153 to 250)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>152 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>126 per 1000</B>
<BR/>(99 to 161)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Exit-site/tunnel infection (number of patients with one or more episodes)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.97 </B>
<BR/>(0.74 to 1.27)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>913 (7)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>238 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>230 per 1000</B>
<BR/>(176 to 302)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>222 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>215 per 1000</B>
<BR/>(164 to 282)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Catheter removal or replacement (number of patients)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.89 </B>
<BR/>(0.57 to 1.38)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>792 (6)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>97 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>86 per 1000</B>
<BR/>(55 to 134)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>93 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>83 per 1000</B>
<BR/>(53 to 128)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Unclear allocation in several studies<BR/>
<SUP>2</SUP> Imprecision due to small number of patients and events in several studies</P>
<P>Abbreviations: CKD - chronic kidney disease; GRADE - Grading of Recommendations Assessment, Development and Evaluation</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2017-01-05 16:52:45 +1100" MODIFIED_BY="Narelle Willis" NO="4" READONLY="YES">
<TITLE MODIFIED="2015-08-21 16:55:58 +1000" MODIFIED_BY="Grade Profiler">Antifungal versus placebo/no treatment for preventing peritonitis in peritoneal dialysis patients</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Antifungal versus placebo/no treatment for preventing fungal peritonitis in peritoneal dialysis patients</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with CKD on peritoneal dialysis<BR/>
<B>Settings: </B>tertiary settings<BR/>
<B>Intervention:</B> antifungal versus placebo/no treatment during antibiotic course<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Antifungal versus placebo/no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Fungal peritonitis (number of patients with one or more episodes)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.28 </B>
<BR/>(0.12 to 0.63)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>817 (2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>64 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 1000</B>
<BR/>(8 to 40)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>64 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 1000</B>
<BR/>(8 to 40)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> High risk of bias in one study (<LINK REF="STD-Lo-1996" TYPE="STUDY">Lo 1996</LINK>)<BR/>
<SUP>2</SUP> Imprecision due to small number of events and studies</P>
<P>Abbreviations: CKD - chronic kidney disease; GRADE - Grading of Recommendations Assessment, Development and Evaluation</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2017-04-04 16:08:05 +1000" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2017-04-04 16:08:05 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE>Guidelines on antimicrobial interventions to prevent peritonitis in PD</TITLE>
<TABLE COLS="4" ROWS="7">
<TR>
<TH>
<P>Guideline</P>
</TH>
<TH>
<P>Country</P>
</TH>
<TH>
<P>Year</P>
</TH>
<TH>
<P>Recommendation</P>
</TH>
</TR>
<TR>
<TD>
<P>Kidney-Disease Outcomes Quality Initiative</P>
</TD>
<TD>
<P>United States of America</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>No guideline</P>
</TD>
</TR>
<TR>
<TD>
<P>The Renal Association</P>
</TD>
<TD>
<P>United Kingdom</P>
</TD>
<TD>
<P>April 2008</P>
<P/>
<P>July 2010</P>
</TD>
<TD>
<P>
<B>Guideline 3.1 - PD Access: Implantation Protocol</B>
</P>
<UL>
<LI>Recommended that renal units have clear protocols for peri-operative catheter care including the use of antibiotic prophylaxis (1A)</LI>
</UL>
<P>
<B>Guideline 5.1.4 - PD Infectious Complications: Prevention Strategies</B>
</P>
<UL>
<LI>Recommended that initial catheter insertion be accompanied by antibiotic prophylaxis (1B)</LI>
</UL>
<P>
<B>Guideline 5.1.5 - PD Infectious Complications: Prevention Strategies</B>
</P>
<UL>
<LI>Recommended that invasive procedures be accompanied by antibiotic prophylaxis and emptying the abdomen of dialysis fluid for a period commensurate with the procedure (1C)</LI>
</UL>
<P>
<B>Guideline 5.1.6 - PD Infectious Complications: Prevention Strategies</B>
</P>
<UL>
<LI>Recommended that topical antibiotic administration be used to reduce the frequency of <I>S. aureus</I> and Gram-negative exit-site infection and peritonitis (1A)</LI>
</UL>
</TD>
</TR>
<TR>
<TD>
<P>Canadian Society of Nephrology</P>
</TD>
<TD>
<P>Canada</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>No guideline</P>
</TD>
</TR>
<TR>
<TD>
<P>European Renal Best Practice</P>
</TD>
<TD>
<P>Europe</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>No guideline</P>
</TD>
</TR>
<TR>
<TD>
<P>International Society for Peritoneal Dialysis</P>
<P/>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>July 2010</P>
<P/>
<P>November 2011</P>
</TD>
<TD>
<P>
<B>Guideline 3.1: Implantation Protocol (1A)</B>
</P>
<UL>
<LI>Recommended that renal units have clear protocols for perioperative catheter care, including the use of antibiotic prophylaxis</LI>
<LI>Recommended that perioperative catheter care protocol include screening for MRSA and nasal carriage of <I>S. aureus</I>
</LI>
<LI>Recommended that prophylactic antibiotics be administered to reduce the risk of catheter-site infection, peritonitis and wound sepsis and there is RCT evidence for the use of vancomycin</LI>
</UL>
<P>
<B>Position Statement: Catheter Placement to Prevent Catheter Infections and the Related Peritonitis Episodes</B>
</P>
<UL>
<LI>Prophylactic antibiotics administered at the time of insertion decrease the infection risk. A first-generation cephalosporin or vancomycin can be used, but suggested each program should weigh the potential benefit against the risk of vancomycin use (development of resistant organisms)</LI>
<LI>There is no data on the effectiveness of obtaining nose cultures before catheter insertion, and treating patients positive for <I>S. aureus</I> nasal carriage</LI>
</UL>
<P>
<B>Position Statement: Exit-Site Care to Prevent Peritonitis</B>
</P>
<UL>
<LI>Antibiotic protocols against <I>S. aureus</I> are effective in reducing the risk of <I>S. aureus</I> catheter infections</LI>
<LI>All PD patients should use topical antibiotic either at the catheter exit-site or intranasally or both</LI>
<LI>Topical antibiotic ointments (as opposed to antibiotic creams) should not be used at the exit site of polyurethane catheters</LI>
</UL>
<P>
<B>Position Statement: Prevention of Fungal Peritonitis</B>
</P>
<UL>
<LI>Most episodes of fungal peritonitis are preceded by courses of antibiotics</LI>
<LI>Fungal prophylaxis during antibiotic therapy may prevent some cases of Candida peritonitis in programs that have high rates of fungal peritonitis</LI>
</UL>
</TD>
</TR>
<TR>
<TD>
<P>Kidney Health Australia-Caring for Australasians with Renal Impairment</P>
<P/>
</TD>
<TD>
<P>Australia/ New Zealand</P>
</TD>
<TD>
<P>February 2014</P>
</TD>
<TD>
<P>
<B>Guideline 6. Prophylactic Antibiotics for Insertion of PD Catheters</B>
</P>
<UL>
<LI>Recommended that intravenous antibiotic prophylaxis be used prior to peritoneal dialysis catheter insertion to reduce the risk of early peritonitis</LI>
<LI>Vancomycin, cephalosporins and gentamicin have demonstrated effectiveness in reducing the risk of peritonitis</LI>
</UL>
<P>
<B>Guideline 8. Treatment of Peritoneal Dialysis-Associated Fungal Peritonitis</B>
</P>
<UL>
<LI>Oral antifungal prophylaxis should be considered when antibiotics are administered to patients undergoing peritoneal dialysis to reduce the risk of developing fungal peritonitis</LI>
<LI>Prophylactic antifungals should be administered before gynaecological procedures</LI>
</UL>
<P>
<B>Guideline 10. Prophylaxis for Exit-site/Tunnel Infections Using Mupirocin</B>
</P>
<UL>
<LI>Recommended that prophylactic therapy using mupirocin ointment be used, especially for <I>S. aureus</I> carriage (intranasally or at the exit site) to decrease the risk of <I>S. aureus</I> catheter exit-site/tunnel infections and peritonitis</LI>
<LI>Suggested that clean the PD catheter exit site daily and apply a topical antimicrobial agent (either mupirocin or gentamicin)</LI>
</UL>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>MRSA - methicillin-resistant <I>S. aureus</I>; NA - not applicable; PD - peritoneal dialysis</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2017-04-04 16:08:05 +1000" MODIFIED_BY="Narelle S Willis" NO="2">
<TITLE MODIFIED="2015-04-20 15:42:23 +1000" MODIFIED_BY="[Empty name]">Comparisons in original review and updated review</TITLE>
<TABLE COLS="2" ROWS="11">
<TR>
<TH>
<P>Comparisons in 2004 review</P>
</TH>
<TH>
<P>Comparisons in 2017 review</P>
</TH>
</TR>
<TR>
<TD>
<P>Oral antibiotics versus none</P>
</TD>
<TD>
<P>Oral or topical antibiotics versus placebo/no treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>Nasal antibiotics versus none</P>
</TD>
<TD>
<P>Oral or topical antibiotics versus other antibiotic</P>
</TD>
</TR>
<TR>
<TD>
<P>Peri-operative IV prophylaxis versus none</P>
</TD>
<TD>
<P>Nasal antibiotics versus no treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>Peri-operative IV prophylaxis head-to-head</P>
</TD>
<TD>
<P>Pre/peri-operative IV prophylaxis versus none or head-to-head</P>
</TD>
</TR>
<TR>
<TD>
<P>Topical disinfectants versus none</P>
</TD>
<TD>
<P>Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant)</P>
</TD>
</TR>
<TR>
<TD>
<P>Germicidal chamber versus none</P>
</TD>
<TD>
<P>Germicidal chamber versus none</P>
</TD>
</TR>
<TR>
<TD>
<P>Antistaphylococcal vaccine (Staphypan) versus placebo</P>
</TD>
<TD>
<P>Dressing systems (any)</P>
</TD>
</TR>
<TR>
<TD>
<P>Antibiotic prophylaxis head-to-head agents</P>
</TD>
<TD>
<P>Silver ring system on catheter versus none</P>
</TD>
</TR>
<TR>
<TD>
<P>--</P>
</TD>
<TD>
<P>Antistaphylococcal vaccine (Staphypan) versus placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>--</P>
</TD>
<TD>
<P>Antifungal versus placebo/no treatment</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2017-01-05 16:54:57 +1100" MODIFIED_BY="Narelle Willis" NO="3">
<TITLE MODIFIED="2015-06-02 14:29:58 +1000" MODIFIED_BY="Ann Jones">Other outcomes analysed</TITLE>
<TABLE COLS="4" ROWS="17">
<TR>
<TH>
<P>Outcome analysed</P>
</TH>
<TH>
<P>Number of studies</P>
</TH>
<TH>
<P>Number of patients</P>
</TH>
<TH>
<P>RR (95% CI)</P>
</TH>
</TR>
<TR>
<TH COLSPAN="4">
<P>
<B>Oral antibiotic prophylaxis</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Pruritus</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>3.00 (0.13 to 71.00)</P>
</TD>
</TR>
<TR>
<TD>
<P>Diarrhoea</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>0.09 (0.01 to 1.58)</P>
</TD>
</TR>
<TR>
<TD>
<P>Nausea</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>9.00 (0.50 to 160.59)</P>
</TD>
</TR>
<TR>
<TD>
<P>Allergy</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>5.00 (0.25 to 100.20)</P>
</TD>
</TR>
<TR>
<TH COLSPAN="4">
<P>
<B>Nasal antibiotic prophylaxis</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Nasal irritation</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>2.10 (0.10 to 44.40)</P>
</TD>
</TR>
<TR>
<TD>
<P>Rhinitis</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>267</P>
</TD>
<TD>
<P>0.74 (0.27 to 2.09)</P>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>267</P>
</TD>
<TD>
<P>0.99 (0.14 to 6.94)</P>
</TD>
</TR>
<TR>
<TD>
<P>Diarrhoea</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>267</P>
</TD>
<TD>
<P>1.65 (0.40 to 6.78)</P>
</TD>
</TR>
<TR>
<TD>
<P>Nausea</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>267</P>
</TD>
<TD>
<P>0.99 (0.14 to 6.94)</P>
</TD>
</TR>
<TR>
<TD>
<P>Vomiting</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>267</P>
</TD>
<TD>
<P>2.98 (0.61 to 14.94)</P>
</TD>
</TR>
<TR>
<TD>
<P>Pruritus</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>267</P>
</TD>
<TD>
<P>1.49 (0.25 to 8.77)</P>
</TD>
</TR>
<TR>
<TH COLSPAN="4">
<P>
<B>Topical disinfectants</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Technique failure</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>149</P>
</TD>
<TD>
<P>0.19 (0.01 to 3.83)</P>
</TD>
</TR>
<TR>
<TD>
<P>Pruritus</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>149</P>
</TD>
<TD>
<P>10.29 (0.58 to 182.92)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis">
<COMPARISON ID="CMP-001" MODIFIED="2017-01-12 12:21:15 +1100" MODIFIED_BY="Narelle Willis" NO="1">
<NAME>Oral or topical antibiotics versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="5.969149905282167" CI_END="1.1893610502258751" CI_START="0.5704530740393003" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8236957370558387" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="72" I2="32.988782934394806" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.07531371190922122" LOG_CI_START="-0.2437800752142015" LOG_EFFECT_SIZE="-0.0842331816524901" METHOD="MH" MODIFIED="2017-01-05 09:38:53 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.20146416943708068" P_Q="0.3820237411716402" P_Z="0.300777336881755" Q="0.7641795375353853" RANDOM="YES" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.057984739281064894" TOTALS="YES" TOTAL_1="195" TOTAL_2="200" WEIGHT="100.00000000000001" Z="1.0347678895938128">
<NAME>Peritonitis (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.998768724004431" CI_END="1.3222060665959832" CI_START="0.5763080893222002" DF="3" EFFECT_SIZE="0.87292499788364" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="60" I2="39.98522104865956" ID="CMP-001.01.01" LOG_CI_END="0.12129914547591772" LOG_CI_START="-0.23934528442118128" LOG_EFFECT_SIZE="-0.05902306947263179" MODIFIED="2015-03-26 12:25:50 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1718874978626891" P_Z="0.5211748706293025" STUDIES="4" TAU2="0.07253918606392168" TOTAL_1="122" TOTAL_2="119" WEIGHT="87.53895274805649" Z="0.6415354339806173">
<NAME>Oral antibiotic versus placebo</NAME>
<DICH_DATA CI_END="3.1510687283977536" CI_START="0.42376373131482986" EFFECT_SIZE="1.1555555555555554" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.49845787573457684" LOG_CI_START="-0.372876216015666" LOG_EFFECT_SIZE="0.06279082985945544" MODIFIED="2015-01-21 13:13:36 +1100" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.5118259586674088" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="13" VAR="0.261965811965812" WEIGHT="10.98067500872637"/>
<DICH_DATA CI_END="3.5862406343245112" CI_START="0.6273979438147214" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5546394270702987" LOG_CI_START="-0.20245690895893617" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2015-01-21 13:14:03 +1100" MODIFIED_BY="[Empty name]" ORDER="93859" O_E="0.0" SE="0.4447221354708778" STUDY_ID="STD-Low-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.19777777777777777" WEIGHT="13.736465618597725"/>
<DICH_DATA CI_END="0.9313814061086491" CI_START="0.2377686367204527" EFFECT_SIZE="0.47058823529411764" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="-0.030872436475239684" LOG_CI_START="-0.6238454322974211" LOG_EFFECT_SIZE="-0.32735893438633035" MODIFIED="2015-03-26 12:25:50 +1100" MODIFIED_BY="[Empty name]" ORDER="93861" O_E="0.0" SE="0.348315273009618" STUDY_ID="STD-Zimmerman-1991" TOTAL_1="32" TOTAL_2="32" VAR="0.12132352941176472" WEIGHT="19.59348025451823"/>
<DICH_DATA CI_END="1.2169368976122583" CI_START="0.6690767982807038" EFFECT_SIZE="0.90234375" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="32" LOG_CI_END="0.08526805914271794" LOG_CI_START="-0.1745240299821285" LOG_EFFECT_SIZE="-0.04462798541970525" MODIFIED="2015-03-26 12:25:25 +1100" MODIFIED_BY="[Empty name]" ORDER="93858" O_E="0.0" SE="0.1526031591435162" STUDY_ID="STD-Churchill-1988" TOTAL_1="56" TOTAL_2="49" VAR="0.023287724180581327" WEIGHT="43.228331866214155"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4026664702183906" CI_START="0.21943702695203188" DF="0" EFFECT_SIZE="0.5547945205479452" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.14695441560158468" LOG_CI_START="-0.6586900894131593" LOG_EFFECT_SIZE="-0.25586783690578735" MODIFIED="2015-03-26 11:54:48 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2131518131999739" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="81" WEIGHT="12.461047251943528" Z="1.2449454865414467">
<NAME>Mupirocin ointment versus standard care</NAME>
<DICH_DATA CI_END="1.4026664702183909" CI_START="0.21943702695203185" EFFECT_SIZE="0.5547945205479452" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.14695441560158476" LOG_CI_START="-0.6586900894131594" LOG_EFFECT_SIZE="-0.25586783690578735" MODIFIED="2014-09-08 17:49:17 +1000" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.47323957025027824" STUDY_ID="STD-Wong-2003" TOTAL_1="73" TOTAL_2="81" VAR="0.22395569085066802" WEIGHT="12.461047251943528"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9384890992209272" CI_END="1.1445641685310306" CI_START="0.4002812306378174" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6768659792924676" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.05864014585960565" LOG_CI_START="-0.3976347736758937" LOG_EFFECT_SIZE="-0.16949731390814401" METHOD="MH" MODIFIED="2017-01-05 09:39:50 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.6254746433407075" P_Q="1.0" P_Z="0.14534356390436398" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="668" TOTAL_2="772" WEIGHT="100.0" Z="1.4561774777120777">
<NAME>Peritonitis rate (episodes/total patient-months on PD)</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9384890992209272" CI_END="1.1445641685310306" CI_START="0.4002812306378174" DF="2" EFFECT_SIZE="0.6768659792924676" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="37" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.05864014585960565" LOG_CI_START="-0.3976347736758937" LOG_EFFECT_SIZE="-0.16949731390814401" MODIFIED="2015-04-01 17:39:15 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6254746433407075" P_Z="0.14534356390436398" STUDIES="3" TAU2="0.0" TOTAL_1="668" TOTAL_2="772" WEIGHT="100.0" Z="1.4561774777120777">
<NAME>Any systemic antibiotic versus placebo/no treatment (excluding nystatin)</NAME>
<DICH_DATA CI_END="3.4979162531295005" CI_START="0.35294381337175534" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.5438094074184939" LOG_CI_START="-0.4522944262971436" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2014-09-08 15:12:23 +1000" MODIFIED_BY="[Empty name]" ORDER="93862" O_E="0.0" SE="0.5851163227180652" STUDY_ID="STD-Sesso-1994" TOTAL_1="72" TOTAL_2="96" VAR="0.3423611111111111" WEIGHT="20.981859338620612"/>
<DICH_DATA CI_END="1.463106045120039" CI_START="0.21037228371561506" EFFECT_SIZE="0.5547945205479452" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.1652758046908691" LOG_CI_START="-0.6770114785024439" LOG_EFFECT_SIZE="-0.25586783690578735" MODIFIED="2014-09-08 15:12:23 +1000" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.4947637195370469" STUDY_ID="STD-Wong-2003" TOTAL_1="365" TOTAL_2="405" VAR="0.24479113817013362" WEIGHT="29.34490492607065"/>
<DICH_DATA CI_END="1.301062775750121" CI_START="0.29302803207896533" EFFECT_SIZE="0.6174527227158806" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="0.11429825159936186" LOG_CI_START="-0.533090831540497" LOG_EFFECT_SIZE="-0.20939628997056756" MODIFIED="2014-09-08 15:12:23 +1000" MODIFIED_BY="[Empty name]" ORDER="93863" O_E="0.0" SE="0.38027955206399816" STUDY_ID="STD-Zimmerman-1991" TOTAL_1="231" TOTAL_2="271" VAR="0.1446125377179951" WEIGHT="49.67323573530874"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3987388104752778" CI_END="1.0396844055203123" CI_START="0.1904943003652488" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.44503253075505783" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.016901529932190122" LOG_CI_START="-0.72011801398811" LOG_EFFECT_SIZE="-0.35160824202796" METHOD="MH" MODIFIED="2017-01-05 09:40:20 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.49689860553989873" P_Q="1.0" P_Z="0.061473938908993636" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="89" TOTAL_2="102" WEIGHT="100.00000000000001" Z="1.870071144590343">
<NAME>Exit-site/tunnel infection (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3987388104752778" CI_END="1.0396844055203123" CI_START="0.1904943003652488" DF="2" EFFECT_SIZE="0.44503253075505783" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="18" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.016901529932190122" LOG_CI_START="-0.72011801398811" LOG_EFFECT_SIZE="-0.35160824202796" MODIFIED="2016-12-28 17:13:28 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.49689860553989873" P_Z="0.061473938908993636" STUDIES="3" TAU2="0.0" TOTAL_1="89" TOTAL_2="102" WEIGHT="100.00000000000001" Z="1.870071144590343">
<NAME>Any systemic antibiotic versus placebo/no treatment</NAME>
<DICH_DATA CI_END="4.020812706283332" CI_START="0.012590738166164326" EFFECT_SIZE="0.225" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6043138436768775" LOG_CI_START="-1.8999488074541524" LOG_EFFECT_SIZE="-0.6478174818886375" MODIFIED="2014-09-08 15:12:23 +1000" MODIFIED_BY="[Empty name]" ORDER="93864" O_E="0.0" SE="1.471016277574415" STUDY_ID="STD-Blowey-1994" TOTAL_1="7" TOTAL_2="8" VAR="2.1638888888888888" WEIGHT="8.661602636427077"/>
<DICH_DATA CI_END="4.649263461972468" CI_START="0.1994504453496811" EFFECT_SIZE="0.9629629629629629" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6673841572475794" LOG_CI_START="-0.7001649896239182" LOG_EFFECT_SIZE="-0.01639041618816937" MODIFIED="2015-01-21 14:39:52 +1100" MODIFIED_BY="[Empty name]" ORDER="93865" O_E="0.0" SE="0.8033051383497714" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="13" VAR="0.6452991452991452" WEIGHT="29.045049635462586"/>
<DICH_DATA CI_END="1.0004224290531323" CI_START="0.11651294392565395" EFFECT_SIZE="0.34141201264488935" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="1.8341986855723778E-4" LOG_CI_START="-0.9336258243099181" LOG_EFFECT_SIZE="-0.46672120222068053" MODIFIED="2014-09-08 15:12:23 +1000" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.5485241724607448" STUDY_ID="STD-Wong-2003" TOTAL_1="73" TOTAL_2="81" VAR="0.30087876777374495" WEIGHT="62.29334772811035"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4112846347967323" CI_END="1.0533618036306107" CI_START="0.16550221272961863" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41753288410103473" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.022577566182833388" LOG_CI_START="-0.7811961954239769" LOG_EFFECT_SIZE="-0.37930931462057177" METHOD="MH" MODIFIED="2017-01-05 09:40:34 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.5213182099748742" P_Q="1.0" P_Z="0.0643344010708702" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="438" TOTAL_2="501" WEIGHT="100.0" Z="1.849855347780225">
<NAME>Exit-site/tunnel infection rate (episodes/total patient-months on PD)</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4112846347967323" CI_END="1.0533618036306107" CI_START="0.16550221272961863" DF="1" EFFECT_SIZE="0.41753288410103473" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.022577566182833388" LOG_CI_START="-0.7811961954239769" LOG_EFFECT_SIZE="-0.37930931462057177" MODIFIED="2015-04-01 15:46:54 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5213182099748742" P_Z="0.0643344010708702" STUDIES="2" TAU2="0.0" TOTAL_1="438" TOTAL_2="501" WEIGHT="100.0" Z="1.849855347780225">
<NAME>Any systemic antibiotic versus placebo/no treatment</NAME>
<DICH_DATA CI_END="3.4924681375265934" CI_START="0.12379534140162536" EFFECT_SIZE="0.6575342465753424" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.5431324526503564" LOG_CI_START="-0.9072956981400937" LOG_EFFECT_SIZE="-0.18208162274486872" MODIFIED="2015-01-21 14:47:01 +1100" MODIFIED_BY="[Empty name]" ORDER="93866" O_E="0.0" SE="0.8519886755094501" STUDY_ID="STD-Sesso-1994" TOTAL_1="73" TOTAL_2="96" VAR="0.725884703196347" WEIGHT="30.709674234723515"/>
<DICH_DATA CI_END="1.0377173879941206" CI_START="0.11232553653509227" EFFECT_SIZE="0.34141201264488935" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="0.01607909383398635" LOG_CI_START="-0.9495214982753474" LOG_EFFECT_SIZE="-0.46672120222068053" MODIFIED="2014-09-08 15:12:23 +1000" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.5671985676050412" STUDY_ID="STD-Wong-2003" TOTAL_1="365" TOTAL_2="405" VAR="0.3217142150932105" WEIGHT="69.29032576527648"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7585878455372232" CI_END="1.459942309775307" CI_START="0.4615958683840924" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8209161578817964" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.16433569479727422" LOG_CI_START="-0.33573808708373815" LOG_EFFECT_SIZE="-0.08570119614323195" METHOD="MH" MODIFIED="2017-01-05 09:40:52 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.4396621931390703" P_Q="1.0" P_Z="0.5017200105621442" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="WEIGHT" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="195" TOTAL_2="200" WEIGHT="100.0" Z="0.6717859002362365">
<NAME>Catheter removal or replacement (number of patients)</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7585878455372232" CI_END="1.459942309775307" CI_START="0.4615958683840924" DF="4" EFFECT_SIZE="0.8209161578817964" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.16433569479727422" LOG_CI_START="-0.33573808708373815" LOG_EFFECT_SIZE="-0.08570119614323195" MODIFIED="2015-04-01 15:47:58 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4396621931390703" P_Z="0.5017200105621442" STUDIES="5" TAU2="0.0" TOTAL_1="195" TOTAL_2="200" WEIGHT="100.0" Z="0.6717859002362365">
<NAME>Any systemic antibiotic versus placebo/no treatment</NAME>
<DICH_DATA CI_END="26.919163659736437" CI_START="0.33433430970448363" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4300615628474915" LOG_CI_START="-0.47581905340816644" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-09-08 15:12:23 +1000" MODIFIED_BY="[Empty name]" ORDER="93868" O_E="0.0" SE="1.1195237082497775" STUDY_ID="STD-Low-1980" TOTAL_1="25" TOTAL_2="25" VAR="1.2533333333333332" WEIGHT="6.884569448993573"/>
<DICH_DATA CI_END="11.760938356656052" CI_START="0.4187379621536106" EFFECT_SIZE="2.219178082191781" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.070441973684002" LOG_CI_START="-0.378057664839652" LOG_EFFECT_SIZE="0.34619215442217505" MODIFIED="2014-09-08 15:12:23 +1000" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.8508558578576444" STUDY_ID="STD-Wong-2003" TOTAL_1="73" TOTAL_2="81" VAR="0.7239556908506679" WEIGHT="11.9187686278604"/>
<DICH_DATA CI_END="1.9128896710037826" CI_START="0.08364308847777954" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.28168992211510563" LOG_CI_START="-1.077569939459181" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-09-08 15:12:23 +1000" MODIFIED_BY="[Empty name]" ORDER="93870" O_E="0.0" SE="0.7984359711335656" STUDY_ID="STD-Zimmerman-1991" TOTAL_1="32" TOTAL_2="32" VAR="0.6375" WEIGHT="13.535153531093247"/>
<DICH_DATA CI_END="2.1582418222113557" CI_START="0.24168048867534378" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.33410010400218704" LOG_CI_START="-0.6167584095951256" LOG_EFFECT_SIZE="-0.14132915279646932" MODIFIED="2015-01-21 14:55:41 +1100" MODIFIED_BY="[Empty name]" ORDER="93869" O_E="0.0" SE="0.5585389977126145" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="13" VAR="0.31196581196581197" WEIGHT="27.65899353425801"/>
<DICH_DATA CI_END="1.6911969763862977" CI_START="0.27386275558935147" EFFECT_SIZE="0.6805555555555556" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.22819419350880982" LOG_CI_START="-0.5624670263143194" LOG_EFFECT_SIZE="-0.16713641640275478" MODIFIED="2014-09-08 15:12:23 +1000" MODIFIED_BY="[Empty name]" ORDER="93867" O_E="0.0" SE="0.4644383143602657" STUDY_ID="STD-Churchill-1988" TOTAL_1="56" TOTAL_2="49" VAR="0.215702947845805" WEIGHT="40.002514857794765"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6244645407755236" CI_END="1.8876153493227898" CI_START="0.413741118180425" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.883733039624153" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.27591350019193595" LOG_CI_START="-0.38327131615672794" LOG_EFFECT_SIZE="-0.053678907982395996" METHOD="MH" MODIFIED="2017-01-05 09:41:08 +1100" MODIFIED_BY="Narelle Willis" NO="6" P_CHI2="0.6538555178942279" P_Q="1.0" P_Z="0.749568347539466" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="101" TOTAL_2="100" WEIGHT="100.0" Z="0.3192085854091869">
<NAME>Mortality (all-cause)</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6244645407755236" CI_END="1.8876153493227898" CI_START="0.413741118180425" DF="3" EFFECT_SIZE="0.883733039624153" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.27591350019193595" LOG_CI_START="-0.38327131615672794" LOG_EFFECT_SIZE="-0.053678907982395996" MODIFIED="2015-04-01 16:36:27 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6538555178942279" P_Z="0.749568347539466" STUDIES="4" TAU2="0.0" TOTAL_1="101" TOTAL_2="100" WEIGHT="100.0" Z="0.3192085854091869">
<NAME>Any systemic antibiotic versus placebo/no treatment</NAME>
<DICH_DATA CI_END="4.020812706283332" CI_START="0.012590738166164326" EFFECT_SIZE="0.225" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6043138436768775" LOG_CI_START="-1.8999488074541524" LOG_EFFECT_SIZE="-0.6478174818886375" MODIFIED="2015-03-26 11:52:09 +1100" MODIFIED_BY="[Empty name]" ORDER="93853" O_E="0.0" SE="1.471016277574415" STUDY_ID="STD-Blowey-1994" TOTAL_1="7" TOTAL_2="8" VAR="2.1638888888888888" WEIGHT="6.928745948803689"/>
<DICH_DATA CI_END="20.20677971602992" CI_START="0.10325345168341071" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.3054971070336816" LOG_CI_START="-0.986095421298658" LOG_EFFECT_SIZE="0.15970084286751188" MODIFIED="2015-03-26 11:52:09 +1100" MODIFIED_BY="[Empty name]" ORDER="93855" O_E="0.0" SE="1.3460927947083783" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="13" VAR="1.811965811965812" WEIGHT="8.274458752775349"/>
<DICH_DATA CI_END="5.791236787487896" CI_START="0.36723349245639114" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7627713223840769" LOG_CI_START="-0.4350577171067376" LOG_EFFECT_SIZE="0.16385680263866959" MODIFIED="2015-03-26 11:52:09 +1100" MODIFIED_BY="[Empty name]" ORDER="93854" O_E="0.0" SE="0.7036107071462772" STUDY_ID="STD-Churchill-1988" TOTAL_1="56" TOTAL_2="49" VAR="0.4950680272108843" WEIGHT="30.28480036777575"/>
<DICH_DATA CI_END="2.0653915286717166" CI_START="0.2643553176405033" EFFECT_SIZE="0.7389162561576355" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.31500239140346376" LOG_CI_START="-0.5778119491185271" LOG_EFFECT_SIZE="-0.13140477885753168" MODIFIED="2015-03-26 11:52:09 +1100" MODIFIED_BY="[Empty name]" ORDER="93856" O_E="0.0" SE="0.5244435631248798" STUDY_ID="STD-Swartz-1991" TOTAL_1="29" TOTAL_2="30" VAR="0.27504105090311987" WEIGHT="54.511994930645216"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:41:19 +1100" MODIFIED_BY="Narelle Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="56" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Mortality due to peritonitis</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:41:47 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Oral antibiotic versus placebo</NAME>
<DICH_DATA CI_END="89.20435434479174" CI_START="0.21564741265212264" EFFECT_SIZE="4.385964912280702" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9503860541716402" LOG_CI_START="-0.6662557481725475" LOG_EFFECT_SIZE="0.6420651529995463" MODIFIED="2015-01-22 11:19:11 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="93857" O_E="0.0" SE="1.537028347282794" STUDY_ID="STD-Churchill-1988" TOTAL_1="56" TOTAL_2="49" VAR="2.362456140350877" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-12 12:21:15 +1100" MODIFIED_BY="Narelle Willis" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="137" TOTAL_2="141" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="5" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-21 15:57:42 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="1.57880948328344" CI_START="0.005234616904333385" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.19832972636630716" LOG_CI_START="-2.2811150966827576" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2015-01-21 15:57:42 +1100" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="1.4564381625088383" STUDY_ID="STD-Zimmerman-1991" TOTAL_1="32" TOTAL_2="32" VAR="2.121212121212121" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-26 14:18:55 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="160.58911584049116" CI_START="0.5043928386806436" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.205716107003693" LOG_CI_START="-0.29723108812504273" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2015-01-21 16:00:57 +1100" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="1.470243572207055" STUDY_ID="STD-Zimmerman-1991" TOTAL_1="32" TOTAL_2="32" VAR="2.1616161616161618" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-01-12 12:21:15 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Pruritus (generalised)</NAME>
<DICH_DATA CI_END="70.99720406421005" CI_START="0.12676555532891653" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8512412461360563" LOG_CI_START="-0.8969987366967316" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-09-08 15:12:23 +1000" MODIFIED_BY="[Empty name]" ORDER="93871" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Zimmerman-1991" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-05-17 14:37:00 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Nasal irritation</NAME>
<DICH_DATA CI_END="92.86129006963176" CI_START="0.1899607466875886" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9678347127808398" LOG_CI_START="-0.7213361319850388" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2015-05-17 14:37:00 +1000" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="1.5796322658258455" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="13" VAR="2.495238095238095" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.08.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-21 16:13:00 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Allergy</NAME>
<DICH_DATA CI_END="100.2049917255156" CI_START="0.2494885690772842" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0008893565097607" LOG_CI_START="-0.6029493478377235" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2015-01-21 16:13:00 +1100" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="1.5295077441431735" STUDY_ID="STD-Zimmerman-1991" TOTAL_1="32" TOTAL_2="32" VAR="2.3393939393939394" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" NO="2">
<NAME>Oral or topical antibiotics versus other antibiotic</NAME>
<DICH_OUTCOME CHI2="3.306012107688077" CI_END="1.843836291547606" CI_START="0.8911676861057937" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2818608822709145" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="44" I2="9.256230700923657" I2_Q="27.543187917876033" ID="CMP-002.01" LOG_CI_END="0.2657223587817687" LOG_CI_START="-0.05004056947776617" LOG_EFFECT_SIZE="0.10784089465200125" METHOD="MH" MODIFIED="2017-01-05 09:44:18 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.3468068156421804" P_Q="0.2515454713770229" P_Z="0.1806511252717946" Q="2.760264966851096" RANDOM="YES" SCALE="50.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.014799704969445064" TOTALS="YES" TOTAL_1="154" TOTAL_2="160" WEIGHT="100.0" Z="1.338752910251542">
<NAME>Peritonitis (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Oral/topical</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other antibiotic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8234036401673401" CI_START="0.03427655765470785" DF="0" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.2608828174719286" LOG_CI_START="-1.4650028001278534" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2015-04-01 16:44:27 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.17148983309167573" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="3.2998115996016737" Z="1.3674323344514239">
<NAME>Sodium fusidate ointment versus ofloxacin (oral)</NAME>
<DICH_DATA CI_END="1.8234036401673401" CI_START="0.03427655765470785" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2608828174719286" LOG_CI_START="-1.4650028001278534" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="93860" O_E="0.0" SE="1.0137937550497031" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="9" VAR="1.0277777777777777" WEIGHT="3.2998115996016737"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3319535955059667" CI_START="0.67003906210277" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.3677199039702478" LOG_CI_START="-0.1738998779541349" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2015-04-01 16:44:27 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4830670708942164" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="29.65292608527866" Z="0.7013781312131504">
<NAME>Mupirocin ointment versus rifampin (oral)</NAME>
<DICH_DATA CI_END="2.3319535955059663" CI_START="0.67003906210277" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.3677199039702477" LOG_CI_START="-0.1738998779541349" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="93932" O_E="0.0" SE="0.3181501409635425" STUDY_ID="STD-Bernardini-1996" TOTAL_1="41" TOTAL_2="41" VAR="0.10121951219512196" WEIGHT="29.65292608527866"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5412828115447741" CI_END="2.0685575645598893" CI_START="0.9320807528919282" DF="1" EFFECT_SIZE="1.3885469715408532" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.3156676111018988" LOG_CI_START="-0.03054645994632842" LOG_EFFECT_SIZE="0.1425605755777852" MODIFIED="2015-04-01 16:44:27 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4619016599568896" P_Z="0.10650382346848973" STUDIES="2" TAU2="0.0" TOTAL_1="104" TOTAL_2="110" WEIGHT="67.04726231511967" Z="1.614108825223556">
<NAME>Mupirocin ointment/cream versus gentamicin cream (topical)</NAME>
<DICH_DATA CI_END="4.700433035212845" CI_START="0.7567097805049131" EFFECT_SIZE="1.8859649122807018" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6721378698804518" LOG_CI_START="-0.1210706527221863" LOG_EFFECT_SIZE="0.2755336085791328" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.4659346126223014" STUDY_ID="STD-Chu-2008" TOTAL_1="38" TOTAL_2="43" VAR="0.21709506323949407" WEIGHT="14.835648503950082"/>
<DICH_DATA CI_END="2.012184445759993" CI_START="0.8295921765363521" EFFECT_SIZE="1.2920110192837466" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="22" LOG_CI_END="0.30366778756894414" LOG_CI_START="-0.0811353522110026" LOG_EFFECT_SIZE="0.11126621767897077" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.22603526911300292" STUDY_ID="STD-Bernardini-2005" TOTAL_1="66" TOTAL_2="67" VAR="0.051091942882987657" WEIGHT="52.21161381116959"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="88" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:44:41 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="2726" TOTAL_2="2410" WEIGHT="0.0" Z="0.0">
<NAME>Peritonitis rate (episodes/total patient-months on PD)</NAME>
<GROUP_LABEL_1>Oral/topical</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other antibiotic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="48" EVENTS_2="40" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:44:42 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1442" TOTAL_2="1298" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus polysporin triple ointment (exit site)</NAME>
<DICH_DATA CI_END="1.6322558308750998" CI_START="0.714814127984291" EFFECT_SIZE="1.0801664355062413" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="40" LOG_CI_END="0.21278822870082773" LOG_CI_START="-0.14580687244369772" LOG_EFFECT_SIZE="0.03349067812856499" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.21064053748667297" STUDY_ID="STD-MP3-Study-2008" TOTAL_1="1442" TOTAL_2="1298" VAR="0.04436943603267448" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:44:42 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>Sodium fusidate ointment versus ofloxacin (oral)</NAME>
<DICH_DATA CI_END="1.6036470530064715" CI_START="0.022987601873422473" EFFECT_SIZE="0.192" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.20510879050768857" LOG_CI_START="-1.6385063331005894" LOG_EFFECT_SIZE="-0.7166987712964504" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="1.0829486496495473" STUDY_ID="STD-Sesso-1994" TOTAL_1="75" TOTAL_2="72" VAR="1.1727777777777777" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:44:42 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus neomycin sulphate ointment (nasal)</NAME>
<DICH_DATA CI_END="2.579899413918759" CI_START="0.19776123010070165" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.41160277385795424" LOG_CI_START="-0.7038588452144303" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="93933" O_E="0.0" SE="0.6552276766671847" STUDY_ID="STD-Perez_x002d_Fontan-1992" TOTAL_1="133" TOTAL_2="76" VAR="0.4293233082706767" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="22" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:44:42 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="538" TOTAL_2="488" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus rifampin (oral)</NAME>
<DICH_DATA CI_END="1.6169910863536727" CI_START="0.5088238583024023" EFFECT_SIZE="0.9070631970260223" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.20870762586924382" LOG_CI_START="-0.29343253319660084" LOG_EFFECT_SIZE="-0.04236245366367854" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="93934" O_E="0.0" SE="0.2949596150691523" STUDY_ID="STD-Bernardini-1996" TOTAL_1="538" TOTAL_2="488" VAR="0.0870011745217425" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="13" I2="0.0" ID="CMP-002.02.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:44:42 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="538" TOTAL_2="476" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus gentamicin cream (exit site)</NAME>
<DICH_DATA CI_END="1.7724742957998414" CI_START="0.3763095116748197" EFFECT_SIZE="0.8167000285959394" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.24857994581660833" LOG_CI_START="-0.42445480422682424" LOG_EFFECT_SIZE="-0.08793742920510797" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.395343943751256" STUDY_ID="STD-Chu-2008" TOTAL_1="538" TOTAL_2="476" VAR="0.15629683386079624" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.891118122414352" CI_END="2.3070859250934874" CI_START="0.7104790657232491" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.280287566370805" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="41" I2="56.46570053353071" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.36306376968322474" LOG_CI_START="-0.14844871404167245" LOG_EFFECT_SIZE="0.1073075278207761" METHOD="MH" MODIFIED="2017-01-05 09:44:59 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.07545044689573277" P_Q="0.38430531376559796" P_Z="0.410882753461981" Q="1.912636294653996" RANDOM="YES" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.19848576385943412" TOTALS="YES" TOTAL_1="163" TOTAL_2="173" WEIGHT="99.99999999999999" Z="0.822341180286287">
<NAME>Exit-site/tunnel infection (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Oral/topical</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other antibiotic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9465866593791898" CI_START="0.42456177176068177" DF="0" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.28927374268168143" LOG_CI_START="-0.3720591129981315" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2015-04-01 16:44:55 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8061873976414846" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="25.83873057684617" Z="0.24534747196290904">
<NAME>Mupirocin ointment versus sodium fusidate ointment (topical)</NAME>
<DICH_DATA CI_END="1.9465866593791898" CI_START="0.42456177176068177" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.28927374268168143" LOG_CI_START="-0.3720591129981315" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.3884701930767545" STUDY_ID="STD-Danguilan-2003" TOTAL_1="50" TOTAL_2="50" VAR="0.15090909090909094" WEIGHT="25.83873057684617"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.616123987927122" CI_START="0.7609658711474634" DF="0" EFFECT_SIZE="2.4074074074074074" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.8817340056015048" LOG_CI_START="-0.11863482063376825" LOG_EFFECT_SIZE="0.38154959248386827" MODIFIED="2015-04-01 16:44:55 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.13488952307856863" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="13" WEIGHT="16.602004515479262" Z="1.4950954887281516">
<NAME>Sodium fusidate ointment versus ofloxacin (oral)</NAME>
<DICH_DATA CI_END="7.616123987927122" CI_START="0.7609658711474634" EFFECT_SIZE="2.4074074074074074" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8817340056015048" LOG_CI_START="-0.11863482063376825" LOG_EFFECT_SIZE="0.38154959248386827" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.5876216004361525" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="13" VAR="0.3452991452991453" WEIGHT="16.602004515479262"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.805038146118382" CI_END="3.4648316944586757" CI_START="0.4118362932088965" DF="1" EFFECT_SIZE="1.194547379402994" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="27" I2="79.18851069251505" ID="CMP-002.03.03" LOG_CI_END="0.5396821434375425" LOG_CI_START="-0.38527538368733955" LOG_EFFECT_SIZE="0.07720337987510141" MODIFIED="2015-04-01 18:12:33 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.028376744127524667" P_Z="0.7435284077936508" STUDIES="2" TAU2="0.4712376313104827" TOTAL_1="104" TOTAL_2="110" WEIGHT="57.55926490767455" Z="0.32718441572189844">
<NAME>Mupirocin ointment/cream versus gentamicin cream (topical)</NAME>
<DICH_DATA CI_END="1.5042777221347043" CI_START="0.2896511666409843" EFFECT_SIZE="0.6600877192982456" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.17732802379287088" LOG_CI_START="-0.5381247179340541" LOG_EFFECT_SIZE="-0.18039834707059163" MODIFIED="2015-04-01 18:12:11 +1100" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.4202604820385847" STUDY_ID="STD-Chu-2008" TOTAL_1="38" TOTAL_2="43" VAR="0.17661887276330357" WEIGHT="24.067736401723195"/>
<DICH_DATA CI_END="3.3095055326243847" CI_START="1.1638904388523066" EFFECT_SIZE="1.9626262626262627" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="15" LOG_CI_END="0.519763111451185" LOG_CI_START="0.06591210055328023" LOG_EFFECT_SIZE="0.29283760600223263" MODIFIED="2015-04-01 18:12:33 +1100" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.2665943304001659" STUDY_ID="STD-Bernardini-2005" TOTAL_1="66" TOTAL_2="67" VAR="0.07107253700151281" WEIGHT="33.49152850595136"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:45:11 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="2054" TOTAL_2="1847" WEIGHT="0.0" Z="0.0">
<NAME>Exit-site/tunnel infection rate (episodes/total patient-months on PD)</NAME>
<GROUP_LABEL_1>Oral/topical</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other antibiotic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="30" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:45:08 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1442" TOTAL_2="1298" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus polysporin triple ointment (exit site)</NAME>
<DICH_DATA CI_END="0.7886647895078336" CI_START="0.2237381146830079" EFFECT_SIZE="0.42006472491909386" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="30" LOG_CI_END="-0.10310754812262797" LOG_CI_START="-0.6502600257983405" LOG_EFFECT_SIZE="-0.3766837869604842" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.32140007383515934" STUDY_ID="STD-MP3-Study-2008" TOTAL_1="1442" TOTAL_2="1298" VAR="0.10329800746124589" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="15" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:45:08 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="538" TOTAL_2="476" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus gentamicin cream (exit site)</NAME>
<DICH_DATA CI_END="1.2018622786691633" CI_START="0.23447532696627715" EFFECT_SIZE="0.5308550185873606" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.0798547047376054" LOG_CI_START="-0.6299028498621102" LOG_EFFECT_SIZE="-0.27502407256225236" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="0.4169151009284309" STUDY_ID="STD-Chu-2008" TOTAL_1="538" TOTAL_2="476" VAR="0.17381820138216375" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:45:08 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="73" WEIGHT="0.0" Z="0.0">
<NAME>Sodium fusidate ointment versus ofloxacin (oral)</NAME>
<DICH_DATA CI_END="14.186764958111556" CI_START="0.6173641642787838" EFFECT_SIZE="2.9594594594594597" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1518833735394338" LOG_CI_START="-0.20945858332114953" LOG_EFFECT_SIZE="0.4712123951091422" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="0.7996590042112743" STUDY_ID="STD-Sesso-1994" TOTAL_1="74" TOTAL_2="73" VAR="0.6394545230161668" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:45:20 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="217" TOTAL_2="220" WEIGHT="0.0" Z="0.0">
<NAME>Catheter removal or replacement (number of patients)</NAME>
<GROUP_LABEL_1>Oral/topical</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other antibiotic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="9" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:45:21 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus polysporin triple ointment (exit site)</NAME>
<DICH_DATA CI_END="1.4248183816152413" CI_START="0.14418070882665215" EFFECT_SIZE="0.45324532453245325" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.1537595093345898" LOG_CI_START="-0.8410928437122555" LOG_EFFECT_SIZE="-0.3436666671888328" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.5843811967782875" STUDY_ID="STD-MP3-Study-2008" TOTAL_1="101" TOTAL_2="103" VAR="0.34150138314802353" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:45:21 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Sodium fusidate ointment versus ofloxacin (oral)</NAME>
<DICH_DATA CI_END="4.329594317451765" CI_START="0.41061070562936947" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6364472049108398" LOG_CI_START="-0.38656973169424" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="93938" O_E="0.0" SE="0.6009252125773314" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="9" VAR="0.36111111111111105" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:45:21 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment (exit site) versus rifampin (oral)</NAME>
<DICH_DATA CI_END="2.768580389957433" CI_START="0.231165402428441" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.44225713843420245" LOG_CI_START="-0.6360771644503151" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="93939" O_E="0.0" SE="0.6334189073552525" STUDY_ID="STD-Bernardini-1996" TOTAL_1="41" TOTAL_2="41" VAR="0.4012195121951219" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-002.05.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:45:21 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="67" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin cream versus gentamicin cream (exit site)</NAME>
<DICH_DATA CI_END="3.337690864112269" CI_START="0.42025143357471206" EFFECT_SIZE="1.1843434343434343" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5234461099863128" LOG_CI_START="-0.3764907964071709" LOG_EFFECT_SIZE="0.07347765678957092" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.5286273935750644" STUDY_ID="STD-Bernardini-2005" TOTAL_1="66" TOTAL_2="67" VAR="0.27944692123796605" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 10:03:21 +1100" MODIFIED_BY="Narelle Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="189" TOTAL_2="196" WEIGHT="0.0" Z="0.0">
<NAME>Mortality (all-cause)</NAME>
<GROUP_LABEL_1>Oral/topical</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other antibiotic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="12" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-01-05 10:03:21 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus polysporin triple ointment (exit site)</NAME>
<DICH_DATA CI_END="1.5929655253509154" CI_START="0.2901635171118139" EFFECT_SIZE="0.6798679867986799" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.2022063769863958" LOG_CI_START="-0.537357193252699" LOG_EFFECT_SIZE="-0.1675754081331516" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.4344233020571592" STUDY_ID="STD-MP3-Study-2008" TOTAL_1="101" TOTAL_2="103" VAR="0.18872360537024574" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:45:31 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Sodium fusidate ointment versus ofloxacin (oral)</NAME>
<DICH_DATA CI_END="7.2400905220167475" CI_START="0.01534664667150609" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8597439961649092" LOG_CI_START="-1.8139865056042341" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="93926" O_E="0.0" SE="1.5705625319186327" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="9" VAR="2.4666666666666663" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-002.06.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:45:31 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus rifampin (oral)</NAME>
<DICH_DATA CI_END="34.27506180246845" CI_START="0.46681170386241855" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5349782465526318" LOG_CI_START="-0.3308582638967071" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="93927" O_E="0.0" SE="1.0960016022776253" STUDY_ID="STD-Bernardini-1996" TOTAL_1="41" TOTAL_2="41" VAR="1.201219512195122" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-002.06.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:45:31 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus gentamicin cream (exit site)</NAME>
<DICH_DATA CI_END="7.37173414429964" CI_START="0.48250026123152867" EFFECT_SIZE="1.8859649122807018" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.867569664346059" LOG_CI_START="-0.3165024471877934" LOG_EFFECT_SIZE="0.2755336085791328" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="0.695529819566466" STUDY_ID="STD-Chu-2008" TOTAL_1="38" TOTAL_2="43" VAR="0.4837617299061608" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:45:44 +1100" MODIFIED_BY="Narelle Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="101" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Technique failure</NAME>
<GROUP_LABEL_1>Oral/topical</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other antibiotic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="13" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-04-01 16:48:19 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus polysporin triple ointment (exit site)</NAME>
<DICH_DATA CI_END="1.578135482000504" CI_START="0.3158535276359988" EFFECT_SIZE="0.7060167555217061" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.19814428439906276" LOG_CI_START="-0.5005142682890272" LOG_EFFECT_SIZE="-0.15118499194498222" MODIFIED="2015-02-26 13:49:18 +1100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.4103954922645965" STUDY_ID="STD-MP3-Study-2008" TOTAL_1="101" TOTAL_2="103" VAR="0.16842446007110046" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.324373449142823" CI_END="1.2385912051066224" CI_START="0.25330296844960815" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5601239407033812" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="26" I2="39.83828740673849" I2_Q="40.40718355064597" ID="CMP-002.08" LOG_CI_END="0.09292799187957243" LOG_CI_START="-0.5963597206961055" LOG_EFFECT_SIZE="-0.25171586440826654" METHOD="MH" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.18972385449524154" P_Q="0.19518322872848015" P_Z="0.1522900015086433" Q="1.678054603862979" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2710684556631192" TOTALS="SUB" TOTAL_1="208" TOTAL_2="211" WEIGHT="200.0" Z="1.431489404428935">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Oral/topical</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other antibiotic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5926450784959862" CI_START="0.0051891428426237216" DF="0" EFFECT_SIZE="0.09090909090909086" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="0.20211900390875703" LOG_CI_START="-2.2849043742252078" LOG_EFFECT_SIZE="-1.0413926851582254" MODIFIED="2015-05-13 16:34:31 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.10071573275582041" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="100.0" Z="1.6413936230909343">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="1.592645078495987" CI_START="0.005189142842623727" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.2021190039087572" LOG_CI_START="-2.2849043742252073" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2015-05-13 16:34:31 +1000" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="1.4608898432801614" STUDY_ID="STD-Bernardini-1996" TOTAL_1="41" TOTAL_2="41" VAR="2.134199134199134" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.502240444663694" CI_END="1.4882817485990767" CI_START="0.28529494530103006" DF="1" EFFECT_SIZE="0.6516128145295295" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="21" I2="33.43276014487351" ID="CMP-002.08.02" LOG_CI_END="0.17268515585965058" LOG_CI_START="-0.5447059228655915" LOG_EFFECT_SIZE="-0.18601038350297044" MODIFIED="2015-05-13 16:34:18 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.22032733134944937" P_Z="0.3094449231479355" STUDIES="2" TAU2="0.11906184995923781" TOTAL_1="167" TOTAL_2="170" WEIGHT="100.0" Z="1.0163874718490493">
<NAME>Pruritus (local)</NAME>
<DICH_DATA CI_END="2.7346607007678423" CI_START="0.37684111905548734" EFFECT_SIZE="1.0151515151515151" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4369034495267277" LOG_CI_START="-0.4238417152088122" LOG_EFFECT_SIZE="0.006530867158957755" MODIFIED="2015-05-13 16:34:18 +1000" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="0.5056059705229382" STUDY_ID="STD-Bernardini-2005" TOTAL_1="66" TOTAL_2="67" VAR="0.2556373974284422" WEIGHT="47.39192248119037"/>
<DICH_DATA CI_END="1.092474684434506" CI_START="0.17485044794849094" EFFECT_SIZE="0.43705799151343705" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.03841138199231361" LOG_CI_START="-0.7573332507364431" LOG_EFFECT_SIZE="-0.3594609343720648" MODIFIED="2015-05-13 16:32:55 +1000" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="0.4674243362643311" STUDY_ID="STD-MP3-Study-2008" TOTAL_1="101" TOTAL_2="103" VAR="0.2184855101321505" WEIGHT="52.60807751880963"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" NO="3">
<NAME>Nasal antibiotics versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="1.4275529369827473" CI_END="1.3115468335765676" CI_START="0.6680570716147082" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9360492171487057" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.11778380327613794" LOG_CI_START="-0.1751864344876414" LOG_EFFECT_SIZE="-0.028701315605751735" METHOD="MH" MODIFIED="2017-01-05 09:49:11 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.48979108993781395" P_Q="1.0" P_Z="0.7009619575444963" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="168" TOTAL_2="170" WEIGHT="100.0" Z="0.38402224966993265">
<NAME>Peritonitis (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Nasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nasal antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.495014695564524" CI_START="0.06358048055529116" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.161218659994524" LOG_CI_START="-1.1966761939153874" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2015-01-22 11:01:32 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="114" O_E="0.0" SE="1.3850391089544487" STUDY_ID="STD-Sit-2007" TOTAL_1="25" TOTAL_2="24" VAR="1.9183333333333332" WEIGHT="1.5438252431920274"/>
<DICH_DATA CI_END="2.0749608005023745" CI_START="0.04022089964458645" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.3170098965727774" LOG_CI_START="-1.3955482195097912" LOG_EFFECT_SIZE="-0.5392691614685069" MODIFIED="2015-01-22 11:01:32 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="93881" O_E="0.0" SE="1.0059651146862956" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="13" VAR="1.011965811965812" WEIGHT="2.9265528438195494"/>
<DICH_DATA CI_END="1.3697332352620442" CI_START="0.6868932517637557" EFFECT_SIZE="0.9699796472184532" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="44" LOG_CI_END="0.13663599362746928" LOG_CI_START="-0.16311075023611477" LOG_EFFECT_SIZE="-0.013237378304322736" MODIFIED="2015-01-22 11:01:32 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="93880" O_E="0.0" SE="0.17607272111578134" STUDY_ID="STD-Mupirocin-Study-1996" TOTAL_1="134" TOTAL_2="133" VAR="0.031001603121115717" WEIGHT="95.52962191298842"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2040372251829683" CI_END="2.7721461985966633" CI_START="0.16230776815277975" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6707763133023087" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="70" I2="54.62871549653682" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.44281613054636976" LOG_CI_START="-0.789660694066851" LOG_EFFECT_SIZE="-0.17342228176024063" METHOD="MH" MODIFIED="2017-01-05 09:49:35 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.13764989521024185" P_Q="1.0" P_Z="0.5812398779359931" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.7044647673397443" TOTALS="YES" TOTAL_1="1465" TOTAL_2="1332" WEIGHT="100.0" Z="0.5515745522817403">
<NAME>Peritonitis rate (episodes/total patient-months on PD)</NAME>
<GROUP_LABEL_1>Nasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nasal antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7340241529087015" CI_START="0.026245949939491607" EFFECT_SIZE="0.21333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.23905514239158573" LOG_CI_START="-1.5809377038631363" LOG_EFFECT_SIZE="-0.6709412807357752" MODIFIED="2015-01-22 11:01:22 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="143" O_E="0.0" SE="1.0690728069999098" STUDY_ID="STD-Sesso-1994" TOTAL_1="75" TOTAL_2="96" VAR="1.1429166666666666" WEIGHT="28.37109856251381"/>
<DICH_DATA CI_END="1.4593564433120338" CI_START="0.7640349012064396" EFFECT_SIZE="1.0559352517985612" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="64" LOG_CI_END="0.16416137993807833" LOG_CI_START="-0.11688680234686603" LOG_EFFECT_SIZE="0.023637288795606146" MODIFIED="2015-01-22 11:01:22 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="93882" O_E="0.0" SE="0.16508909348511583" STUDY_ID="STD-Mupirocin-Study-1996" TOTAL_1="1390" TOTAL_2="1236" VAR="0.02725440878773731" WEIGHT="71.62890143748619"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7612319613898428" CI_END="2.870726014824801" CI_START="0.6214102582253183" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3356266672114698" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="28" I2="43.22156184294606" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.45799174494240974" LOG_CI_START="-0.20662158169920114" LOG_EFFECT_SIZE="0.12568508162160433" METHOD="MH" MODIFIED="2017-01-05 09:49:47 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.18447104521000746" P_Q="1.0" P_Z="0.4585128374365892" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1555878961722039" TOTALS="YES" TOTAL_1="168" TOTAL_2="170" WEIGHT="100.0" Z="0.7412979051055294">
<NAME>Exit site and tunnel infection (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Nasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nasal antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-22 11:21:08 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="115" O_E="0.0" SE="0.0" STUDY_ID="STD-Sit-2007" TOTAL_1="25" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.616123987927122" CI_START="0.7609658711474634" EFFECT_SIZE="2.4074074074074074" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8817340056015048" LOG_CI_START="-0.11863482063376825" LOG_EFFECT_SIZE="0.38154959248386827" MODIFIED="2015-01-22 11:21:08 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="93884" O_E="0.0" SE="0.5876216004361525" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="13" VAR="0.3452991452991453" WEIGHT="30.428006381283424"/>
<DICH_DATA CI_END="1.6913852007677403" CI_START="0.6299670542624047" EFFECT_SIZE="1.0322388059701493" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" LOG_CI_END="0.2282425262948433" LOG_CI_START="-0.20068216249272627" LOG_EFFECT_SIZE="0.013780181901058527" MODIFIED="2015-01-22 11:21:08 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="93883" O_E="0.0" SE="0.2519524854052706" STUDY_ID="STD-Mupirocin-Study-1996" TOTAL_1="134" TOTAL_2="133" VAR="0.0634800549018931" WEIGHT="69.57199361871658"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4576583579520586" CI_END="2.9189955500278413" CI_START="0.28630718480300615" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9141823660413569" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="69" I2="71.07869267360782" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.4652334329120204" LOG_CI_START="-0.5431677533366025" LOG_EFFECT_SIZE="-0.03896716021229112" METHOD="MH" MODIFIED="2017-01-05 09:49:59 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.06295952901963275" P_Q="1.0" P_Z="0.87960033308183" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5288907079958107" TOTALS="YES" TOTAL_1="1464" TOTAL_2="1332" WEIGHT="100.00000000000001" Z="0.15147588407747578">
<NAME>Exit site and tunnel infection rate (episodes/total patient-months on PD)</NAME>
<GROUP_LABEL_1>Nasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nasal antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.64611175220372" CI_START="0.5697625567743224" EFFECT_SIZE="1.945945945945946" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.8225676395243019" LOG_CI_START="-0.2443060947957548" LOG_EFFECT_SIZE="0.2891307723642735" MODIFIED="2015-01-22 11:21:15 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="144" O_E="0.0" SE="0.6266869126497588" STUDY_ID="STD-Sesso-1994" TOTAL_1="74" TOTAL_2="96" VAR="0.39273648648648646" WEIGHT="38.070328022509464"/>
<DICH_DATA CI_END="0.8405000520368778" CI_START="0.39277285346354324" EFFECT_SIZE="0.5745655783065855" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="65" LOG_CI_END="-0.0754622553365528" LOG_CI_START="-0.40585853615595346" LOG_EFFECT_SIZE="-0.24066039574625317" MODIFIED="2015-01-22 11:21:15 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="93885" O_E="0.0" SE="0.19407641084128283" STUDY_ID="STD-Mupirocin-Study-1996" TOTAL_1="1390" TOTAL_2="1236" VAR="0.0376656532450344" WEIGHT="61.92967197749055"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.018179037741245442" CI_END="1.7769342321380308" CI_START="0.4774175570149433" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9210535272629723" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.24967135400219917" LOG_CI_START="-0.3211016138703119" LOG_EFFECT_SIZE="-0.03571512993405636" METHOD="MH" MODIFIED="2017-01-05 09:50:08 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.8927465592370805" P_Q="1.0" P_Z="0.8062375434485546" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="143" TOTAL_2="146" WEIGHT="100.0" Z="0.24528270368106947">
<NAME>Catheter removal or replacement (number of patients)</NAME>
<GROUP_LABEL_1>Nasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nasal antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4581937046953337" CI_START="0.3772272568541693" EFFECT_SIZE="0.9629629629629629" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3906161021329053" LOG_CI_START="-0.4233969345092441" LOG_EFFECT_SIZE="-0.01639041618816937" MODIFIED="2015-01-22 10:49:03 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="134" O_E="0.0" SE="0.4781552871531158" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="13" VAR="0.2286324786324786" WEIGHT="49.1659089352067"/>
<DICH_DATA CI_END="2.2175168416663738" CI_START="0.35101179754814293" EFFECT_SIZE="0.8822553897180763" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.34586692690962506" LOG_CI_START="-0.4546782865998314" LOG_EFFECT_SIZE="-0.05440567984510314" MODIFIED="2015-01-22 10:48:45 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="133" O_E="0.0" SE="0.4702442211781722" STUDY_ID="STD-Mupirocin-Study-1996" TOTAL_1="134" TOTAL_2="133" VAR="0.22112962755146573" WEIGHT="50.8340910647933"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7068837281915789" CI_END="1.46986957701503" CI_START="0.5338043466894102" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8857893481393575" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.16727880107772636" LOG_CI_START="-0.272617894138733" LOG_EFFECT_SIZE="-0.052669546530503306" METHOD="MH" MODIFIED="2017-01-05 09:50:21 +1100" MODIFIED_BY="Narelle Willis" NO="6" P_CHI2="0.7022669187378424" P_Q="1.0" P_Z="0.6388270948998912" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="168" TOTAL_2="170" WEIGHT="100.0" Z="0.4693393490080514">
<NAME>Mortality (all-cause)</NAME>
<GROUP_LABEL_1>Nasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nasal antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="67.5293252326011" CI_START="0.12322062879346876" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8294924101789118" LOG_CI_START="-0.9093165793371476" LOG_EFFECT_SIZE="0.46008791542088207" MODIFIED="2015-01-22 11:01:41 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="113" O_E="0.0" SE="1.6087899577648812" STUDY_ID="STD-Sit-2007" TOTAL_1="25" TOTAL_2="24" VAR="2.588205128205128" WEIGHT="2.5797517114597306"/>
<DICH_DATA CI_END="10.317921118847973" CI_START="0.02110674963195429" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.013592203341515" LOG_CI_START="-1.6755786414243636" LOG_EFFECT_SIZE="-0.3309932190414244" MODIFIED="2015-01-22 11:01:41 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="93879" O_E="0.0" SE="1.5796322658258455" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="13" VAR="2.495238095238095" WEIGHT="2.675867534179708"/>
<DICH_DATA CI_END="1.4695892619400486" CI_START="0.5191143800840136" EFFECT_SIZE="0.8734328358208955" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" LOG_CI_END="0.167195969987177" LOG_CI_START="-0.2847369404822835" LOG_EFFECT_SIZE="-0.05877048524755323" MODIFIED="2015-01-22 11:01:41 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="93878" O_E="0.0" SE="0.26546762871374746" STUDY_ID="STD-Mupirocin-Study-1996" TOTAL_1="134" TOTAL_2="133" VAR="0.07047306189490007" WEIGHT="94.74438075436056"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0175532980431177" CI_END="2.5444766162661483" CI_START="0.719829760461867" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3533624766438899" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.4055984640624311" LOG_CI_START="-0.14277020194931472" LOG_EFFECT_SIZE="0.1314141310565582" METHOD="MH" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.8066405754536581" P_Q="0.896305799980655" P_Z="0.3475287908324777" Q="1.6405251204437243" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="813" TOTAL_2="811" WEIGHT="600.0" Z="0.9393934405616229">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Nasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nasal antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.94301643519494" CI_START="0.14188794276256264" DF="0" EFFECT_SIZE="0.9925373134328358" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.8415481933000537" LOG_CI_START="-0.8480545080954974" LOG_EFFECT_SIZE="-0.0032531573977218464" MODIFIED="2015-01-21 17:18:51 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9939780865941185" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="133" WEIGHT="100.0" Z="0.0075474208585349185">
<NAME>Headache</NAME>
<DICH_DATA CI_END="6.94301643519494" CI_START="0.14188794276256264" EFFECT_SIZE="0.9925373134328358" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8415481933000537" LOG_CI_START="-0.8480545080954974" LOG_EFFECT_SIZE="-0.0032531573977218464" MODIFIED="2015-01-21 17:18:51 +1100" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.9924809904680062" STUDY_ID="STD-Mupirocin-Study-1996" TOTAL_1="134" TOTAL_2="133" VAR="0.9850185164403547" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.7831627994892365" CI_START="0.40342141092461503" DF="0" EFFECT_SIZE="1.654228855721393" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="0.8314322404870141" LOG_CI_START="-0.3942410560497451" LOG_EFFECT_SIZE="0.21859559221863456" MODIFIED="2015-01-21 17:19:53 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.48448405029071495" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="133" WEIGHT="100.0" Z="0.6991087904718474">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="6.7831627994892365" CI_START="0.40342141092461503" EFFECT_SIZE="1.654228855721393" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8314322404870141" LOG_CI_START="-0.3942410560497451" LOG_EFFECT_SIZE="0.21859559221863456" MODIFIED="2015-01-21 17:19:53 +1100" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="0.7199665615663604" STUDY_ID="STD-Mupirocin-Study-1996" TOTAL_1="134" TOTAL_2="133" VAR="0.5183518497736879" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.94301643519494" CI_START="0.14188794276256264" DF="0" EFFECT_SIZE="0.9925373134328358" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.07.03" LOG_CI_END="0.8415481933000537" LOG_CI_START="-0.8480545080954974" LOG_EFFECT_SIZE="-0.0032531573977218464" MODIFIED="2015-01-21 17:20:31 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9939780865941185" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="133" WEIGHT="100.0" Z="0.0075474208585349185">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="6.94301643519494" CI_START="0.14188794276256264" EFFECT_SIZE="0.9925373134328358" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8415481933000537" LOG_CI_START="-0.8480545080954974" LOG_EFFECT_SIZE="-0.0032531573977218464" MODIFIED="2015-01-21 17:20:31 +1100" MODIFIED_BY="[Empty name]" ORDER="147" O_E="0.0" SE="0.9924809904680062" STUDY_ID="STD-Mupirocin-Study-1996" TOTAL_1="134" TOTAL_2="133" VAR="0.9850185164403547" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.488310379905837" CI_START="0.6119535428578986" DF="0" EFFECT_SIZE="2.977611940298508" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-003.07.04" LOG_CI_END="1.1610177412014004" LOG_CI_START="-0.21328154655751916" LOG_EFFECT_SIZE="0.4738680973219407" MODIFIED="2015-01-21 17:21:01 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.17649728040193116" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="133" WEIGHT="99.99999999999999" Z="1.3516188394277175">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="14.488310379905837" CI_START="0.6119535428578986" EFFECT_SIZE="2.9776119402985075" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1610177412014004" LOG_CI_START="-0.21328154655751916" LOG_EFFECT_SIZE="0.47386809732194063" MODIFIED="2015-01-21 17:21:01 +1100" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="0.8072702045207795" STUDY_ID="STD-Mupirocin-Study-1996" TOTAL_1="134" TOTAL_2="133" VAR="0.6516851831070212" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.767158659442986" CI_START="0.25282344062117007" DF="0" EFFECT_SIZE="1.4888059701492538" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-003.07.05" LOG_CI_END="0.9428588660612497" LOG_CI_START="-0.5971826627453308" LOG_EFFECT_SIZE="0.1728381016579594" MODIFIED="2017-01-12 12:21:48 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="1.0" P_Z="0.6599866611705344" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="133" WEIGHT="100.0" Z="0.43993158375201036">
<NAME>Pruritus</NAME>
<DICH_DATA CI_END="8.767158659442986" CI_START="0.25282344062117007" EFFECT_SIZE="1.4888059701492538" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9428588660612497" LOG_CI_START="-0.5971826627453308" LOG_EFFECT_SIZE="0.1728381016579594" MODIFIED="2015-01-21 17:23:32 +1100" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.9046280173495004" STUDY_ID="STD-Mupirocin-Study-1996" TOTAL_1="134" TOTAL_2="133" VAR="0.8183518497736879" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0845426131802147" CI_END="2.939225099859059" CI_START="0.29667389842597697" DF="1" EFFECT_SIZE="0.9338047808437633" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="7.795232031714237" ID="CMP-003.07.06" LOG_CI_END="0.46823284768646833" LOG_CI_START="-0.5277206615301988" LOG_EFFECT_SIZE="-0.029743906921865206" MODIFIED="2015-01-21 17:25:11 +1100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.29768400960179364" P_Z="0.9068064165042021" STUDIES="2" TAU2="0.11717281874318193" TOTAL_1="143" TOTAL_2="146" WEIGHT="100.0" Z="0.11706768596501853">
<NAME>Nasal irritation/rhinitis</NAME>
<DICH_DATA CI_END="92.86129006963176" CI_START="0.1899607466875886" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9678347127808398" LOG_CI_START="-0.7213361319850388" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2015-01-21 17:25:11 +1100" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="1.5796322658258455" STUDY_ID="STD-Sesso-1994" TOTAL_1="9" TOTAL_2="13" VAR="2.495238095238095" WEIGHT="13.10122323974697"/>
<DICH_DATA CI_END="2.087120616112494" CI_START="0.26550253009342506" EFFECT_SIZE="0.7444029850746269" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3195475479626431" LOG_CI_START="-0.5759313359746866" LOG_EFFECT_SIZE="-0.1281918940060218" MODIFIED="2015-01-21 17:24:41 +1100" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.5260087291167526" STUDY_ID="STD-Mupirocin-Study-1996" TOTAL_1="134" TOTAL_2="133" VAR="0.2766851831070212" WEIGHT="86.89877676025303"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2017-01-05 09:53:46 +1100" MODIFIED_BY="Narelle Willis" NO="4">
<NAME>Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:52:58 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="324" TOTAL_2="320" WEIGHT="0.0" Z="0.0">
<NAME>Peritonitis (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="12" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-21 17:57:01 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Vancomycin versus placebo</NAME>
<DICH_DATA CI_END="0.606403919775933" CI_START="0.010701114091185234" EFFECT_SIZE="0.08055555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.21723800010100938" LOG_CI_START="-1.9705710056356531" LOG_EFFECT_SIZE="-1.0939045028683312" MODIFIED="2015-01-21 17:47:24 +1100" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="1.0299164865894024" STUDY_ID="STD-Gadallah-2000c" TOTAL_1="90" TOTAL_2="87" VAR="1.0607279693486589" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="12" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-21 17:47:49 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Cefazolin versus placebo</NAME>
<DICH_DATA CI_END="1.6699025316543772" CI_START="0.32923391368620614" EFFECT_SIZE="0.7414772727272727" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.22269112312363645" LOG_CI_START="-0.4824954354033366" LOG_EFFECT_SIZE="-0.12990215613985007" MODIFIED="2015-01-21 17:47:49 +1100" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="0.4142300752085064" STUDY_ID="STD-Gadallah-2000c" TOTAL_1="88" TOTAL_2="87" VAR="0.17158655520724486" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-22 11:27:12 +1100" MODIFIED_BY="Elisabeth M Hodson" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>IV gentamicin versus no antibiotics</NAME>
<DICH_DATA CI_END="1.1980897031031716" CI_START="0.02318505676647631" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07848933566954441" LOG_CI_START="-1.6347918364368317" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2015-01-21 17:59:50 +1100" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="1.006389841373865" STUDY_ID="STD-Bennet_x002d_Jones-1988" TOTAL_1="13" TOTAL_2="13" VAR="1.012820512820513" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-22 11:27:16 +1100" MODIFIED_BY="Elisabeth M Hodson" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>IV cefazolin + gentamicin versus no antibiotics</NAME>
<DICH_DATA CI_END="20.6706293264143" CI_START="0.1935112829336326" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3153536991153598" LOG_CI_START="-0.7132937077873972" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-01-21 18:00:23 +1100" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Lye-1992" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-004.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-22 11:27:19 +1100" MODIFIED_BY="Elisabeth M Hodson" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>IV cefuroxime + cefuroxime (intraperitoneal) versus no antibiotics</NAME>
<DICH_DATA CI_END="2.133867799335914" CI_START="0.007067712237239543" EFFECT_SIZE="0.12280701754385964" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3291675098413186" LOG_CI_START="-2.1507211411577876" LOG_EFFECT_SIZE="-0.9107768156582345" MODIFIED="2015-01-21 18:00:50 +1100" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="1.4566988692436766" STUDY_ID="STD-Wikdahl-1997" TOTAL_1="18" TOTAL_2="20" VAR="2.1219715956558063" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="9" I2="0.0" ID="CMP-004.01.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-22 11:27:19 +1100" MODIFIED_BY="Elisabeth M Hodson" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="88" WEIGHT="0.0" Z="0.0">
<NAME>Vancomycin versus cefazolin</NAME>
<DICH_DATA CI_END="0.8396960146516766" CI_START="0.014056371106941272" EFFECT_SIZE="0.10864197530864197" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.07587790804901223" LOG_CI_START="-1.8521267854079504" LOG_EFFECT_SIZE="-0.9640023467284812" MODIFIED="2015-01-21 17:48:11 +1100" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="1.043377383134388" STUDY_ID="STD-Gadallah-2000c" TOTAL_1="90" TOTAL_2="88" VAR="1.0886363636363636" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:53:46 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="324" TOTAL_2="320" WEIGHT="0.0" Z="0.0">
<NAME>Exit site/tunnel infection (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-21 17:48:44 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Vancomycin versus placebo</NAME>
<DICH_DATA CI_END="1.3218541667601003" CI_START="0.09941055019865028" EFFECT_SIZE="0.3625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1211835443592102" LOG_CI_START="-1.0025675225451853" LOG_EFFECT_SIZE="-0.4406919890929875" MODIFIED="2015-01-21 17:48:44 +1100" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.6600969393571364" STUDY_ID="STD-Gadallah-2000c" TOTAL_1="90" TOTAL_2="87" VAR="0.435727969348659" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-21 17:48:58 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Cefazolin versus placebo</NAME>
<DICH_DATA CI_END="2.048416983104413" CI_START="0.2683967915252586" EFFECT_SIZE="0.7414772727272727" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.31141836784482124" LOG_CI_START="-0.5712226801245215" LOG_EFFECT_SIZE="-0.12990215613985007" MODIFIED="2015-01-21 17:48:58 +1100" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.518467720720844" STUDY_ID="STD-Gadallah-2000c" TOTAL_1="88" TOTAL_2="87" VAR="0.26880877742946707" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="7" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-22 11:28:35 +1100" MODIFIED_BY="Elisabeth M Hodson" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>IV gentamicin versus no antibiotics</NAME>
<DICH_DATA CI_END="1.0588146526714648" CI_START="0.004197566054862192" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.024819942763736506" LOG_CI_START="-2.377002460875099" LOG_EFFECT_SIZE="-1.1760912590556813" MODIFIED="2015-01-21 18:01:26 +1100" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="1.4108423691100966" STUDY_ID="STD-Bennet_x002d_Jones-1988" TOTAL_1="13" TOTAL_2="13" VAR="1.9904761904761903" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-004.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-22 11:28:38 +1100" MODIFIED_BY="Elisabeth M Hodson" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>IV cefazolin + gentamicin versus no antibiotics</NAME>
<DICH_DATA CI_END="2.19205941209886" CI_START="0.3351614803394235" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.34085232079637595" LOG_CI_START="-0.4747459000576024" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2015-01-21 18:01:55 +1100" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.4790864322059325" STUDY_ID="STD-Lye-1992" TOTAL_1="25" TOTAL_2="25" VAR="0.22952380952380955" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.02.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-22 11:28:41 +1100" MODIFIED_BY="Elisabeth M Hodson" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>IV cefuroxime + cefuroxime (intraperitoneal) versus no antibiotics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 18:02:16 +1100" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.0" STUDY_ID="STD-Wikdahl-1997" TOTAL_1="18" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-004.02.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-22 11:28:41 +1100" MODIFIED_BY="Elisabeth M Hodson" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="88" WEIGHT="0.0" Z="0.0">
<NAME>Vancomycin versus cefazolin</NAME>
<DICH_DATA CI_END="1.8941644820818064" CI_START="0.12618352204362038" EFFECT_SIZE="0.4888888888888889" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2774176887954997" LOG_CI_START="-0.8989973547017746" LOG_EFFECT_SIZE="-0.31078983295313745" MODIFIED="2015-01-21 17:49:34 +1100" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.691032019898682" STUDY_ID="STD-Gadallah-2000c" TOTAL_1="90" TOTAL_2="88" VAR="0.4775252525252525" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:52:58 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Catheter removal or replacement (number of patients)</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.060808530068375" CI_START="0.015823601309021718" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9063786053951907" LOG_CI_START="-1.8006946680796287" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2015-01-22 11:21:47 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="159" O_E="0.0" SE="1.5901482410679288" STUDY_ID="STD-Bennet_x002d_Jones-1988" TOTAL_1="13" TOTAL_2="14" VAR="2.528571428571428" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:52:58 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Mortality (all-cause)</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 18:27:57 +1100" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Lye-1992" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2017-01-12 15:04:32 +1100" MODIFIED_BY="Narelle Willis" NO="5">
<NAME>Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant)</NAME>
<DICH_OUTCOME CHI2="1.565291302261873" CI_END="1.0630204153147609" CI_START="0.6465982825655303" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8290640354487833" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="97" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.02654160523205324" LOG_CI_START="-0.1893654532557089" LOG_EFFECT_SIZE="-0.08141192401182776" METHOD="MH" MODIFIED="2017-01-12 11:27:14 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.9054145004916332" P_Q="0.8970762141498574" P_Z="0.13938516059790343" Q="0.016732893788406346" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="441" TOTAL_2="412" WEIGHT="100.0" Z="1.478084506295457">
<NAME>Peritonitis (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Disinfectant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disinfectant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7891261853694487" CI_END="1.2605399099445918" CI_START="0.5194978392899654" DF="2" EFFECT_SIZE="0.8092266428850343" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="32" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.10055660042446124" LOG_CI_START="-0.2844162544328798" LOG_EFFECT_SIZE="-0.09192982700420932" MODIFIED="2015-02-26 13:03:50 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6739746486412532" P_Z="0.3492414923389473" STUDIES="3" TAU2="0.0" TOTAL_1="212" TOTAL_2="181" WEIGHT="31.453824979610523" Z="0.9360615833551">
<NAME>Disinfectant versus standard care</NAME>
<DICH_DATA CI_END="2.8570219006602735" CI_START="0.0327763286037083" EFFECT_SIZE="0.30601092896174864" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45591356950400724" LOG_CI_START="-1.4844396949524654" LOG_EFFECT_SIZE="-0.5142630627242291" MODIFIED="2015-01-22 11:49:16 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="93916" O_E="0.0" SE="1.139773112445297" STUDY_ID="STD-Waite-1997" TOTAL_1="61" TOTAL_2="56" VAR="1.2990827478532396" WEIGHT="1.2381466017657186"/>
<DICH_DATA CI_END="1.5830452063531568" CI_START="0.4148531690641539" EFFECT_SIZE="0.8103896103896104" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.19949331700347817" LOG_CI_START="-0.3821055879835939" LOG_EFFECT_SIZE="-0.09130613549005785" MODIFIED="2015-01-22 11:49:22 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="93917" O_E="0.0" SE="0.34163407575041704" STUDY_ID="STD-Wilson-1997" TOTAL_1="77" TOTAL_2="72" VAR="0.11671384171384169" WEIGHT="13.781183671518248"/>
<DICH_DATA CI_END="1.6056739861026332" CI_START="0.47105617342999506" EFFECT_SIZE="0.8696911196911197" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.20565737132286316" LOG_CI_START="-0.3269273001831656" LOG_EFFECT_SIZE="-0.060634964430151254" MODIFIED="2015-01-22 11:49:27 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="93915" O_E="0.0" SE="0.3128428723792836" STUDY_ID="STD-Luzar-1990" TOTAL_1="74" TOTAL_2="53" VAR="0.09787066279852072" WEIGHT="16.434494706326557"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7723520834731215" CI_END="1.131891286900248" CI_START="0.6209035576031546" DF="2" EFFECT_SIZE="0.8383288894320515" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="65" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.05380471681110146" LOG_CI_START="-0.20697585176137304" LOG_EFFECT_SIZE="-0.07658556747513581" MODIFIED="2015-01-22 11:49:55 +1100" MODIFIED_BY="Elisabeth M Hodson" NO="2" P_CHI2="0.6796510496629642" P_Z="0.2496510613359526" STUDIES="3" TAU2="0.0" TOTAL_1="229" TOTAL_2="231" WEIGHT="68.54617502038948" Z="1.1511973826003228">
<NAME>Disinfectant versus other active treatment (antibiotics, other disinfectant)</NAME>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-01-22 11:49:32 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="209" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Wadhwa-1995" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="0.6210865415545688"/>
<DICH_DATA CI_END="7.465209844173012" CI_START="0.1823272405629066" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8730420200832162" LOG_CI_START="-0.7391484408219897" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2015-01-22 11:49:35 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="132" O_E="0.0" SE="0.9470086572072067" STUDY_ID="STD-Wadhwa-1997" TOTAL_1="18" TOTAL_2="21" VAR="0.8968253968253967" WEIGHT="1.7934983725490004"/>
<DICH_DATA CI_END="1.1144765013766362" CI_START="0.6047449367118927" EFFECT_SIZE="0.8209592080559822" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="63" LOG_CI_END="0.04707091585793662" LOG_CI_START="-0.21842775912530682" LOG_EFFECT_SIZE="-0.08567842163368508" MODIFIED="2015-01-22 11:49:37 +1100" MODIFIED_BY="Elisabeth M Hodson" ORDER="98" O_E="0.0" SE="0.1559552359247941" STUDY_ID="STD-HONEYPOT-Study-2009" TOTAL_1="186" TOTAL_2="185" VAR="0.02432203561235819" WEIGHT="66.13159010628591"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.855364734676222" CI_END="1.3334658145008524" CI_START="0.7480638464160609" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.99875801186265" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="107" I2="20.95187256839805" I2_Q="63.61204624339529" ID="CMP-005.02" LOG_CI_END="0.1249818863446449" LOG_CI_START="-0.12606133400336256" LOG_EFFECT_SIZE="-5.397238293588253E-4" METHOD="MH" MODIFIED="2017-01-12 15:04:32 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.2632079128792464" P_Q="0.0973663630406002" P_Z="0.9932758699713574" Q="2.748162226128178" RANDOM="YES" SCALE="500.0" SORT_BY="WEIGHT" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03526878655284261" TOTALS="YES" TOTAL_1="501" TOTAL_2="472" WEIGHT="100.0" Z="0.008427546983144442">
<NAME>Exit site/tunnel infection (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Disinfectant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disinfectant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.088038543708444" CI_END="1.1997342707026009" CI_START="0.45391331848577865" DF="3" EFFECT_SIZE="0.7379534972582846" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="49" I2="26.615173317848292" ID="CMP-005.02.01" LOG_CI_END="0.07908506475837035" LOG_CI_START="-0.34302707423000284" LOG_EFFECT_SIZE="-0.13197100473581622" MODIFIED="2015-06-18 12:20:07 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2521132437913638" P_Z="0.22037049428139843" STUDIES="4" TAU2="0.06544620895795618" TOTAL_1="242" TOTAL_2="211" WEIGHT="42.02657052362504" Z="1.2255436050982147">
<NAME>Disinfectant versus standard care</NAME>
<DICH_DATA CI_END="0.8654220538208824" CI_START="0.0032008464427998057" EFFECT_SIZE="0.05263157894736842" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.0627720417341568" LOG_CI_START="-2.4947351601715013" LOG_EFFECT_SIZE="-1.278753600952829" MODIFIED="2015-06-18 12:20:07 +1000" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="1.4285471741816855" STUDY_ID="STD-Mendoza_x002d_Guevara-2007" TOTAL_1="30" TOTAL_2="30" VAR="2.0407470288624787" WEIGHT="1.047469873576391"/>
<DICH_DATA CI_END="1.6763223119939297" CI_START="0.3365569063781543" EFFECT_SIZE="0.7511177347242921" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.22435752554873667" LOG_CI_START="-0.4729414929956702" LOG_EFFECT_SIZE="-0.12429198372346678" MODIFIED="2014-10-23 12:13:09 +1100" MODIFIED_BY="[Empty name]" ORDER="93913" O_E="0.0" SE="0.4095968951787945" STUDY_ID="STD-Waite-1997" TOTAL_1="61" TOTAL_2="56" VAR="0.16776961654010836" WEIGHT="10.710111932471019"/>
<DICH_DATA CI_END="1.6778400008339647" CI_START="0.4539484648020112" EFFECT_SIZE="0.8727272727272727" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.2247505440564785" LOG_CI_START="-0.3429934482937918" LOG_EFFECT_SIZE="-0.05912145211865665" MODIFIED="2014-10-23 12:13:09 +1100" MODIFIED_BY="[Empty name]" ORDER="93914" O_E="0.0" SE="0.3334956314846361" STUDY_ID="STD-Wilson-1997" TOTAL_1="77" TOTAL_2="72" VAR="0.11121933621933622" WEIGHT="14.844643938113666"/>
<DICH_DATA CI_END="1.4513231998793104" CI_START="0.40574260093461084" EFFECT_SIZE="0.7673745173745173" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.1617641376575338" LOG_CI_START="-0.39174939116302165" LOG_EFFECT_SIZE="-0.11499262675274395" MODIFIED="2015-01-21 18:40:25 +1100" MODIFIED_BY="[Empty name]" ORDER="93912" O_E="0.0" SE="0.3251365867653511" STUDY_ID="STD-Luzar-1990" TOTAL_1="74" TOTAL_2="53" VAR="0.10571380005342271" WEIGHT="15.424344779463967"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6592381001657475" CI_END="1.6035587567678018" CI_START="0.8885831588732127" DF="3" EFFECT_SIZE="1.1936897861368905" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="58" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.2050848777490375" LOG_CI_START="-0.05130192210768754" LOG_EFFECT_SIZE="0.07689147782067501" MODIFIED="2015-05-06 19:02:26 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6460338611500367" P_Z="0.23975363389517168" STUDIES="4" TAU2="0.0" TOTAL_1="259" TOTAL_2="261" WEIGHT="57.97342947637497" Z="1.1756028573296327">
<NAME>Disinfectant versus other active treatment (antibiotics, other disinfectant)</NAME>
<DICH_DATA CI_END="13.691755493981939" CI_START="0.6573298803032126" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1364591349471005" LOG_CI_START="-0.18221662550777554" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-05-06 19:02:26 +1000" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.7745966692414834" STUDY_ID="STD-Nunez_x002d_Moral-2014" TOTAL_1="30" TOTAL_2="30" VAR="0.6" WEIGHT="3.4230613399337724"/>
<DICH_DATA CI_END="3.82415621117103" CI_START="0.5125313642456595" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5825356242588624" LOG_CI_START="-0.29027955290238633" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2015-02-26 15:10:17 +1100" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.5126959555693247" STUDY_ID="STD-Wadhwa-1995" TOTAL_1="25" TOTAL_2="25" VAR="0.2628571428571429" WEIGHT="7.294112350506737"/>
<DICH_DATA CI_END="2.1469073221228068" CI_START="0.6339868969123826" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3318132971798939" LOG_CI_START="-0.19791971791866741" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2015-02-26 15:10:22 +1100" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.3111677952896103" STUDY_ID="STD-Wadhwa-1997" TOTAL_1="18" TOTAL_2="21" VAR="0.09682539682539684" WEIGHT="16.462223907990047"/>
<DICH_DATA CI_END="1.6131206661742101" CI_START="0.7719668713905115" EFFECT_SIZE="1.1159192237083662" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="41" LOG_CI_END="0.20766685510970037" LOG_CI_START="-0.11240133681582819" LOG_EFFECT_SIZE="0.047632759146936085" MODIFIED="2015-02-26 15:10:10 +1100" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.1880096403001578" STUDY_ID="STD-HONEYPOT-Study-2009" TOTAL_1="186" TOTAL_2="185" VAR="0.03534762484579472" WEIGHT="30.794031877944406"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4936247348970655" CI_END="4.9308558609533275" CI_START="0.3148523259646052" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.245990143146149" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" I2="71.37643347863853" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.6929223073967768" LOG_CI_START="-0.5018930940091729" LOG_EFFECT_SIZE="0.09551460669380198" METHOD="MH" MODIFIED="2017-01-05 09:55:58 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.06160568167139757" P_Q="1.0" P_Z="0.7540052480979434" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.7190698005576589" TOTALS="SUB" TOTAL_1="896" TOTAL_2="856" WEIGHT="100.0" Z="0.3133625309768761">
<NAME>Exit site/tunnel infection rate (episodes/total patient-months on PD)</NAME>
<GROUP_LABEL_1>Disinfectant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disinfectant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4936247348970655" CI_END="4.9308558609533275" CI_START="0.3148523259646052" DF="1" EFFECT_SIZE="1.245990143146149" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" I2="71.37643347863853" ID="CMP-005.03.01" LOG_CI_END="0.6929223073967768" LOG_CI_START="-0.5018930940091729" LOG_EFFECT_SIZE="0.09551460669380198" MODIFIED="2015-05-06 18:57:15 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06160568167139757" P_Z="0.7540052480979434" STUDIES="2" TAU2="0.7190698005576589" TOTAL_1="896" TOTAL_2="856" WEIGHT="100.0" Z="0.3133625309768761">
<NAME>Disinfectant versus other active treatment (antibiotics, other disinfectant)</NAME>
<DICH_DATA CI_END="10.278182310738817" CI_START="0.7674248001216215" EFFECT_SIZE="2.8085106382978724" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0119163167783867" LOG_CI_START="-0.11496417023812194" LOG_EFFECT_SIZE="0.4484760732701324" MODIFIED="2015-05-06 18:57:15 +1000" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.6619351762218711" STUDY_ID="STD-Nunez_x002d_Moral-2014" TOTAL_1="329" TOTAL_2="308" VAR="0.4381581775198797" WEIGHT="42.56551607868033"/>
<DICH_DATA CI_END="1.4151017610075847" CI_START="0.32890613709294386" EFFECT_SIZE="0.6822284469343293" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.15078767141861898" LOG_CI_START="-0.48292802289699205" LOG_EFFECT_SIZE="-0.16607017573918653" MODIFIED="2014-10-23 12:16:41 +1100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.3722477357842688" STUDY_ID="STD-Cheng-1999a" TOTAL_1="567" TOTAL_2="548" VAR="0.13856837679651476" WEIGHT="57.43448392131967"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.9666631913473704" CI_END="1.379740234450562" CI_START="0.5703132658511854" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8870649125829407" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.13979732889113874" LOG_CI_START="-0.24388652633009444" LOG_EFFECT_SIZE="-0.05204459871947782" METHOD="MH" MODIFIED="2017-01-09 17:18:10 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.7051257315066677" P_Q="0.5328189774051393" P_Z="0.5949222894762998" Q="0.38901309881181145" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="430" TOTAL_2="422" WEIGHT="100.00000000000001" Z="0.5317166083060716">
<NAME>Catheter removal or replacement (number of patients)</NAME>
<GROUP_LABEL_1>Disinfectant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disinfectant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.24298108710951766" CI_END="1.554227020220606" CI_START="0.34259831300880245" DF="1" EFFECT_SIZE="0.7297092264459026" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.19151445489484065" LOG_CI_START="-0.46521477987830734" LOG_EFFECT_SIZE="-0.13685016249173332" MODIFIED="2017-01-09 17:18:10 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.6220612878630469" P_Z="0.41401981542127353" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="128" WEIGHT="34.13299138189703" Z="0.8168401087090404">
<NAME>Disinfectant versus standard care</NAME>
<DICH_DATA CI_END="3.0035939603233657" CI_START="0.2805919205222925" EFFECT_SIZE="0.9180327868852459" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.47764122237016693" LOG_CI_START="-0.5519248383793001" LOG_EFFECT_SIZE="-0.03714180800456661" MODIFIED="2014-10-23 12:14:30 +1100" MODIFIED_BY="[Empty name]" ORDER="93918" O_E="0.0" SE="0.6047722005184318" STUDY_ID="STD-Waite-1997" TOTAL_1="61" TOTAL_2="56" VAR="0.36574941451990634" WEIGHT="13.88796504747899"/>
<DICH_DATA CI_END="1.6638657071154768" CI_START="0.23355154980994552" EFFECT_SIZE="0.6233766233766234" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.2211182708655856" LOG_CI_START="-0.631617246459375" LOG_EFFECT_SIZE="-0.20524948779689467" MODIFIED="2014-10-23 12:14:30 +1100" MODIFIED_BY="[Empty name]" ORDER="93919" O_E="0.0" SE="0.5009010639855698" STUDY_ID="STD-Wilson-1997" TOTAL_1="77" TOTAL_2="72" VAR="0.2509018759018759" WEIGHT="20.245026334418036"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3367667262234186" CI_END="1.691538625573356" CI_START="0.569538637009965" DF="3" EFFECT_SIZE="0.9815276884829887" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="0.22828191916913318" LOG_CI_START="-0.24447680842237474" LOG_EFFECT_SIZE="-0.008097444626620749" MODIFIED="2015-05-06 19:06:03 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5055141415718708" P_Z="0.9464696126240869" STUDIES="5" TAU2="0.0" TOTAL_1="292" TOTAL_2="294" WEIGHT="65.86700861810299" Z="0.06714080104174114">
<NAME>Disinfectant versus other active treatment (antibiotics, other disinfectant)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-05-06 19:06:03 +1000" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.0" STUDY_ID="STD-Nunez_x002d_Moral-2014" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-02-26 15:29:47 +1100" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Wadhwa-1995" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="1.9613969140054075"/>
<DICH_DATA CI_END="30.772099938279613" CI_START="0.3980878791038031" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4881571342223876" LOG_CI_START="-0.4000210455218362" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2015-02-26 15:29:53 +1100" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="1.1091252094144872" STUDY_ID="STD-Wadhwa-1997" TOTAL_1="18" TOTAL_2="21" VAR="1.23015873015873" WEIGHT="4.129154198119574"/>
<DICH_DATA CI_END="2.3088529658051478" CI_START="0.1559215789535823" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3633962767141877" LOG_CI_START="-0.8070937759469005" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2015-02-26 15:30:06 +1100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.6875516509523286" STUDY_ID="STD-Cheng-1999a" TOTAL_1="33" TOTAL_2="33" VAR="0.4727272727272728" WEIGHT="10.74512806439846"/>
<DICH_DATA CI_END="1.7652553050182096" CI_START="0.4998766786857103" EFFECT_SIZE="0.9393667861409797" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.24680752532850675" LOG_CI_START="-0.30113712440837603" LOG_EFFECT_SIZE="-0.027164799539934656" MODIFIED="2015-02-26 15:29:56 +1100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.32186539962520566" STUDY_ID="STD-HONEYPOT-Study-2009" TOTAL_1="186" TOTAL_2="185" VAR="0.10359733547589335" WEIGHT="49.03132944157955"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2792210095992995" CI_END="1.4407501578145632" CI_START="0.5346943372720999" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8777020854523083" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="31" I2="0.0" I2_Q="1.695508870076071" ID="CMP-005.05" LOG_CI_END="0.15858867582444364" LOG_CI_START="-0.2718944153096129" LOG_EFFECT_SIZE="-0.05665286974258466" METHOD="MH" MODIFIED="2017-01-05 09:56:27 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.7340731736348111" P_Q="0.31317308164718605" P_Z="0.6059421981926087" Q="1.017247521965555" RANDOM="YES" SCALE="20.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="354" TOTAL_2="343" WEIGHT="100.0" Z="0.5158743123860663">
<NAME>Mortality (all-cause)</NAME>
<GROUP_LABEL_1>Disinfectant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disinfectant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.023708272964737216" CI_END="2.8374810812799423" CI_START="0.5390191783625402" DF="1" EFFECT_SIZE="1.2367120606878412" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="0.45293297458069753" LOG_CI_START="-0.26839578229220934" LOG_EFFECT_SIZE="0.09226859614424411" MODIFIED="2015-02-26 15:07:03 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8776295338719143" P_Z="0.6160779243435807" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="128" WEIGHT="35.6160459047092" Z="0.5014166525975702">
<NAME>Disinfectant versus standard care</NAME>
<DICH_DATA CI_END="4.0607974363051795" CI_START="0.3242836732715423" EFFECT_SIZE="1.1475409836065573" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6086113262324631" LOG_CI_START="-0.48907491622548344" LOG_EFFECT_SIZE="0.059768205003489776" ORDER="93910" O_E="0.0" SE="0.6447863324543305" STUDY_ID="STD-Waite-1997" TOTAL_1="61" TOTAL_2="56" VAR="0.4157494145199063" WEIGHT="15.379979367007968"/>
<DICH_DATA CI_END="3.939571573551439" CI_START="0.43500136404923384" EFFECT_SIZE="1.309090909090909" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5954489950846383" LOG_CI_START="-0.3615093812105891" LOG_EFFECT_SIZE="0.1169698069370246" ORDER="93911" O_E="0.0" SE="0.562122087256177" STUDY_ID="STD-Wilson-1997" TOTAL_1="77" TOTAL_2="72" VAR="0.315981240981241" WEIGHT="20.236066537701237"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2383237797223526" CI_END="1.346526604537745" CI_START="0.3914875603212228" DF="1" EFFECT_SIZE="0.7260498710957133" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="0.0" ID="CMP-005.05.02" LOG_CI_END="0.12921493857916097" LOG_CI_START="-0.40728203327316875" LOG_EFFECT_SIZE="-0.13903354734700385" MODIFIED="2015-05-06 18:51:03 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6254194252025346" P_Z="0.3096999107787164" STUDIES="2" TAU2="0.0" TOTAL_1="216" TOTAL_2="215" WEIGHT="64.3839540952908" Z="1.015851942284504">
<NAME>Disinfectant versus other active treatment (antibiotics, other disinfectant)</NAME>
<DICH_DATA CI_END="2.5270106054871775" CI_START="0.09893112417381524" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.402607064593003" LOG_CI_START="-1.0046670559209654" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-05-06 18:51:03 +1000" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.8266397845091497" STUDY_ID="STD-Nunez_x002d_Moral-2014" TOTAL_1="30" TOTAL_2="30" VAR="0.6833333333333333" WEIGHT="9.357391342188002"/>
<DICH_DATA CI_END="1.508953636273003" CI_START="0.39660002163599684" EFFECT_SIZE="0.7735961768219832" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.17867589595840533" LOG_CI_START="-0.40164726643834653" LOG_EFFECT_SIZE="-0.11148568523997059" MODIFIED="2015-02-26 15:07:03 +1100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.34088469823783535" STUDY_ID="STD-HONEYPOT-Study-2009" TOTAL_1="186" TOTAL_2="185" VAR="0.11620237749270007" WEIGHT="55.0265627531028"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:56:37 +1100" MODIFIED_BY="Narelle Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="77" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>Technique failure</NAME>
<GROUP_LABEL_1>Disinfectant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disinfectant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8337900690014903" CI_START="0.009138779064629631" EFFECT_SIZE="0.18717948717948718" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5836283280594183" LOG_CI_START="-2.0391118218715047" LOG_EFFECT_SIZE="-0.7277417469060433" MODIFIED="2015-02-26 16:14:32 +1100" MODIFIED_BY="[Empty name]" ORDER="93920" O_E="0.0" SE="1.54061054684255" STUDY_ID="STD-Wilson-1997" TOTAL_1="77" TOTAL_2="72" VAR="2.373480857042501" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.3943566995199355" CI_END="6.484749884422552" CI_START="1.2103964727911682" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8016278102271177" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="13" I2="44.38632505953895" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="0.8118932300870385" LOG_CI_START="0.08292764944212623" LOG_EFFECT_SIZE="0.4474104397645824" METHOD="MH" MODIFIED="2017-01-05 09:56:48 +1100" MODIFIED_BY="Narelle Willis" NO="7" P_CHI2="0.14509565475062414" P_Q="1.0" P_Z="0.016132776596094488" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.28880887925149357" TOTALS="YES" TOTAL_1="306" TOTAL_2="303" WEIGHT="100.0" Z="2.405897813364555">
<NAME>Pruritus (local)</NAME>
<GROUP_LABEL_1>Disinfectant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disinfectant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="182.92141170683868" CI_START="0.5793984656247022" EFFECT_SIZE="10.294871794871796" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2622645444149874" LOG_CI_START="-0.23702265923858656" LOG_EFFECT_SIZE="1.0126209425882007" MODIFIED="2015-02-26 16:14:15 +1100" MODIFIED_BY="[Empty name]" ORDER="93921" O_E="0.0" SE="1.4680936750972953" STUDY_ID="STD-Wilson-1997" TOTAL_1="77" TOTAL_2="72" VAR="2.1552990388606825" WEIGHT="7.50185856020878"/>
<DICH_DATA CI_END="385.3960200185923" CI_START="1.3579729589542149" EFFECT_SIZE="22.877005347593585" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.585907225387186" LOG_CI_START="0.1328911220108346" LOG_EFFECT_SIZE="1.3593991736990103" MODIFIED="2015-05-13 16:42:16 +1000" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="1.4409138017488143" STUDY_ID="STD-HONEYPOT-Study-2009" TOTAL_1="186" TOTAL_2="185" VAR="2.076232584070221" WEIGHT="7.752655584233088"/>
<DICH_DATA CI_END="5.086565769437817" CI_START="1.0703576226531681" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7064246643098825" LOG_CI_START="0.029528906279306287" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2015-05-13 16:41:26 +1000" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.3976119189552019" STUDY_ID="STD-Wadhwa-1995" TOTAL_1="25" TOTAL_2="25" VAR="0.15809523809523807" WEIGHT="41.02748485831999"/>
<DICH_DATA CI_END="3.722580398473296" CI_START="0.9028981919341673" EFFECT_SIZE="1.8333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5708440862056099" LOG_CI_START="-0.04436121665644711" LOG_EFFECT_SIZE="0.2632414347745814" MODIFIED="2015-05-13 16:41:55 +1000" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.36137464021653565" STUDY_ID="STD-Wadhwa-1997" TOTAL_1="18" TOTAL_2="21" VAR="0.1305916305916306" WEIGHT="43.71800099723815"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2017-01-05 09:57:54 +1100" MODIFIED_BY="Narelle Willis" NO="6">
<NAME>Germicidal chamber versus none</NAME>
<DICH_OUTCOME CHI2="0.027244831249319895" CI_END="1.5058038316995233" CI_START="0.735867780103071" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0526502376874411" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.17776839792075808" LOG_CI_START="-0.13320021219798864" LOG_EFFECT_SIZE="0.022284092861384698" METHOD="MH" MODIFIED="2017-01-05 09:57:41 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.868896715648527" P_Q="1.0" P_Z="0.7787847422521114" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="867" TOTAL_2="988" WEIGHT="100.0" Z="0.28090307519966107">
<NAME>Peritonitis rate (episodes/total patient-months on PD)</NAME>
<GROUP_LABEL_1>Chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chamber</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.002431163373731" CI_START="0.4297227348318956" EFFECT_SIZE="1.135875402792696" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.477473059135845" LOG_CI_START="-0.36681166900437023" LOG_EFFECT_SIZE="0.05533069506573734" MODIFIED="2014-09-08 13:00:28 +1000" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.4959370285863692" STUDY_ID="STD-Ryckelynck-1987" TOTAL_1="266" TOTAL_2="235" VAR="0.24595353632307715" WEIGHT="13.566106992820524"/>
<DICH_DATA CI_END="1.528758871929198" CI_START="0.7077104880302026" EFFECT_SIZE="1.0401532037798638" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="53" LOG_CI_END="0.1843389904163545" LOG_CI_START="-0.1501443682496356" LOG_EFFECT_SIZE="0.017097311083359445" ORDER="93922" O_E="0.0" SE="0.19647718059973107" STUDY_ID="STD-Nolph-1985" TOTAL_1="601" TOTAL_2="753" VAR="0.03860328249641934" WEIGHT="86.43389300717948"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:57:54 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="74" TOTAL_2="93" WEIGHT="0.0" Z="0.0">
<NAME>Mortality (all-cause)</NAME>
<GROUP_LABEL_1>Chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chamber</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.376887370565544" CI_START="0.1516836091106703" EFFECT_SIZE="0.457002457002457" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.13889841640621417" LOG_CI_START="-0.8190613464208215" LOG_EFFECT_SIZE="-0.34008146500730374" ORDER="93923" O_E="0.0" SE="0.5627103066619044" STUDY_ID="STD-Nolph-1985" TOTAL_1="74" TOTAL_2="93" VAR="0.31664288922353445" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2017-01-05 10:05:00 +1100" MODIFIED_BY="Narelle Willis" NO="7">
<NAME>Dressing systems (any)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 10:04:41 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="76" TOTAL_2="84" WEIGHT="0.0" Z="0.0">
<NAME>Exit site/tunnel infection (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Dressing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dressing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-01-05 10:04:31 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Chlorhexidine gluconate + water versus povidone-iodine solution</NAME>
<DICH_DATA CI_END="76.5975747998518" CI_START="0.1435353516416592" EFFECT_SIZE="3.3157894736842106" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8842150194013312" LOG_CI_START="-0.8430411223998254" LOG_EFFECT_SIZE="0.5205869485007527" MODIFIED="2014-09-08 12:30:47 +1000" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.6020037578296284" STUDY_ID="STD-Fuchs-1990" TOTAL_1="18" TOTAL_2="20" VAR="2.5664160401002505" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-21 18:47:25 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Sodium hypochlorite solution versus povidone-iodine solution</NAME>
<DICH_DATA CI_END="144.74908225485" CI_START="0.38860350009656297" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1606158188732705" LOG_CI_START="-0.4104932920898702" LOG_EFFECT_SIZE="0.8750612633917001" MODIFIED="2014-09-08 12:34:07 +1000" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.5102822189751095" STUDY_ID="STD-Fuchs-1990" TOTAL_1="13" TOTAL_2="20" VAR="2.280952380952381" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="16" I2="0.0" ID="CMP-007.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-01-05 10:04:41 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Shower + gauze versus dressing pack + fixomull</NAME>
<DICH_DATA CI_END="1.224529212436632" CI_START="0.38599017908236255" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.087969150137501" LOG_CI_START="-0.41342374513290053" LOG_EFFECT_SIZE="-0.16272729749769974" MODIFIED="2014-09-08 11:53:55 +1000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.2945206686166936" STUDY_ID="STD-Cocksedge-1993" TOTAL_1="30" TOTAL_2="30" VAR="0.08674242424242426" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-007.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-21 18:47:51 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Blisterfilm versus gauze</NAME>
<DICH_DATA CI_END="1.51731949556677" CI_START="0.14352796389558709" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1810770379733295" LOG_CI_START="-0.8430634760561784" LOG_EFFECT_SIZE="-0.3309932190414244" MODIFIED="2014-09-08 17:42:04 +1000" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="0.6015852075182384" STUDY_ID="STD-Moore-1989" TOTAL_1="15" TOTAL_2="14" VAR="0.36190476190476195" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 10:05:00 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="337" TOTAL_2="342" WEIGHT="0.0" Z="0.0">
<NAME>Exit site/tunnel infection rate (episodes/total patient-months on PD)</NAME>
<GROUP_LABEL_1>Dressing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dressing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="25" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-01-05 10:05:00 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="337" TOTAL_2="342" WEIGHT="0.0" Z="0.0">
<NAME>Shower + gauze versus dressing pack + fixomull</NAME>
<DICH_DATA CI_END="1.1943897950272087" CI_START="0.3531882722684282" EFFECT_SIZE="0.6494955489614244" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="25" LOG_CI_END="0.07714608408208558" LOG_CI_START="-0.45199372574471847" LOG_EFFECT_SIZE="-0.1874238208313164" MODIFIED="2014-09-11 16:46:12 +1000" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.3108193435765666" STUDY_ID="STD-Cocksedge-1993" TOTAL_1="337" TOTAL_2="342" VAR="0.09660866434136776" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2017-01-05 10:00:02 +1100" MODIFIED_BY="Narelle Willis" NO="8">
<NAME>Silver ring system on catheter versus none</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:59:25 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="97" TOTAL_2="98" WEIGHT="0.0" Z="0.0">
<NAME>Peritonitis (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Silver ring</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours silver ring</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.656330208037578" CI_START="0.4869189932394759" EFFECT_SIZE="0.8980526918671249" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.2191469225652255" LOG_CI_START="-0.3125432846074881" LOG_EFFECT_SIZE="-0.04669818102113127" MODIFIED="2014-10-23 12:28:28 +1100" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="0.31231745960222435" STUDY_ID="STD-SIPROCE-Study-1997" TOTAL_1="97" TOTAL_2="98" VAR="0.09754219557238702" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:59:38 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="97" TOTAL_2="98" WEIGHT="0.0" Z="0.0">
<NAME>Exit site/tunnel infection (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Silver ring</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours silver ring</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9030553100200711" CI_START="0.8380642175003097" EFFECT_SIZE="1.2628865979381443" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="28" LOG_CI_END="0.27945141071867524" LOG_CI_START="-0.07672270185006241" LOG_EFFECT_SIZE="0.1013643544343064" MODIFIED="2014-10-23 12:28:23 +1100" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="0.20921843681316846" STUDY_ID="STD-SIPROCE-Study-1997" TOTAL_1="97" TOTAL_2="98" VAR="0.04377235430254576" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 09:59:49 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="97" TOTAL_2="98" WEIGHT="0.0" Z="0.0">
<NAME>Catheter removal or replacement (number of patients)</NAME>
<GROUP_LABEL_1>Silver ring</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours silver ring</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.562482854600243" CI_START="0.3495646142853332" EFFECT_SIZE="1.2628865979381443" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6592012454280389" LOG_CI_START="-0.4564725365594262" LOG_EFFECT_SIZE="0.1013643544343064" MODIFIED="2014-10-23 12:28:37 +1100" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.6553523022137264" STUDY_ID="STD-SIPROCE-Study-1997" TOTAL_1="97" TOTAL_2="98" VAR="0.42948664001683146" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 10:00:02 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="97" TOTAL_2="98" WEIGHT="0.0" Z="0.0">
<NAME>Mortality (all-cause)</NAME>
<GROUP_LABEL_1>Silver ring</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours silver ring</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.862215738338369" CI_START="0.21411087426890632" EFFECT_SIZE="0.6314432989690721" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.27002999272611844" LOG_CI_START="-0.669361275185468" LOG_EFFECT_SIZE="-0.19966564122967478" MODIFIED="2014-10-23 12:28:34 +1100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.5518030808330373" STUDY_ID="STD-SIPROCE-Study-1997" TOTAL_1="97" TOTAL_2="98" VAR="0.30448664001683146" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2017-01-05 10:00:51 +1100" MODIFIED_BY="Narelle Willis" NO="9">
<NAME>Antistaphylococcal vaccine (Staphypan) versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="57" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 10:00:42 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="552" TOTAL_2="547" WEIGHT="0.0" Z="0.0">
<NAME>Peritonitis rate (episodes/total patient-months on PD)</NAME>
<GROUP_LABEL_1>Vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5855362935059472" CI_START="0.7736235268713716" EFFECT_SIZE="1.1075234441602728" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="51" LOG_CI_END="0.200176187636498" LOG_CI_START="-0.11147033127892415" LOG_EFFECT_SIZE="0.04435292817878691" MODIFIED="2015-01-21 18:55:22 +1100" MODIFIED_BY="[Empty name]" ORDER="93924" O_E="0.0" SE="0.18306270788606757" STUDY_ID="STD-Poole_x002d_Warren-1991" TOTAL_1="552" TOTAL_2="547" VAR="0.0335119550185797" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="43" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 10:00:51 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="565" TOTAL_2="542" WEIGHT="0.0" Z="0.0">
<NAME>Exit site/tunnel infection rate (episodes/total patient-months on PD)</NAME>
<GROUP_LABEL_1>Vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4777498865193204" CI_START="0.6527382655405527" EFFECT_SIZE="0.9821323219553308" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="42" LOG_CI_END="0.16960093467019935" LOG_CI_START="-0.18526092686893034" LOG_EFFECT_SIZE="-0.007829996099365522" MODIFIED="2015-01-21 18:56:41 +1100" MODIFIED_BY="[Empty name]" ORDER="93925" O_E="0.0" SE="0.2084476140626294" STUDY_ID="STD-Poole_x002d_Warren-1991" TOTAL_1="565" TOTAL_2="542" VAR="0.0434504078084029" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2017-01-05 10:01:45 +1100" MODIFIED_BY="Narelle Willis" NO="10">
<NAME>Antifungal versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="0.4910062261540228" CI_END="0.6318634891504427" CI_START="0.12027456731710488" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.27567572936521934" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-0.19937673866766087" LOG_CI_START="-0.9198261967794349" LOG_EFFECT_SIZE="-0.559601467723548" METHOD="MH" MODIFIED="2017-01-05 10:01:31 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.4834788399498726" P_Q="1.0" P_Z="0.0023286417056228356" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="409" TOTAL_2="408" WEIGHT="100.0" Z="3.0447624329082217">
<NAME>Fungal peritonitis (number of patients with one or more episodes)</NAME>
<GROUP_LABEL_1>Antifungal</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antifungal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6806590402186888" CI_START="0.058766574211882076" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.16707038299643295" LOG_CI_START="-1.2308696256756047" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2014-10-23 12:30:36 +1100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.6248809410409238" STUDY_ID="STD-Restrepo-2010" TOTAL_1="210" TOTAL_2="210" VAR="0.3904761904761905" WEIGHT="45.865663922053734"/>
<DICH_DATA CI_END="1.117055060010602" CI_START="0.11718830153833404" EFFECT_SIZE="0.36180904522613067" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.048074580160771756" LOG_CI_START="-0.9311157401176482" LOG_EFFECT_SIZE="-0.4415205799784382" MODIFIED="2015-01-21 19:02:07 +1100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.5751812412018017" STUDY_ID="STD-Lo-1996" TOTAL_1="199" TOTAL_2="198" VAR="0.3308334602304452" WEIGHT="54.13433607794627"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-01-05 10:01:45 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="3576" TOTAL_2="3288" WEIGHT="0.0" Z="0.0">
<NAME>Fungal peritonitis rate (episodes/total patient-months on PD)</NAME>
<GROUP_LABEL_1>Antifungal</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antifungal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9493447570806075" CI_START="0.09894688620250722" EFFECT_SIZE="0.30648769574944074" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.02257604372897975" LOG_CI_START="-1.0045978682220797" LOG_EFFECT_SIZE="-0.5135869559755297" MODIFIED="2015-03-06 14:53:52 +1100" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="0.5768444807936767" STUDY_ID="STD-Lo-1996" TOTAL_1="3576" TOTAL_2="3288" VAR="0.3327495550221264" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-04-04 15:57:38 +1000" MODIFIED_BY="Narelle S Willis">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA1IAAAM/CAYAAADbTOODAACAAElEQVR42uy9D4RWT///f5MkSSJJ
kkSSJIkkK8mSJLllSd6St0SSJIkkSRIrSZJIkiSRJEkiSZJEkqwkkiRJJCtJ5vd7zvcz1z3X7Dkz
c8517e611z4eHLvX+TNn/p0zr+eZmdf8x3j85z//YWNjY2Nja3nrNCgTNjY2NrZ2t2//8RsZAACA
dgkX4gIAAN3cvv2HRgYAALpVwNC+AQDAcLUt/6GRAQCAbhQytG8AADCcbQxCCgAAEFIAAAAIKQAA
QEghpAAAACEFAAAIKYQUAAAgpAAAACGFkAIAAIQUAAAAQgoAABBSAO3h9evXZAIAQgohBbQr5BPA
+BFSg4ODZteuXWbKlClm0qRJpq+vz3z//r1xXP9v3LjRTJ482Z6zZcsW8/Xr1+zjPjdu3BjxBm80
GtiDBw+aqVOn2jxRfn758qVxTP//97//tXntjvv5lSqPTkVxBQCEVCfdu9X2zfHr1y+zYMGCIft/
/PjhGtimDQHZnjgPZ7tSZI+k2mfaXwCE1BD27t1rzp07Z/7+/Ws3iQC9PBzHjh0zR48ebRy/cuWK
OXz4cPZxx8ePH82aNWu6/sthf3+/OXv2bCM/jh8/btPtWLt2rbl+/XrjuP7v7e3NLg+MKADgHZB3
71bbN/Hnzx+zefPmwnvcuXNnTLyfx2o9Ga46VWaPpNpnnj0AhNQQpk+fbl8YfqPhf93QS+TNmzdN
x9evX5993LFu3Trz9u3b5AOv48+ePTMzZ840y5cvb2rwpk2bZr8a7tu3z+77+fOnmTNnjv1a6PP7
92+zZMmSwhdMUThi3rx55tu3b/b/Dx8+2OueP39uf+srlY7nvLDmz59vv4L6TJw4sfD/on2p8mgl
v/xrLl++bGbMmGGP79mzZ0geyuDQMX2VU4Pz6dOn0nsWfY29e/euTdeECRNsWTx69IgnEQADeUTv
3Wr7JvT+k+FddA99KDtz5kyleHZy+5aTr/6+VFuivN+9e7cdoTF79mxz7dq1puvfv3/f6BFUe7Fw
4UJz69Yt33AZ0suXattyKLNHUu0z7S8AQiqJXtJ6QB16AfoNkduXe9w1NuqlyXnR6bheLArz8+fP
dt/58+fNpUuX7D41dHoZnzx50h7TsI1Tp041hXH69Gn7IgvvFwvnn3/+MTdv3rT/6yuUGlud735v
27atcsZr2IfisXXr1iFfvBwaXrB69ers8mg1v9w1y5Ytsy9nnaM46sutQ/np96opPD/9RfcsapDu
3btn/79//74VmACAkBrNe1dt38SDBw9K76GeKokxGc26TgZwN7VvOUIq1pYoridOnLDHNESup6en
6fqlS5eaq1evNtoatTt++YT3T7VtOcTskartM+0vAEJqCBracOTIkewvNKnj+urld43nCCn/64vQ
Syds7NyLYWBgwH61c8f1V1/XXBj+/WLh6AuRGi2xY8cOK36cANq+fbt9GVZBY+31RUnby5cvG/sV
X30ldV+P9L/25ZZHq/nlrnn69Gnjt3rQlIeOxYsXW4PDNz709Sx2z7Bc1RiqEQIAhFSn3Ltq+5a6
x6xZs2yYru25cOFCW9/Xo92+5QipWFuiHhO/LXnx4kWyrNSLUnb/VNuWImWPVG2faX8BEFJNqOtf
AkBfUYpeakUNTey4hiboReo7W8gRUkXhhd3X/n31xUhfgIS+bmmoQFF4sXD0stTXMaGu8FevXjVe
bhpuoOEQddAXSjcMQyhu+uLkvjZpTpW+auaWRzvyS7/DF31umeY0ru4rmPvypjkIAICQGs1712nf
qt5D71WJq25p33KEVKwtCfNS54ZhapiaxKeEnUREGH6VvIqRY49UaZ9pfwEQUk2ocVH3f+ihJhzm
EO6LHdeXLjecoBUhlXpRasKvGgPXSLihGGF4qXD09Unpdw3M3Llz7fh5/2tRVZSv/ktQQyr8l6j+
1zjo3PJoR36VvfxjhkSscSvbpwZSZaPx6AcOHOBJBEBIjcq967ZvddIXe/+OtfYtR0i10paop2zR
okXm4sWLNl0aqhYLP1c0FZFjj+S2z7S/AAipJvSlTt3+RV+l9BD6zhM0KdL3Qhc7XuQWNuUetuiY
Gg/NN4qhRkHjscNJs354qXD05enff/9tDHlwwx/8OU4p1KXuN9Zht3z4UtaLWsP/csujHfmla/RF
0iEXwL7xoOvDoQX+BO3cF7lD98KrEABCajTu3Ur7lrqH3u3q6fDflU70dEP7FsbXOarIbUtWrlzZ
1JZIuPnX61w/zkXhV82rhCEUtUdy2mfaXwCEVBNPnjyxQwf87m4fTYR0k0W16cuR31WcOl61sS06
rq52/x76HTZ2mswpr0DhxFM/vFQ48r6khlHucoXGu+vF6oZV5KChfL473UOHDtnNoUmiyiN9IdVx
NY7yapRbHu3IL12j3xJ8Lo7+8AWdr7xw1ys//DVUiu6pfNK4bdcA6CujPAcJTXqNeT4CAITUcNy7
1fYtdY/9+/fbMNz1an9c+9EN7ZvvtECeCzX0LRQ6sbZEQxHl3ME5m5AzB/96CUTnpU8ia8WKFUOE
jd+u5ORVK/Um1T7T/gIgpIagbv3YFxp1tevlpy8i2jZs2NC0oGHqeDuElNDaHvpqo3voZe681fhf
HXUsHLoRhhcLR42u7xbWTYyVm9Tc+OsFrJexwteXrNCLk754uuPa9JL2XZ+myqMd+aVr1HhpLL96
0GQMhGXm3K9qk8egd+/eRe+pBt6lSWhYgca7a5iDXuLupQ4ACKmRuner7VvqHnp379y5016roXMy
oMdy+xbijHC9x2XM6z0eCqlUW6J5RhJw8mwoD3T+9Y8fP7aOGHQPGf/hIrlhu5LTtrVSb1LtM+0v
AEIKgG5+ABgXQgrId/IMABBSwIscAHiv8E6jzMkzAEBIwWjiD5MAAEBIAW0JeQYACCkAAEBIAQAA
IKQAAAAhhZACAACEFAAAIKQQUgAAgJACAAAaGoQUAAAgpAAAABBSAABA+4aQAoBO4fXr12QCQgoh
BbwrAKA7hNT9+/ftiu6OFStW2JW3i7h586Y9HgQeXT2+6JhW29aq6VUawzDMa9euJc9JxS0z86Jh
tJJfkydPNuvWrWtaudzx8OFDe86DBw+GHPv586fZu3evXTFeeanV4Y8dO1Y57jl8+/bN7Nu3z67C
rntpxfQw73PrQTvKrKguaRX5Xbt22Xypko+tGmBV4zIahuRIxTE3L0fb/W9Yl0baWO9Wo79ThVTY
vuW8Ozsln+rW1U4vu5F8V2zcuNG2AQAAwyakli1bZgYGBpoukPH/69evpvN+//5tli5dWvnlXnSO
RJREhC+mqgqp5cuXD4ljuxue3PTVzS+dc/z4cStOQv773/+aAwcOmE2bNg05tnXrVnPlyhXz9+/f
RjgHDx60WzvTL6ND+Xzp0iV7D/H8+XMzb948c/ny5cr5lCqzuvsVT+XV7t27K+VjO4RUlbiMlpDq
hDh2ipAY7/cfb0IqbN9y3p3jLU87tU62I14qe7U7AADDIqSePHlient7h1zQ399vLly40LRfjc/R
o0fbIqScmNIXwbpCSvFTfDpBSLWaXxKVPp8/fzZz5syx/0u0fPnypem4n2++cTx9+vS2pv/IkSPm
1KlTQ/ZLTPmNU24+pcqslf0yjKZMmVIpH4dDSJXFRV+9p02bZverhy8MR2J17ty5ZsKECUN6bN+/
f2+/rKqe6NjChQubekGrCqk6cXTH1Zulenb27NnSun337l0bT6VlyZIl5tGjR/7LaEgvYypvnj17
ZntEcw0iGcfbtm2z+aW8evr0afIdkSoD/9xY+K2UFUKqvfcuat9y3536UKReK9XJPXv2DPkAFKuz
ufWvSl3Jeb5y4qbnXh9Q9BzPnj3bjhJIvT+Knr+x9K5QHVBdAABou5DSEAe/Z8Fd8OHDB7Nq1aqm
/RqC9vbt27YJqarCp+hc9QR9+vRp1IVU3fxSo3bixIkhYkW9VIcOHbL/Hz58eMjQk0WLFpmTJ082
eomGy7DRfT5+/Ni2fEqVWStCSoTCIJWPwyWkwricP3/eGukq7z9//ljjReXnhyODyuVL+JFBPZtX
r16112uTYSJjoRUhVTWOOqZeLB3/+vWrre9lddsXIRpapeFTZfHJyRsZsjouYZz7AeDGjRv2/zt3
7th6nCOkYmXgnxsLv5WyQki1995F7Vvuu1M9WaoLKkO9NxRWbp3NrX9V6kru85WK2+nTp22b457j
np6e5PsjfP7G2rvi4sWLTeUHANA2ISWj9s2bN4WNkl5+EgJCX/L10i96uefMaRkuIfX48WOzZcuW
0nNGYo5UO/JLvVc++iqur5VCIk29KT4vXrywDY4aIY3/V0+P8qJq3FMUfb1tNZ9iZVZXSEnsyUBQ
I1olH4dDSBXFRUaZG0rkCA0GX1zmxE1fcOsKqTpxXLlyZVOPnupg2fMrY9AZkqn41MmbnA8AYZg5
QipWBv7/sfBbKSuEVHvvXdS+5b47/V6kwcHBRs92Tp3NrX9V6kru85WKm3pqfBEZPsdF8Q2fi7H2
rlAd8OcqAwC0TUhpSEH4YnLnnjlzpvE1X0aX+/LTST1SQka5awhHq0eqbn4p7/VFUkM6HPoqt2bN
mqbz1q5dW+gsQcMYdC99SZdhoCGG7Ux/OOSwHfkUK7NcIRVuGqKiOQ76SlklH9vtbKIsLiqb8LyU
cR3uU1nrS7fmeGhOXZWPFe2IYzjxW3W3LA7Ke/dVPzWUs07etPIBICakcs9NfWCoW1YIqfbeu6h9
y313htf5ZZ6qs7n1r0pdyX2+qsYtfI5z8nasvSuKhjEDALRFSPkvofBlpK5xGVx6Ceklpy/6nSik
9HXdfW0aTSHVSn75DY8a9iLjV/tjyFVsbFhEHdSrpqEZITLAq877yCmzXCHl0FfP9evXm1evXg05
Lycf29kjFYtL0XOWSqu/T8OT9JVbQ1QkBFXX6vT6thLHlAFWZCBqWJOGuGqYT9l5dfKmk4VUK2WF
kGrvvVN1q8q70y/zqs9KO57r3OerTtyqCqmx+K7IHV0BAFBJSMV6pIS+6KuXRV31dcRP7JxWnU34
6EuWhmiMppCqm18SJZrULDQsQcPRwjLRb+13wyU0gbfoS6v/1a0d6Ve+akx6iIYi+nPC6tSDojKr
KqRc/kkc3b59u7EvNx/bPbSvKC5Ck6h//PhRW0hp0rZ/vUR6HSHVShwlfH1R/fLly6w4SLTFzquT
NykWLFhQa2hf7rmx8FspK4RUe+9d1L7lvjv9jw3fv3+35ZpbZ3PrX5W6kvt8peKmtskf2qdhb1WF
1Fh7V+idR48UAAyLkNILT+OXy15Gmtypr0AaAtFOISVPPWrk9LcdQkoeldQLNNpCqmp+Kd4SXu4r
nMRFkZc8oaEnzlmChmXpPOcIQuFoaKE/56Ud6ZcBoeEm586ds/MEZBxobSwZI/68gjr1oKjM6ggp
IWGkL8quFzA3H4djjlQYF6G4uAne2vTbH3aYMuIl/lwPoBvvX1dI1Y1jOIFcx2JziNyzHX4w0XMv
oeuMuTp5k0JDpTRkSGgNmVxnE7nvnFj4rZQVQqq99y5q33LfnaqDqueqk3pHb968OftZya1/VepK
7vOVipuGkssJj3uONdy56vtjrL0rJOSYIwUAwyKk5MlGxn/Zi1OGtISB7wGn1QVUYwvyxsJKGSOh
G9dcZwtV55fEnGlUzS8JEt+1robShW52HRIy+iLnkBjQl0/dTz1aMhD8L43tSL+QwfHPP//YL3q6
lyYrhwsc1nU6EnO9W3W/4rR69epK+dhOZyllcXHIa6C+QGsYp3qEyupI0T6JVjdBXoaHJmePdByF
DDC5HtYQVr03/CGp/n00VEcC3LkR9z+YaO6grvOvrZo3qTSr7Pv6+hoLSPvGdDuEVCz8VsoKIdXe
exe1b7nvTgmcWbNmWWcI+/fvt+/23Gclt/5VqSu5z1fOc6yPSUq3nmXlT533x1h6V2jkA177AGBY
hJQ8E4UT8scbO3bsIP1A/lRExqLvyYxyoaHptHvXbd+6VeyO13eFXLxLsAEAtF1ICQ2v0mTb8YqG
YYxnxnv6yZ889AVbE8LdGi76iu9PDKdcaGg68d512jeEVPe8KzRkUnUAAGDYhJSG2G3atImcAoBS
5FVMwzo1pEZDUjXcyXefDjQ0nXjvOu1b6L4bxu67QmUfDkUHAGirkAIAAOhGIQUAAICQAgAAhBRC
CgAAEFIAAICQQkgBAABCCgAAEFIIKQAAQEgBAAAgpAAAACHVAYxnN+sAAAgphBQAACCkahG6le3U
BjAVryrxLludfjjRiu+4fAUAhBQAAECXCKluafDqCqmRYmBgwK7jAQCAkAIAABgGIaX9ly9ftiuR
T5kyxezZs8f8+vWr6fizZ8/MzJkzG4b5+/fvbY/H5MmTzcSJE83ChQvNrVu3Gtf8/v3bbNu2zR7X
sadPn/oRaWxhA1h2nePYsWNm2rRpNp779u1LJlznT5061S4IePbs2WTPUNlxrc6+e/duG9bs2bPN
tWvXhlwfi1tZuPr/0qVLZu7cuWbChAk2L7V4ZG64d+/etdfo2iVLlphHjx41He/t7TVPnjzhCQAA
hBQAAMBwCKlly5aZT58+WcEgw33v3r1NxyWudOzz589239KlS83Vq1ftPm0SKRJajiNHjpgbN27Y
/+/cuWMWLVpU2uD5v2PXnT9/3ooO3U8rpEvMnDx5sjTROvfAgQP2/K9fv5pVq1bVFlKnT582J06c
aITV09PTdDwVt5iQkiBV3guJKAmj3HB94XX//n0zf/78pvRcvHixqSwBABBSAAAAbRRSfs/P4OCg
mTNnTtNxZ+jHUK+IQwJIxn9Og+f/jl0nsRceC4WDz8qVK82XL18av1+8eFFbSKknTr1lZWGl4hYT
UmHeVglX4tUJzyLevHljVqxYwRMAAAgpAACA4RBSobHu94qUXafhfupB2rp1q1m8eHHTef71VYRU
7DodC4cG+uItJHRqoTTWFVJhvMKwUnGLCalYHFLhqhfK9SgePXp0SFiKp4YEAgAgpAAAAIZBSBWJ
lthxzalS75GGjj148MAO+RtuIRUTTWXCa7iEVHg8Fbe6QionzRK0Gga5bt06O5QxlQ8AAAgpAACA
NgmpV69eNX5///7dOlWINVA6/uPHj8bvDx8+NJ23YMGCWkP7YtfJmYJ/zxQa0qb5TI6XL19GRUyY
Bv9/DRP0h/ZpyJx/PBW3ukKqSppVhmF4mldFjxQAjAcxg5gCAIDhaluiQmrNmjVWdEjEHDp0yGze
vDnaOMnLnPPS5+bhhE4jNOxMaC0j32mEPPJpXpATJrnXnTp1quHwQZt+K95lhM4mdG7Yy+QcNXz8
+NE6fSgTOXKscfz48UZYa9eubTqeiltdIZUKV/kjz30idFThxCNzpABgvAgZxBQAAAxHmxIVUhJF
s2bNss4L9u/fb3ulYg3T48ePrdMDGe4y5uXwwD9P7tP7+vrscc2fknMGh7zOaf6Sm8OUe504fPiw
7Q3TtRI+zotgGRI/ch0ul+XygOfPm3LCQ8Pn1BMmQRITOf39/dZFvMJTWOHxWNzqCqlUuBrWp3xy
rtOdqHJcuHABr30AMK5ETDivlI2NjY2Nrc4WtC3/6ejGb7iRSPO9EY4H5KZdYgsAYLwIKQDgeQUY
hmdmfAkp9R7JCYNbg+ngwYOFzhi6FQ25lDc/AAAMMwDgeQUYBiEVugnvFuRNUOs/KX3Tp0+3QxYl
qMYLmzZtsvPMAAAwzACA5xVgGIQUAAAAhhkAzysAIKQAAADDDAB4XgEQUgAAgGEGADyvAAgpAADA
MAMAnlcAhBQAAGCYAQDPKwBCCgAAAMMMgOcVgGeGhwYAADDMAIDnFQAhBQAAGGYAwPMKgJACAAAM
MwDgeQVASAEAAIYZAPC8AiCkAAAAMMwAeF4BEFIAAAAYZgA8rwCAkAIAAAwzAOB5BWjTM8ODAwAA
GGUAwDMLUENI8fAAAAAGGQDPLQDUEFLuAWJjY2NjY2t1AwCEFMC4ElIAQEMDAAC0bwCAkAKgoQEA
AKB9A0BIAdDQAAAA0L4BIKQAaGgAAABo3wAQUgA0NAAAALRvAAgpAKChAQAA2jcAQEgB0NAAAADQ
vgEgpABoaAAAAGjfABBSADQ0AAAAtG8ACCkAGhoAAADaNwCEFAANDQAAAO0bAEIKAGhoAACA9g0A
EFIANDQAAAC0bwAIKQAaGgAAgDa3a+EGAAgpAIQUAAAAQgoAIQWAkAIAABg+MQUACCkAhBQAAABC
CgAhBYCQAgAAQEgBIKQAEFIAAAAIKQCEFABCCgAAgPYNACEFADQ0AABA+wYACCkAGhqA8fjcsrGx
sbGxtbohpAAQUgA8swAAAC20KbQuABhlADyvAAAAFdsWWhgADDMAnlUAAICKbQytDADGGQDPKgAA
AEIKAOMMAHhWAQAAIQWAcQYAPKsAAICQAsA4AwCeVQAAQEgBYJwBAM8qAAAgpAAA4wyAZxXax+vX
r8kEyhwAIQWAcQYAY/VZ1f5r166N+LPdrvBbDWe0rp80aVJb0z5S7+LBwUGza9cuM2XKFJuGvr4+
8/3798Zx/b9x40YzefJke86WLVvM169fo2Hev3/fbNiwIfseP3/+NNu2bbPHZsyYYfbt29d0vFOp
UubKw4cPH/LiAoQUQNc+MMEGAGNTSC1fvtz8+vVrRIVUpwiy0bq+Hfk7GmW0d+9ec+7cOfP371+7
HTx40Aodx7Fjx8zRo0cbx69cuWIOHz4cDXPZsmVmYGAg+x47d+40J0+ebBw/c+aM2bx5c1fVVeWH
nksAhBQAQgoAOlhIXbhwwRq/sfNlIE+bNs32EqgHwDFv3jzz7ds3+/+HDx/sdc+fP7e/v3z5Yo+n
4qP/L126ZObOnWsmTJhgJk6caO7du9c4/vv3b9sDoV6OhQsXmqdPn5aGE7uPjO7du3ebqVOnmtmz
Z9ueuNx05l7vc/fuXZsWpWnJkiXm0aNHhe/PdsS9SjrK4pVj7E+fPt3GxfHnz5+mnpbe3l7z5s2b
puPr168vDe/Jkyf2mir30P/+cf2vfInV/WfPnpmZM2c2iZNYHumay5cv2x4vHd+zZ8+Qjw0SeDqm
erlmzRrz6dOn0nsWlXmsHFxeKn8AEFIAXS6mAGDsCimxYsWKIYag4/z581boyGCVUSsjXj0C4p9/
/jE3b960/1+/ft0auTrf/ZYAyhFSGsrk7i8RJQPTceTIEXPjxg37/507d8yiRYtqCanTp0+bEydO
2HRouFlPT092OnOuD/EFoYavzZ8/vzSurca9Sjpi8aqKRK7EgkOCxhc5bl8Z6n2SYKlyj1BI6Xhs
2JzyRkJI13z+/Dkrj3SNespUJ3WORJfi6jh16pQ5e/Zso1dM4fl1veieYRmnyuHixYtN9wRASAEg
pACgA4XU48eP7XyWovNlUIbGsTP6ZARrPovYsWOH2bp1q93E9u3bC+dfFQkgX8SFxyWcwvvXEVLq
GZDR7Xjx4kV2OnOuD5Hx7wRgqjxajXuVdMTiVRUN3ZPQ9cVBkaAsQwLe78HKuYcEi4bzKY3qJZLY
UK9OrO6H9SuVR7rG7/nUvK05c+Y0fi9evLipPPS/eq9y63ROOShflD8ACCkAhBQAdLCQEhJSElTh
fhnC4dAkZ7hqLsfSpUvt/xqe9OrVq4bBqWF4Gu7XqgCKGeKthCNDOjedOdeHqJfB9Wykhk62Gvcq
6YjFqwoa0qk6ox4dR5GgiZWfhsWVieSye8ixhPYp3AULFtj0pHqkiuIUyyP9DuPlpyOVzlR55pSD
7q+hgwAIKQCEFAB0uJD6+PFj4wu4vz/2tV9oTouGmzkBpblO+pruf8HvRCFVNZ2p64vQPBkNR1y3
bp05cOBA24RULO2pdMTilYuEjYZ1hh75iobxxYb2xeJado8Q1TXNG6tS91N5VCa+6pRHbF+qHGJ1
HwAhBdClxhkAjD0hJfRlXM4n/P3qafrx40dp2PKY9u+//zaG9Lnhfe53qwJIvQ51hvY55xeOlStX
Ng3HkgFeJZ2p62Oopy4W11bjXiUdsXjloF4iDecs6m2UINAwOIeG3skRQxllPVKxe4Rojl5uXcvN
I12jvHGoF8wXhLo+HNrn94rlCqlYOUhI0iMFCCkAhBQAjBEhJcNXQ438/ZpY7xwdaNNv3zjWfBXN
D5HLaiEhJgNZk/nbIaQ0P0bDoITW1ilzNuFP3lfvmhxY+MevXr1qjh8/3nDYsHbt2krpTF0fonjK
M5sIHWgofzSHxhnjrca9Sjpi8UohL3KrV6+2HhmLkFMG/95ymBAbPqgeUM33qnIPxd85OHn//r0V
b2EYqbqfyiNdo9/Kax0/dOhQk4t1ne/maWlT3Zfgj90zLPNUObx8+ZI5UjB2hVSRe2c2NjY2Nraq
21gSUqLIrbfWAtIXeX11l5HvPJE5w9d3e+4cIbx9+7YtQkriTusIydDUJH/faPbPc8aohm3JqJWR
Gobd399vRZ/cXsvTWpV05lzvo2Fbiq9z6e6MZiEPcbqH68VoNe5V0hGLV6q+arhmrI7rPhJ5Lm1a
aDe2WK4cRTgvj7n3UPnL+YabI5VynFGWplge6Zpbt26ZWbNmWacQ+/fvH5IO5/5cmxxgvHv3LnrP
sMxj5eA+SOC1D8akkOIrOwAADLeIGW9xAAiRZ7zY0L/x/LzIxb3EFsCYElI0NgAA0G2GGW0bdCoa
Svr69WueVw/NgVO+AIwpIUVDAwAA3Wic0b5Bp6JhjZs2beqoOMXcqY8Eyg/NBwRASAEAACCkAAAA
IQUAAICQAgAAQEgBAABCCgAAACEFAAAIKYQUAAAgpAAAACGFkAIAAIRUu+g0l6HdxHDkbSxMynJ0
8oV8B4QUAADAMAmpcHVtrUCt1bB37dplfv78OaoRH20Xne1urEfzeq0qrrJ1azcMR96GYfrxjR0b
62XbyrXDXcc77RkaS8bywYMH7btw8uTJpq+vz3z58qVx7MePH0PenX78UscRUggpAADoEiEVIgF1
4MABs3v37nHbMHebkJKI0noWw5m3sTDDYwipkckHDMx69Pf3m7Nnz5q/f//a7fjx42bNmjWN43fu
3LHiqozUcYQU9RwAALpUSAkZD1OmTGnad+zYMTNt2jS7f9++fUPCuXz5spkxY4Y9vmfPHvPr16+m
c/SFV8f0hVdGyadPn5quf/bsmZk5c6ZZvnx54Zdc16syYcIEs2TJEvPo0aNowsviu2XLlqbF4BTu
+vXr7f+/f/8227Zts3FcuHChefr0aWFeFeWbv0/5JyGqL9qzZ882165dG3JNLD9zrvd5//692bhx
o4238khxv3Xrll8BSrfc8vXLp6SSNYXp/y07lnPvKml1YV+6dMnMnTvX1pVQRLYzb939VJddvVFd
evHiRVP9Kqq3ZfkS5nPq/mV1Nqc3JPZMpZ6FovqQKsdUHYuVW/j8xc5191IZT58+3Yqi1PPrM3/+
fDM4ODjkY4RDwurMmTOl16eOI6QQUgAA0MVCSvhC6vz589ZwkRH6588fa3yePHmyKRwNG5NBqXNk
xOzdu7dx/NSpU01feBWejDT/eokvHfv8+XNh3Hxj6f79+9bYKSMWX4W/YsUKe0xiT+EMDAzYY0eO
HDE3btyw/+ur8qJFi2oJqdOnT5sTJ07Ye3z9+tX09PQ0HU/lZ+r6kKVLl5qrV6828ld5LSO3LL7h
75zyDcsnVZdi+VUlL+qkVcLDCXXVGd8IHo68XblypR36peM3b94027dvz6q3RfkS5nPq/rl1tohY
3FLhhvFMlWNOHYuVW1ifYufqPupVd2W8atWq2sa2hunpfbZ169bGvs2bN5ve3l4rCiXW9JHIJ3Uc
IYWQAgCALhVSHz9+tMamDCWHRJKMEp/QIPS/WOtr7pw5cxq/Fy9ebL9wO/S/eq/86/0eqqK4yXh0
hl2KVHxl1CmNMuR8wSdjMbyujpDSV3o/veqh8I+n4pe6Pgd9qc8VUjnlG5ZPu4RU6t510hqrS8OR
t34PlNLi5qKl6m1RvqTyObx/bp0tIha3VLhhPFPlWKeOldWh1LlO2LZSxkK91/qgpO3ly5eN/bNm
zTJXrlxplPeFCxes8Mw9jpBCSAEAQJcIqXDTcCd9QdVXY4e+9obnhcZkaCT5X4j9c4uOp4SJ0Bdz
1/N19OjRaKJT8XWGncTct2/fCuPUipAKw1HehMdj8UtdX4SGWslY05dzCddcIZNbvlWNmdz755RV
K2mtWjbtuJ9/j1i9zZ07Frt/bp0tIha3quHm1OmqdSwmpGLnhk42cso4ht6HGvpYhsKXeKp7HCGF
kAIAgDEqpBz6gqv5Ha9evRpyXsqwTRmTRUZZFcPINyg1zGjdunV26E4ZqfiKDRs22K/uIyGkwuOp
+KWuD9H8NKXl4sWL5sGDB3a4VRUhVad82yWkcsqqlbRWLZt23C805MvqbY6QSt2/FSEVi1vVcFPl
WKeO1RVSdcRyDH1UiuVHO9KPkEJIAQDAGBZSzmDQ3IPbt2837dfXWM0ViN3EF2Dfv3+3cwP868Oh
fb6xmSukHLpX7HgqvufOnbPzKGSc+kP7FixYUGto34cPH4YMLfLT++bNm6bjqfilrg9RXvvhhfFJ
Gew55TtcQip171bTGu4bjrx1c+xc3faHtcbqbY6QSt0/t86mCONWNdxUOdapY3WFlOZAam6UQ8Py
quSFhjz614dDkfW/vzyEjsshR+5xhBRCCgAAulBICfVMae6CDDaHnEW4Cfra9Nt3B6xw9FvGh44f
OnTITrj2r5cXK3e9hIwMtVg85C1M8yCc0auv8vIyJsLJ5SGx+OqLviaf+wbe27dv7f8aPqXhTkKe
/com7vuT9DWnTOLTPy7nAPLc5Sa7r127tul4Kj9T14fIe5nz5CZhIEMyZniGeZtTvinCMP1rYsdS
9241reG+4chbORZQz6bCVFp8ZxOxehvLl9z7x+psGH5ILG65z0JuOdapY3WFVOhsQvepYmxrKJ+G
Orq46n2mzbF//37rgMId11xLvdNyjyOkEFIAANClQsoZTqtXr27ad/jwYft1XD1JEg6+9zaFI2NP
8wD0NVeGhHqlQuPETdyWx753795F4yHjQ/dyPVcagqT5Ic7dsTMAyyiLr9Z38d2f638dF/Lip+MK
X/fynQj4cXRGp+IiQai4hGnQWjT6Mi3PXXJuER6P5WfO9T6PHz+24ldxksErBwIxwzPM25zyTRGG
6V8TO5aTF62ktWhfu/NWYSgsxV+iyneEEKu3qXzJuX+szhaVs08sbrnPQpVyrFrH6gopIbGsMtGc
T5VPqgfcRz3zcraja/S+Cr3uKW927txpj8u9ugRileMIqe659+vXr7EyyGugzGC8CqluaMgAAGJI
2JQNt4TuFVI56+e1mp7wI8Vw5kO7wh6ri8uXfRCqe+/RqLPhh7AyNBpA87hbCaMTqFJm+rjmf+QG
QEgBAIwC6m2UAw23ZpV6lGLOaaB7hVQ3p3u8Cal25PVolpemAeQOM5YnVX/ubZ0wxlpdU3r9Bd4B
xpWQaseXIgCAdiDvhmqQ3dA6DTX2l3MAhJTQOmH+F3ANbZXn2vBa7XdDuTWn9tGjR37j2tTLFfZ4
aL6e5jm64bNubq1Dc+k03FX1VIttx+JcJWzNi9QQes2TlKMTf53HKsNk9TFi9+7dNo4aJquFtMNr
lAYNo9Uw2H379jUdy7nep25e14l7lXSUxatK3ZdnVM3HTp3/5MkTO0S8lTB0XEO3NdXCFyexNOoa
eYnVhygd1/Bm9eb7uCkaqlcSdP4w9vCeRWUWy0ehdCv9AONOSAEAAEJqLAkpzdGT8xYZ3DIYNRfR
9QKUORfSkKtwIemY2NFwJWdshg5dQqcocoJURUjFwpazGLfYtnpny5zFpMSIFq53TmIUx56enqbj
mn+odLjeX4kVzc3MvT6kbl7XiXuVdMTilYPmbEoo59RLeRKWoGklDB2XEFJ63FzUVBrdmoKqUzpH
osv3aiwHQbq/c6Kj8CTWY/csWrMylo+hJ2UAhBQAACCkRklIpeZIyRiUwS2D0jfg/HP0hd2JktS9
Q0Pd/2IfHtdSDPKS65BDlypCKha2hFOdpTzCfepZ8L1+hnGU4R3exzeOU9eH1M3rOnGvko5YvFI8
f/68qYcp9axI3MtDaythFNWPVBp1jd9zOTg42DS3VE6HwmVs/GUhUnUyJx+dZ1oAhBQAACCkRllI
5SADUwahvzi7f62+nLuv9XKLX0VIxeIUDolPLRzd6sLj7QgnjKOOhyLVX3y66uLYdfO6TtyrpCMW
rxhaT06CzhfMqXqpYXO+4KkTRtHxVBr1OxRafh4WLSruH8/xpprKR91fQwcBEFIAAICQGgNCSt7R
1INTJqSE5n5oiJzmqPiOS1oRUlVFRicIqfB4kXFdZmjnlkudvK4T9yrpiMUrhtYUvHnzZqX0h3Gp
E0bR8VQay8RXnfyM7UvlY6zuAiCkAAAAIdUhQkoLJWveSDg3o+zaV69eRY3HKoalhjBp7o7j5cuX
bRNSWt+wztC+Dx8+DBl+6A/n0tAr/7gcBvz48aM0zqnrY1TJ6zpxr5KOWLwyDLBKLvjDHqk6YRQd
S6VR1yhtDq0FKkcd/vXh0L7U+nyxOBblo+Zu0SMFCCkAAEBIdbiQ0oR4OXjwDUV5RAuvVW+VW6w6
dOogo1fzQpyBWUXshM4mUm6tq4QtZxMaRiXkmbDM2YQ/+V+uteXAwj9+9epV6+TAxXHt2rVNx+WA
wDl00KbfSkfu9SFV8rrVuFdJRyxe7X5WJLD9BdDrhFF0PJVGXaPfyisdP3TokNm8eXPT9WfOnGlc
r48QEuyxe4ZllspHfUxgjhQgpAAAACHVAUIq9iW/r6+vyf25/pcxHoapoUiaaO/cjDtDUMhJhb7K
uy/zVYc6ydCXO2q555bji9hSIlXClhdCpU/xVdx9w9w/zxmzSpuMYqUtDLu/v9/OIVM8Fcfw+OHD
h23PheKu/HMe23Kv96mS163GvUo6YvGqWvdzvPYpru0WUqk06ppbt26ZWbNmWacQWjZCvVI+zv25
Nnnse/fuXfSeYZnF8lFcuHABr32AkAIAAITUeLh3O5H48b2kwfhEnvP8nqLx9BzJRb3EFgBCCgAA
EFIIqVLUU6JJ925dH33tz3ViAN2NvNq9fv16XD1HmsOmdAMgpAAAACGFkIry4MED69Zaw56mT59u
h1JJUAFo2OKmTZtG9J6xYaUjgdLrD7UFQEgBAABCCiEFAAAIKQAAAIQUAAAgpAAAABBSAAAAZUKK
xgYAALpRyNC2AQDAsAspGhwAAOg2EUO7BgAAIyKkGjvY2NjY2Nha3BBzAAAwroQUAGCcAfCsAgAA
IKQAMM4AeFYBAAAQUgAYZwDAswoAAAgpAIwzAOBZBQAAhBQAxhkA8KwCAABCCgAwzgB4VgEAABBS
ABhnADyrAAAACCkAjDMA4FkFAACEFADGGQDwrAIAAEIKAOMMAHhW4f/n9evXZAJlDl2Qb+O5XBFS
ABhnAOPuWdX+a9eudcWz3WqcR+v6SZMmtTXtI112v379MgsWLBiy//v372bjxo1m8uTJZsqUKWbL
li3m69ev0bDu379vNmzYkH0Pnxs3boyZelulzJWHDx8+TJ5Xlnfd9Ny241kZyXId7voYlrkVM8E2
YcKEynUJIQWAkAKATCG1fPlya6gipEbn+nbk9WiV158/f8zmzZsL73/s2DFz9OhR8/fvX7tduXLF
HD58OBresmXLzMDAQPY9HB8/fjRr1qwZM/W2SjyVH3pGUxTlHTZHd8cvVea3b99ueuZy6xJCCoCX
GgBkCqkLFy5Ygzd2voziadOm2Z6Fffv2NfbPmzfPfPv2zf7/4cMHe93z58/t7y9fvtjjZZSFqZ4L
/6vp3bt3zfr16+3/v3//Ntu2bbO9HAsXLjRPnz4tjHNRev19Mux3795tpk6dambPnm175XLTnHu9
j9IwceJE+3V4yZIl5tGjR/8zPrytHXGvko6yeOW+3yVeJGKKzu3t7TVv3rxpEkSuHIt48uSJvabK
PRzr1q0zb9++TcZZx589e2ZmzpzZZFDG8kjXXL582cyYMcMe37Nnz5APDwcPHrTHVC8V30+fPpXe
s6jMY+Xg8lL5k5t3uc9lWX6k0nPp0iUzd+5cG1/F+969e0PqnOrn9OnTzdmzZ6PlEtbdsrCL8i2n
7Fz6JDrmzJkzpOz0TlGe54ZXJX5hulvN15znxX9PLF261Pz8+TNal9plxyGkABBSAONSSIkVK1YM
adQd58+ftw28GmYZwzLcT548aY/9888/5ubNm/b/69ev26EtOt/9lugpIhbm58+fbXx0TEbP/Pnz
G19djxw5YodwiTt37phFixbVElKnT582J06csPfQcLOenp7sNOdcH+IbRRqOozSVxbXVuFdJRyxe
OTx48KA0zjKkdd9wXxl79+61gqXKPcTx48etsZ7TJum4hJDipXqWk0e6Rka4ng+dI0NbcXWcOnXK
3t/1vCk8v94X3TOMZ6ocLl682HTPVN7lPpdFcctJj4aIufeF4q34O5SXBw4caNTPVatWVRJSsbDD
cHLKzk/frl27bPp89DypTHPDqxI//3er+Zr7vPh5U9QDnKpLCCkAhBQAVBRSjx8/tj1BRefLiAwN
YmfoqSGXcSJ27Nhhtm7dajexffv2wvlXqTCdESADR0aM3+hLOIXX1RFS+vquL9GOFy9eZKc55/oQ
fRF3AjBVNq3GvUo6YvFqtX4VGYExw1Di2e/ByrmHeln8r/I5Qsr/YJCTR7rG7/kcHBy0PRuOxYsX
N5WH/lfvVeyeYTxT5aB8Uf7k5l3uc1kUt1bTs3LlStvrlftshHU3FnYYTk7Z+eHpg4zKzl2jv+qd
c+dUDS8VP/93O+pJledFvVHqjaxalxBSAAgpAKgopISElARVuF/Gb9kEZhkmarCFhse8evWqYWRq
6F1RQ54K0zeSZGi4IUopQ7yKkArDkfGUm+ac60PUy+B6NlLDKFuNe5V0xOLVav0KyzNVfhruVCaS
i+6hIUsSlb7RniOkqtZF/Q7j5acjlc5UeeaUg+6vIWG5eZf7XNYpt1R6QocLqWejynNb1JOXKruQ
1atX214ncfXqVdsL1Ep4uUKqHfUk93lR+ZeJpVRdQkgBIKQAoIaQ0jwU1/imDAAfzYPQEB5nqGmM
v756+l/tc4y1EHmjUg/USAipqmlOXV+E5mpoOKLm82joU7uEVCztOflcFq9W61fRML7Y0L5UXMN7
qGfFDV9rRUhVvW9YBlXKI7YvVQ6xul+UhpznMrcnsZ0fKdoppOqUnfJYYtKJTDd0tG54uUKqXfUk
J65nzpyx87GqvL8QUgAIKQBoQUgJfQ2X8wl/v4yNHz9+lIYtj2r//vtvY+iQG0bkfheRCvPcuXP2
q3E4nl8usOsM7XMT7h0afuQPs5GBWSXNqetjqHcg1/iqE/cq6YjFq9X6JUGgYXAOzXfTBPsyqvZI
Fbl6Dh0R5MQzlUe6RnnjkFt3XxDq+nDIlt8rU9VALioHzdep0iOV+1yW5Ucr6dHHGN/N/cuXL4dN
SOWUXRESlRo6HDrDqRNe7rPc7noSe15U9hKMRaTqEkIKACEFADWFlIxdDS8KJ0k75wba9Ns3iPX1
U0PwJH6EhJgaeTd8pohYmJoUrgnqvgEij2xCziY0DErIs1+Zswl/8r562jR8xz+uIT1yUuAmxK9d
u7ZSmlPXhyie8swmwknkyivNjXBGVqtxr5KOWLxarV+awO/fW6I4NnxQBrjm07TS3tTpkUrlka7R
b+W1jh86dMgaqv71egbc9XoO/DWviu4ZlnmqHCRGUnOkwrzLeS7L8qNqevx9obOJlFv6KkIqzLec
sitCcy/l8dJ3JFE3vFj8wmexlXyt8rxoXpdzHhKSqksIKQCEFADUFFKiyJW3vD/pK7y+oMqw9xtp
udL13Su7yeVO/JRRFmZfX1+T+3P97+YxSOjpuAxNTd72DQk/zs4Y1fAXGSsyUsM09ff3W0NTro7l
3KJKmnOu99GwLcXXuTV2RrMz6nQP93W61bhXSUcsXlXe70Xn6j4SeS5tGqqp3pwy1PPoPMuNpJBK
5ZGuuXXrlpk1a5Z1CrF///4h6XBurbXJE9u7d++i9wzLPFYOTgSlvPaFeZfzXJblR9X0hPsk9FU3
JVYUr9hCulWEVJhvOWVXhIYL6/yiBaKrhheLX5n787r5mvu8qA6V9VaFdQn35wAIKQDgWYUxjjzj
xYb+jednRy7uJbbGWt65jx+x+ZIwss9LWJfk1REhBYBxBgA8qzDG0bDS169f8+x4aA6c8mWs5J16
SjU/x63FpF6Yuk5MoL1lXlSXNFwaIQWAcQYAPKswxtGwxk2bNnVUnGLD0kYC5Yc/1LXT805e8OSW
Xvkmz4EaCilBBaP/vOTWJYQUAMYZAPCsAgDACLUxtDIAGGcAPKsAAAAIKQCMMwDgWQUAAIQUAMYZ
APCsAgAAQgoA4wwAeFYBAAAhBYBxBgBd8qx2mitqAABASAEgpACg45/V0PXzSD3z9+/fNxs2bGja
p/Vopk6daiZPnmz6+vrMly9fGsc2btw4xK1v0T4AAEBIASCkAGDYn9XwupF65rVo5MDAQON3f3+/
OXv2rF3kU9vx48fNmjVrGsd1rtau8SnaBwAACCkAhBQAtOVZVU/PlClTbE+PxMmnT5/+1zB6m9t3
5swZM3fuXDNhwgQzceJEuyikz7Fjx8y0adNsmPv27RsSj2fPnpmZM2eWipwnT56Y3t7epn3z5883
g4ODTft0bx9do2tT+wAAACEFMLoPTIGRBQBjS0idOnWqqafn/PnzZtu2baXX6beG3DmxJRHlCxpd
f+nSJRvWnz9/zLVr18zJkyebrt+zZ489/vnz58I47d2711y+fLk0LT9+/LBibevWrU37L168aK9N
7QMAAIQUAEIKAFoSUosXLza/f/9u/Nb/M2bMiAopJ6KKztGQPIkkH/Umxa4PWbFihXnz5k3hsS1b
ttieLm0vX75sOqZrdG1qHwAAIKQAOkZMAcDYFFIanhfi9zDlzJHy9+na8COLf4+c94WGGIZiLETD
EZcsWdK0T9dIYKX2AQAAQgoAIQUALQmpcJ5ReG5VIVUkzHLikRJ3IRo2WBT33H0AAICQAkBIAUBt
IaVenXBon+/yvKqQUniaw9SKkCrqkZJziq9fvzbF0x+C6MRV2PtUtA8AABBSAAgpAGhJSMnZhLzw
OWcT586dMwsWLGgSNZrT5MRWSkgpvBMnTjTC02/fTXnO+0Jzml68eNG0T0P5jh492gj30KFDdvPR
nKlwPlTRPgAAQEgBdKxxBgBj51l17s+1yWPfu3fvGsfkcU89VK6XKiWkxOHDh+3CubpGi+L63vly
3hnysifvfz7qWZK3P4WpeCrOIRcuXBjioa9oHwAAIKQAEFIA0HXP6tOnT5t6sXLp6emxa1Sl9gEA
wDALqSL3zmxsbGxsbFU3hFR15Eb99evX2efLzbmuSe0DAIBhFlJ8ZQcAgG4SMWOtXdNCv5s2bco+
X+c+fPgwuQ8AAIZRSCGiAACg24QMbRsAAAyrkKKhAQCAbhQztG8AAICQAgAAhBRCCgAAEFIAAICQ
QkgBAABCCgAAACEFAAAIKQAAAIQUAAAAQgoAABBSAAAACKnhpMqiiECZk1/EERBSAACAkGprA9Rq
OKN1/aRJk9qa9pFu0H/9+mUWLFgwZP/Pnz/Ntm3bbPpmzJhh9u3bZ75//x4N6/79+2bDhg2N34OD
g2bXrl1mypQpNpy+vr4hYRw8eNBMnTrVTJ482R7/8uVLxz8Q7SjzKnkUK6fU9bnhj2R+5dbxkXwW
qpTpxo0bWcgUIQUAAICQavX6dqR/tBrxP3/+mM2bNxfef+fOnebkyZPm79+/djtz5ow9N8ayZcvM
wMBA4/fevXvNuXPnGmFINMmQd/T395uzZ882jh8/ftysWbNmXBl8qTxKlVPq+pzwMVKrxVF1fPny
5bQMCCkAAID2CSn9f+nSJTN37lwzYcIEM3HiRHPv3r3G8d+/f9teDvU+LFy40Dx9+rQ0nNh9ZBDu
3r3b9mTMnj3bXLt2bcg1x44dM9OmTbNf4tWb4pNzvc/du3dtWpSmJUuWmEePHvkZ09jaEfcq6SiL
V65hINHy8ePHwnP1hV5x9eOtOJfx5MkT09vb27Rv+vTpTWFIEPhf/ufPn297THyUnlhFfPbsmZk5
c2aTIRvLI11z+fJl26um43v27LG9Oz4SFzqmeqk8+fTpU+k9i8o8Vg4pUnmUKqfU9TnhV8mv9+/f
2x4Z5ZXSrOf41q1blfLLT0eVd0Kr8Sp7N9UpU9V11XlASAEAALRNSMmYcYaoDBXfMD5y5Ii5ceOG
/f/OnTtm0aJFtYTU6dOnzYkTJ6yB+PXrV9PT09N0/Pz589Zo0nEZjhIr6l3JvT7EN7o0fE0CoCyu
rca9Sjpi8crhwYMHpXEOhZQM3pgBrp4PGboxFIYM7CJ+/PhhBdHWrVujFVEGtOL1+fPnrDzSNeop
U53UObqH4uo4depUU6+YwpNhH7tnmF+tlkMqj2LlVCWPc46n8mvp0qXm6tWrjfxS3vnh5eSX/7vK
O6HVeMXeTVXL9OLFi033B4QUAABAy0LK/5ofHpeR5BvnsXBix/WlWwah48WLF03HZXCF9/ENodT1
ITLInLGXaoBbjXuVdMTi1aoRITGh4Xy6v778y2jU1/kyVqxYYd68eRO9z5UrV6zhHLJlyxbby6Dt
5cuX0XiG9SuVR7rG7+VQD9icOXMavxcvXtxUHvpfvR65dbqd5RDLo1xjL3Z9zvFUfhXh14uc/Kr7
ThjOeFUtU9V11XlASAEAALRNSMWOp4Zt1Q1Hhlh4PByu4xtVqetD9EXafRE/evRoS0Iqde8q6YjF
q1UjQg4JJHAUBzk50L1iPVIaUlVmEItv377Z8NRrVIaG2GkYVZV4pvJIv8N4+WVQJA5jPRVF+9pV
Dqk8Shl7qetzyiCVX0JD9yTG1HsoIVrl2W3lnTCc8apapoqLhD8gpAAAAMa0kAqPx3pOcq4vQkaa
hh6tW7fOHDhwoG1CKpb2VDpi8Wq3EaEv8JrTVUYsrjLc//nnHzuUMYbOy60juXlUJr7qlEdsX6vl
kJNHsXJKXZ9bBqn80vBN9SJpaJuGHGr43kgJqeGMV50yjcUdEFIAAABtFVLq2agztO/Dhw9N+1au
XNk0HEtGvn9cvRqac1NG6voYr169isa11bhXSUcsXu02Im7evBmdv1TWI6VeELnfVj6EaPiUb9iH
w+py4pnKI12jvHGop813mqHrw6F9fs9brpBqpRxieZRz39T1ueHn5Jf+9/M7rN9VhVSVd8Jwxqtq
mUqY0iOFkOp2WF8NqJcAHSSkNOxGQ2aE1mEpm1juT/SWtzJNEvePa1K5XGU7hw1r165tOi4HAs6h
gzb99t1qp64PUTzlxUuEk9QlIDT3whnjrca9Sjpi8WrViFDYEk9CHtH0VV7zucrQfJHwuLyarV69
unRtKA3l07Apl75Dhw7ZrUo8U3mka/Rbee3u4btx1/luLpg2uQr312squmdY5q2UQyqPUulPXV8l
/Jz8ktc75w3PzRNKvQPC/KrzThiOePn7qpap5vIxR6r7hZT2y4HNeBVe7VwzL8R5xtTw2fFU/zqp
7rB+58iWiT4AOu+y+hCnofapUSKAkGraJ6cFWsNGL0/NYfANb/88Z7ho2JaMWr1ww7C1BpF6L+T2
Wp7WwuOHDx+2X6n1wKniOg9iudf7aIiP4uvcJjsDS8hDnO7hHuxW414lHbF4VXkxFJ2rspFjDDdH
KuVMQc4olBYfOQMI5y/599JXfXl4U9r0UpGwqvPSjeWRrpGBPWvWLNsDtn///sJFgZ2zCznZePfu
XfSeYZnHyiFVFqk8SoWTur5K+Dn59fjxY+vMQ+mU2FC9SL0Dwvyq804Yjnj5+6qW6YULF/DaN06E
lN6D4ZIJ40VIDWc6w+VRqOcIqZHMw9EoB3mb9T8ey/mT7BcY50IKQMijWicuptsJ9XbHjh008l0W
Ly1bILEF3S+kJJpTTobK1rKbN2+eHVor3HDT58+f29/qJdbxsvt2w5p5ZffL/XAUS0+VPPr586f9
qBTmh3qgnYOjMB6pvIrVodQaj/pYpyUbQvRxUfFUfMsM8aLyV8+GevT9+69fv76RRtbv7Iz1O7X+
oO/dWOXtygkQUgB2iEanjV3uhHobczeOMTv24qWGsFOGIyGkhl9ICQ3jLDOkY2vZycGLGyJ9/fp1
2+Ppeu7121+zLrzvWF8zL+d+qTKJpadqHmmeqOLko3UdFW4YnzpxL5ueULb2pIb1h0JUcd+5c2dh
fsTSpvSrjrrlSnS/gYGBRvvD+p2dsX6nhFw4J9if6wsIKRjn6OWyadOmjorTcI7x70Y6Nb86KV6q
4/7XX+h+IaWho/rqX3R+bC079ajIgBfqmZbDHue0Z/v27YXzr1z4Y33NvJz7pcoklp6qeSRhoevd
cf1Vj6DfS9ZK3P19OWtPOo+gPupZK1tLMVX+EgASDDL6fcHJ+p2ds35n0fxpvL8ipAAAALpaSAkJ
KQmqcH9sLTsZ724Il4YByQOkEwMaZlXmSbMb1syrc7/w3rH01MkjOd5Rb4OQ4yfNqS0Kr9W8yl17
Uk5yXM+Rm5ccM8JjaXMiQILPDSdNGeqs32kqPc9Vn4GqzwQgpAAAALpSSMkLq/PUWGW9v+nTp9vh
RE5AyXjW8FC/dyUnPmNtzbw696uSnjp5pHhLwDphqzXncgzvOnmVs/akPPi6HksNHdR8vCpGeMiG
DRtsD9RICKmqzwHrdxYP42NoH0IKAACg64WU0BdoGbtV1vuTm/5///23MaTPDe+LrcvXDWvm1blf
lfTUySMnZDUELnT0EZZplbiH69bF8sn/XwJbTiDkeETODUJnGFXSpqU71NumRcn9oX2s39k563dK
eGmIqkPl3YlOugAhBQAACKm2CykZPhrSU2W9P61Tp+FWMnSFhJiMZzfELDc+Y23NvDr3C/Mglp46
eSQ0h0ie23wHAmF4qbin1ouM5VMYb/VEad6lHGfEiKVNziZWrVrVJAbevn1r/2f9zs5Zv1OOTfyw
JXqrDg8EhBQAAMCYFFKiyG1zbC07LYrtuz13E92doVslPp2+Zl5I1fuFeRBLT508Ehr2pmPhQqhl
7s+L4p5aL7LKGo9yqKF9OR5vy9Kmtfh8Bzj6383/Yv3O9L1Hav1OhSMR5+KuoZjhMwoIKQAAgK4Q
UuQf6RluZFxruCEAIKQAAAAQUqSB9GSg4V3q/WB4FwBCCgAAACE1SnTbmnnjYQ1AzfXp7e2NOpkA
AIQUAAAAQgoAABBSAAAACCkAAACEFAAAIKQAAAAQUgAAgJBCSAEAAEIKAAAQUggpAABASAEAACCk
AAAAIQUAAICQAgAAQEhV5/Xr12QCZQYACCkAAIC4kPq/g4XbaDZso3V9OxYR9O89Ug384OCg2bVr
l5kyZYpNQ19fn/n+/Xv0mvv375sNGzYUHrtx48aYMU6qlNnGjRvNw4cPeSsAIKQAAABaF1Kd2LCN
1vXtyI/RaNT37t1rzp07Z/7+/Wu3gwcPWjEVY9myZWZgYGDI/o8fP5o1a9aMGeOkSjyV3uXLl/NW
AEBIAQAADK+Q2rJlS9MX/Lt375r169fb/3///m22bdtmJk+ebBYuXGiePn1aGG7RPfx9Mvx3795t
pk6dambPnm2uXbs25Jpjx46ZadOm2R6Xffv2NR3Lud5HaZg4caKZMGGCWbJkiXn06JGfUU09cq3G
vUo6yuKVU07Tp0+3cXH8+fMn2lPz5MkT09vbW3hs3bp15u3bt8l76vizZ8/MzJkzm8RJLI265vLl
y2bGjBn2+J49e8yvX7+azpEI1DHVKwm6T58+ld6zqMxi+SiUbqUfABBSAAAAwyakPn/+bFasWGGN
dBm88+fPb/RiHDlyxA4BE3fu3DGLFi2qJaROnz5tTpw4Ye/x9etX09PT03T8/Pnz5tKlS/a4BILE
ysmTJ7OvD5GRfe/ePfu/hrcpTWVxbTXuVdIRi1dVJHIlNspQD5YETcjx48fN2bNns+qGjksIKT2q
Jzlp1DXqCZM40jkSXYqL49SpU/b+rmdN4Umsx+4ZxjOVjxcvXmy6JwAgpAAAAGoJqdQcKRmzEgwy
iH0DVMLJ7wUpa9hSYkQ9CzL8HS9evGg6LsM7vI9vHKeuD5HAcAIw1SC3Gvcq6YjFqypXrlyxQrcM
ieM3b9407Xv+/HlTL1WOkPJ7i3LSqGv8nkvN7ZozZ07j9+LFi5vyU/+r9yp2zzCeqXxUupV+AEBI
AQAAtCSkcpCBLIP227dvjX368p/TsKXESBiODPHweCjyNGwr9/oQ9VK4npGjR4+2JKRS966Sjli8
qqAy0pBM9QiVoWFzvuD5+fOnFYVfvnypJKRCUmnU71Bo+Xnon1t0PFUeOfmo+2voIAAgpAAAAIZd
SMm7m3qgRkJIhceLjOsyQzs3XZpno+GImg904MCBtgmpWNpT6YjFKxeJp3/++ccOM4wRxmX79u3m
5s2blfKw6HgqjWXiq05+xval8jFWdwEAIQUAANAWISVvcJr3Es4tWbBgQa2hfR8+fGjat3Llyqbh
XBp65R+Xw4AfP36Uxi91fYxXr15F49pq3KukIxavHCRy5QJdcUwR9kjVcYNfdCyVRl2jtDnkol2O
Ovzrw6F9vtOMXCEVy0eJTXqkABBS0F5Y048yA0BIBWhC/6pVq5oMXXl0E5qDo2FUQp79ypxN+JP/
5Vpba/n4x69evWqdHDiHDWvXrm06LgcEzqGDNv2WN7fc60MUT3l2E4qX3zshgaE5OM6YbzXuVdIR
i1cKeaFbvXp109C8GJojpPlcrRgnRcdTadQ1+q280vFDhw6ZzZs3N11/5syZxvUS8RLssXuGZZbK
x5cvXzJHCmAcCCntl8Ob8Sa8Rit9Y3UdRoccavntTYyydRirhNEJhGXGWosANYRUrCdCaxH5D5X+
14PmXhg6LkNVTgJ8w9y/nzNmNexLLxgZuWF8+vv77Rwsuc2Wc4vw+OHDh23PhR563d95bMu93kfD
vhRfxUfxcka3kEMN3cO9XFqNe5V0xOKValDksKFKb5J6FhXXdgupVBp1za1bt8ysWbOsU4j9+/cP
WTjYuT/XJo997969i94zLLNYPooLFy7gtQ9gnAgpzf0Ml1igB6tz68BolY1GKuijXpV54+E6jFXD
6MQyY61FgIpCCsYn8pzn9xSNB2PLIRf1ElsA0P1CSh9OUk6Fyta+mzdvXmNesBvWLe+mQr3/Ol5G
aj08DZefO3du44OPG/ngx0kfpLRGoJaECOOcCr+d9/LpxnUYhfJQo05yzi1bh7FKGJ26DqNgrUUA
hBRkoC9qIz0+erTroeawKd0AMD6ElNBQ3jKhEVv7To57nBOe69ev215v15Ov3/4adz456+Gpt97F
KRyCrPjISY4bMq7h9eEw8VT47bpXSLeuw/jgwYPsely2DmOVMDp1HUbBWosACCnIQI3Opk2bRvSe
7RhD3wpKL+O/AcaXkHr8+LFdEqLo/NjadzKW5cBH7Nixw2zdutVuQp5Oi+ZfiVbXw5MTI3++a7g+
YU747bpXSLevw5hTj4vWYawaRqeuwyhYaxEAIQUAAAipxv8SUhJU4f7Y2neaL7J06VL7v4aLyQuo
M1wXLlxY6iG11fXwwg9O4fqEVcJv9V4h3b4OY049Dr3e1hVSRWU42uswunLAsy0AQgoAABBSFs1d
cV/Zq6zvp3lDGnbmBJTmGumLvd8TEDNe64ibnEXqc8Nv9V5FdOs6jLn1uM56iTnndMo6jGVhASCk
AAAAxqGQEuqpkPOJKuv7yQvbv//+2xjS54b3ud9FtLoengSfv6i6lmwI45wbfqv3itFN6zBWqcfD
1SPVKeswstYiAEIKAAAQUk2/5eFMQ7+qrO+nde00z0Rr2gkJMRnScgpQRp318Px9oQMIxSeMc274
rd4rpBvXYaxaj1PrMNYVUp2wDqMT08yRAkBIAQAAQqqJ0MW2iK19JzfQvttz5xDBLUxfRtX18MJ9
Ehhygy234PK+Fs5lyg2/Hffy6cZ1GKvW49Q6jHWFVCqNI7EOo/tYgNc+AIQUAACMYyHVLagnLTYn
a6zea6zS7eswstYiAEIKAAAQUmMS9dDIaYJbT0i9DHWdJ3TSvbqJbl2HkbUWARBSAACAkBqzaGFX
rbGk4VbyGqghXBI5Y/1e3US3rsPIWosACCkAAEBIAQAAIKQAAAAhhZACAACEFAAAIKQQUgAAgJAC
AACEFEIKAAAQUgAAAAgpAABASNHYAABANwoZ2jYAABh2IUWDAwAA3SZiaNcAAGBEhFRjBxsbGxsb
W4sbYg4AAMaVkAIAjDMAnlUAAACEFADGGQDPKgAAAEIKAOMMAHhWAQAAIQWAcQYAPKsAAICQAsA4
AwCeVQAAQEgBAMYZAM8rAACA17bQwgBgmAHwzAIAAFRsU2hdADDKAMbFc8vGxsbGxtbOdRKxCAEQ
UgAAALRvAFWfGbIAgIYGAACA9g0AIQVAQwMAAED7BoCQAqChAQAAoH0DQEgB0NAAAADQvgEgpABo
aAAAAGjfABBSAEBDAwAAtG8AgJACoKEBAACgfQNASAHQ0AAAANC+ASCkAGhoAAAAaN8AEFIANDQA
AAC0bwAIKQCgoQEAANo3AOCJAaChAQAAoH0DQEgB0NAAAADQvgEgpABoaAAAAGjfABBSADQ0AAAA
tG8ACCkAGhoAAADaNwCEFADQ0AAAAO0bACCkAGhoAAAAaN8AEFIANDQAAAC0bwAIKYAx09CwsbGx
sbF14wYACCkAAOiSDxcAAAAIKQAAAIQUAAAgpAAAABBSAACAkAIAAEBIAQAAIKQAAAAhBQAAgJAC
AACEFAAAAEIKAAAAIQUAAAgpAAAAhBQAACCkAAAAEFIAAAAIKQAAQEgBAAAgpAAAACEFAACAkAIA
gHEsoMINAAAAIQUAAICQAgAAhBQAAMDwiSkAAACEFAAAAEIKAAAQUgAAAAgpAABASAEAACCkAAAA
EFIAADBWxRQAAABCCgAAACEFAAAIKQBoxUBkY2NjY2NrdQMAhBTAuBJRAAAAtCkACCkAoMEDAADa
FgCEFADQ0AEAAG0MACCkAGjkAACANgYAEFIANHIAAAC0MQAIKQAaOQAAANoYAIQUANDIAQAAbQwA
QgoAaOQAAIA2BoBnjiwAoJEDAADaGABASAGMuUbu2rVrZuHChWbixIlmxowZZu/evebnz59Nxxcs
WGCP67wrV64UhrN+/foh99Dvsm0086FbGvyqaXn69KlZs2YNDwMAIKQAEFIA0Eojd+vWrUKRs2XL
Fnv8yZMnhccfPXrUCGNgYMD09vYWGvVlImrHjh0UyCgIqW4SkQCAkAJASAHAqDVya9eutfuPHTtm
f9+9e9f+njx5sv3d19dnf+/evdv8+fPH7Nq1y/7Wfj/cFStWZBnpR48eNdOnTzc/fvxIGvvPnj0z
M2fONKtWrWocu3r1aqN3bMmSJebOnTuNY/fv37fX/fe//20Kb/PmzXa/jpeJiVi4ixcvtudLMIqz
Z8/a3/39/fb327dv7W9dlytewn3u97lz52yap02bZv8Pcce16f8wnA8fPtgeJ5Wf0rJ8+XLbC1Um
anPSDwCAkAJASAHQyAXI6J46daoVSUJ/dd68efPsb4ke/R4cHLS/JYD0W/t9ofL9+/ekkPr8+bM1
8J1oSwkptzlh5EReuDmhIObMmWPFgOIjvn37ZiZMmGBmz55dKmJS4R45csT+PnPmTJO4dGLSCavD
hw+3LKTC7caNG41zNKQyNUxSwik8puGYMSGVk68AAAgpAIQUAI1chIMHDzYZ8BIhRSJAYiVHMPgc
OHDAhvf169csIbVv3z77W70sYvXq1Xb/vXv37G8NLwx7xyRmfNGjv/p96NCh0nimwn3+/Ln9vWHD
hoZYmzRpku0VEps2bWr0oLUqpPbs2WN/669+Sxg5li1bZvdpDpvQ31iev3//3h5TXGNxyclXAACE
FABCCoBGrgQJF51z+vTpxr4yIeUb5zlC6vfv32bKlCkNMZIjpD5+/Ni0X/cs6jlRj5pDossXIEuX
LrW/NfyuLJ454c6aNcuKxy9fvjREhv5++vTJ7vd7vFoRUuq1EwrXH2Lpl4U7R/lTFLZ6kiRanfAq
uk/VfAUAQEgBIKQAaOQCNAxu3bp1TfN+HJqro/1uqNyvX7/sb3n3qyKk5PkvFGlVhIeQYCky+CUw
fNy8L+dIo6enJxp+Trg7d+60+/79999G75NzmuHmkOWmR6KyTOC4eVhFQsoJHje/rEhIuXlT6plT
WDlCKjdfAQAQUgAIKQAaOU9EuV4bCY8Q56hBTiaEBIPv1S9XSG3dutUee/DgQW0h5eb/aE5PDDlO
0Hlz5861fy9duhQNPydcDXvTORKWbkifeqGc0HSOLIpwQkVh/P37t5GHRQJHQk3nuN5B39HGypUr
G+cI5/jDD0e9SPqtnjnnfKPoPhLEbt5bbr4CACCkABBSADRy/8f+/fujDgwkfFLuz3OElDzC6Zh6
Y+oKqevXrxfGRb1pPnKY4ZxkqEdHoiEWfk64EjcamujPHZKY1G/t1/Ey1COWchJRdvz27duNc27e
vJkMR05C/P0uzq4Xy4lLXwzn5isAAEIKACEFQCP3f2juT8o4dwvyap/+li3IGxNSrlcmN55l56p3
adGiRXbYmXqD1Lvjhh36OEcMrvcmFX5OuE44ueGJzltfUe+cj4bYqddHYc+fP7/J+14YJ8VDPV4a
Onn58uUhYV28eNHGT+XmHGn44Wh+lNy1K7+1QPK7d+/scQlmoV5HN9/L7+3KzVcAAIQUAEIKgEYO
OqpsKB8AoI0BAIQUAI0cIKQAgDYGABBSADRyMHzII1+RS3kAANoYAEBIAdDIAQAAbQwAIKQAaOQA
AABoYwAQUgA0cgAAALQxAAgpAKCRAwAA2hgAhBQA0MgBAABtDABCCgBo5AAAgDYGABBSADRyAABA
GwMACCkAGjkAAADaGACEFACNHAAAAG0MAEIKAGjkAACANgYAIQUANHIAAEAbAwAIKQAaOQAAoI0B
AIQUAI0cAAAAbQwAQgqARg4AAIA2BgAhBQA0cgAAQBsDgJACgNFp5F6/fk0GQtdBvQZASAEgpACg
diP38+dPs3fvXjNjxgwzceJEM3/+fHPs2LGmcyZNmtTW+w9Xg9uucFsNZ6SvP3jwoJk6daqZPHmy
6evrM1++fGkq323bttkyVBnv27fPfP/+PRre/fv3zYYNGxq/f/z4YeMUbj7Xrl0z8+bNs/dZsWKF
efXqVcc/E+2o10XcuHEjWoZlx2PlmFMG3WQ8D2faMPjJVwCEFAC0pZHbunWruXLlivn796/9/fv3
b2vQaWtnAzmWGtmxJKT6+/vN2bNnbflpO378uFmzZk3j+M6dO83Jkycbx8+cOWM2b94cDXPZsmVm
YGCg8fvOnTvWsC/j+fPnZuXKlebDhw/2HlevXjWLFi0al4bfx48fbf6XhV12PFWOqTLAeMbgJ18B
EFIAMMKNnHqhQtSLMX369MZ14RfworD8fTIEd+/ebb+uz5492/ZWxHqk1AM2bdo0M2XKFNtj4nP3
7l0bxwkTJpglS5aYR48eZaVR/1+6dMnMnTvXXqsw7t271zguwaieGn39X7hwoXn69GlpOK2kNZW+
qnkVoh7EwcHB0jJVr4sTye5+ulcZT548Mb29vU37ZNRLgJUhMS4hUKUuPnv2zMycOdMsX748K590
zeXLl22vmo7v2bPH/Pr1q+kciX8dU5lKhHz69Kn0nkX1ukpdK2PdunXm7du3peVWdjxVjqkyyMnj
9+/fm40bN9r8Udiq97du3cp+ZnLqeqoMLl68aMtQ75fr16+bU6dO2fDCe/nhpsqllecLEFIACCkA
qN3IqedAPRYSFrnXpsTF6dOnzYkTJ6wR8/XrV9PT01MqDs6fP2+NN537588fa+goPr4x6QwsDTmT
wZkrpGQ0OkNOYfiG6ZEjR+wQK6Gv/X4PShUhlUprKn2p66ug4V8yKiVsyoSUyjk2pE3DPCVYfNSD
JXElY1UGqd9bKWR4V5lvpPRJCClenz9/zsonXaOeMpWnzlE6FVeHDHK/R0fhSSjH7hnmc5W6VoTE
juJQVm9Sx2PlmCqDnDxeunSp7S10eaS4SGjlPjOpuppTBtu3b7fle/v2bZsO9Zjqd3gvP9xYuYzk
8wUIKQCEFACNXBMvXrywhomMFc2LuXDhgnn8+HFLQkpfwH1hpnuUiRMZx76hL3xDSYaeEzxV0qj/
/a/h4XEJp/C+dYRUKq2p9KWuz2XLli32i7y2ly9fNvbLkFVPhuKgHhyJD33ZL0Pzm968edO0b9as
WXb4p1A4qiMSor6hKwNXPRxufk9sHlZR2aTySdf4vYbqvZkzZ07j9+LFi5vyUf+r5yO3PlStayEa
3uj35IVhp46nyjFVBjl5XIRfF1J5lKqrVctAvyUaU89drFxG6vkChBQAQgqARq4UDQPS11t9kZZh
7A/VqiqkwuGCMnTKjCSdGw6z8o07GeiuN+Lo0aOVhFSVOLYrnDCtqfSlrq+Keio0/MkhQSPjXPdZ
sGCBzc9Yj5SEUJnA9OMow97Pj127dlmj2PVE+L0pOXUxlU/6HcbLz7sicVjWw1G2r0pd89FQWBns
vnMIP+zU8ZxyTJVB7vOu51wCTOUj4dPOul61DGK//f9j5TLSzxcgpAAQUgA0clE0TCvsDWhFSMWM
pFjviG/8afid5pccOHCgo4VU1fSlrq+KhjfF0qbeJs0VKSOnPMLzNETL/+ovYzUm1orSl7pvmfiq
U+di+3Lrmo+Gq928ebM07NTxOuWYyrOi8DVkUz2xmqf04MEDO+SvnXW9ahnkCqlYuYz08wUIKQCE
FACNXANN+i7qgdDQolwDSN7a/H3y4OYb1jLey4wkfXX3h/fEkEvtWGNdxShU70ydoX1V05pKX+r6
FBr2pLkfjnA4VYgM+lhvUVGPlMJTr4p/Dw3jc6xfv77pfF2vcKrUxVQ+6Rrfpbp62nynGbo+HFbm
i7lcIZVb18Jwyrac4znlmCqDnLQpv/w8DutyKo9y6nqVMqgipMrKZbifL0BIASCkAKC0kdMQIk0S
l1tmoXk0mlOjieq+ca25Dc4g8Sd/6zoNB/TD14R2Tax3E7zXrl1baiTp3m4yuDb99t0+6wu6vHaJ
cEJ6K0JKw5s0ZEg8fPiw1NlEq2lNpS91fQqVn4Y7ufAPHTpkNz//XG+IvLbpi77miZShOVLh8f37
91vnB+4emsx/7ty5xnHNX9Hmu1hXOFXqYiqfdI1+K49cOn037jrfzQXTpvhJLMfuGdbrKnWtVaOy
yNtdrBxTZZBzfzkFcV76JChURlWemZy6XqUMcoVUrFyG+/kChBQAQgoAoo2cDDQZPBomoy/fMur8
r7gy2vRl2X1ddsaMztd1MnKK1sVRWPIypjkzMYPt8OHD9mu5wpdQcV7GhIb0aC6Hc8fsDKpWhZQE
o5wiKEyF74sH/7xW05pKX9W8CtEQMIleha1exNCbm9Kl+TlujlTKmYKcUSgOPsoreVfTPdSDKcM1
RAa0elVcGuXiu2pdjOWTrpEI0Lwg3UfCInRo4Vxva5OTjXfv3kXvGdbrVF2rYihWFVKpcswpg9T9
5UTGOZaROAkXBs7ptUvV9SplkCukUuXSyvMFCCkAhBQA0MhBW5BnPP+LPvX3f+zYsYMKAkAbA4CQ
AqCRAyhG3tGqrAs1XupvzN04AG0MbQwAQgqARg7GORrOuGnTpo6KU8wLIADQxgAgpACARg4AAGhj
AAAhBUAjBwAAtDEAgJACoJEDAACgjQFASAHQyAEAANDGACCkAIBGDgAAaGMAEFIAMLYauU5znT1W
4wgAQBsDAAgpgHHUyIWuqnPvPZpxjLFx40bz8OFDKhEAAEIKACEFQCM3vhvUKnEcGBgwy5cvpxIB
ACCkABBSADRy/9t/+fJlM2PGDDNlyhSzZ88e8+vXr8bx9+/f2x6ZyZMnm4kTJ5qFCxeaW7duNV3/
7NkzM3PmTCs29Nvfwnv//v3bbNu2zYansJ4+fVoYx3bE69KlS2bu3LlmwoQJ9hwtNOuOhXG8e/eu
PUfnLlmyxDx69Kgpn3p7e82TJ0+oSAAACCkAhBQAjdz/279s2TLz6dMn8/fvX3Ps2DGzd+/exvGl
S5eaq1ev2mPazp49a0WTf71Ejo59/vy58F7+7yNHjpgbN27Y/+/cuWMWLVpUKqRajZeElq4XElES
SmX54Qut+/fvm/nz5zcdv3jxYtP9AQAAIQWAkAIY50LK7xUaHBw0c+bMiYalXhv/eidWyu7l/5Zw
kvBJxXG44xXGUSLMCbwi3rx5Y1asWEFFAgBASAEgpABo5P7f/lDY+D03QkP31JO0detWs3jx4qgg
SQmpMOyY0BnOeIXH1QvlesGOHj065FrFRUMMAQAAIQWAkAKgkSvc7wsWzVNSL5KGtj148MAO3xsp
ITWc8So6LmGm4Ybr1q0zBw4ciN4fAAAQUgAIKYBxLqRevXrV+P39+3czderUxm/9/+PHj8bvDx8+
tCSkFixYkD20bzjjFWv0dd/w+J8/f+iRAgBASAEgpABo5P63f82aNebr169W4Bw6dMhs3ry5cVxe
75w3PDdPKCVI5ElP85PkoS88R0PxNIxOaG2mmLOJdsfL3xfGUfGQ5z4ROqYQL1++ZI4UAABCCgAh
BUAj97/9EiSzZs2yDhf2799ve38cjx8/th7sJCwkNuSQISVYTp48aRe8dYve+ufIhXlfX58NT/Oa
Xrx4USqk2h0vf18YRw3rU3ycq3QnqhwXLlzAax8AAEIKACEFQCPX2Y1fp8Wrp6fHii0AAEBIASCk
AGjkEFIZaOigvPkBAABCCgAhBUAjZ3FD2zqNTorXpk2b7HwuAABASAEgpABo5AAAAGhjABBSAEAj
BwAAtDEACCkAoJEDAADaGABASAHQyAEAAG0MACCkAGjkAACANoY2BgAhBUAjBwAAQBsDgJACABo5
AACgjQFASAEAjRwAANDGACCkAIBGDgAAaGMAACEFQCMHAAC0MQCAkAKgkQMAAKCNAUBIAdDIAQAA
0MYAIKQAgEYOAABoYwAQUgBAIwcAALQxAICQAqCRAwAA2hgAQEgBjI9G7vXr12QgdDXUcQCEFABC
CgAqNXI/f/40e/fuNTNmzDATJ0408+fPN8eOHWs6Z9KkSW29/1hqcFuN62hc/+vXL7NgwYIh+wcH
B82uXbvMlClTbJn29fWZ79+/R8O6f/++2bBhQ/Y9FN9wmzBhQseXc5U6vnHjRvPw4UNeKgAIKQCE
FMB4buS2bt1qrly5Yv7+/Wt///792xw8eNBu7Wwgx2ojO9aE1J8/f8zmzZsLr5NgPnfunC1rbSpj
iakYy5YtMwMDA9n3CLl9+7Y5fPhwV5Wz8mP58uW8VAAQUgAIKYDx3MipFypEvVTTp09vXOdvZWH5
+2Sk796920ydOtXMnj3bXLt2LdojpR6wadOm2Z6Sffv2NR27e/eujaN6NZYsWWIePXoUTWdZWFu2
bGnqRVC469evb4jHbdu2mcmTJ5uFCxeap0+fFsa11XSn0lo134pYs2aN+fjxY+G5KlMnmJ0givXE
PHnyxPT29la6R5iepUuX2voUq5fPnj0zM2fObBInsXzSNZcvX7a9qDq+Z88e20PmI5GoYypTxffT
p0+l9yyq46l6p3xR/gAAQgoAIQUwThu5RYsWmZMnT1oxkXttSlCcPn3anDhxwhrSX79+NT09PaWC
4Pz58+bSpUv2XBn2Eg+Kjy/07t27Z//XMDMNPSwjFtbnz5/NihUr7DEZ3QrH9bQcOXLE3Lhxw/5/
584dmyd1hFQq3am0pq7P4cGDB9lGjcpcYqIM9WBJsNS9h9Kb6o1SGBJCSrPKKCefdI16yiSOdI5E
l+LqOHXqlDl79myj503hSSjH7hmmJVXvLl682HRPANoYzDoAhBTAOGvkXrx4YY1EGY6aC3PhwgXz
+PHjloSUvvL7wkz3KBMkMoj9XhLhG60y9J3ISZEKSwa1xIqMct8IlnAKr6sjpFLpTsUvdX27jRoN
6ZSILEPC882bN7Xvod6oDx8+JOPp9xbl5JOu8XsNNfdrzpw5jd+LFy9uykf9r96r2D3DtKTqnfJF
+QMACCkAhBTAOG/kNNRJIkMT6SWq+vv7awupcLigjOIyQaJzY84J1BvgeiCOHj0aTUMqLGeky6j+
9u1baXzrCqlUulPxS13fzvJW+jXcUT0+ZWhYXJnATN1DvX05QqMojFQ+6XcYLz/vipxb+MdT5ZhT
73R/DR0EAIQUAEIKgEaugVxBhz0ArQipmCDJ8egmkachd+vWrTMHDvx/7J1/hJXNH/f/SJKVRFaS
lSXJWiuR3JKsWEnylUhuyeMRuSVJIllJEkmSJJLcVrJkJbmtSJKsWyRJbomsJEmsJEnm8R7mPHNm
r2tmruuc/VWvF8fuuX7Mj8/MOZ95XzPzOUdLr8tJS7NumoGaDiFVta6p+9vV3hJPf/75p10+GCNV
3lgeFy9ebApYUiWNOvn6tqvS/2LHUv0u1m8A8DEAgJAC+MWdXBiAwOE/bU8JKS3f8o9t2LChaWmV
lkGVDWS1kX9iYiKrDs+fP48661RailinvTfh/haF8a6ztK9qvVPlS93fjvaWgFQI9NSSO9HKjJSi
+kmE1Clnyk66R33BoRDuCtDh3x8u7fODauQKqVi/kxhlRgoAIQWAkAL4jZ2cZg20OV9R2IQCMWg2
QZvx/QG19pS4wam/EV/3aTmgn/7Q0JA5ffp0I2hCf39/qSBR3i7Agl56ryhrDs0eKYKaUJ6xWYBY
Wgoq8McffzQNtv/77z/7v/YJaSmXUGS/smATrdY7VdfU/a22t6LMbdq0yXz48CErDS3N0z6tOgMn
zWi6QA5Vy5myk+7Re9lI548fP26Fm3+/+rC7XwLa/82rojzDPp7qd8+ePWOPFABCCgAhBfC7OzlF
PdNAU0uqtH9I4sp/oq/gDHqi757qu4Glrtd9GnCG6WuPldJSCGsFeYjN7Ciym2YUlL7EiT8A1/Iq
BQ9QXsrTDW7LKEtLv5fkhz/X/zrvxKPOK33l5YsHv6yt1jtV16p2q9reCshQ9IO5ZWjWTmWo06dk
p9hsViqNmJ10z8jIiFm2bJkNCnHkyJFJPyzswp/rpYh9r1+/juYZ9vFUv1NQFqL2ASCkABBSADg5
gEkoMp4/E0Rf/v8oNL3EFgDgYwAQUgA4OYBJKGqdgo/Ql/8/2rsmuwAAPgYAIQWAkwMoRMsZd+zY
MavK5AeOmAlkD3+ZKADgYwAQUgA4OQAAAHwMAEIKAHByAACAjwFASAEATg4AAPAxAAgpAMDJAQAA
PgYAEFIAODkAAMDHAABCCgAnBwAAgI8BQEgB4OQAAADwMQAIKQDAyQEAAD4GACEFADg5AADAxwAA
QgoAJwcAAPgYAEBIAeDkAAAA8DEACCkAnBwAAAA+BgAhBQA4OQAAwMcAIKQAACcHAAD4GACEFADg
5AAAAB8DAAgpAJzcXOPFixcYAQAAHwOAkAKAak7uy5cv5tixY2bZsmVm/vz5ZsWKFfb9xMTEb+GI
FyxY0NayT3c9vn37ZlatWkUnBwCEFABCCgCmy8l9//7dbNy40Zw5c8Z8+vTJHvv586cZGxszW7Zs
mXYxNVcHADM1iPjx44fZuXMngxgAQEgBIKQAYDqdnATU+fPnC8/duHHDDA4ONqVx/fp109XVZebN
m2dnr/7555+me06dOmUWLVpklixZYi5dujQpX810dXR0mIULF5rNmzebd+/eFZaxHXn53Lt3z6ah
tHp7e83Dhw8b+fivMlv5xyQ0//rrL5v38uXLzc2bN6MzUirn4sWLbb0PHz6cVa7cgYlsOD4+ziAG
ABBSAAgpAJhOJ9fX11c66/Tx40fT09PTlMb27dsb4kfCRiLAIeFz9OhRKzR07x9//NGUrwSbBI/O
63XlyhWzd+/eUiHVSl4hvhAbHR013d3dpbZJCakLFy5YAery1oxemZBSHVVWXavZI4mus2fPZpUr
h/v37zOIAQCEFABCCgCm28ml9gf555WGP4MUprthwwbz4cOHxvunT582nZco01JCh/5funRpqZBq
Ja+Qzs5OMzw8nGWblJBat25dUz3CvP3/165da0WUjy+WYuViEAMACCkAQEgB/CJCKpZumJYEhH9e
y9dC/FmmVMCGKnmFaLZH5yVsTp482ZKQ8stclHd4bbh80LdDrFwMYgAAIQUACCmAWerkNIBX1L4i
vn79avfttEtghOdj4qnVvIpQAI27d++agYEBuyywXUIqVvYi8ZhbLgYxAICQAgCEFMAsdXLat3Tx
4sXCcyMjI+bEiRPZAmP9+vV2z5Dj2bNnTeclysKlfWUzXq3mFeP58+fRvML3b9++nbSs0K/Hy5cv
S9NTnXMjH4blYhADAAgpAEBIAcxSJ6cACP39/VZMuQG/ZncePHhgtm7daj5//pwtbsIAEIooFwab
UD4u2MTly5ebfv+oipBK5RWyZs0aGyFPhIErFEFQ+7GcOPIDQCginoJe+GkPDQ2Z06dPN/KW/crK
rjq7wBR66b3KmlMuBjEAgJACAIQUwCx2cvpBV808KdS4+0FeiRRfROWIGyGBoVDfCguuiHXhXiYX
/lwvRex7/fp1LSGVk5ePls8p2IULpe7Ei1AUPd3r7neCRtdK6OnaMO9z587ZQBnKX3nHyi7bKlS6
0pcoe//+fVa5qgxMGMQAAEIKACEFAL+Ik5NAkyj71fICAACEFABCCgAn1zY0Q6OgCe43kzT7VDd4
wmzKCwAAEFIACCkAnNyUoR+H1W8saQnbkiVLzJEjR6zImet5AQAAQgoAIQWAkwMAAMDHACCkAAAn
BwAA+BgAhBQA4OQAAAAfAwAIKQCcHAAA4GMAACEFgJMDAADAxwAgpABwcgAAAPgYAIQUAODkAAAA
HwOAkAIAnBwAAOBjAIBPHABODgAA8DEAgJACwMkBAAA+BgAQUgA4OQAAAHwMAEIKACcHAACAjwFA
SAEATg4AAPAxAAgpAMDRAQAAvgUAEFIAODwAAMCnAABCCmDuOz5evHjx4sWr1RcAIKQAAAAmPXAA
AABASAEAACCkAAAAIQUAAICQAgAAhBQAAABCCgAAACEFAAAIKQAAAIQUAAAgpAAAABBSAAAACCkA
AEBIAQAAIKQAAAAhBQAAgJACAABASAEAAEIKAAAAIQUAAAgpAAAAhBQAACCkMAIAACCkAAAAEFIA
AICQAgAAQEgBAABCCgAAACEFAACAkAIAAIQUAAAAQgoAABBSAAAACCkAAACEFAAAIKQAAAAQUgAA
gJACAABASAEAACCkAAAAIQUAAICQAgAAhBQAAABCCgAAEFK4KQAAQEgBAAAgpAAAACEFAACAkAIA
AIQUAAAAQgoAAAAhBQAACCkAAACEFAAAIKQAAAAQUgAAAAgpAABASAEAACCkAAAAIQUAAICQAgAA
QEgBAABCCgAAACEFAAC/loAKXwAAAAgpAAAAhBQAACCkAAAApk5MAQAAIKQAAAAQUgAAgJACAABA
SAEAAEIKAAAAIQUAAICQAgCAuSqmAAAAEFIAAAAIKQAAQEgBQCsDRF68ePHixavVFwAgpAB+KxEF
AACATwFASAEADg8AAPAtAAgpAMDRAQAAPgYAEFIAODkAAMDHAABCCgAnBwAAgI8BQEgB4OQAAADw
MQAIKQDAyQEAAD4GACEFADg5AADAxwDwmcMEADg5AADAxwAAQgpgTjq5jx8/mgMHDpjFixebBQsW
mL6+PjM8PDzn6/srOvYnT56YzZs3T4mNpstm//zzj1m1atWM2atqPWeqL9Vp69WrV5vR0VG+8AAh
BYCQAoCpdnJfvnyxg1o3WPRfc11M/art2K4By0wJhLVr15r/83/+D4J6Csr+f//v/7UPQgAQUgAI
KQCYYic3ODhoz+nJ94cPH8y3b9/M//73P3usp6en6VoJKx2bP3++ffI9MjJSOPC7ePGind1auXKl
efXqlTl06JC9p6uryzx+/HjS9ZcvXzadnZ32Hv3v8/btW1u2hQsX2jTWrVtnn9SHaYyNjdk0/vjj
j8JB6MuXL83GjRttGkpLaY6Pj9eqn67TeVee58+fZ+eTGhzH7i8Su2VpFh1zdtZL/+fMSA0NDVmh
rfL09vaau3fvZpe3CLW/8rh58+aU94Mq9rp+/bpZvny5nZGVyPvx40epXdpZ3rK+VFb2lL1lV137
6NEjvvQAIQWAkAKAqXRyGhzrnAZoDg3M+vv7mwZ+Wo5VNLh78ODBpMGh/3Lp++9j14czYRpchuc1
8CxLQyKwaPArgRReu379+pbrp5fKmJtPSkjF7m9FSP3999+l5S+75969e4XX+/0iVd8QiepwoD9V
/SDXXsonvO7kyZNJIdXO8oZ9qazsKXurbXRMS3UBEFIACCkAmEInpyfbOQ5QT7513f79++3Tev3V
+02bNk0aHGoW482bN433N27cMP/995/9X/mF1x88eNC+199QmPi4NDVrEKZx+PBh+14zAUWD33nz
5tn3ZbMlVeq3bds2e41mrMLypPJJkbo/d/YpPKbldHovIeMLmpiQUt31XiJTPHz40L7ftWtX7fo6
gaGZz5noB0XHNmzYYN9rtk0zqPq/u7s7KaTaUd5YXyoqe8resqvOq70BEFIACCkAmAVCSgM8Xff9
+3f7Xn/1XsuLwoHfz58/o+/D69+/f2/fv3v3blKaQk/Zjx492hADRWmEA8vwOi3X0nsNRLXsSzMO
nz9/rlU/lbNuPilS99cVUm4A7mwte6WElLNJ+Fq0aFHt+sqeZWWdjn5QdCz1GZjKfhvrS0Vlz7F3
UVkAEFIACCkAaLOT03IjnfP3+bj9Hf4SrlBo6JoyoVH1vWYBygakbi/PiRMnGrMFOZHmwuN66q9B
p2YAtBdG57R8sZX61cknRer+nDI4EVgkiiYmJrKFlBMY4UuD+Lr1LRIt09kPYvV0gj9XSLW7vDnX
5Ng7nPkFQEgBIKQAYAqcnJ6Yu8GYwqArit+OHTvsMT/6l1vmpSVvGnC6pW9+eOa6QkpP2ZWmlmXp
vQsYITT7oWMSNgrr3MoA2vHp06dJg8069auTTxWK7nf5aQnX169fm4SAluCp7H/99Vfp8jUXLU97
aFK2dMvwtFeqbnlDYjNSU9kPfHuV2ebOnTvmxYsX9n8FkJjuflt2jV/2HHuHs4YACCkAhBQATIGT
07IgRdcrmnnwI7S5PRzhqyhoQNX34UsDWkdYto6OjqaZlVwh5QbL/ssf+NapX518UsEmUvcr8qE7
vnv3bntMUdxSgSRu375dOdjErVu3Cq8fGBjILm+IE6xFe6Smoh8U2Ssn2ITb/zSd/TY8VlT2lL0l
uMIHAAAIKQCEFABMkZPTTJSermuwp2VbmokomoXQgFNR9/QEfM2aNZOuqSukFHpaYaSXLl1qA1P4
aHmhC0m+detW8/r1a3vPkSNHKgkp7WfZuXNnIxy1xIC/P6VO/erkkxJSqfsl+JYtW2bPuQG0lo6p
zdR2CpLgR+jzuXbtmp1p0f0KUZ8zS6K2kS2Utu7VbJe/JyfHrj5u9kaBK6ajHxTZq+jaK1eu2Lxd
+HN/Bmi6+m14rKjsKXtL+CuNY8eO8aUHCCkAhBQA/KpObi7/WCrU499//7VtrtmuudoPZnN53Szi
06dP6WyAkAJASAEAQgp+JfS7R9qDhpBqP9r7puV/APgYAIQUAPzCTk7LqPzfzYHfAy3r07K3udoP
ZnN5ZVf/R6QBEFIACCkAwMkBAAA+BgAQUgA4OQAAwMcAAEIKACcHAAD4GABASAHg5AAAAPAxAAgp
AJwcAAAAPgYAIQUAODkAAMDHACCkAAAnBwAA+BgAQEgB4OQAAAAfAwAIKQCcHAAAAD4GACEFgJMD
AADAxwAgpAAAJwcAAPgYAIQUAODkAAAAHwMACCkAnBwAAOBjAAAhBYCTAwAAfAwAIKQAcHIAAAD4
GACEFABODqaCFy9eYIRfwEa/UztOV135bOBjAAAhBYCTm2K+fPlijh07ZpYtW2bmz59vVqxYYd9P
TEzM+rovWLBgVrbVVNe7SvrtttFU1GG2lXEq2y+sq59XKt9W2p3BNj4GABBSADi5NvL9+3ezceNG
c+bMGfPp0yd77OfPn2ZsbMxs2bKlZTE1mwTF79rmc2GQNdvKOJXliaXdznwZXONjAAAhBYCTm0Ik
oM6fP1947saNG2ZwcLCpHhJYnZ2dZt26dfbYmzdvzPbt283ChQvtbNbq1avNyMhIdt0189XR0WHv
37x5s3n37l00v9Cu/is3TdVr6dKl9pqDBw+ab9++FZZXInPv3r02HdXryZMnjXMzWe8wff1//fp1
09XVZebNm2fL888//5TaqG47xuwmTp06ZRYvXmzPHz58eFJ5wzz98tRpx7I655SnlfbLubdqe/j3
qp6u323dutU8ffq0tFxlNkrlE+vb9+7ds2VW2Xt7e83Dhw8n2UCz2Jq5DvuA0tU9dftELO+iNvGP
5ZQbHwMACCkAnFw0r7KBaRF9fX2ls04fP340PT09TWlrAK0Zq/fv3zfuHxoassf0unTpkh0Y5dRd
Ak7Xu3uvXLliB3ex/FK2zUlz7dq1dsCp8xroHTp0qDA9icjh4WH7/927d82aNWua7DZb6q3/NbB3
g2gN2jWgLCtL3XaM2U11kHjQuR8/fpibN2+as2fPRvOMLWnLsVGszqnytNJ+OfdWbQ///w0bNpgP
Hz7YtG/fvm327dtXeG2OjcryifVtX/iNjo6a7u7uQjscOHBg0kOYCxcu2L5Rt0/E8k4Jqdxy42MA
ACEFgJPLElEpMZXam+Kfd0/LU+iJcE7dJdL0BNuh/zXjUSW/MP2cNP2n71+/frVP1ovS0+BSg7xc
ZqreRdfHRErddozZTSIrtFU4CK5Sxjo28tNIlaeV9su5t2p7+P/7M1Cqg+pSdG2OjcryifVtiUIn
smK8evXK9gGXjv6uXLmyUfc6fSKWd0pI5ZYbHwMACCkAnNyMCKkitDxHT7j37NljB3e5m+f9wacj
9uQ+x7Y5aYaDu7I8/eOzud6pAWZsQF2lPjG76f+wz6WESayMdWwUtl2sPK20X517qwip3HpXtVFu
39ZsjpuBPHnyZNQOmzZtsrNOQrN0molrpU/E8k7ZtUq58TEAgJACwMlliahY/hp0aL9DEZp18Pc7
FKWjfTN6un3t2jVz//59u0Qnd0BaNJirMpgtuqZOmnWE1GyqdzuEVJ36+PUoGtRXGQS3ox1TIqNd
7Vfn3laEVNnDjKo2qvqQQEv+BgYGzNGjR0uv0zXaYyX0XSF7tNInYnmn7Fql3PgYAEBIAeDkssVU
GdrjcPHixcJz2kB/4sSJaD0WLVrUtMfq7du32QNSDbzCpUk5M2Ax2+ak+fz588b7z58/2zoUpbdq
1arS5U+zqd7tEFI59YnZTXWKRXisWsY6NvKPpcrTSvvVubeKkNKSOb/eZUtPq9oot2/7qM1T/VFB
NbQ3Ssv6wjas2idieYfXh3avWm58DAAgpABwci0JKW0C7+/vt2LKDXo0wHrw4IGNGKYBc6weGkS5
iGUvX74069evzx6QOhHnNstfvnzZDvCq2E1Rx7TPwg0oc9JUdDMF0tD548ePm507dxbmqaVbWi4k
ZA9/Q/5M17vKwD20Ud12jNlNdVIESFcnvdf1dctYx0ZhIIZYeVppvzr35raH/tfPDuinCFRu1SEW
bCJmo1g+sb6t/xUBT4SBMopQAInly5c3BZKo2ydiefvBJMbHx+0ywnDfV5Vy42MAACEFgJNLiqkU
CmGsmScNEN0P8mpZjC+iyurx6NEju4Fc92kgo83eVZapufDNeini2OvXryvZTYM3PYX3n8Sn0tQg
WD8+rM3pR44cKRWLssuuXbts3bQPxg8CMNP1rjJwD21Utx1jdhPqQ5qtUT4a5PoRB6uWsY6NwmOx
8rTSfnXuzW0P/a9odwoZrvMSVWHY99x+FMsn1re1PE7HXOh2J07KkOhTHhLZIVX7RCxvJ450ToJR
5/w0qpYbHwMACCkAnBzQFtgNgM8nACCkAHByQFtgNwDg8wmAkALgA4eTmzWkwr0DdgPAxwAAQgoA
JwcAAPgYAEBIAeDkAAAA8DEACCkAnBwAAAA+BgAhBQA4OQAAwMcAIKQAACcHAAD4GABASAHg5KAq
L168+CXymI15AwA+BgAhBQC/nJObrrK3I583b96YNWvWTEn5piP890yGGK+at9orfM2bNy96z+jo
qNm2bVvhueHh4cI+cPPmTbNy5UpbvvXr15vnz583zn358sXs3bvXnlu6dKk5fPiw+fz5c+P89u3b
zYMHD/gCAnwMACCkAHByCKkYFy9eNMeOHZuzdpjJftJq3nfu3DEnTpyIXrN27Vrz6tWrScfHx8fN
5s2bJ5Xh33//NRs2bDBv3741P3/+NENDQ01Cef/+/ebs2bP2nF5q/507dzbOK69169bxBQT4GABA
SAHg5KambDdu3LBP9Ds6OszBgwfNt2/fCsuuGR895V+4cKGZP3++Wb16tRkZGWmc//79u50h0Hmd
e/LkSVNep06dMosXL7b5aPYgLMe7d+8a92/dutU8ffq06RqJJN2r8xp463qf/v5+8/jx40Z6169f
N11dXXamROX9559/KqXnl81/uWNjY2Oms7OzabAeq2PMfmV5XLt2zbbNkiVLzK1bt8z58+fNokWL
CuuTsm+ZPcryzkUipq+vz84QlaF22bJlS+G5gYEB899//03Kc8+ePebcuXOlaWomSnn75ZBtfJSn
6xMA+BgAQEgB4OTaWjbNFEhEaCCqwfihQ4cKy67BsmYF3AzApUuXrJBwDA4O2iVa4u7du02zB1eu
XLEDed3348cPu2RLswl+Ppp9+PDhg73m9u3bZt++fY3zEhDKz+Wt9CS6HBJ/Eht+ehItThxJNEg8
5KaXakO9l+jUve/fv8+qY8p+RXnIBkpLMz4SCZqF0fuwPjn2jdmjlT6qvFOzUepTEuwhp0+ftnYo
KoNEX2zvViikJOTDJYoSon5/BsDHAABCCgAn17ay+TNHX79+NStWrMguu78vRsLJH9j6SKyF57q7
u5vy8WegdK3ucfT09NiBsj9o1kyNQ7M1f/75Z1N64QyTX5dUejlCKkw/VceU/VJ56P3ExETh9Tn2
jdmjlT4qgajldzG0v+nly5dNx7R0z5+lCssgoad9VZq50yzerl27mvZASfhqOZ/qLSEtwRTu01Ke
yhsAHwMACCkAnFzbyxYOwGMzFVrOppknLbuSGPHP+/eF6FwsOEGRjfz0igIZ+OclotxsWFl6/rFU
ejlCqmodU/ZL5RF7X8e+7RBS2oeUI1QkhPx+pmWAWhKpGchY/Q4cOGDFo5s1lN0cElW7d++2dV+1
apUVXeGMlO7TUkcAfAwAIKQAcHJTXrYyIaWlWZp10nKp+/fv2yVtuUIqFdGtqBz+oLgobf8eLesr
29tVJjyqtFOOkErVMWW/VoRUHfu2Q0jlBvgIy6cli1q+GSujljL6s4YSRbHogpp9Wr58eSWBDICP
AQCEFABOrnbZ/JDSesrvb9j3y67j/tIyLefyz2tWoGxpX29vb9O9ReXwI7ppAO0vMdT94VI8N6h+
+PChDVhQRTjE0qsrpFJ1TNmvFSGVY9+pEFKKkqf9cCnCGb6YEPMAAFPdSURBVKmi8Ol+sAuhgCM+
ul/plCFh5s9YCe0XY0YK8DEAgJACwMlNSdkUse7jx492oHr8+PGmENJ+2bX530WZc3tP/PNasqbl
VUK/3+MHm1BwhzNnzjQCLei98vXz0X6ZT58+2fO6Ngw24fbD6HX58mUr3IRmRHSuinCIpVcmBLTH
yImvovRTdUzZL5VH7H2OfWP2CPPORfuwXLCNGKprGIUx9TnRUk29/PDm/jJC9S83q6WIiBLTYR7P
nj1jjxTgYwAAIQWAk5uasmlwv2zZMhtB7siRI00b+v2yP3r0yA6ctVRKg9jwR1S1tE4BAXRe+3/C
Qa0iu2lWRjM/iiDnD8CVjvbAKHy3zktUhcERXLhyvRRo4PXr140BtQbSVYRULL0iFAFP5XKzVmVt
Gqtjyn6pPFLvU/aN2SO3fiGqS9kspI8CQah9q35OJJ7UL12dFCbdof6lfVZuj5S/R85x9epVovYB
PgYAEFIAODkcMMxNFBnSnyGbLjZu3GgDfADgYwAAIQWAk8MBw5xEIdpjvwvVbrR80g+hD4CPAQCE
FABOrm3EAiwAtBP9CPCOHTumLT/lpb16APgYAEBIAeDkAAAA8DEACCkAnBwAAAA+BgAhBQA4OQAA
wMcAIKQAACcHAAD4GABASAHg5AAAAB8DAAgpAJzc78t0htPGRrTjXKorn43fx3b4GACEFABCaob4
8uWLOXbsmFm2bJmZP3++WbFihX0/MTEx6+ve7vDt7SrvVNe7SvqzNcS9X4fZVsapbL+wrn5eqXxb
aXcG2+aXtR1tC4CQAkBIzQDfv383GzduNGfOnDGfPn2yx37+/GnGxsbMli1bWhZTs0lQ/K5tPhcG
WbOtjFNZnlja7cyXwXX7bIeQAgCEFABObhISUOfPny88d+PGDTM4ONhUDwmszs5Os27dOnvszZs3
Zvv27WbhwoV2Nmv16tVmZGQku+6a+ero6LD3b9682bx79y6aX2hX/5Wbpuq1dOlSe83BgwfNt2/f
Cssrkbl3716bjur15MmTxrmZrHeYvv6/fv266erqMvPmzbPl0Y/fltmobjvG7CZOnTplFi9ebM8f
Pnx4UnnDPP3y1GnHsjrnlKeV9su5t2p7+Peqnq7fbd261Tx9+rS0XGU2SuUT69v37t2zZVbZe3t7
zcOHDyfZQLPYmrkO+4DS1T11+0Qs76I28Y/llLsV2128eLF2f8v5TCOkABBSADDDTi4cBKTy7uvr
K511+vjxo+np6WlKWwNozVi9f/++cf/Q0JA9ptelS5fsYCGn7hJwut7de+XKFTu4i+WXsm1OmmvX
rrWDJp3X4OfQoUOF6UlEDg8P2//v3r1r1qxZ02S32VJv/a+BvRsIaoCngV5ZWeq2Y8xuqoPEg879
+PHD3Lx505w9ezaaZ2xJW46NYnVOlaeV9su5t2p7+P9v2LDBfPjwwaZ9+/Zts2/fvsJrc2xUlk+s
b/siYXR01HR3dxfa4cCBA5Mewly4cMH2jbp9IpZ3Skjllruu7bZt21a7v+V8phFSAAgpAJhBJ1ck
olJiKrU3xT/vnpan0BPbnLpLpOkJtkP/a8ajSn5h+jlp+k/fv379ap+sF6WnwaUGPrnMVL2Lro+J
lLrtGLObRFZoq3AQXKWMdWzkp5EqTyvtl3Nv1fbw//dnoFQH1aXo2hwbleUT69sShU5kxXj16pXt
Ay4d/V25cmWj7nX6RCzvlJDKLXdd27XS33I/cwgpAIQUAPzCQqoILVnRE+49e/bYAUru5nl/8OmI
PbnPsW1OmuGApyxP//hsrndqgJm73yNVn5jd9H/Y51LCJFbGOjYK2y5Wnlbar869VYRUbr2r2ii3
b2s2x81Anjx5MmqHTZs22ZkYoVk6zcS10idieafsWqXcrdiuTn/7XfeKAiCkAGBOOLmYiIrlr0GH
9jsUoVkHf79DUTraN6On29euXTP379+3y1ZyB6RFg7kqg9mia+qkWUdIzaZ6t0NI1amPX4+igWmV
gWg72jElMtrVfnXubUVIlT3MqGqjqg8JtORvYGDAHD16tPQ6XaM9VkLfFbJHK30ilnfKrlXK3Yrt
6vQ3hBQAQgoAZrmTqyOktFdAm6iL0Ab6EydOROuxaNGipj1Wb9++zR6QauAVLq/JmQGL2TYnzefP
nzfef/782dahKL1Vq1aVLn+aTfVuh5DKqU/MbqpTLMJj1TLWsZF/LFWeVtqvzr1VhJSWzPn1Llt6
WtVGuX3bR22e6o8KwKC9UVrWF7Zh1T4Ryzu8PrR7lXK3Yrs6/Q0hBYCQAoBfUEhpY3R/f78VU24g
oAHWgwcPbMQwDZhj9dAgykUse/nypVm/fn32gNSJOLfh+/Lly3aAV8VuirilvQduUJSTpiJ0KZCG
zh8/ftzs3LmzME8t3dJyISF7+BvyZ7reVQbuoY3qtmPMbqqTIkC6Oum9rq9bxjo2CgMxxMrTSvvV
uTe3PfS/fnZAP0WgcqsOsWATMRvF8on1bf2vCHgiDKpQhIIqLF++vCm4Qt0+EcvbDyYxPj5ulxGG
+75yy92K7er0N4QUAEIKAOaAk6satU8ohLFmnjRAdD/Iq2Uxvogqq8ejR4/spmrdp4GMNntXWabm
QhDrpahZr1+/rmQ3Dd70JNl/mpxKU4Ng/fiwNqcfOXKkVCzKLrt27bJ10z4YPwjATNe7ysA9tFHd
dozZTagPabZG+WiQ60cnq1rGOjYKj8XK00r71bk3tz30vyLAKYy2zktUhWHfc/tRLJ9Y39byOB1z
Yb6dOClDok95SGSHVO0TsbydONI5iR6d89OoWu66tqvT3xBSAAgpAMDJ0RbYDQD4fAIgpAAAJ0db
AHYD4PMJAAgpAJwcREmFewfsBoCPAQCEFABODgAA8DEAgJACwMkBAADgYwAQUgA4OQAAAHwMAEIK
AHByAACAjwFASAEATg4AAPAxAICQAsDJtY8XL178UvkAAOBjAAAhBYCTm3LCsNh+XVP1rmKXWD6t
tk34mjdvXvSe0dFRs23btqZjN2/eNCtXrrTlXL9+vXn+/HnhvcPDw5PK/vnzZ7N9+3azcOFC09HR
YXbv3m0+fvzYOK9zDx484IMEAAgpAIQUAE7ud6hbO+s9XTa8c+eOOXHiRPSatWvXmlevXjXe//vv
v2bDhg3m7du35ufPn2ZoaMisWbNm0n3j4+Nm8+bNk+py6tQpc/LkSXuvXn///XdTGZTXunXr+CAB
AEIKACEFgJObLbx586YxGzJ//nyzevVqMzIy0lT269evm66uLjtTo2v++eefxjn/FdZV/797987s
3bvXpr9161bz9OnTUrscO3bMzsjoWgkO3ZuTz/fv3xt5qPxPnjypZXuJmL6+PvPly5fSax4/fmy2
bNnSdGzPnj3m3LlzyfQHBgbMf//9N6lMSu/ly5eN9z9+/LC2Cq9R3gAACCkAhBQATm4WIOGgGRQ3
G3Lp0iXT2dnZVHYJLSdqJKIkpsrqFgopzdR8+PDBpn379m2zb9++wmvPnz9v83bluHLlihVHOfkM
Dg7aJXPi7t27hbNBOSjP1GzUoUOHzI0bN5qOSWSm9nCdPn3a1q+oLosWLbJ1Do/5XLt2zeYNAICQ
AkBIAeDkZin+HiE3qxQTS7Fz/gyUxIKWxRVd29PTY2eWHPp/6dKlWflIOIVCpK6o1PK8GNr/5M8e
CQlL7ZvSbJhmxXbt2mX3PTm09M+fxQrr4gvTsmPKU3kDACCkABBSADi5WcLY2Jid1dESNQmaVMCI
KkIqJhD880UBHnJnvoqESFW0DylHqEgohaJNZTlw4ICZmJhozKbJlkLLBLW/SbNyZXVJ1d2JUC17
BABASAEgpABwcrMALVPTjI6Wjt2/f9+8f/9+SoWUH30vJYZy82mHkLp48aLdo5WiSPRoGZ4/mybR
4+qppYxa0hjrD+EyvrJj7agnAOBjAAAhBYCTawMasGsmxaGlbe0UUn50O4mNFStWFF7b29s7aWlf
megK369atarlpX07d+60+6tSFM1IhYEhdF7XuXKWvRwKQvH169fG+2/fvtlgGz4KQMGMFAAgpAAQ
UgA4uVmCAiW4KH1uH04VISXBoD1UTgSF92pv0KdPn6y4OHPmTDTYhGaFXLCJy5cvW4GUk4+WJWqP
ktDvLdUJNtHd3W1n41LIPv6+L6FAF3q5sqsesWWCReHPZRt3v2YHFQ7d59mzZ+yRAgCEFABCCgAn
N1t49OiRFRFaNiYBEv5gbEpInT171s4cudmj8F7tF1q8eLE9L1HlB64oC3+ulyL2vX79OisfzeAo
wIPqoD1esRDrZejenFktRc5TnUIknhTtUOVTlEOFOc/tDxJw/f39jfrpx379YBXi6tWrRO0DAIQU
AEIKACcHcxP9RlW47G462Lhxow0KAgCAjwFASAHg5GBOohDuqd+NaidacumHjQcAwMcAIKQAcHIw
59CPEu/YsWPa8lNe2vsFAICPAUBIAeDkAAAA8DEACCkAwMkBAAA+BgAhBQA4OQAAwMcAAEIKACcH
AAD4GABASAHg5AAAAB+DEQAQUgA4OWgf0xWifDpDodOmL37p9qQvAT4GACEFAHPEyalsN2/enLEy
T2U+CxYsKM0rlW+VcsXygalt07maRzvzPnbsmFm0aJFZuHCh2bVrl/nw4UP0+tHRUbNt27ZKacTO
6////e9/tuzu/MePHxvnt2/fTvh+hBQAQgoAfk0htW7dOvPt27dfTkjF0m5nvgxifq3P0ky2Z9W8
z507Zy5dumR+/vxpX6dPnzabN2+O3qMfd3716lV2Gqnz/f395tatW43z+n/Lli2N88pL3zGAkAJA
SAHALyekrl69ak6ePFla5jdv3tinynraPH/+fLN69WozMjLSOH/v3j17fN68eaa3t9c8fPgw+96Y
bXLuvX79uunq6rJ56xr9WK4757/CvPT/u3fvzN69e236W7duNU+fPi0tl57Id3R02Gs1iNS9Ofl8
//69kYfK/+TJkyy7Ob58+WJWrFgxSegqXd3jOHXqlFm8eLEt4+HDhye15djYmOns7GwMaGN5F7WJ
fyyn3DltlLJtUVpFtg7rlrJHrF+V5XHt2jWzdOlSs2TJEisUzp8/b2doiuqTaou6fbaI7u5u8/Xr
16ZjSrOMx48fN4mcnDRS54vyC48pT+UNCCkAhBQAzFonFw7GcpewrV+/vmkA69/X19dnhoaGGk+c
9XRaA1d/0OQGg1o2pIFX7r2x8uXcqwGxK7fK4A/gwrRDIbVhwwa7LElp37592+zbt6/wWg2a/Sfy
V65cseIoJ5/BwUEzPDxs/797965Zs2ZNlt18Dhw4YMvgc+HCBTtgFyqPBucq248fP+xSzbNnzzaV
5+DBg/b8+/fvk3mnhFRuuXPaKGXb1GepqG4pe1Ttk3qvvqG07ty5YwXU/v377fuwPjltUaXPVmFi
YsL2iT179pRec+jQIXPjxo3aaRSddzNSDvX3TZs2Nd0nIaq8ASEFgJACgFnp5IpEVEpMuXOPHj0y
u3fvzi6znqY7NAh1YiEH/96qtgnvDWcvYvugwnP+DJQGvlryVHRtT0+PnQFy6H/NTuTkI+GktIvI
tZuWRmlWyqWjvytXrmzUXeUO8wiFUWinWN4pIVWlvVNtlLJtjpAK00/Zo2qfDPPQewmKouvrtEWV
vXtl6LOrGTC9nj17VnqdHpi8fPmyVhpl59U/NVPnvmv0v790UChP5Q0IKQCEFAD8ckLKDZQkqIrK
rOVTml3Rk2gNfv3zmpXQew0iwyWCqXtTtql6bxUhFVI2M+APslPXhu9jy6xSdvPRE37NdAjNpmhW
w88jbO+UWI3lnbJrlXKn0krZNkdIFd0fs0fVflXlfZ22aIeQcmiZpL/kM0TLGcuEfW4a4Xn1Rc0s
uhk+7anauXNn0z06LgEGCCkAhBQAzDonFxNRuUJqfHy88dTYP66lQJpZ0fKc+/fv2yVURUJLS9cG
BgbM0aNHs++Nla3Ova0IKT9iWkoM5eYTEwUxu4XoGu3lERrEyh4xMZLT/8ryTtm1SrlzlglW+bzk
CKmUPar2qyrv67RFO4WUlhPG+lyqfDlphOf1ufHFmf6XYKsikAEhBYCQAoAZdXKtCimhGQYFn/CP
a0+Iv5Tp7du3pWk+f/680r2xstW5t4qQ8pcfaUmZls8VXSvhEi4/KxNd4ftVq1YlZwCK7FaEAhRo
b5SW9fmofL6dqva/MO/w+irtXVU4pGxbR0il7FG1X1V5X6ctWhFSWmbphxpPLY0smpFKpZE6H4qm
otkniS9mpBBSAAgpAPilhZSiw2nJln9cA3gX1cztdQj3ASmSmwg3z6fujZWtzr3+MQ3wtB/FDdTD
exVJ7NOnT3bgd+bMmWiwiYsXLzaWLl2+fNkKpJx8tHxMS+GEfkvHDzYRs1sRClqwfPnypuAFrnwq
vyuf3vvhqYvsFMvbDyahWUot3cpt76rCIWXbIiFQZutce6T6VSqP2Ps6bRHLO4WW2enhh8vv+PHj
9lWG6urvDcxJI3VewT40uyexpPMS+3/99VdTHtpTxR4phBQAQgoAZrWTqxu1z0eRxvzj2jelDfMa
MGsQrUAD/nkt89I+ExfO2Q2yc+6Nla/Ovf4xCQ7NbrgZjvBeRVhTmGqdl6gqi1roBpNuo72iyr1+
/TorHwlT/UCp6iAb+YPYmN2KkOhTHv7sgOPEiRN2pkXnJXxcBLsyO8XyduJI5yRqdC63vasKqZRt
i8Rkma1z7ZHqV6k8Uu+rtkWVvEMkXiRkdL3sJ1vGUOQ89fsqaaTOq4+783pJRIXh+jXLTdQ+hBQA
QgoAcHIAMCfR75ilfrB3Kti4caMV4ICPAUBIAQBODgDmJFq6++LFi2nLT8sn/Z8WAHwMAEIKAHBy
ADDn0NLNHTt2TFt+ykv7AwEfA4CQAgCcHAAA4GMAEFIAgJMDAAB8DAAgpABwcgAAgI8BAIQUAE4O
AAAAHwOAkALAyQEAAOBjABBSAICTgzTTGXYaAH6Pzzw+BgAhBYCQmqGyude8efPMwoULza5du8zH
jx9bTvvNmzdmzZo1DB48FixYMC11ULpfv341q1evNj9//iy8Rsd1/tOnT3P+c9IOOzIY5bt2KvIM
P/N8FwIgpADgFxJS4eD69u3bZvfu3S2nffHiRXPs2DE6wAz0BZeP7H/t2rXCa4aGhszhw4d/Cdsw
kITZKqSmo0z0fwCEFADOfRaVzX+KqmvGxsZMZ2enWbduXeP4qVOnzOLFi01HR0fhgLy/v988fvy4
kcaNGzfM0qVL7fUHDx403759a7o+ll5RGXLsKiGh9DTTtnnzZvPu3bumNNtdJs3Cbd++3eY3f/58
O+MzMjLSuN5/uWNfvnwxK1asmJT39+/fTW9vb7a9i9r1/fv3pq+vr/CatWvXmrdv35beH7NNWZ9o
xd46L/Hd1dVlZ0dlP/147OvXrwvr8OPHD2s32c/vC7E20AMC/8dh7927Z7Zu3TqpP+m47lU51AYP
Hz6clH872q3IjrG8i/p81XL7912/fn2Svat8flL3V+mzOfkV9bmwTkV9KLdMsb7jHjT99ddfZtGi
RWb58uXm5s2b0e+hos98qp4IKQCEFADMkJMLHXedp6UaLMjJ+9do0KvjGpiLK1eu2EGUjmlAqwHF
2bNnG/docLlkyZKmNDRw14BB92gwc+jQocb5VHpFZUjV7fz58+bSpUv2Hr2Ux969e6e0TBrwa6bH
5an8NfArs7d7f+DAAVtenwsXLtgy5ZQl1q779++fNJiUmNizZ0/0/phtiureqr11ftu2bY1Bpcqs
wawT5aEokD1Ut7C+sTZQWdevX2+Pq492d3ebV69eTUrDH4CPjo7a64potd2K7BjLOyWkcsvt7pNo
KLJ3bnvG7q/aZ3PyC21VVKeyPpRTptTnV2175swZe07Lnzdu3Fj5OzZVT4QUAEIKAGbAyRWJqJSY
KlraJyevp67+NeETUw2Iw703/qDt1q1b5s8//2xK48mTJ4332r+jp/m56RWVIWXXnp4eOzvg0P+a
DZnKMhWhJ+MpIaXBvPJ2+envypUrG+mnyhJrV6W9adOmpvMSJi9fvozeH7NNUd1btXesje/evWsG
BgaazmlW4tmzZ1l9wW8DDVw1INYAOhRyDg2eh4eHk23barsV1TmWd0pI5ZY75zOV056x+6v22Tr5
Va1T1TKFfUd9zi/j06dPKwupVD0RUgAIKQCYQ0LKf2kWSU/ZtWwpVn495Q3v9QccElH+gE7nwwGM
/6Q4lV5qAJkaABXlORVlElp+NDg4aGd8NGjyrysTUkJiR0/LhZ6K62l/bllSttFT+ufPn9v/JT62
bNmS7Esx2xTVvVV7p9pYy7Xc7JEGsP7yrvDeWBu4AbUGr36gDf8azea4GbSTJ09GbdVKuxXVOZZ3
ykZVyp1KK6c9Y/dX7bN18qtap5wyxfqOXx4nnKsKqVQ9EVIACCkAmGYnFxNRVWakcq+JDYiEBFm4
/yU2eEilFxsgldW1aHASEzXtKJP2AClSoQI83L9/3y5ByhVSmnXRngyh/S26P7csqbI9evSosZRP
Ije2dybHNqnzdeydGgSfPn3ainyhpVBXr14tvC7VBk5Y6poyIeUG1G4m7OjRo6W2aqXdYmK8KO+c
Bwq55c4RHVXbMyXEYtTJrx3isMrnN1bGsu+hsEypeiKkABBSADADTm46hZQGjBMTE4XXa5AeLsNS
Gm5GRHz+/Nlu2M5JL3cAWVTGcAlNGESj3WXS/f49CuaQK6SEZl207EzLw3LtnVu2DRs22OAfZRv1
q7RXWZ9oxd6pNtaeFG3O//Dhgw0WUCbUU21w+fJlO4OkwXLZ0j4flTnV1+q2WyrdMO/w+rBuVcqd
sndOe6bur9Jn6+RXp06xMqX6jj5Dfhm1PLbqjFSqnggpAIQUAPziQkobpt2ma730XtGnhCJSKXJW
mIbOazCs648fP2527tyZlV5dIaU0VA6XpgbQq1atmtIyaUDtonxpkKXABv51EgLaw+EGUmEa2rej
aGDhpvxUWXJso7D22g+Ss4cmZZuyPtGKvXPaWDNRO3bssEEHyq6LtYFmGP7444+mQe1///03KQ3N
SigCnggDFhRRt92K6hzL2w8mMT4+bpcR1i13yt457Zm6v0qfrZNfnTrFypT6/GrppmZGXbAJ7TVM
lSv8zKfqiZACQEgBwAw5uXZE7cu95sSJE/YJrp6makDnImlpMKcwwmEaGqAsW7bMbog/cuSInZHI
Sa+ukHKiThEI9dIgXKG0p7JMWkInsaIBrOwg0eJfp4G20nJPoMM0tNRM54p+EDlWllzbpPZG5dqm
LP1W7J3TxgpWoWMvXrwovS7WBvqxaT/8uf53e5r8NLQ8TvtjXAhtJ07KqNtuRXWO5e3Ekc5p8K1z
dcudY+9Ue6bur9Jn6+RXp06xMqU+v+LcuXN2f51mRRW4JFWu8DOfqidCCgAhBQA4uVlvA9plem3T
jjQ16NWsAQDwXQaAkALAyWEDyoSQykDLoDSbkIpGB8DnFQAQUgA4uV+GVjdT/y5l+pVt02qa2mui
pYl+kAkAwMcAIKQAcHIAAAD4GACEFADg5AAAAB8DgJACAJwcAADgYwAQUgCAkwMAAHwMACCkAHBy
AACAjwEAhBQATg4AAAAfA4CQAsDJ/fZlq5vn8PBw1r2jo6Nm27ZtTceOHTtmFi1aZENo79q1y3z4
8KGpPOFr3rx5jfNfvnwxe/futeG7ly5dag4fPmw+f/7cOL99+3bz4MEDOjoA4GMAEFIAgJCaXXmO
j4+bzZs3Z927du1a8+rVq8b7c+fOmUuXLtkfdNXr9OnTNq0y7ty5Y3/41bF//35z9uzZxv0XL140
O3fubJxXXuvWraOjAwA+BgAhBQC/k5CSMOjq6rKzMPPnzzf//PNP0zWnTp0yixcvNh0dHXY2xufN
mzd2RkYzPbp39erVZmRkpHFewuOvv/6ys0HLly83N2/ebLJHrm0GBgbMf//9l7z+8ePH9kdbfbq7
u83Xr1+bjqmsRai8fX19dhbKoZkoHfevUX18lKfyBgDAxwAgpADgNxFSWgb37t07+14iyhcZV65c
MdevX7fi4cePH1YIaXbGIdExNDTUmK3RzE9nZ2fj/IULF8yZM2fsuY8fP5qNGzdWtodmkJRuji0P
HTpkbty4UXp+YmLCCsM9e/YUnld9/dmoIiH1/ft3e8zn2rVrNm8AAHwMAEIKAH4TIeVEVFF5tUzO
FxFCMzwx/P1FWvIm4eF4+vRpJXv8+++/TTNMqXvXr19vXr58WXhu9+7ddlZNr2fPnhVeI2H49u3b
pmPaH6VZO9nh27dvVjD5dRTKU3kDAOBjABBSAPCbCKnYMc1OxQIxiLGxMTM4OGhneXp6eibd7yMx
kmsPLa+TEAsDQ8TQEsNQ+IUo8ERvb++k49rrVCSGFFhCIkx1WbVqlQ1mEc5IKU8JNAAAfAwAQgoA
EFKTRFOIltGtWbPGLm27f/++ef/+fVRIVbHHvn37zO3btyvdmyqv0BLFonJp1kkiK4Vmn7TfK6Rs
3xUAAEIKACEFAL+ZkNLMjfYVlaGgC/55LYvz79+wYUPT0j6JkFx7FIUld68yimaktGdL+7McKo/C
mIcoEt/du3eT5ZK4C/dYSZwxIwUA+BgAhBQAIKQs58+fbwSL0Evv/dDhivbnovS5fUL+/QpEoWAR
LthEf39/S/bI2SOlfVg+mmU6efJkow7Hjx+3rxDt/dKMWohm3NzMmKIUKoJgmIf2XLFHCgDwMQAI
KQBASDVQFDvNPGlfkEKd+2Lj0aNHVoBoWZsER9GP5up3nDQDpBDqiopXJ/x57vUKBKE8fDRbdPDg
QVt+zRqVLd9THYr2V0k0aa+W2yOlOoZcvXqVqH0AgI8BQEgBAE5ubvLkyZPoj+1OFQrrrqAbAAD4
GACEFADg5OYkCtn+4sWLactPSxqVJwAAPgYAIQUAOLk5i35UeMeOHdOWn/J68OABhgcAfAwAQgoA
cHIAAICPAQCEFABODgAA8DEAgJACwMkBAADgYwAQUgA4OQAAAHwMAEIKAHByAACAjwFASAEATg6m
hHaHa5/O8O+/o32BdptN5cXHACCkABBSM1S2stdsq3/VdPzrc++tkse9e/fM/Pnz2/IbUgsWLGhr
u7Y7vbnOdNhjKj7nv/sAOWy32W6PmSovQgoAIQWAkKKcUyakpgKJKP1m1Wy0PQOr6bcHQmrqbfqr
fUfRTwAQUgDwGwipY8eOmY6ODrNw4UKzefNm8+7du6b7bty4YZYuXWqvOXjwoPn27Vthut+/fzd7
9+616axevdo8efKkce7Nmzdm+/bt9pxEis6PjIxkle/nz5/mr7/+MosWLTLLly83N2/eLJ2RcjNJ
8+bNM729vebhw4eF1+n/69evm66uLnutL5zKZu9OnTplFi9ebO1w+PDhpjKW1b0orRxbVClbrM6O
L1++mBUrVjS1nSu37smpo/IbGxsznZ2dZt26dZXsXbWtQsqubbd9c/pbTvqhnVJphrT6WQrzT7Vt
ne+Fojxy0yhqN/29ePFiabvU6Z8hKdtV+Rzrbzs+VwgpAIQUAEJqmvKqu0Sv7Nrz58+bS5cu2YGe
XleuXLEDCf8+LW/TAEjnNSA4dOhQYbqDg4NmeHjY/n/37l2zZs2axrm+vj4zNDTUyEd5asCTY8cL
Fy6YM2fO2Ps+fvxoNm7cWCqk/MHX6Oio6e7uLhVSGlC5gZ3u0b1l5ZFdNPhWGX78+GEHwmfPns2q
e5hWji2qlC1WZ58DBw7Y9g5tqzbNqaPylZDW+ffv31eyd9W2CqmST6v2TfW3nPRDO6XSDGn1sxTm
n2rbOt8LYR510gj7xrZt20rbpU7/DEnZrsrn2L1v9XOFkAJASAEgpGZARFURU2XX9fT02KenDv2v
2Sf/Pv9p+NevX+0T2KJ0NejQYCEXPXXOsaOeLvtlfPr0aamQ0qDIDYRiNtD//hP2ovM+EpNh3fzB
fKzuOW0U2qJK2WJ19nn16pVtO1dO/V25cmUjr1Qdi8qVa++qbRVSNZ9W7Jvqb3XSr5pmq5+lMP9U
29b5XgjzqJNG2AaxdqnTP6varsrn2L1v9XOFkAJASAEgpOaokPIHEY5w9iMcBJTNjvjHi9CyGz3x
3bNnjx1k5QaMCNNVecru1WyFm0U7efJkthhJnVcZQrv7tovVvSivqraInY/VOWTTpk326bjQk3nN
zOTWsahcufau2lat5tOKfVP9rU76OWnGrm+1fqm2rfO9UEWg5KSR0y5V+2dV21X5HPvvW/lcIaQA
EFIACKkZElGtCqmigUOVQWHuIET7rPS099q1a+b+/ft26U1dIZUqowZKWpYzMDBgjh492hYhlRr4
VBmA1bFF6nxZnUN0jfZ+CO3hUP65dSxroxx7V22rVvJp1b6p/lYn/VSaVfpTnfyrDNzrfi+0mkaq
Xer2zyq2qyukWvlcIaQAEFIACKkZFFOtlFNOP1x+44f51X3Pnz9vvP/8+bPdMF+U7qpVq0qXxeie
iYmJxvu3b99mD8w2bNjQVMaXL19m3atyl11XVazITn75Q2J1D9OqY4tcW4V1LkKb+bWHQ8uPqtQx
lW7M3kX1rFru3HxatW+qv9VJP5Vmlf5UJ/9U29b5Xmh3Gql2abV/5tiuyuc4fF/3c4WQAkBIASCk
5qiQ0iZpRcpym68vX75sBxP+fYq2pQ3yOn/8+HGzc+fOwnS1XEZLsMSDBw+aNmprkOGiY2kQuX79
+mxxoKUyp0+fbmzU7+/vL71XeSrCm4gFaagqVmQnFyxAL72XXXLqrghg2i/hBpV1bOEfC9OL1bkI
bXRX5Lhww3uqjkXliuXtB4gYHx+3y51y26pKPu22b6q/1Uk/lWZIuz9Lqbat872QIpVG2G6pdqnT
P4seIsRsV+VzHOZX93OFkAJASAEgpGZITLWjnC5EsV6KqvX69eum+zTwWLZsmd3wf+TIETsrVZSu
QgDv2rXLDnK190Ab6h2PHj2yG6x1ToMTBQ6oslTo3LlzdqO6QggrClbZvVr+pbxd+GQ3+G5VSIkT
J07YJ9p6qi5R4EcGi9VdAyvd457G17GFfyxML1bnIj59+mTv1YC+Sh3LlhSW5e0Ej85pAK1zuW1V
JZ922zfV3+r25ViaIVPxWYq1bZ3vhRxiaYTtltMuVftnSMp2VT7HYX51P1cIKQCEFABCivoBAADf
wQAIKQDAyeHEAQD4DgZASAEATq4G/uZwAADAxwAgpAAAJwcAAPgYAEBIAeDkAAAAHwMACCkAnBwA
AOBjAAAhBYCTAwAAwMcAIKQA+MDh5AAAAB8DgJACgF/Hyb148eKXyGM25g0AgJACQEgBwC/q5KYj
dPlMhkevmveXL1/M3r177X1Lly41hw8fNp8/f47eMzo6arZt2zbp+Ldv38yqVasmHVd627dvNwsX
LjQdHR1m9+7d5uPHj03XHDt2zCxatMhes2vXLvPhw4fsMirtBw8e8MEDwMcAAEIKACc3l8s2k/Wv
mvf+/fvN2bNnzc+fP+3r4sWLZufOndF71q5da169etV07MePH/a+ovxPnTplTp482cjj77//NidO
nGicP3funLl06VLj/OnTp83mzZuzy6iyrFu3jg8eAD4GABBSADi5qSqX/3LHxsbGTGdnZ9NgXIP/
xYsX2xkUzYD4vHnzpjHDMn/+fLN69WozMjISzePatWt2NmXJkiXm1q1b5vz583YGRvf/888/k4RH
Wd5K6/r166arq8vMmzev6f6yvGNolkfixKH/Va4yHj9+bLZs2TLpuITP+Ph4YX66/uXLl02ia+vW
rY333d3d5uvXr033qF5Vyqg8VDYAwMcAAEIKACc3DWXT+4MHD9rB+fv37+2xK1euWLGiYxr037x5
086IOPr6+szQ0FBjhkSzKRJisTz27dtn07pz544VAZpl0XuJIF80pPJWWhJx7969s+/D+6vaPhQp
379/jy4PPHTokLlx48ak4/fv3y/NX/X183DHipiYmLBCcs+ePZXKKKGqsgEAPgYAEFIAOLlpElJO
lDi0dC0c+GvWJIZmh3Lz0HsJhqLrU3kXlde/v6rttfdIS+WUp/Y4SYz4dQlZv3590+xSTtv7Qi92
THunNAun17NnzyqVUWVS2QAAHwMACCkAnNw0CamiQX64TC4cuGs54ODgoJ056enpiYqZKu9TeReV
txUhpaANEjDKV4EiFEgiNiOl5Yyh0EvZs0iYFQkphwJP9Pb2ViqjyiQBBgD4GABASAHg5GZISMVm
ZISWtq1Zs8YuJ9OSNi0JbJeQSuXdbiEVopmd5cuXl56vU76iZXyxfVha0hgTWmVljN0DAPgYAEBI
AeDkplhIaTbEX3pXJAL882/fvm2bkErlPdVC6vbt2037k0LqzEgNDAw0BZPQ8jw/Kp/2l/nh0LUH
SoE5qpRR4osZKQB8DAAgpABwclOEhID2GGmwXlZWRdQ7c+ZMI5iE3vsDf0XMc1H63N4cP51UHrH3
qbxTQirMO4Vm1iRMhKIRSvQ8ffq09HrVNXa+LPy5XyfN5CkcukNL+fzw6MePH7evKmXUnir2SAHg
YwAAIQWAk5siFAFP+2vcHpuysup3jjTzpOsUJc9F9BOPHj2yASC0lEyD/OHh4aZ0Unmk3sfyTgmp
3Po5JEgU9t3tP1JdYijQgyILVml7lb+/v79RLv2Yr/+DuppNUuREndOskoRV1TJevXqVqH0A+BgA
QEgB4ORgdvLkyZOmGbLZwsaNG20AEADAxwAAQgoAJwezEoVof/Hixawpj5ZXqkwAgI8BAIQUAE4O
Zi36EeAdO3bMmvKoLA8ePKBhAPAxAICQAsDJAQAA4GMAEFIAODkAAAB8DABCCgBwcgAAgI8BQEgB
AE4OAADwMQCAkALAyQEAAD4GABBSADg5AADAx2AEAIQUAE5uJrh3756ZP3++Lad7LVy40Dx8+HBW
2il1XRV7122b6WxTBklzl69fv5oDBw6Yjo4Os2DBArNr1y7z+fPn6D2jo6Nm27ZtldP49u2bWbVq
VWH/CV/z5s1rnN++fTvh8vExAICQAsDJVUW/gSTRpL8+IyMjZtGiRebJkye/tL0RUjCVHDp0yFy+
fNn8/PnTvo4dO2aFUAz9mPKrV68qpfHjxw+zc+fOrL5y584dc+LEicZ75bVu3ToaCx8DAAgpAJxc
FTQTpRmpIiSmuru7m46dOnXKLF682D4dP3z48KR6jo2Nmc7OzsbATMeuXbtmli5dapYsWWJu3bpl
zp8/b0Wa8vYFnG+n79+/m71791qRt3r16iZB51+ngeVff/1l01u+fLm5efNm0/k3b97YJ+5KR/kp
LdUrp21SZbh48aLp6uqyT/fDuuTkW8Uu7969a5Rl69at5unTpy21i+PLly9mxYoVdjYjrHtvb2/t
9N0sp2yjdPzZzSKb+8di9xbdd/369dJ2EBIeKrdst3nzZmvLKven6h5Dbas+6gsezSqV8fjxY7Nl
y5bKaahe4+PjyfIonb6+PtvuPspTeQM+BgAQUgC/rZMrWsbTStk0aHNcuXLFDjo1GNNxiZazZ882
pXXw4EF7/v37941j+/bts9frSbiEwv79++17DVg1cC0qy+DgoBkeHrb/371716xZs6bwugsXLpgz
Z87YPD9+/Gg2btzYdF6DxqGhocbT/EuXLtkBf079U2XQ8is3KA/rkpNvFbts2LDBfPjwwaZ1+/Zt
e28r7eKjZWMScT6yqwRE3fR9QaKlar4gTwmp2L1F90mwlrWD6iXbu3ZQXSRIc+9P1b0qEqh+PwjR
7NONGzcqp3H//v2sz7Pq489GOSTqlTfgYwAAIQXwWzq5IhGVElNVyqYlR/6TcREOkP2n/UXH9H5i
YqIwf/9/iZYwr6LrNAOigaVDMzWpOvn7Q2LXpspQVNcq+Vaxiz8DpTKpLVppFx8t7dKslEtDf1eu
XNm4p076Gug7EZrT5/xjsXurtkNPT09T/9D/mgXMvT9V96r8/fffVqCXsX79evPy5cvaaaT6oAT+
27dvJx1Xnsob8DEAgJACQEi1IKTK7g0DUoSb1lMD5NT7MK+cMofXadAb5qFlZxp47tmzxw6sy/IM
yS1D2bEq+ebapahsddolZNOmTXbmRWgmTbM0raSvmSQdlxA5efJkJdvF7q3aDn45i2yXMzsWq3sV
Pn36ZHbv3t00yxui5Ydl4j0njVhbSzCXiSXlqaWLgI8BAIQUwG/n5GIiqpUZqdSgtKq4mGohFZ7X
MinNLGnpkpY/aenZdAipqvlWFVL+Hpk67RKipYvaxyW0L8ktFWslfQlJpTswMGCOHj1aWYQW3Vu1
HVL9o44Qq4OEz59//mmXn8aI5ZeTRqyttadP+8Xq9HfAxwAAQgrgl3ZydYRU0eZ6R7hfRANsf/nZ
VAophXHOWdqnvUP+0i0tUfLPa++RX2Yta8oVUrllKDpWNd+UXfwobqqvluK10i5FKOCC9kZpWZ9P
q+k/f/48WvfQNrF7q7aDyh4u7fNFaM79sbrnoFkk7UMrWlIXUjYjlZtGzFaK6idxWibSmJHCxwAA
QgoAIVVBSJWFP1fkNB33I/pp474L7KCX3ita2FQIKS2J0xIvod+4KQs2oWVop0+fbgSb6O/vbzov
ceCi5bl9ILlCKrcMRceq5puyi6KqaTCteqoN/GATddqlCAVRUOTDMJhCnfRlK9d3QkHui3dFmtMy
wnB/XNm9VYWUyqqZGFd2hRH3f2sp5/5Y3VMoEp6WTSpQSA7qJ2FExippxNpae7uKgo2IZ8+esUcK
HwMACCmA39vJVY3a5w9W/XvKZqoU8UuzLXqqrwGwPzBrp5BSOG79Vo7Kof1F/uAyTOPcuXM2gIBC
VCsqmX/+0aNHdgCpdDRAVxCDXCFVpQzhsar5puyieql+srtEVRggoWq7FCGhpvuLlo5VTV9L82Qz
F1LcF+Suv+mcRI3O+WnE7q0qpIQLf66XIva9fv260v2t2FYzh1U+k4qcp7aum0Zq9rlshvXq1atE
7cPHAABCCgAnBwBzE/1WWZUZr3ahnw2QgAV8DAAgpABwcgAwJ1G0whcvXkxbflp66ofTB3wMACCk
AHByADDn0NLHHTt2TFt+ykt7AAEfAwAIKQCcHAAA4GMAACEFgJMDAADAxwAgpABwcgAAAPgYAIQU
AODkAAAAHwOAkAIAnBwAAOBjAAAhBYCTg6lhOkNVAwDgYwAQUgA4uVlStvA1f/58G4IZe+WxYMGC
WVOW0dFRs23btmnJa/v27bXCZh87dswsWrTILFy40Ozatct8+PChVp2+fftmVq1aFb13eHh4Un/6
/PmzLbvy7+joMLt37zYfP35suV4AfGcCIKQA4DcTUiESURpkzqSYon3roR9WffXq1bTkpXzWrVtX
6Z5z586ZS5cumZ8/f9rX6dOnzebNmyvX6cePH2bnzp1R24+Pj9u0w2tOnTplTp482SjD33//bU6c
ONFSvQD4DgJASAEAQqohpjQz5V83NjZmOjs7mwaZGpQuXrzYPtk/fPhwUxr37t2zacybN8/09vaa
hw8fZp3zy6T/r1+/brq6uuy1RbNlKoNmOJYsWWIH6TF7F+X7+vVr09fXN+laDdZXrFhhvnz5Ulre
cDYvxy667tq1a2bp0qW2zLdu3TLnz5+3dQjrF7NTyOPHj82WLVuajr1586Yx+6J0Vq9ebUZGRpL2
zbGJUH7KN7evd3d3m69fvzYd8/tZTp2EBJKEUiy/gYEB899//026Rum9fPmyqU5bt26ddI1fLwB8
DAAgpAB+cSdXtFSvbtlCQXPw4EH7BP/9+/f22JUrV+wgXMc0GL1586Y5e/Zs0wDZiQItz9IgOudc
mK+EwLt37woFnvI/evSoLYOWZ/3xxx/ROpXl29/fP0mkKO39+/dXKm+OXXT9vn377Lk7d+5YAaV8
9D6sXyzfkEOHDpkbN240HZMYGhoaasy+SGhKDOfYN2UTIUGofOswMTFhBeeePXsq1Uncv38/2n81
06W6Fl0je8sW4TGfVuoFgJACQEgBwBxzckUiKiWmqggpN9h2aMlVOCD1B/oasGuPShGxc6l8/fMb
Nmxo2mPz9OnTaJ3K8r17966dwfDRzNuzZ88qlTfHLmGd9F6ioii9WL4h69evb5ppKUMzTzn2TdlE
KD/lWxXtS9JsnV5+elXrVNTW//77b9MsVnhN0QxYeKxuvQAQUgAIKQBASE0SNEWDzzAff5CuGRQd
k7DQnhSf2LlUvv6xMNCDBEysTrF8tbzN7cWRIPOXMOaWN8cu4fWx97F8Q7R8LxRwQksyBwcH7cxP
T09PJfvGbOLsLTFUFwWe0JLFqnUqK7+WHKqMvrgOr/HbokxItVovAIQUAEIKAOaIk4uJqKkSUkUD
0qJBvJvZ0BK8nHNVBvpFA+CUvcvy1XKwAwcO2P/37t1rrl69Wrm8OXapIqRSNkzlq2Vxa9assUvV
tBxOyzKr2Ddlk6I2qIKWM8bur2pLLZm8fft29JpwGV/ZsVbqBYCQAkBIAcAccnLtFFJFwSZCNJPg
L0mL8fz589K8wnNVBvpafuWHrtYysVx7h/kqHc2AaDZDgSIUXrtqeXPsUlVI5dhQFM3eSCD4ZXn7
9m0l+6ZsIiFUZeZGSxX99vr+/bsNulGlTinbpT4DEqR+wAvVKYwcWLVeAAgpAIQUACCkbKQ4DWD1
N3adIs2dOXOmEchA7/0BqWZCXBqhMIudqzLQD4NNFIW79onlKzTrsmPHDhtYI/c+2Ur7jCQKcuxS
RUilyusjUanldz5amuei9Ll9P1XsG7OJE65V9hJpKZ8fevz48eP2VaVOVT9bReHP/fbRbF24bLJq
vQAQUgAIKQCY406uTtS+nB/kLUtHv7+jWQ/tVVL0NxfRT2hJmvbkuLDavjCLnas60NfyM82WLF++
3EbMi/1Abixf8eTJE5v+ixcvsu9TRD7l6ecbs0sVIZUqr4+izKn+Po8ePbKBLnSvRFn4A7U59i2z
idBSPz+6Xaq/aaZHgkx20YyPhFWMojq1KqTUFopI6NpMP/arH+mN1QsAHwMACCkAnNwvjZZp6XeO
6qJBtmZx5iISPKkft223TTZu3GjF3lyrU4qprhcAPgYAIQUAOLkZRftrFIjB/WaTZjhiARliKA3N
JKWi481mFN2vaOaoLjGbaKmg8ptrdUoxXfUCwMcAIKQAACc3YygSncJda4nWkiVLzJEjR6ygqoP2
Oun3h8qCTMwFtCRT+5naRcwmyufBgwdzrk4ppqteAPgYAIQUAODkAAAAHwOAkAIAnBwAAOBjAAAh
BYCTAwAAfAwAIKQAcHIAAAD4GACEFABODgAAAB8DgJACAJwcTGfY7l+53r+rHQHwMQAIKQCc3Czl
y5cv5tChQ/b3mObPn2+6u7vNqVOnSss/03WZawMGhWX/HQnr3Wq7/a52nMsoZP6qVauyrh0dHTXb
tm3LTkPfW3v37rX9Qt9dhw8fNp8/f26cn5iYsH0ufDm2b9/+S4W4R0gBIKQAEFIzwJ49e8zff/9t
f3hVfP/+3f6orV44bAY47ap3q3ag380t9FtuO3fuzG43/QDyq1evstPYv3+/OXv2rP3e0uvixYv2
Wod+pHvXrl2l+Skv/f4c3zMAgJACwMnVRrNQIXraqx+3LSq//tf5FStWTPqRVomw3t7exnvNbC1e
vNh0dHTYJ8ahTcbGxkxnZ2fpgKbomrAs169fN11dXWbevHm2LvrxVh+VYdGiRbY+ly5dirbFvXv3
bBpKS/V4+PChef36tenr6yscKMoGskXRfa58RU/DU3a5du2afcquMt+6dcucP3/e1qGofiESwEpX
P6S7efNm8+7du0r2CttTT/2V1urVq82TJ08a5968eWOf6uuc0tH5kZGR0nrrrwa7qbYqsktdO5b1
r6nqv2X9oOw7wD8Wu7fovlQ7ttoPUnVPoTzHx8ezrn38+LH90ecqaWgmyj38EfpfnxHH6dOnbX+L
oTyVNz4GABBSADi5wkFnKu81a9bYJ7saROaU3/1/4MABO8D3uXDhQmNZ4JUrV+xgTQMciY6bN2/a
fPx0Dh48aM+/f/++NN/wmrAsGsy7QaIGg74wVP5Hjx6193/8+NH88ccfUXv4A0otNdIyR9Hf3z9p
YKu09VQ8dl9R2+fYZd++ffbcnTt37OBQ+eh9WL8QtYfEontKr7wkhHLtFTI4OGiGh4ft/3rCr77i
kLgcGhpq5KV8JSrK6q33WrpVlneOXaraMda/pqL/VukH4bHYvUX3xdqx1X6QqnsO9+/fz/7u09Li
GzduVEojFFL6/vKXf2p2SkJJYlCfoaIZdj2wUN74GABASAHg5ApFVEpMPX361A7aNJDSQPfq1avm
0aNHSSGlpTF6qu8GM/q7cuXKxuBMS3X8gY4IB5b+U/Ky+oTXhGWJnd+wYYP58OFDU11jtpAQcMLB
RyJiYGCg6ZhmIZ49exa9r6jtq9pF77XfI6cv9fT0NAli/a+ZrVx7FYnssKwxNLsRE1KxvHPs0ood
Q6ai/1bpB+Gx2L1VPxet9oNU3dv93bd+/Xrz8uXLSmlIGGrGSeXUzKIEkd//li1bZpcsu7bV95oe
DPgoT+WNjwEAhBQATq6WkHJomZKeyOtJtUTVuXPnokJKbNq0yT65Fpqd0L0OpRGWITbQrjP4TJ0P
AxRoQBXLVzMBOq+B5MmTJ5vOaRmU28MhQeYvF4vdF+ZX1S5V9hr56fj55dordm9Zn9HgVPvsNHiP
tU3OjEwVu7Sjf7W7/1bpB+Gx2L1VPxet9oNU3dv93aflhzHBXpSGAkvs3r3bllXBKGS/WEASpS9x
FR7T0kV8DAAgpAB+cycXE1FV81eo6bLZAP9/zdRob4zQvg63FKdsMFfVJq0KqVAIpISUEwduBkrL
Ah3ac6HlYEJPw/WEO+e+ML+qdqkipIqETxV7VRFSWoqlGSstj1K7a3lbK0Kqql3a0b+mov/m9oOi
Y2X3Vv1ctNoP6oqmuu3QjrbU7NLy5csr55N6WICPAQCEFMBv4uTqCCkFNCh6Guw/qY0NwjRTo5ks
LYvy0cDUX5I2E0JKy3a0N8qhpXi5bfH8+fOma5WOnpxrqaD2XYSBCsruC/OrapcqQkpph0u6/Kf0
VYWUnvSXzRRo34lfj7dv37YkpKrapR39ayr7b6ofhPaK3Vv1c9FqP0jVvd3ffXVmpEJu375tZ0Yd
WsqooCK+DZxodmj/FzNSAICQAsDJ1RZS2oStzemKjiUkELT3QBvpc8SLNqHrSXC4GV1pnjlzprHh
Xe8VhWs6hVQYbEL5p/YEKXqaKArEoJmoHTt2NNkmdZ8GidqP4ga2Ve1SRUgpLbdvRK/Lly83/QZP
VSGlZXtaMiX0mzt+sAkJEBelz+018dMK653KO2WXVu1YRjv7b6wf+MEk9FnTMkI/jVTfq/K5aLUf
pOre7u8+9R0tl62Shuwl8SQUQVKzeH4aR44csYFDXB3UvrKDjx6ssEcKABBSADi5qJhKoQGHBlpa
+qInuRJX/hPtmHj59OmTfdrtz/w4Tpw4YWcudF4DRz962nQIKaEleZpB0mBZ0chi+yi0tEp7fVxI
aDewdSj8t9LX0sfc+zSAU55+vlXsUvX3mFzYa70k/BS+va6QkqjWb/GoTqqfP1BVQBIXpESDWgVK
8NMK652Td8wurdqxjHb231g/cOJI5/RZ0zk/jVTfq/K5aEc/aIdtc69VoAh9Nquk4fYpuj1SYaAO
9V1Fu1T5NesuYRii5blE7QMAhBQATg4y0OBKkdrqosGkZmIAoH3oAUXdGa9W2LhxoxWw+BgAQEgB
4OQgQLNr2rzvfg9HT+ljm/hjKA09pU9FVAOA6ihaYTjTO5VoOaryxMcAAEIKACcHBSgKm5b/uOU9
2jchQVUH7dHRD3yWBZkAgPpo6aP2H04Xykv7/vAxAICQAsDJAQAAPgYAEFIAODkAAAB8DABCCgAn
BwAAgI8BQEgBAE4OAADwMQAIKQDAyQEAAD4GABBSADi56aFu2OLpDHcMQH8DfAwAIKQAcHJtR6GA
VU6FDK+KwovXqW9430zaea4PRGZb+ae6PKOjo2bbtm2N91++fDGHDh2yvx02f/58093dbU6dOjVr
+9tUs3379l8qvPdsbJfZ1P4IKQCEFACOfQb53//+Z3+sts5vudStX7vtgpD6fdCPqb569arxfs+e
Pebvv/+2P5wsvn//bn+AWa/Z2N+mGtlGv6HG9y1CCgAQUgA49ink/fv3ZsWKFfb/lStXmg8fPkwq
//Xr101XV5eZN2+efeKvH9B05/xXWN979+7Z63Vfb2+vefjwYel9b968sU/S9eO3umf16tVmZGSk
qRw3btywsw4dHR3m4MGDTT+Qq/MXL16cVM7Xr1+bvr6+SfXWj/Oq3prNCNtIA3DlobJs3rzZvHv3
rnFOg/S9e/facyrjkydP2nJv7FyObUJUL9Uv/BFh5aO2yEm3bnn98sT6j0OzR4sXL7Z2O3z4cLS/
Pn782P44so/SLKq/foh5tva3WNo5ZUvZVDaSrer0i1SbKP+xsTHT2dnZEGxln/Wy/pnzPVH2fZpq
l1w7pj7LKRvos+3u37p1q3n69Gn2d0E7/QJCCgAhBYCQalNeRYPGGKdPnzbHjx+3/584cWLSkiil
ocGIGwRowOYPXMM8/Pf+AE/LsbTkquw+DT6HhobsrIJely5dsgM1/3rNRKgcOq9yajmXf17LvYrK
2d/fP2lwpoHo/v37J5Xl/PnzNm9XjitXrtjBkmNwcNAMDw/b/+/evWvWrFnTlntj53JsU8SBAwds
mXwuXLjQaONUunXLGwqpWP+RjdQWyl9i4+bNm+bs2bOl/VVtroG0j/LWPRoY534OZ7q/xdLOKVvM
puLatWtNaVbpF6k2Uf4SMDqvBzFVP+tVvieK7ku1S64dY304xwYbNmywD550ze3bt82+ffuyvwt+
p4d1AAgpAJj1Tq5IROWIKT3V1pNb8fbtWzsrFabrP0ktGiiXndOgxQ1U6thFT6j96/0nxl+/fm3M
pKXKqUHSwMBA0zk9SX/27NmksvT09DQNyPW/nn77g3a3hCyklXtj53JsU4SWeMlGLl39VfuGdipL
t255w/4R6z8aFIfpxAbS69evNy9fvmw6ppkA3aMBucTN1atXzaNHj2Z1f4ulnVO2mE2FbCRb1ekX
qTYpyr/qZz33e6LovlS75Nox1odzbODPQOla3ZP7XYCQAkBIAcAcF1J6+qslJz56mu4HnUgNgmJC
Sum7J8gnT55M2kXLhfSUWHteNBAJ8wkHNrGZsfCYBKPbV6MBkL+HxL/OH2gV5VO0jKwd98bO5dim
jE2bNtkn60JP5zWTkZtu3fKmyhbmEfbXIjs6tEyqbPCrumhmRXVUuufOnZu1/S2Wdp32Do8pfS0r
q9MvUm1SlH/Vz3ru90TRfVXapZX+XdUGfnqp7wKEFABCCgBmiZOLiahY/ho8FV3vD6paEVJuIOOe
0CugRdl1Wq6lJ8RakiQhpyVDqcFjlYGtljBqSZPQEhvNWpQN7FMD/yrioh3CpI5tHLK99n8I7T/x
RXIq3ekQUjHRlCtWi1C489jystnS34rSrlO2VJpV+kXKxmX9LfezXuV7omo9/fOt9O86NvAjQ6a+
CxBSAAgpAJhFTq6qkNLSHD01D5/u6r2Ou6ATrQopx/Pnz6P3LVq0yExMTDTea5lheL3ScHz+/Nne
kztY+/jxo53NUL20gbxsg7oGleGSHH+AtGrVqtIZkVbujZ3LsU0MtadmasJlm6l065a3yqBfNvPL
kKJoRkpBJYrK4s/IzLb+Fku7TnuHx7SvJzYjFesXqTZJ9bfUZz2sT+zeorxz26WV/p1jAz9ypD7r
/hLD1HcBQgoAIQUAc1hIaQlNuOHcoSVRbuN5atCmwaJEmRs0+Of0NFgRuUS4IT68T4M6F1HL7e8I
B2NahqgBqgY/CpCxc+fOSoNLzQwoxLs2ypddJ5soGpvbJH758mU74HJomZCWIgn9Vk8YbKLuvbFz
ObaJoU3yy5cvnxTEIZVu3fJWGfTLZmfOnGnYTO/D5aY+KmNRdDTdNz4+bt9LtKgd/Haebf0tlnad
9g6PaT9W2R6pVL9ItUlR/rHPuh9MQm3kZsJz7i2qZ267tNK/c2ygyIifPn2y53VtGGwi9l2AkAJA
SAHALHNyVZb1KaJVGALZoQ3cLhRyatCmQZietLqnrf45LdfRvgQXotkNloruU3AAFzBAAxptPg8H
jxoULVu2zG5OP3LkiH0aXWVwqU3qOqZlX7HrXNhivTQYVkhrh2y2a9cuW07VrSzkcdV7Y+dybBND
gz3ZWYNPn1S6dctbddCvaJGaPVAZNch2keCKUIQ2RUALkfDXQFV9TZv61Q7+jMBs62+xtOu0d3hM
SwnLoval+kWqTcr2m5V91p040jm1kc7lfk8U1TO3XVrp3zk2UD/UbKPOS1SFAThi3wWEPwdASAEA
Tm5O2VEDIT2lhrmLxElsxmou9Lfp+E7YuHGjFSh8D/DdCAAIKQCcHHZs6X4tr9ET5lRUMJj9KLpb
OMszl/rbVH8naBmbH4qb7wG+GwEAIQWAk/uNaXWjtvbIaPlN2XJGmDtoqZj2Hs3V/jZVQQccso32
/PA9gI8BAIQUAE4OAAAAHwOAkALAyQEAAOBjABBSAICTAwAAfAwAQgoAcHIAAICPAQCEFABO7v+1
d/6RXX1/HP9jJjPJyCSTRJIkGZPMTGIyM5kxmeyvmGSSjGSSSSTJzMRkJsmYJMmMJDOTMZmZJGaS
mRnJZCbn63k5b+d9dn++t7a9v5/Hg7d2u/f8vOf9fr2e55z7ugAAgI0BAIQUAEYOAACwMQCAkALA
yO0SCtF8/PjxVNeOjY2ZxsbG1Hmsra2Zzs5OU15eHoQubm1tNaurq6F5j4yMbOqvpqam/9tQzgAA
CCkAhBQAFKmR29jYMC0tLanrqRd9zs/Pp86jq6vL9Pf3By8o1ae7uzsQUz6Li4umvr5+Ux4qq7q6
moEEAICQAkBIAWDk9g4SLxIxaeo5MTERvGQ0Sx4VFRWBgHJFV9hLNRsaGszXr19D81CZKhsAABBS
AAgpAIzcnmB8fDx1PbW6NDQ0tKU81tfXTWVlZd7/9fb2mr6+vsg8BgcHg7IBAAAhBYCQAsDIFV09
a2pqzNzc3JbyGB4eNj09Pbnjz58/561yheWhMlU2AAAgpAAQUgAYuaKrZ1lZWd42vax5rKysmLa2
tmB7n/j9+3fw/NPS0lJsHipTwSoAAAAhBYCQAsDIFV09S0pKCs5D4qm9vd0sLy/n/q+jo8OMjo6m
yqO0tJTBBACAkAJASAFg5IqvnoWuSGklSiHQFxYWNl0f9fFFGCtSAAAIKQCEFABGrijrqeeUpqen
M+WhaHt1dXV52/ey1mNmZoZnpAAAEFIACCkAjFxx1lOR8wYGBjLlUVVVlbjilJTHs2fPiNoHAICQ
AkBIAWDkipPJycngnVE7TW1trZmammIwAQAgpAAQUgAYueLk7NmzZnZ2dsfKU+hzlQkAAAgpAIQU
AEauaHn//r1pbm7esfJU1ocPHxhIAAAIKQCEFABGDgAAABsDgJACAIwcAABgYwAQUgCAkQMAAGwM
ACCkADByAACAjQEAhBQARg4AALAxAICQAsDIFSE7GQodYC+P0938LvA9xMYAAEIKACO3Cyi8uOo5
Pj6eOe2+ffsi2/vu3TtTWlq6Z94D9V90OHaqzdtRzvfv383Jkyf/Sf38cVqsZWxX2Wtra6azs9OU
l5cHaVtbW83q6mpsmrGxMdPY2Jg7XlpaMpcvXw7Sl5WVBXksLy9vSvfnzx9z/Pjx0DHjf0pKSnLn
m5qaePUBv2sACCkAjNzeRs7Q7du3C3o/VFz7JKL03inuBUIqDU+fPjXd3d1F2w+7Ob6ylt3V1WX6
+/vN379/g4/6XUIoDk2IzM/P544vXLhgXr16lctDf1+8eDEvzcbGhmlpaUlVvzdv3pi7d+/mjlVW
dXU1RoTfNQCEFABGbm/y8+dPU1VVFfx99OjRYJbZr//z58/NkSNHgtliVxz5s8lue+PORfVPXFmW
+/fvm/3795uKigrT19eXl14rGprF1uy40p44ccK8fv069l78/v07aL9mzV3W19fN6dOn88o9cOBA
MIN/8+bNTW2YmpoylZWVOcfPrsapHcrn48ePsfUIW8kLSxuWbmhoyBw8eDCo240bN/LakqV/1Oar
V68G53VucnJyU9/H9cGPHz9y6S9dumSmp6fzrpGzrrQ6X19fH1zvIsd8YmIi9VhIys+tW9hY9O9Z
Uhvj+i+qjMHBweDeaLxKaDx+/DgYv1FjO65/C/keRqH6SPy4giduVUv3xRdJqkPY5ImL7svi4mJi
fVSXM2fOBN9HF5VpxwQgpAAQUgAYuX9aVphTFUdvb6+5c+dO8Ldmg+XM+XnKebROqpw311nyy/CF
UVJf+NfHlSVHUitncrq0hej8+fN56eWIvXjxIjdDLqElRznpXmiLkxxclydPnuT6YmBgIChbecrh
fPnypXn48GFevhIwOi9hah1K6+hqS9SxY8dS90Nc2rB0WilQn6l81VmrDWH5JvVPT0+PGRkZCf5+
+/Zt3ja7NH1w7ty5QIjrmtHRUdPR0ZE7r/5VebZs5SfRZZH4k3Ofdiwk5Zf0PQy7Z0ltzDq+dKw+
UF5abZGAunbtWnDstydN/2b5HmZFItpti4/GlAS7L3wlDi0aO3V1dXnX2O3CSfVT+93VKIuEqDue
ASEFgJACwMjtiIhKI6Y0w62ZdrGwsBCsSvn5+jP9acVSIUIqrizrqFu04pHUPveZi6hrtYVIq1J2
hl7/qh9sXSRU3Nl74Qsjv95ySq0oSTMm3P+LSxuWzl050rMvdoUxzfhz+0fCyW+nJU0fuCtQutZ9
Nu7UqVOBs+467lqpscghb29vTz0WkvJLI6T8/JPamHV8+WXo+NevX6HXFzLG4r5rWRkeHg6EdBQ1
NTVmbm5u0/dG4tf+zuhvd+tflt9BiVT9/vioTJUNCCkAhBQARm5PCSmtdmjrjYtmmd2gE2nEz3YK
qbjz/tYjOZ5+Gm3XkkN45cqVwNlO62xqJl0rAkKrDpr9t2jmP+6h+LB81bd2tejevXuZ+iEubVg6
3wGPW6mI65+wrVpb6QM3P/fasPMSUa54TOqjpPzSCKmsbcw6vrIcF9K/2yWkVlZWTFtbW7ASFoW2
M/rjTN8RrQzaFbpHjx4Fz0Nl/R2U+IoSS8pXWx0BIQWAkALAyO24iIorX45Q2PWuiNhLQsp3lH0h
pa1HWlXRdiCJQW3ZSutsaiubnnkRei7JFZNhTnuaeyynW/k2NDQEWxLTtjMubZqyo4RUUv/ECZFC
+sAVvmF5u2m0mhH1bFeasZB0f9OMxaQ2Zh1fWY4L6d/tEFISTxKxYdH2kvpG99cVV/pbgivr72BS
kJG4cQkIKQCEFABG7p+KqTC0TUjb+vxZZh3r/+0Wun8ppLSVJ4uQ0qy16/DNzMzkndczKO7WqTT5
u6jdejbK394oYeXmm/Uef/nyJbYefj3j0oaVrWssCmGtfggrK6l/FKI6amtfmj5wt3Vpq527xVDp
/a14VmgpmIYEYxbhEJdfoUIqqY1Zx1eW40LG2FaFlFai9Hxg2JY6n7AVKV80xa0exdVPq1iaNIgS
eqxIIaQAEFIAGLk9JaS0ZcwPsGDRFh0baCHJgZMzJVFmndo4584NoqBIXnZFLK2z6Aeb0LZE97yE
kI2iZp+tyOJs6uH+w4cP5z3kL9RPDx48yG1h0rG7JTIsX61cKPqe8AMDJPVDXNqw/lFd1B+qmwKH
uNursvSPtqxpW6HQ+3vcYBNp+kAR1uSc67yu9YNNaOXBplfobftuIa1G6FwW4RCXX5QQiBqnaduY
1H9JZcQdFzLG4spOQpHwtJ3Vj9IZhdrqR2FUsA6tzknsqM6ahLh+/Xrm30E9C2YDfvhosoRnpBBS
AAgpAIzcroipKPRwtx/y26KABTb0d5IDJ9GhlQC7GhAnXKwo0DYhOb0SC1mElFCUQYWIluBRpC93
FeLTp0+BU6YyJAL0zE0WISURoPzCtjkpophWJHRewsd1/MLy1dY8PUNjQ1VbYZSmH+LShvWPnPtD
hw4FQSpu3bqV92JVN9+k/tF40LuEdF7l+45zUh/ofuje6LxElR8cwYYr10cR9r59+5YTjjbgSZax
EJVflEiOGqdp25jUf0llJB1nHWNZyvbRamGW3wtFztP9ddF4kZiy5UpERf2mJL1vLmol9NmzZ0Tt
Q0gBIKQAMHKw3chpc7ePMb4A/g2KDOkHptkJamtrg4kF4DcAACEFgJGDLaDw1nqWwr5rRysScYEY
GF8A24eiSM7Ozu5Yedo+6YbQB34DABBSABg5KBBFSquurg62ESnKm7axxYVs/i8QF2ABYDvRltTm
5uYdK09l6Vk9wMYAIKQAMHIAAADYGACEFABg5AAAABsDgJACAIwcAABgYwAAIQWAkQMAAGwMACCk
ADByAAAA2BgAhBQARg4AAAAbA4CQAgCMHAAAYGMAEFIAgJEDAABsDADwjQPAyAEAADYGABBSABg5
AADAxgAAQgoAIwcAAICNAUBIAWDkAAAAsDEACCkAwMgBAAA2BgAhBQAYOgAAwLYAAEIKAIMHAADY
FABASAEUv+Hjw4cPHz58tvoBgN3hfxKNMtik5mIJAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-04-04 15:57:38 +1000" MODIFIED_BY="Narelle S Willis" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-04-04 15:57:38 +1000" MODIFIED_BY="Narelle S Willis" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAW0AAAXnCAIAAAAIB7/YAABkb0lEQVR42u2dsW4bufe2BwhguHDh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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-06-06 11:08:27 +1000" MODIFIED_BY="Gail Y Higgins">
<APPENDIX ID="APP-01" MODIFIED="2017-06-06 11:08:27 +1000" MODIFIED_BY="Gail Y Higgins" NO="1">
<TITLE MODIFIED="2013-06-18 10:03:31 +1000" MODIFIED_BY="[Empty name]">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2017-06-06 11:08:27 +1000" MODIFIED_BY="Gail Y Higgins">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database searched</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>CENTRAL</P>
</TD>
<TD>
<OL>
<LI>(peritoneal dialysis):ti,ab,kw</LI>
<LI>(CAPD or CCPD or APD):ti,ab,kw</LI>
<LI>{or #1-#2}</LI>
<LI>peritonitis:ti,ab,kw</LI>
<LI>{and #3-#4}</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<OL>
<LI>exp Peritoneal Dialysis/</LI>
<LI>peritoneal dialysis.tw.</LI>
<LI>(PD or CAPD or CCPD or APD).tw.</LI>
<LI>or/1-3</LI>
<LI>Peritonitis/</LI>
<LI>peritonitis.tw.</LI>
<LI>Catheter-Related Infections/</LI>
<LI>infection*.tw.</LI>
<LI>or/5-8</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE</P>
</TD>
<TD>
<OL>
<LI>peritoneal dialysis/</LI>
<LI>continuous ambulatory peritoneal dialysis/</LI>
<LI>(PD or CAPD or CCPD).tw.</LI>
<LI>peritoneal dialysis.tw.</LI>
<LI>or/1-4</LI>
<LI>exp Peritonitis/</LI>
<LI>Catheter Infection/</LI>
<LI>peritonitis.tw.</LI>
<LI>infect$.tw.</LI>
<LI>or/6-9</LI>
<LI>and/5,10</LI>
</OL>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2017-04-04 15:57:35 +1000" MODIFIED_BY="Narelle S Willis" NO="2">
<TITLE MODIFIED="2015-01-12 18:09:13 +1100" MODIFIED_BY="Ann Jones">Risk of bias assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2015-01-12 18:09:20 +1100" MODIFIED_BY="Ann Jones">
<TABLE COLS="2" ROWS="22">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Random sequence generation</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimisation (minimisation may be implemented without a random element, and this is considered to be equivalent to being random).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information about the sequence generation process to permit judgement.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Randomisation stated but no information on method used is available.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</TD>
<TD>
<P>
<I>Low risk of bias</I>: No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias</I>: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Selective reporting</B>
</P>
<P>Reporting bias due to selective outcome reporting</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. sub-scales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Other bias</B>
</P>
<P>Bias due to problems not covered elsewhere in the table</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study appears to be free of other sources of bias.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> Had a potential source of bias related to the specific study design used; stopped early due to some data-dependent process (including a formal-stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_4552_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="4552">
<ADDRESS>
<DEPARTMENT>Cochrane Kidney and Transplant, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 98451469</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 98451491</FAX_1>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_19795_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="19795">
<ADDRESS>
<DEPARTMENT>Sydney School of Public Health</DEPARTMENT>
<ORGANISATION>The University of Sydney</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP>2006</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Department of Emergency and Organ Transplantation</DEPARTMENT>
<ORGANISATION>University of Bari</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bari</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_2" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Medical Scientific Office</DEPARTMENT>
<ORGANISATION>Diaverum</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Lund</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="SE">Sweden</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_3" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Diaverum Academy</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bari</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_4" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Sydney School of Public Health</DEPARTMENT>
<ORGANISATION>The University of Sydney</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Comparisons: studies (participants)&lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Oral or topical or intraperitoneal antibiotics versus placebo/no treatment: 7 (469)&lt;/li&gt;&lt;li&gt;Oral or topical or intraperitoneal antibiotics versus other antibiotic: 7 (640)&lt;/li&gt;&lt;li&gt;Nasal antibiotics versus no treatment: 3 (338)&lt;/li&gt;&lt;li&gt;Pre/peri-operative IV prophylaxis versus none or head-to head: 4 (379)&lt;/li&gt;&lt;li&gt;Topical disinfectants versus standard care or other active treatment: 9 (1039)&lt;/li&gt;&lt;li&gt;Germicidal chamber versus none: 2 (217)&lt;/li&gt;&lt;li&gt;Dressing systems (any): 3 (140)&lt;/li&gt;&lt;li&gt;Silver ring system on catheter versus none: 1 (195)&lt;/li&gt;&lt;li&gt;Antistaphylococcal vaccine (Staphypan) versus placebo: 1 (124)&lt;/li&gt;&lt;li&gt;Antifungal versus placebo/no treatment: 2 (817)&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="400">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;2017 review update&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Studies included: 39 (56 reports, 4435 randomised participants)&lt;/p&gt;&lt;p&gt;Studies excluded: 12 (17 reports)&lt;/p&gt;&lt;p&gt;Ongoing studies: 1&lt;/p&gt;" WIDTH="400">
<FLOWCHARTBOX TEXT="&lt;p&gt;Included studies: 19 (23 reports, 2122 participants)&lt;/p&gt;&lt;p&gt;Excluded studies: 2 (4 reports)&lt;/p&gt;" WIDTH="400">
<FLOWCHARTBOX TEXT="&lt;p&gt;Reports excluded after title and abstract screening: 355&lt;/p&gt;" WIDTH="400">
<FLOWCHARTBOX TEXT="&lt;p&gt;2004 review: 382 reports&lt;br&gt;(MEDLINE, EMBASE, CENTRAL, Renal Register, clinical practice guidelines)&lt;/p&gt;" WIDTH="400"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;New included studies: 20 (29 reports)&lt;/p&gt;&lt;p&gt;Existing included studies: 4 (4 reports)&lt;/p&gt;&lt;p&gt;New excluded studies: 10 (14 reports) (wrong intervention (7); other (3))&lt;/p&gt;&lt;p&gt;New reports of previously excluded studies: 0&lt;/p&gt;&lt;p&gt;New ongoing studies: 1 (1 report)&lt;/p&gt;" WIDTH="400">
<FLOWCHARTBOX TEXT="&lt;p&gt;2015 review update: 48 reports&lt;br&gt;(Specialised register)&lt;/p&gt;" WIDTH="400"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>